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Stereoselective Synthesis using N-Chloroformylimidazolidinones 
N-Acyl imidazolidinones are key intermediates in the stereoselective synthesis of amino acids as shown by 
‘self-regeneration of stereochemistry’ methods. This thesis reports a diastereoselective synthesis of trans N-
chloroformylimidazolidinones, species which represent a powerful new template for the generation of a 
wide range of unnatural amino acid derivatives. In addition to classical alkylations, it also describes a number 
of other reactions in which the N-chloroformylimidazolidinone plays a pivotal role. The thesis gives an 
overview of the development, scope and mechanistic studies of the N-chloroformylimidazolidinone not 
only in asymmetric alkylation, but also in mild Friedel-Crafts acylative cyclisations. It shows how these new 
versions of aromatic and aliphatic Bischler–Napieralski reactions can be used to generate highly 
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HMBC – Heteronuclear multiple bond correlation 
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m.p. – Melting point 
MOM – Methoxymethyl 
MS – Molecular Sieves 
mTOR – Mammalian Target of Rapamycin (a protein) 
µw – Microwave  
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NMO – 4-Methylmorpholine N-oxide 
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1D NOESY – One-dimensional nuclear Overhauser effect spectroscopy 
NOE – Nuclear Overhauser effect 
Nu – Nucleophile 
Pet. Ether – Petroleum Ether 
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rt – Room temperature 
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SM – Starting material 
SRS – Self-regeneration of stereocentres 
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TEA – Triethyl amine 
Tf2O – Trifluoromethanesulfonic anhydride 
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Trp – Tryptophan 
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Tyr – Tyrosine 
UV – Ultraviolet 
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VT-NMR – Variable Temperature-Nuclear Magnetic Resonance (spectroscopy) 
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 Amino Acids 
Amino acids are compounds containing both amino and carboxylic acid functionalities. Of particular 
significance are α-amino acids, where both groups are directly attached to an α-carbon and correspond to 
the general structure 1 (Figure 1) where R is the side chain. 
 
Figure 1: α-Amino acid 
A chiral amino acid exits as L and D enantiomers when R ≠ H. Essential α-amino acids of L-configuration 
act as vital building blocks for the backbone of proteins in the body.1 Owing to the significant role of 
proteins in organisms, unnatural amino acid synthesis is considered as one of the most important fields of 
research. These novel amino acids can exhibit enhanced properties over their corresponding natural ones.1 
In particular, α,α-disubstituted amino acids, in which the α-hydrogen is replaced by another substituent, play 
a key role in the design of peptides with distinctive properties. These amino acids are called quaternary α-
amino acids.  
 Quaternary Amino Acids 
The general structure of α,α-disubstituted amino acids 2 is presented below in Figure 2. These kinds of 
structures have steric hindrance as a result of the presence of the secondary substituent at the α-carbon.2 
 
Figure 2: Quaternary amino acid  
Quaternary amino acids are of wide importance in medicinal and biological chemistry: they are found in 
many natural products and are important components of pharmacologically active compounds.3 These 
bioactive natural products act as enzyme inhibitors and ion-channel blockers, as well as agonists and/or 
antagonists of neuronal receptors and antibiotics.3  For instance, lactacysin 3 is a natural product isolated 
from Streptomyces bacteria which is a 20S proteosome inhibitor, and was synthesised by Corey et al.4 Other 
compounds such as the antifungals sphingofungin E 4a and F 4b5 are known to have inhibitory activity 
over the key enzyme (serine palmitoyltransferase) for the biosynthesis of sphingosin.6 Another important 
example is neooxazolomycin 5 shown in Figure 3, isolated from Streptomyces; this compound is a potent 








Figure 3: Quaternary amino acid residues in bioactive molecules 
The synthesis of the preceding bioactive natural products from natural tertiary amino acids has been 
reported.3 Accordingly, development of new procedures for the synthesis of quaternary amino acids has 
increased greatly over the last thirty years.7 Specifically, asymmetric synthesis of such compounds is of 
major interest since naturally-occurring proteins and peptides are comprised solely of enantiopure amino 
acids. 
 Synthesis of Quaternary Amino Acids  
Such intense interest within the research community in the distinctive properties of enatiopure quaternary 
amino acids has led to the development of several approaches for their synthesis. Cativiela and Díaz de 
Villegas reported between 1998-2007 key reviews focusing on synthetic approaches towards α,α-
disubstituted α-amino acids.8–10 Most approaches for the asymmetric synthesis of α,α-disubstituted amino 
acids can be categorised according to the nature of the bond formed in the asymmetric step.11 
Methodologies which formally attach one of the two substituents to the α-carbon atom of a chiral amino 
acid or a derivative are discussed later. Synthetic approaches using memory of chirality have received 
considerable attention in recent years. Methods in which the carboxylic acid functionality (Strecker reaction) 
or the amino groups (electrophilic α-amination) are introduced via a chemical transformation are also 
described in this text. Among the different strategies, it worth mentioning that the diastereoselective 
alkylation of amino acid derivatives is one of the most popular. In this context, cyclic derivatives of chiral 
amino acids have been exploited in order to achieve higher diastereoselectivity.  Representative examples 
include bis-lactims 6, 12,13 oxazolidinones and imidazolidinones 7, 14 diphenyloxazinones 8 15 and 








Figure 4: Chiral cyclic amino acid derivatives 
 
 Self-Regeneration of Stereocentres  
‘Self-Regeneration of Stereocentres’ (SRS) represents one of the most important strategies in the field of 
asymmetric synthesis of quaternary amino acids, originally developed by Dieter Seebach and co-workers.21 
Generally, SRS proceeds through four steps from an enantiopure starting material: (1) an initial 
diastereoselective transformation in which a second ‘temporary’ chiral centre is introduced; (2) a 
trigonalization process (e.g., enolate generation) by removal of a substituent (e.g, a proton) from the original 
stereocentre; (3) diastereoselective introduction of a new substituent controlled by the configuration of the 
temporary stereocentre; (4) removal of the temporary stereocentre. Regarding the synthesis of quaternary 
α-amino acids, the optically pure tertiary starting materials can be diastereoselectively converted into 
heterocyclic intermediates bearing two stereocentres. The α-stereocentre is then temporarily destroyed as a 
consequence of deprotonation to produce chiral cyclic enolates. Diastereoselective alkylation of the non-
planar cyclic enolates using various electrophiles 22 as shown below in Scheme 1 installs the required α,α-
disubstituted stereocentres.  
 









Seebach et al. described before the first example of ‘Self-Regeneration of Stereocentres’ in 1983 using 
proline as a model substrate, which was reported to undergo diastereoselective alkylation via a derived 
oxazolidinone intermediate (Scheme 1).23 Two years after, in 1985, Seebach et al. expanded this methodology 
to a broader substrate class via analogous imidazolidinone intermediates, which for the first time provided 
good results for acyclic starting materials such as alanine, valine, methionine, phenylglycine and 
phenylalanine.24 
Seebach and co-workers reported an efficient route for the synthesis of the required imidazolidinone 
intermediates. This elegant route allowed greater diversity by introducing various substituents on the 
imidazolidinone ring system. Initially, N-methylamides 15 were prepared from the corresponding α-amino 
esters, which were subsequently reacted with pivalaldehyde to provide isolable aldimines 16. Acylative 
cyclisation of 16 provided either trans or cis imidazolidinones 17, 18 depending on the conditions used as 
depicted below in Scheme 2. 
 
Scheme 2: Synthesis of cis/trans imidazolidinones 
As in the original SRS example, the imidazolidinones obtained by this modified method could be 
deprotonated and then diastereoselectively alkylated by benzylic bromides, allyl halides from the opposite 
face to the bulky tert-butyl group with, in most cases, diastereoselectivities of >98:2 (Scheme 3). 
 









Later, Seebach and co-workers further extended this methodology to the synthesis of (R)- and (S)-α-
methyldopa from (S)-alanine, as well as to more functionalised amino acids, including arginine, aspartic 
acid, histidine, glutamic acid, lysine, tyrosine and tryptophan.25  The synthesis of numerous natural products 
has also been realized using this SRS strategy. 26–28  
  Memory of Chirality 
The concept of memory of chirality (MOC) was defined by Fuji and Kawabata in a 1998 review about their 
discovery as ‘a phenomenon in which the chirality of starting material is preserved in a reactive intermediate 
for a limited time.’29  
Fuji and co-workers first reported MOC when a chiral ketone 24 bearing a single α-stereocentre was 
alkylated via potassium enolate 25 to deliver the corresponding alkylated product 26 in enantiomerically 
enriched form.30 This unexpected result occurred without the presence of an external source of chirality as 
illustrated below in Scheme 4. Efficient levels of chirality transfer were observed with several reactive 
electrophiles which expanded the utility of the reaction and the results showed that variation of the 
alkylating agent did not appreciably affect the level of asymmetric induction. The authors concluded that 
the ketone species itself was responsible for the observed enantioselectivity as a result of the derived enolate 
being an enantioenriched atropisomeric species with hindered rotation about the aryl-alkene (enolate) bond, 
thus exerting substrate control over the diastereoselectivity of the subsequent alkylation. Factors like 
temperature and the introduction of specific bulky groups onto the enolate have been found to exert a great 
influence on the enantioselectivity of the MOC protocol.29 In general, cryogenic temperatures are required 
to distinguish between chiral atropisomeric enolate enantiomers. In this particular study (Scheme 4), it was 
found that installation of the bulky naphthyl group into the ketone 24 was critical as a source of axial 
chirality; replacing the naphthyl group with a less cumbersome phenyl group led to a racemic product as 
there was no mechanism for chirality transfer during the reaction. 
 
Scheme 4: Asymmetric alkylation via MOC 
 
The preparation of optically pure quaternary acyclic and cyclic α-amino acids has been accessed by applying 
MOC protocol to the α-alkylation of amino acid derivatives. In 1994, Kawabata and Fuji reported the 






the nitrogen and found that the highest enantioselectivity was attained by the combination of MOM and 
Boc groups on the nitrogen atom. A plausible explanation for the enantioselectivity is that the N-(α-C) 
bond becomes an axis of chirality at the low temperatures employed, with the configuration of this chiral 
axis influenced by the original stereocentre. This renders the faces of the derived enolate transiently 
diastereotopic under the experimental conditions, leading to the observed overall enantioselectivity. Based 
on the above information, the scope of the methylation was expanded with high yields and 
enantioselectivities observed with a range of amino ester derivatives 27 (Scheme 5).31–33 
 
Scheme 5: Asymmetric α-methylation of amino acid esters 
 
However, in contrast to the methylation protocol above, relatively low enantioselectivities (23-69%) were 
obtained when α-allylation of phenylalanine derivatives was carried out under optimised conditions.34 
Kawabata et al. showed that the enantioselectivity of the allylation could be improved by using an ester with 
a free phenol group 30 because of the formation of a more stable intramolecular enolate aggregate 31 as 
presented in Scheme 6. 
 
Scheme 6: Asymmetric α-allylation of a phenylalanine derivative 
 
In 2006, Kawabata et al. reported the enantio-divergent asymmetric synthesis of quaternary cyclic amino 
acids from acyclic L-α-amino acids 33 by intramolecular cyclisation of the alkyl halide (Scheme 7).35 The 
absolute configuration of the products was dependent on the base used: treatment of 33 with bases such 
as NaHMDS or KHMDS afforded 34 with retention of configuration, whereas treatment with a lithium 







Scheme 7: Stereochemical diversity in asymmetric cyclisation 
Kawabata and co-workers disclosed that the half-life of N-Boc/N-MOM-masked enolate racemisation was 
approximately 22 h at −78 °C but <0.1 s at 20 °C when either KHMDS, NaHMDS or LiTMP were used 
to form these enolates, supporting their original findings that low (cryogenic) temperatures were required 
for high levels of enantioselectivity in intermolecular alkylations.35,36 In contrast, when the alkyl halide 
electrophile was tethered to the enolate (bearing a potassium counterion), the enantioselectivity of 
intramolecular asymmetric alkylation was excellent (>99% ee) even at higher temperatures up to 20 °C, 
indicating a faster rate of intramolecular alkylation compared to enolate racemisation.36 
Although the above examples demonstrate the MOC approach as an efficient way to access enantioenriched 
quaternary amino acids, a potential drawback is that highly reactive electrophiles (e.g., allyl halides, methyl 
iodide) and low reaction temperatures are generally required to achieve useful levels of enantioselectivity, 
limiting the scope of the strategy, especially for intermolecular alkylations. 
 External Sources of Chirality 
In contrast to the previous methodologies (SRS and MOC), where the asymmetry of the final product is 
formally transferred from the enantiopure starting material, a large number of approaches towards 
quaternary amino acids exploit an external source of chirality to control the stereoselectivity. 
 Chiral Auxiliaries 
1.3.3.1.1 Schöllkopf’s Auxiliary 
A chiral bis-lactim 6 is known as Schöllkopf’s auxiliary and is considered one of the prominent examples of 
the use of a chiral heterocyclic skeleton to enable highly diastereoselective alkylation. In 1979, Schöllkopf 
and co-workers reported the first use of 6 as a chiral auxiliary.37 Piperazinedione derivative 36 was prepared 
via the formal cyclocondensation of two equivalents of alanine. Subsequently, selective O-methylation using 
tetramethyloxonium tetrafluoroborate afforded 37, which was subjected to one equivalent of LDA (base) 
to selectively generate the chiral mono-azaenolate 38. A diastereoselective alkylation reaction of 38 afforded 
bis-lactim 39 bearing a fully substituted chiral centre. Finally, hydrolysis of bis-lactim 39 gave the final 
quaternary amino acid derivatives 40 with good to excellent ee as presented in Scheme 8. Thus, in this 
strategy, the starting amino acid itself can be considered as both the reactant and the chiral auxiliary, with 






In addition, the product must be separated from an equimolar amount of the returned starting amino acid 
after hydrolysis. Schöllkopf and co-workers expanded the preceding method to obtain a large number of 
potentially bioactive, non-proteinogenic amino acids. 12,13,38–41 
 
Scheme 8: Stereoselective alkylation from Schöllkopf auxiliary 
 
 Chiral Organocatalysis 
Chiral organocatalysis is a powerful technique to generate quaternary α-amino acids derivatives. In 2000, 
Jacobsen and Vachal achieved the first enantioselective organocatalysed Strecker reaction by reacting 
ketoimine derivatives 41 with HCN in the presence of chiral urea organocatalyst 42 to afford range of the 
aminonitrile derivatives 43 in excellent yield and ee (Scheme 9).42  
 
Scheme 9: Asymmetric Strecker synthesis developed by Vachal and Jacobsen 
Once again, they applied their elegant protocol in the enantioselective synthesis of quaternary amino acids 
through the hydrocyanation of ketoimine 44 in the presence of chiral urea organocatalyst 42 to afford the 
aminonitrile 45 in excellent yield and ee. Subsequent nitrile hydrolysis and hydrogenolysis of the N-benzyl 
protecting group yielded the target enantiopure quaternary amino acid 47 in excellent overall yield.42,43 
Subsequent studies have shown that chiral ureas and thioureas can also catalyse the enantioselective addition 







Scheme 10: Asymmetric Strecker synthesis of quaternary amino acids42 
 
 Synthesis of Isoquinolones 
This section describes several key synthetic methods for the formation of dihydroisoquinolones, 
isoquinolones and their derivatives. Firstly, the Bischler−Napieralski reaction is discussed as a classical 
intramolecular method to link arenes with a vicinal N-acyl group (Scheme 11 (a)).46–49 Additionally, C(sp2)-
H activation/metal-catalysed annulation methods are described (Scheme 11 (b)). The final section describes 
two recent syntheses of (dihydro)isoquinolones which exploit the ring closure of N-benzylimines – namely 
addition−cyclisation of chiral sulfonimines using Grignard reagents, and 6π-electrocyclisation−oxidation 
of vinylic species (Scheme 11 (c)).  
 







 Bischler−Napieralski Cyclisation  
The Bischler–Napieralski reaction is an intramolecular electrophilic aromatic substitution used extensively 
for the formation of dihydroisoquinoline derivatives reported by August Bischler and Bernard Napieralski 
in 1893.46–50 The classical approach involves cyclisation of an acylated derivative of phenylethylamine in 
presence of a dehydrating agent such as POCl3, P2O5, FeCl3, AlCl3, PPA or TFAA yielding 3,4-
dihydroisoquinoline derivatives.50 Reduction of the intermediate imine functionality forms a saturated 6-
membered cyclic amine skeleton.51 
From a formamide starting material, the product is an isoquinoline unsubstituted at the 1-position. For 
example, VanAtten and co-workers reported the synthesis of series of 1,2,3,4-tetrahydroisoquinoline-3-
carboxylic acids which inhibit the binding of Ang-II to the AT2 receptor.52 In this methodology, they carried 
out a Bischler–Napieralski reaction of N-formyl phenylethylamine 48 in the presence of P2O5 to form the 
corresponding 3,4-dihydroisoquinoline derivative followed by imine reduction with sodium 
cyanoborohydride to afford 1,2,3,4-tetrahydroisoquinoline 49 (no yield reported) (Scheme 12).50,52  
 
Scheme 12: Bischler–Napieralski reaction in the synthesis of tetrahydroisoquinoline 49 
1-Substituents may be introduced by using alternative amide starting materials. Thus, Kametani and co-
workers reported the total synthesis of (S)-xylopinine 53 starting from L-3,4-dimethoxyphenylalanine 
methyl ester 50 in 10 linear steps.53 Treatment of key acetylated precursor 51 with POCl3 under typical 
Bischler–Napieralski conditions afforded the corresponding 3,4-dihydroisoquinoline derivative 52 (no yield 
reported). 52 was subsequently exploited in the next 8 steps to smoothly furnish (S)-xylopinine 53 as shown 
in Scheme 13.50    
 






Dihydroisoquinolones may be made directly by a starting from an acylated amine at a higher oxidation level 
– in other words, a carbamate or isocyanate. In 2010, Groutas and co-workers used an isocyanate to make 
3,4-dihydroisoquinolone 56 in two steps from DL-phenylalanine derivative 54.54 They initially heated 54 at 
reflux with diphosgene in dioxane to form the key isocyanate intermediate 55 which was subjected to 
Bischler–Napieralski conditions (AlCl3 in CH2Cl2, reflux, 2 h) to furnish the target product 56 in 71% yield 
(Scheme 14).54 
 
Scheme 14: Synthesis of dihydroisoquinolones 56 via Bischler–Napieralski reaction 
 
The Bischler–Napieralski reaction of carbamates has been used to introduce the 1-carbon unit needed for 
the total synthesis of biologically active compounds which constitute essential components of 
Amaryllidaceae alkaloids. Clayden and co-workers have used similar Bischler-Napieralski transformations 
toward the formal synthesis of lycorine derivatives (described later).55 In 2009, Tomioka and co-workers 
accomplished a 13-step total synthesis of the alkaloid (-)-lycorine.56 Carbamate 58 was synthesised from 
substituted benzene 57 in 7 steps, and utilised as the substrate for their key Bischler–Napieralski cyclisation 
step: 58 was treated with POCl3 at 90 °C for 8 h affording the δ-lactam 59 in 95% yield. This material was 
elaborated in five steps to (-)-lycorine 60 (Scheme 15).56 
 
Scheme 15: Application of Bischler–Napieralski in the total synthesis of (-)-lycorine 60 
In a similar fashion to the abovementioned methodology, the Spivey group established a protocol for the 
total synthesis of the alkaloid (+)-clivonine 65, which is a member of the biologically active Amaryllidaceae 
family. This was the second total synthesis of (+)-clivonine 65 and was completed in only 12 steps - shorter 
than the first total synthesis (17 steps) achieved by Irie and co-workers in 1973.57–59 Key intermediate 62 
was synthesised in 7 steps from (±)-enone 61 in 49% overall yield. N-carbamation of 62 with methyl 
chloroformate produced the key carbamate intermediate to which Banwell-modified Bischler–Napieralski 
conditions60,61 were applied to form the δ-lactam 63 in 82% yield. Subsequently, (+)-clivonine 65 was 







Scheme 16: Application of Bischler–Napieralski in the total synthesis of (+)-clivonine 65 
In 2015, Tomioka and co-workers reported a short, efficient total synthesis of (+)-β-lycorane 69 (another 
biologically active member of the Amaryllidaceae alkaloid family) by forming the isocyanate intermediate 
directly.64 Desilylation and ester deprotection of 66 using HCl in ethanol for 30 min at reflux afforded the 
protodesilylated half ester 67 in excellent yield (98%). Subsequent Curtius rearrangement using 
diphenylphosphorylazide (DPPA) in toluene followed by Bischler–Napieralski cyclisation of the isocyanate 
intermediate gave the δ-lactam product 68 in 70% yield. Finally, Amaryllidaceae alkaloid (+)-β-lycorane 69 
was formed in 70% yield by treatment 68 with boranedimethyl sulfide complex. This reaction involved 
three successive chemical transformations: lactam reduction, γ-lactam (5-membered ring) formation 
between the resulting amine and the ester moiety, and reduction of the resulting γ-lactam to directly afford 
(+)-β-lycorane (Scheme 17).64 
 






Recently in 2019, the Sarlah group reported a short (6-7 steps) and scalable  synthetic approach from 
benzene toward the total syntheses of the anticancer Amaryllidaceae alkaloids (+)-pancratistatin, (+)-7-
deoxypancratistatin, (+)-lycoricidine and (+)-narciclasine.65 The group exploited the Bischler–Napieralski-
type reaction to generate the δ-lactam functionality by treating 70 with triphenylphosphine oxide and 
trifluoroacetic anhydride (Hendrickson reagent) in the presence of a Lewis acid (BF3). The reaction yield 
was 87% and the example shown below formed part of the total synthesis of (+)-narciclasine (Scheme 18).  
 
Scheme 18: Key Bischler–Napieralski-type reaction in the total synthesis of (+)-narciclasine 
 
 Metal-catalysed Annulations 
In 2010, Cheng and co-workers reported an effective nickel-promoted annulation of 2-halobenzamides 72 
with alkynes 73 to synthesise isoquinolone derivatives 74.66 After screening several nickel complexes, the 
authors discovered that the optimal catalyst was NiBr2(dppe), with Zn and TEA as additives in dry 
acetonitrile at 80 °C as shown below in Scheme 19. The scope of the method was demonstrated with 19 
examples. 
 
Scheme 19: Nickel-catalysed annulation of 2-halobenzamides 72 
Furthermore, the method was utilised in the formal total synthesis of the alkaloid oxyvicine. First, the 
annulation reaction of 2-bromobenzamide 75 with alkyne 76 under the optimised Ni-catalysed conditions 
gave the corresponding isoquinolone 77 in 83% yield. Subsequent Swern oxidation of the primary alcohol 
77 formed the aldehyde functionality in 95% yield. Finally, the oxyvicine alkaloid 79 was successfully formed 









Scheme 20: Application of nickel-catalysed annulation in the formal total synthesis of oxyavicine 79 
The postulated mechanism for the Ni-catalysed annulation included three stages. Firstly, the formation of 
five-membered nickelacycle 81 through the oxidative addition of 2-iodobenzamide 72 to Ni(0) in the 
presence of TEA (Ni(0) was produced in situ by reduction of Ni(II) by zinc powder). Subsequent migratory 
insertion of the alkyne 73 into the Ni−C bond of complex 81 led to seven-membered nickelacycle 
intermediates 82 or 83. Finally, regioisomers 82 and 83 underwent reductive elimination to afford the final 
isoquinolinones 74 with concomitant regeneration of the Ni(0) catalyst as shown in Scheme 21.67–69 
 
Scheme 21: Postulated mechanism for the formation of isoquinolinone derivatives 74  
The regioselectivity of this reaction was examined by reacting the unsymmetrical alkynes (1-phenyl-1-
butyne 85, and ethyl phenyl propiolate 87) with 2-iodo-N-(p-tolyl)benzamide 84. It was found that the bond 
formation occurred between the arene-substituted carbon of the alkyne with the nickelacycle intermediate 
followed by reductive elimination to afford the final isoquinolin-1-one in which the phenyl group ends up 
distal to the fused arene ring in good regioisomeric ratio. When the 1-phenyl-1-butyne 85 was used, the 
isoquinolinone regioisomers 86a, 86b were formed in 65% and 13% yield respectively (Scheme 22, (a)). In 
case of ethyl phenylpropiolate 87, the isoquinolinone regioisomers 88a, 88b were formed in 82 and 8% 
yield respectively (Scheme 22, (b)). The NOE experiments were used to confirm the structures of 







Scheme 22: (a) Annulation of 84 with 1-phenyl-1-butyne 85 (b) Annulation of 84 with ethyl phenylpropiolate 87 
In 2020, Song and co-workers developed a robust protocol for cobalt-catalysed C(sp2)−H bond 
activation/(4+2) annulation of benzamides with alkynes to synthesise substituted isoquinolone derivatives. 
Notably, the hydroxamic ester acted as both a protecting group for the amide nitrogen and an internal 
oxidant, the N−O bond of which was readily cleaved during the annulation process, rendering the overall 
catalytic cycle redox neutral. The desired isoquinolone derivatives 91 were formed in good to excellent 
yields by reacting the N-(pyridine-2-ylmethoxy)benzamide derivatives 89 with alkynes 90 at 110 °C in 
trifluoroethanol in the presence of Co(OAc)2.4H2O (40 mol%), AgOAc and PivOH. The transformation 
was demonstrated using 34 substrates with up to 94% yield (Scheme 23). Ortho-, meta- and para-substituted 
benzamides were investigated and it was found that the outcome of the reaction relied on the steric 
hindrance about the positions of the substituent on benzamide ring.70 The annulation reaction occurred 
only from less hindered positions explaining the high regioselectivity of the reaction.  
 
Scheme 23: Cobalt-catalysed annulation of N-(pyridine-2-ylmethoxy)benzamide derivatives 89 
 
Only 1-phenylpropyne 92 (unsymmetrical aryl alkyne) was used to investigate the regioselectivity of the 
reaction, where substituted isoquinolones 93a, 93b were formed in a 2:1 regioisomeric ratio in 94% total 







Scheme 24: Cobalt-catalysed annulation of 89 with 1-phenylpropyne 92 
The proposed mechanism of this annulation process is illustrated below.70–83 Firstly, complexation of cobalt 
diacetate with 89a led to the formation of intermediate 94 with the elimination of acetic acid. Cobalt(II)-
containing intermediate 94 was oxidised to cobalt (III) complex 95 by the silver(I) salt, providing the first 
entry point into the catalytic cycle. Next, C(sp2)−H activation of the benzamide through a 
metalation/deprotonation process gave aryl-Co(III) species 96, rendering it active toward coordination with 
the alkyne 90 giving 97. Alkyne migratory insertion into the C−Co bond gave seven-membered cobaltacycle 
98 from which reductive elimination formed the key C−N bond of the isoquinolone. The remotely 
coordinated Co(I) in 99 then underwent oxidative addition into the N−O bond of the hydroxamic ester to 
give intermediate 100 with concomitant restoration of the Co(III) oxidation state. From there, ligand 
exchange gave the isoquinolone 91 accompanied by 2-hydroxymethyl pyridine 101 as a by-product and 
release of the catalytically active Co(III)L3 species able to engage benzamide 89a for the next catalytic cycle 
(Scheme 25) 
 






In a strategy conceptionally similar to Song’s method above, Guimond and co-workers established a 
rhodium(III)-catalysed transformation for the synthesis of substituted isoquinolone derivatives. The 
method was operationally simple, air-tolerant and did not require an external oxidant. Heating N-
methoxybenzamides 102 with alkynes 103 in methanol at 60 °C in presence of [Cp*RhCl2]2 and CsOAc as 
catalysts gave the desired skeletons 104 in good to excellent yields (Scheme 26).83 Similarly to described 
above, the hydroxamic ester functionality served a dual role as both a directing group for ortho-rhodation 
of the C−H bond and an internal oxidant to render the process redox neutral. 
 
Scheme 26: Rhodium-catalysed synthesis of substituted isoquinolone platform 104 
As described above for the related Ni(II) method, Guimond and co-workers showed the effect of using the 
aryl alkyl unsymmetrical alkyne on the regioselectivity of the reaction exemplified with few examples of 
unsymmetrical alkynes. One example, 104a was formed in 75% yield with complete regioselectivity when 
1-phenylpropyne 92 was employed (Scheme 27). In addition, for unsymmetrically-substituted arenes, the 
reaction was completely regioselective with respect to the site of C−H activation: in all cases the aryl 
rhodation occurred at the less hindered of the inequivalent ortho-positions. 
 
Scheme 27: Rhodium-catalysed annulation of N-methoxybenzamides 102 with 1-phenylpropyne 92 
 
A truncated version of the proposed mechanistic pathway is presented in Scheme 28. Key seven-membered 
rhodacycle intermediate 106 was formed via a sequence of C−H activation and alkyne migratory insertion, 
as described above for the related Co(III) process. Subsequent concerted C−N bond formation/N−O bond 







Scheme 28: Postulated mechanism for the formation of isoquinolone derivatives 104 
In 2014, Marsden and co-workers devised a practical synthetic pathway towards the synthesis of 
isoquinolone derivatives 109 by employing vinyl acetate 108 as a cheap and easy-to-handle surrogate of 
acetylene, the latter of which is potentially explosive and difficult to handle.84 The optimal conditions of 
the reaction were reacting N-(pivaloyloxy)aryl amide 107 with vinyl acetate 108 in methanol at 45 °C in the 
presence of catalytic quantities of [Cp*RhCl2]2 and CsOAc. This methodology was characterised by its 
redox-neutral nature, the reasonably mild conditions required for C(sp2)−H activation and the tolerance of 
a wide variety of aromatic substituents. Furthermore, only benign formic and pivalic acids were produced 
as easy-to-remove by-products. The method was applicable to 16 isoquinolone examples and 5 additional 
heteroaryl-fused examples with an average of 77% yield (Scheme 29).  
 
Scheme 29: Isoquinolones 109 by rhodium-catalysed annulation of N-(pivaloyloxy)aryl amide 107  
Several multistep syntheses of isoquinolone derivatives from substituted benzoic acids have also been 
reported based on transition metal-mediated C(sp2)−H activation including with the use of Fe,85,86 Co,71,87,88 
Ni,89–91 Rh,83,84,92–96 Ru,97–99 Pd,100,101 and Ir.102 In 2019, Chen and co-workers were able to establish the first 
one-step oxidative route to isoquinolone derivatives 112 from benzoic acid using rhodium catalysis. Heating 
benzoic acids 110 with N-vinyl formamide 111 at 80 °C in benzonitrile in the presence of [Cp*RhCl2]2, 







Scheme 30: Rhodium-catalysed synthesis of isoquinolone 112 from benzoic acid 
The proposed catalytic cycle begins by the conversion of dimeric rhodium chloride complex A to the active 
monomeric acetate complex B. After ligand exchange with the benzoate substrate, ortho C(sp2)−H activation 
ensues to form the five-membered rhodacycle intermediate 113. Regioselective migratory insertion of N-
vinyl formamide gives the 7-membered rhodacycle intermediate 114 which undergoes ring opening via β-
hydride elimination to give the acyclic rhodium hydride species 115. Subsequent reductive elimination 
affords benzoic acid 116 accompanied by the release of Rh(I) which is oxidised in stiu to Rh(III) by silver(I) 
acetate to re-enter the catalytic cycle. Off-cycle, 116 undergoes dehydrative cyclisation forming N-formyl 
isoquinolone 117 (detected by GC-MS) followed by deformylation to afford the desired isoquinolone motif 
112a (Scheme 31).103  
 









Ackermann and Fenner developed ‘green’ methodology to synthesise substituted isoquinolones through 
ruthenium-catalysed (4+2)-annulation using water as the solvent. Specifically, heating N-
methoxybenzamides 118 with substituted alkynes 119 in water at 60 °C in the presence of the metal catalyst 
[RuCl2(p-cymene)]2 (2.5−5 mol%) and the base KO2CMes (30 mol%) gave isoquinolone motifs 120 (15 
examples) under sustainable conditions (Scheme 32).104 
 
Scheme 32: Ruthenium-catalysed annulation to form isoquinolone platform 123 
Recently, in 2019, Yi and co-workers reported an osmium-catalysed annulation of alkynes 122 and N-
methoxybenzamides 121 to form a broad range of isoquinolone derivatives 123 (35 examples) (Scheme 33). 
They concluded from DFT calculations and experimental mechanistic studies that the reaction proceeded 
via an Os(IV)→Os(II)→Os(IV) catalytic cycle, with the initial Os(II) pre-catalyst ([Os(p-cymene)Cl2]2)  
undergoing HOAc-assisted oxidation to a catalytically active Os(IV) species.105 
 
Scheme 33: Osmium-catalysed annulation to form isoquinolone derivatives 123 
 Other Methods  
Recently, Wei and co-workers devised a strategic method for the synthesis of enantioenriched 1-substituted 
dihydroisoquinolones motifs 126 with 27 examples.106 They smoothly synthesised chiral N-sulfinyl aryl 
aldimine 124 in 4 steps according to the known precedent literature.107 124 was then reacted with Grignard 
reagents in the presence of the essential 2,2'-bipyridyl ligand at −15 °C for 1 h to afford N-sulfinyl 
dihydroisoquinol-3-one motifs 125 with excellent diastereoselectivity (dr > 99:1). The importance of the 
ligand in the reaction was attributed to stabilisation of the Grignard reagent, preventing side reactions which 
occurred in its absence, and to augment the diastereoselectivity of the reaction. Subsequent cleavage of the 
chiral auxiliary was successful at room temperature using HCl/MeOH generated in situ from oxalyl chloride 
to afford 1-substituted dihydroisoquinol-3-ones 126 (Scheme 34).  
 







This methodology was applied to the straightforward total synthesis of (S)-(+)-cryptostylline 129 which was 
prepared in 3 steps with excellent yield after the removal of the auxiliary as shown below in Scheme 35. 
 
Scheme 35: Application in the total synthesis of (S)-(+)-cryptostylline 129 
 
Oh and co-workers reported two straightforward procedures to access N-aryl-isoquinolones 133 via aerobic 
oxidation mediated by copper(II) acetate (one-pot method) or palladium(II) acetate (two-step method).108 
The one-pot method involved heating commercially available 2-vinylbenzaldehyde 130 and aniline 
derivatives 131 under air in DMSO at 150 °C in the presence of Cu(OAc)2 (2 equiv) and MgSO4. 
Mechanistically, the reaction proceeded via 1) imine formation, 2) thermal 6-electrocyclisation and 3) 
installation of the lactam’s carbonyl group through aerobic oxidation. Alternatively, 133 was synthesised in 
a stepwise approach, which enabled the oxidation (second step) to be amenable to palladium catalysis. Thus, 
the imine 132 was first formed (and isolated) by condensation of 2-vinylbenzaldehydes 130 with aniline 
derivatives 131. Next, heating the imine aerobically in DMSO at 150 °C in the presence of a catalyst system 
comprising Pd(OAc)2/PPh3 and Na2CO3 furnished N-aryl-isoquinolones 133 as demonstrated with 20 
examples (Scheme 36). 
 








The proposed mechanism of this aerobic oxidation strategy starts with condensation of 2-
vinylbenzaldehyde 130a with aniline derivatives to form the Schiff base 132a, followed by thermal 6-
electrocyclisation forming dihydroisoquinoline 134, which rearomatises to isomer 135. From 135, the 
mechanistic course diverges based on the transition metal utilised. In the presence of copper(II) acetate, 
benzylic C−H activation of 135 occurs to give copper complex 136. Formal oxygen insertion into 136 
provides the peroxy copper complex 137 which decomposes to the desired N-aryl isoquinolones 133a 
accompanied by the loss of acetic acid and Cu(II) oxide.  
 
The second pathway involving palladium catalysis is initiated by the in situ reduction of Pd(II) to Pd(0) by 
PPh3. Subsequent reaction of Pd(0), O2 and 135 leads to the formation of Pd peroxide complex 138. 
Reductive elimination of the C−Pd(II)−O bond gives the peroxide derivative 139 and releases Pd(0) to start 
another catalytic cycle. Finally, dehydration of 139 yields the desired target motif 133a (Scheme 37). 
 













































2 Dihydroisoquinolones by Cyclisation of Aromatic Amino Acids 
Abstract 
This chapter describes the diastereoselective synthesis of substituted dihydroisoquinolinone 
scaffolds. Imidazolidinone derivatives of a range of aromatic α-amino acids undergo a highly 
diastereoselective one-pot tandem acylation/cyclisation followed by a mild intramolecular 
Friedel−Crafts acylation (promoted by potassium iodide) that corresponds to a Bischler–Napieralski 
reaction. The lactam products were amenable to further regio- and diastereoselective 
functionalisation to generate a library of medicinal-like dihydroisoquinolinones in enantioenriched 
form.   
 
 
The contents of this chapter have been communicated in:55,109  
Amer, M. M.; Carrasco, A. C.; Leonard, D. J.; Ward, J. W.; Clayden, J. Org. Lett. 2018, 20, 7977. 
Amer, M. M.; Abas, H.; Leonard, D. J.; Ward, J. W.; Clayden, J. J. Org. Chem. 2019, 84, 7199. 
Author contributions for the Org. Lett. 2018 publication are as followed: Ana C. Carrasco (Erasmus 
master student) performed initial experiments, Mostafa M. Amer repeated the initial experiments, 
and performed the remainder of the experimental work. The manuscript was drafted by Mostafa M. 
Amer then refined and edited by Mostafa M. Amer, Daniel J. Leonard, Jonathan Clayden and John 
W. Ward. X-ray diffraction analysis was performed by Dr. Hazel Sparkes and Dr. Natalie Pridmore 
with the University of Bristol X-ray crystallographic service. 
Author contributions for the J. Org. Chem. 2019 publication are as followed: Mostafa M. Amer 
performed all experimental work. Hossay Abas added few experiments. The manuscript was drafted 
by Mostafa M. Amer then refined and edited by Mostafa M. Amer, Jonathan Clayden, Hossay Abas, 
Daniel J. Leonard, and John W. Ward. X-ray diffraction analysis was performed by Dr. Hazel Sparkes 






  Previous Work within the Clayden Group 
In 2014, while investigating the direct acylation of trans phenylalanine derived carbamoyl chloride 140, a 
remarkable intramolecular cyclisation was discovered.110 The trans isomer 140 was treated with N-
methylaniline 142 and potassium iodide to form urea derivative 145 as major product, but surprisingly 
benzolactam 143 was also formed as the minor cyclised product. Treatment of cis isomer 141 with the same 
conditions gave urea derivative 144 as the sole product, suggesting that the cis isomer 141 fails to undergo 
this kind of cyclisation. A trans:cis (typically 60:40) mixture of N-chloroformyl imidazolidinones 140, 141 
was formed over three steps starting from different amino acid derivatives 19 as illustrated below in Scheme 
38.  
 
Scheme 38: Synthetic route toward α-arylated amino acids 
 Aim of the Project   
The aim of this project was to establish an efficient and diversity-oriented practical synthetic route toward 
novel analogues of architecturally diverse drug-like motifs 148. These interesting motifs 148 can be 
amenable to additional derivatisation. For example, a further diastereoselective functionalisation followed 
by hydrolysis may be possible which should  lead to families of enantiomerically-enriched novel 
dihydroisoquinolone derivatives 149 that can be considered as cyclic, quaternary amino acids  (Scheme 39, 
route A). A secondary aim was to establish a complementary method toward the synthesis of novel 
dihydroisoquinolones with stereocentres from inverted those accessible in the first route (Scheme 39, route 
B).  In route B, the aim was to initially alkylate N-chloroformylimidazolidinones 140 followed by Friedel-






carbonylative reaction. The obtained products should be amenable to acid-catalysed hydrolysis to form the 
corresponding dihydroisoquinolone derivatives 151.    
 
Scheme 39: Two possible avenues for functionalisation of amino acid derived trans imidazolidinones 140 
 
In order to achieve these aims, we initially had to optimize a recent methodology developed within the 
Clayden group in order to enhance its potential as shown below in Scheme 40. This would include an 
optimisation of a one-pot tandem acylation/cyclisation of imine precursor 153, and alkylation steps then 
expanding the methodology to a broad substrate scope to form versatile structures 148 of expected 
medicinal potential. This optimisation of the one-pot tandem acylation/cyclisation required an investigation 
into obtaining the trans imidazolidinone 154 in good to excellent yield with high diastereoselectivity. 
Obtaining trans imidazolidinone 154 with high selectivity was vital because previous work suggested that 
the corresponding cis diastereomer imidazolidinone 155 does not undergo intramolecular Friedel-Crafts-
like cyclisation presumably due to the large steric effect of the bulky t-Bu group.  
 






According to the ‘Self-Regeneration of Stereocentres’ principle of Dieter Seebach, imidazolidinone motifs 
such as 158 can be deprotonated using organolithium bases to give non-racemic enolates 159 which can 
undergo stereoselective alkylation when reacted with a wide range of electrophiles, such as alkyl halides or 
carbonyl-containing compounds, followed by hydrolysis to give quaternary amino acid derivatives 161.111  
It is anticipated that the isoquinolinone-derived structure 156 generated through the above ring-closing 
reaction may also be diastereoselectively alkylated in a similar manner to form compound 163 through non-
racemic enolate 162. 163 therefore can undergo diastereoselective alkylation, and subsequent hydrolysis to 
afford highly functionalised cyclic quaternary amino acid motifs 164 (dihydroisoquinolone-derived motifs) 
(Scheme 41). 
   
 
Scheme 41: Projected application of SRS to benzolactam obtained by Friedel-Crafts cyclisation 
 
  Diastereoselective formation of N-chloroformylimidazolidinone derivatives   
 Phenylalanine 
Phenylalanine is an essential α-amino acid which acts as a vital building block on the backbone of the 
protein structure in the body. It is described as essential because it cannot be synthesized by the human 
body. L-Phenylalanine is a precursor for various biological amino acids for example, Tyrosine, Dopamine, 






Initially, phenylalanine derivatives were used as model substrates as they are commercially available, 
inexpensive, easily handled, and the products are expected to have potential biological activity.113 The 
synthetic methodology toward these interesting skeletons was achieved by starting from the addition of 
MeNH2 (33% in EtOH) to enantiomerically pure L-phenylalanine ester hydrochloride 165 to afford 166 in 
high yield (Scheme 42).   
 
Scheme 42: Synthesis of phenylalanine derived N-methylamide 166 
 
The second step involves nucleophilic addition of the free amino group of N-methyl amide of phenylalanine 
166 with the carbonyl functional group of pivaldehyde followed by dehydration to form corresponding 
imine 153a. This intermolecular condensation step was carried out in presence of magnesium sulfate as a 
drying agent in dichloromethane for 2 h to afford 153a in excellent yield as depicted below in Scheme 43.  
 
Scheme 43: Synthesis of phenylalanine derived imine 153a 
 
The crucial trans imidazolidinone carbamoyl chloride moiety 154a was installed through one-pot tandem 
acylation/cyclisation of imine precursor 153a using phosgene (15% in toluene). It was found that this key 
reaction initially led to a mixture of 154a and 155a in moderate yield (60% combined) with modest 
diastereoselectivity (60:40, trans:cis) as shown below in Scheme 44. As aforementioned, the cis diastereomer 
155a does not perform the key intramolecular cyclisation, therefore we set out to improve the trans 
selectivity and yield.  
 







 Optimising the Formation of the N-Chloroformylimidazolidinone 154a 
 Initial Condition Screen  
Initially, solvents and temperature were investigated with 153a as a model substrate and employing 
phosgene or triphosgene (Table 1). We found that treatment of 153a with triphosgene (0.5 equiv. – 1.5 
equiv. of phosgene) in dry dichloromethane at -78 °C to rt for 18 h provided a good selectivity for the trans 
isomer (81:19, trans:cis), but with poor mass recovery (Table 1, entry 1). Because the yield was low, we 
decided to increase the temperature to 40 °C which gave complete consumption of starting material but no 
increase in yield (Table 1, entries 2 and 3). Surprisingly, the selectivity of the reaction slightly increased as a 
consequence of elevating the reaction temperature. However, once again the recovered mass of the crude 
product was still unsatisfactory (Table 1, entry 2). Running the reaction in toluene moderately improved 
the recovered mass with phosgene at 60 °C for 18 h being optimal (Table 1, entry 5). In the light of these 
results, we concluded that the temperature has a great impact on the diastereoselectivity of this reaction. 
The lower the reaction temperature, the higher diastereoselectivity was obtained. The mass of the crude 
material from the reaction was higher when phosgene solution (15% in toluene, 1.5 equiv.) was added to 
imine precursor 153a in dry dichloromethane at (rt to 40 °C) for 18 h, however the ratio of trans/cis isomers 
reduced to some extent (Table 1, entry 6). Finally, when the same reaction was carried out at room 
temperature for 18 h using an excess of phosgene solution (15% in toluene, 2.5 equiv.), a significant increase 
in both mass recovery resulted and the targeted product was isolated in 59% yield with excellent 
diastereoselectivity (Table 1, entry 7). A notable observation was that a precipitate started to form after 10 
minutes in toluene and remained in the reaction mixture throughout. However, when the reaction was 
performed in dichloromethane, the precipitation formed after 15 min, but redissolved after 30 min of the 
reaction. Also, the low crude mass recovery was possibly due to the formation of the salt precipitate which 
was lost in the aqueous layer during work-up. 
Table 1: Initial condition screen for the formation of phenylalanine derived carbamoyl chloride 154a 
 
Entry Solvent Temp Reagent Crude mass recovereda Trans : Cis  
1b CH2Cl2 -78 oC to rt Triphosgene 32% 81 : 19 
2b  CH2Cl2 rt to 40 oC Triphosgene 35% 54 : 46 
3b CH2Cl2 -78 oC to 40 oC Triphosgene 35% 95 : 5 
4b Toluene -78 oC to 100 oC Triphosgene  47%  57 : 38 
5b Toluene -78 oC to 60 oC Phosgene  60%  96 : 4 
6b CH2Cl2 rt to 40 oC Phosgene  68%  89 : 11 
7b CH2Cl2 rt Phosgene  94% (59% isolated yield) 96 : 4 







 Condition Screen- Additives 
The precipitate formed in the reaction was assumed to be an imidazolidinone hydrochloride salt which 
would be unreactive to phosgene and therefore require a base to neutralise the hydrogen chloride generated 
in the reaction. We decided to perform the reaction in dichloromethane without any base only for one hour, 
then separate the white solid intermediate from the solution and fully characterise it. The solid precipitate 
was exclusively the trans cyclic imidazolidinonium salt 167. At this point, the NOE experiment was essential 
in order to see the correlation between proton 2, and proton 5 and their environment in space. When 
proton 2 was irradiated, it correlated with N-CH3, and the methyl protons of the t-Bu group. On the other 
hand, when proton 5 was irradiated, it correlated with the benzyl protons and t-Bu protons, therefore 
confirming that proton 5 was on the same face as the t-Bu group (Figure 5).  
 
Figure 5: Illustrated NOE in trans cyclic imidazolidinone skeleton 
 
In order to overcome the generation of the hydrochloride salt, we searched for some bases to neutralise 
the hydrochloric acid produced or to deprotonate the cyclic imidazolinonium salt. We first opted for organic 
bases for example triethylamine and lutidine. Unfortunately, there was no conversion to the target product 
when phosgene solution (15% in toluene, 2.5 equiv.) and TEA were added to imine substrate 153a in dry 
dichloromethane (Table 2, entry 1-2). Lutidine gave a poor diastereoselectivity, and a marginal increase in 
mass recovery (Table 2, entry 3). 5% DMAP gave poor mass recovery but higher diastereoselectivity than 
the other bases employed before (Table 2, entry 4).  
Table 2: Effect of organic base addition on 154a formation 
 
 
Entry Temp Base Mass recovereda Time Trans: Cis 
1 -78 °C (1 equiv.) TEA Mostly SM 4 h - 
2 -78 °C to rt (1 equiv.) TEA Mostly SM 8 h - 
3 rt to 40 °C (1 equiv.) Lutidine 77% 18 h 37 : 63 
4 rt 5% DMAP 50% 18 h 85 : 15 






 Condition Screen- Addition of Inorganic Base 
Inorganic bases were also investigated in an attempt to neutralise the precipitated HCl salt and promote 
redissolution of the freebase of 168. It was found that, the cascade reaction was possible with inorganic 
bases using phosgene or triphosgene in dry dichloromethane at rt for 18 (Table 3). Notably, the 
diastereoselectivity of the process was better than that achieved from the process using organic bases as 
additives (Table 3, entries 1-4).   
Table 3: Effect of inorganic base addition on 154a formation 
 
                       
 
 
                         
aThese experiments were carried out in dichloromethane at room temperature. 
 Further Condition Screen 
Alongside investigations into additives, the concentration of the reaction was also varied in an attempt to 
keep the imidazolidinone HCl salt in solution (Table 4). It was found that running the reaction in THF 
using phosgene solution (15% in toluene, 2.5 equiv.), with slow addition of the imine substrate 153a over 
30 min, provided the desired diastereomer in 70% isolated yield and high trans selectivity after 48 h (Table 
4, entry 3). This preliminary result was promising, since this cascade reaction was possible to proceed 
without any external additives.   
Table 4: Effect of solvent and reagent variations 
 
Entry Solvent Reagent Mass recovery Time Isolated yield  Trans: Cis  
1a CH2Cl2 Phosgene  71% 45 h 48% (50%)
 b 95 : 5 
2a CH2Cl2 Triphosgene 100% 18 h (54%) b 96 : 4 
3a THF Phosgene 100% 48 h 70 % 99 : 1 
a These experiments were carried out at rt. b Internal standard yield. 
Entry Reagent Base (1 equiv.) Yield/ (Int. std) Trans:Cis Isolated yield 
1 Phosgene NaHCO3 - 96 : 4 49% 
2 Phosgene  K2CO3 - 93 : 7 26% 
3 Triphosgene  K2CO3 25% 97 : 3 22% 






 Final Optimisation 
With good yield and diastereoselectivity obtained in THF, we decided to probe this solvent with conditions 
previously optimised in dichloromethane. We discovered that slow addition of the imine substrate 153a 
over 30 min to a solution of phosgene (15% in toluene, 2.5 equiv.) in THF at 0.1 M, followed by addition 
of pyridine (2 equiv.) after 2 h of reaction afforded an excellent 86% yield and the trans imidazolidinone 
154a with >99:1 diastereoselectivity (Table 5, entry 1).  
When the reaction was carried out under the same conditions for less time, the isolated yield dropped to 
78% with the same diastereoselectivity (Table 5, entry 2). In order to decrease reaction duration, we 
increased the reaction concentration from 0.1 M to 0.5 M. The reaction was complete after only 2.5 h with 
84% yield and >99:1 diastereoselectivity (Table 5, entry 3).   
Table 5: Final optimisation studies of 154a synthesis 
 
Entry Conc. Mass recovery Time Isolated yield Trans: Cis 
1 0.1 M 94% 45 h 86 % >99:1 trans 
2 0.1 M 90% 18 h 78 % >99:1 trans 
3 0.5 M 98% 2.5 h 84 % >99:1 trans 
                                 a These experiments were carried out in dry THF using Phosgene at rt. 
 
 Proposed Mechanism 
A plausible mechanism for the formation of the trans imidazolidinone carbamoyl chloride moiety 154a is 
proposed in Scheme 45. This reaction mechanism proceeds through three main steps. The first step 
involves acylation of the imine’s nitrogen of precursor 153a by phosgene giving rise to acylated intermediate 
168, which immediately undergoes intramolecular cyclisation through nucleophilic addition onto the 
iminium bond of 168 to afford the cyclised corresponding desired product 154a. The second step includes 
protonation of 153a at the imine nitrogen to from intermediate 169 followed by intramolecular cyclisation 
of the amide on to the iminium ion and self-sequestering of the regenerated HCl (by the newly-formed 
tertiary amine) to give cyclic imidazolidinonium chloride salt intermediate 167.  Finally, conversion of 167 
to the corresponding final product 154a is then carried out by addition of pyridine to deprotonate the 
hydrochloride salt, followed by a formal acylation to deliver the observed final product 154a and pyridinium 








Scheme 45: Plausible mechanism of phenylalanine derived carbamoyl chloride 154a formation 
 
These results are in agreement with Seebach et al, who report that trans N-acyl imidazolidinones are formed 
under kinetic control condition, via a pathway which requires a smaller activation energy.111 However, the 
cis isomer of the imidazolidinone motif 155a can be synthesized under thermodynamic control. In the 
acylated intermediate 168, the amide amine attacks the iminium carbon from the bottom face which in turn 
forces the t-Bu to point down and the geminal proton to face up as shown below in Scheme 46. Hence, the 
cyclisation leads to trans isomer 154a formation at lower temperature under kinetic control when no base is 
present at the start of the reaction. Employing base at the beginning of the reaction forms the cis isomer 
alongside the trans isomer (mentioned earlier in optimisation section 2.3.2.2).  
 
Scheme 46: Rationalisation for the formation of trans isomer 154a under kinetic control 
 
Some of thermodynamically cis isomer 155a may also be formed alongside with the trans isomer 154a if the 
trans cyclic imidazolidinonium chloride salt intermediate 167 is allowed to epimerise. Conducting the 
reaction at elevated temperatures (> 0 °C) leads intermediate 167 to undergo ring opening via an imine 







Scheme 47: Plausible mechanism of trans imidazolidinone salt 167 conversion to cis isomer 155a 
The question presents itself is which isomer is less hindered and more stable. Although the trans epimer 
may appear less hindered, it is in the cis epimer the t-Bu and benzyl groups are both in equatorial positions 
making it more stable isomer by having less repulsive forces to each other as shown in (Figure 6, (a)). 
Conversely, in trans isomer, the t-Bu and benzyl groups are in equatorial and axial positions, making it less 
stable isomer as illustrated in (Figure 6, (b)). Previous work within the group has furthermore shown that 
reactions including cis epimer were faster and easier than the corresponding trans isomer.110 
 
Figure 6: (a) Puckered shape of cis conformer 155a, (b) Puckered shape of trans conformer 154a 
 Synthesis of Pivaldimine Derivatives of Amino Acids 
Wide range of the pivaldimine derivatives of amino acids (153c-h, 153j-n) were synthesized in excellent 
yields over two steps from their corresponding amino acid esters following the literature precedent as 
shown below in Table 6. The rest of the pivaldimine derivatives of amino acids (153a-b, 153i, 153o-r) were 
synthesized in good to excellent yields over three steps (see experimental section) starting from their 
corresponding amino acids as shown below in Table 6. Finally, tryptophan substrate 153m was synthesized 







Table 6: Scope of the pivaldimine 153 formation 
 
Entry Amino acid Product R2 Total isolated Yield (%) 
1 L-Phe 153a Et 96% 
2 L-Tyr(OBn) 153b Me 95% 
3 L-Dopa(OMe)2 153c Me 93% 
4 3-Fluoro-L-phe 153d Me 95%  
5 4-Nitro-L-phe 153e Me 94%  
6 3-(1-naphthyl)-L-Ala 153f Me 94%  
7 3-(2-naphthyl)-L-Ala 153g Me 95% 
8 L-Homophe 153h Me 89% 
9 D-Phgly 153i Me 88% 
10 2-(2-Furyl)-L-Ala 153j Me 80% 
11 2-(2-thionyl)-L-Ala 153k Me 94% 
12 2-(3-thionyl)-L-Ala 153l Me 91% 
13b L-Trp(NTs) 153m Me 86% 
14 L-Algly 153n Me 84% 
15b L-Ala 153o Et 90% 
16c L-Leu 153p Me 91% 






 Scope of Diastereoselective Formation of trans N-Chloroformyl imidazolidinones  
After the optimal reaction conditions were established, the substrate scope was explored using a variety of 
amino acid precursors having aromatic rings with electron-donating, neutral, and electron-withdrawing 
substituents. The pivaldimine derivatives of amino acids starting materials 153a-r were synthesized in 
excellent yields following the literature precedent as shown above in Table 6. Subsequent tandem 
acylation/cyclisation of these imine precursors 153i was straightforward to form the corresponding trans N-
chloroformyl imidazolidinones 154 in excellent yields, with excellent diastereoselectivity (Scheme 48). 
Pleasingly, the scope of the reaction given trans products included carbocyclic, heterocyclic, and aliphatic 
side chains with high diastereoselectivity in all cases. Following our optimum procedure, we observed that 
N-tosyl-protected L-tryptophan derivative 154m can be easily formed, but when a Bn protecting group was 
used instead, the product underwent a subsequent intramolecular Friedel-Crafts cyclisation to form 156n 
starting from imine precursor 182 (discussed later). Presumably, the stronger electron-withdrawing tosyl 
group on the indole-nitrogen deactivates the ring towards a Friedel-Crafts cyclisation compared to the mild 
electron donating Bn group on the indole ring which retained sufficient nucleophilicity for the cascade 
cyclisation reaction to form the Friedel-Crafts product 156n. We obtained X-ray crystal structures of 154a, 
154c-e, 154m, 154n and 154p to prove the relative stereochemistry of these isomers (see experimental). 
Importantly, this phosegenation reaction was scalable; it was successfully performed on a 25-50 g scale for 
selected substrates (154a, 154b), and on a 5-10 g scale for the rest of the scope (see experimental). Also, it 
was found that only 1.5 equivalents of phosgene were required to afford the corresponding products in 
high yields. It is important to highlight that these trans N-chloroformyl imidazolidinones unusually exhibit 
E and Z rotamers in their room temperature NMR spectra with respect to the carbamoyl chloride 
functionality, with different ratios depending on the substrates. We detected the ratios from 1H NMR 
analysis of the pure products and this observation was reinforced by X-ray crystal structures in few cases 
(Appendix 2). Crystal structures of major and minor conformers of 154c are shown below in Figure 7.   
 
Figure 7: (a) Crystal structure of minor conformer of 154c, (b) Crystal structure of major conformer of 154c 
      
 







Regarding the amino acid histidine, although the derived imine precursor was prepared in good overall 
yield, unfortunately the acylation/cyclisation reaction using the optimal conditions failed to give the desired 
product and a complex mixture of products was obtained. The challenge arises from the presence of a 
basic/nucleophilic nitrogen in the imidazole ring which could undergo a phosgenation alongside the imine 
nitrogen. 
 
Scheme 48: Diastereoselective cyclization of pivaldimines 153 to form 154ii 
 
 






1H NMR spectrum (Figure 8) showed E and Z rotamers of trans isomer 154a in (55:45 ratio). On the 
















Figure 9: 1H NMR (400 MHz, CDCl3) of cis N-chloroformyl imidazolidinone 155a110  
 
  












 Intramolecular Friedel-Crafts Acylation of Amino acid Derivatives 
 Initial Investigation of the Reaction Scope 
Williams and co-workers reported that the addition of stoichiometric alkali metal iodides was important in 
accelerating the coupling reaction between weak nucleophiles (heteroarenes, sulfonamides) and acyl 
chlorides 173 as shown later in section (Scheme 49).114 As described in the Finkelstein-type reaction, they 
hypothesized that the metal iodide functioned as an activating agent for the acyl chloride by generating the 
more electrophilic, transient acyl iodide 174 in situ. It was rationalized that the acyl iodide functionality was 
more reactive than the corresponding acyl chloride owing to its higher electronic dipole polarizability and 
poor overlap of the carbonyl π* orbital with the iodine lone pairs.  
 
Scheme 49: Use of metal iodides as activating agents for acyl chloride reactions 
In the light of the above described literature, we employed potassium iodide (1.1 equiv.) as an activating 
agent for the acyl chloride precursors. Initially, the reaction was tested on four model substrates derived 
from aryl-substituted phenylalanines. Treatment of trans phenylalanine-derived carbamoyl chloride 154a 
with potassium iodide (1.1 equiv.), and 2,6-lutidine (2.0 equiv.) in dry toluene at 170 °C for 2 h under 
microwave irradiation provided the desired product 156a in 90% yield (Table 7, entry 1). However, when 
the reaction was carried out with the 4-nitrophenylalanine derivative 154e, the cyclisation was unsuccessful 
even after prolonged reaction time and elevated temperature leading to decomposition of starting material 
during the reaction (Table 7, entry 2). When the same conditions were applied to the 3-fluorophenylalanine 
derivative 154d, the reaction did not go to completion despite a 2 h reaction time (Table 7, entry 3). The 
reaction produced 34% of the para regioisomer 156c, alongside 14% of the ortho regioisomer 156ca and 
49% starting material was recovered. Finally, when the same reaction was carried out on the 3,4-
dimethoxyphenylalanine derivative 154c, the product 156b was afforded in excellent yield and as a single 
regioisomer (Table 7, entry 4). In the light of these preliminary results, we concluded that the reaction was 







Table 7: Initial substrate screen of Friedel-Crafts cyclisation 
  
Entry Substrate Derived From Temp (ºC) Yield (%) Recovered SM 
1a Phenylalanine 170 90% – 
2b 4-Nitrophenylalanine 170, 200 Decomposition  – 
3a 3-Fluorophenylalanine 170 (34%) para, (14%) ortho 49% 
4a 3,4-Dimethoxyphenylalanine 170 97 % – 
       a These experiments were conducted for 2 h. b This experiment was conducted for 2 h at 170 °C, then 2 h at 200 °C. 
 
 Condition Screen 
Initially, solvents and temperature were examined with the 3-fluorophenylalanine derivative 154d as a model 
substrate (Table 8). It was found that complete consumption of the starting material could be achieved by 
increasing the reaction time to 4 h when using toluene as the solvent in the microwave reactor, providing 
the desired product 156c in 88% yield (Table 8, entry 1). In an attempt to reduce the reaction time, the 
reaction was repeated in a more polar solvent, CH3CN, instead of toluene. Employing the same number of 
of equivalents of potassium iodide and 2,6-lutidine, this 1 h reaction gave rise to a mixture of regioisomers 
156c, 156ca in excellent combined yield (96%) but only modest selectivity (73:23, para:ortho) (Table 8, entry 
2). Fortunately, the regioselectivity of the reaction was dramatically increased as a consequence of reducing 
the reaction temperature; however, the isolated yield was unsatisfactory (Table 8, entry 3). When the 
reaction was submitted for longer time (2.5 h) under the same conditions and temperature, only the para 
regioisomer 156c was observed, which was isolated in 82% yield. (Table 8, entry 4). Increasing the reaction 
temperature to 110 or 120 °C led to the formation of ortho regioisomer 156ca in increasing amounts (Table 
8, entries 5 and 6). Finally, the reaction was attempted at 150 °C for only 5 min; these conditions afforded 






However, the ortho regioisomer was still formed in 3% yield, although the two products could be readily 
separated by flash chromatography (Table 8, entry 7). This result indicated that the cyclisation reaction was 
significantly faster in polar solvents such as CH3CN than in toluene. 
Table 8: Condition screen for the 3-fluorophenylalanine derived carbamoyl chloride 154d 
 
 




                                  a combined isolated yield of the regioisomers after separation by Chromatography. 
 Substrate Scope 
After the optimal reaction conditions had been established (Table 8, entry 7), the substrate scope was 
explored using a variety of alternative amino acid precursors having unsubstituted or electron-rich aryl 
moieties. 3,4-Dimethoxyphenylalanine 154c underwent smooth cyclisation in 5 min, yielding a separable 
mixture of regioisomers in excellent combined yield (94%) and high regioselectivity (89:5 para:ortho) (Table 
9, entry 1). The tyrosine-derived species showed lower reactivity than the 3,4-dimethoxyphenylalanine 
example (75% yield), (Table 9, entry 2). Regarding the phenylglycine substrate, appreciative amounts of the 
cyclised product 156h were only obtained after prolonged reaction time. Complete consumption of the 
starting material was observed after 1 h; however, only 38% yield of the desired product was obtained, 
suggesting significant substrate degradation or a competing reaction pathway (Table 9, entries 3-4). It is 
worth mentioning that the reaction was significantly slower with the phenylglycine derivative compared to 
the others and also the yield was lower, this may be due to the reduced flexibility in the system due to the 
lack of a methylene linker compared to the phenylalanine-type substrates and perhaps increased ring strain 
in the product. 
Entry Solvent Temp (ºC) Time Isolated Yield (%) Para:ortho ratio 
1 Toluene 170 4 h 88% Only para 
2 CH3CN 170 1 h a96%  73:23  
3 CH3CN 100 1 h 40% Only para 
4 CH3CN 100 2.5 h 82% Only para 
5 CH3CN 110 1.5 h a83%  81:2 
6 CH3CN 120 1 h a80% 70:10 






Table 9: Substrate scope of Friedel-Crafts cyclisation 
 
Entry Substrate Time Yield (%) 
1 3,4-Dimethoxyphenylalanine 5 min 89% para, 5% ortho 
2 Tyrosine 5 min 75% 
3 Phenylglycine 5 min – 
4 Phenylglycine 1 h 38% 
                             a These experiments were carried out at 150 °C 
 Optimisation of 3,4-Dimethoxyphenylalanine Cyclisation 
In a continuation of our research into this novel Friedel-Crafts cyclisation reaction, the previously optimised 
conditions were further investigated on the 3,4-dimethoxyphenylalanine derivative 154c (Table 10). When 
smaller amounts of 2,6-lutidine (1.1 equiv.) were employed, the reaction was still successful and so this 
quantity was used henceforth. Surprisingly, the reaction was complete after only 2 min, affording both the 
para 156b (91%) and ortho regioisomers 156ba (9%) (Table 10, entry 1). In an attempt to limit formation of 
this undesired ortho regioisomer, the effect of decreasing the reaction temperature was studied. Executing 
the reaction at both 130 °C and 100 °C gave complete conversion of the starting material after 5 min and 
30 min, respectively, with a marginal decrease in product regioselectivity (88:12 para:ortho) (Table 10, entries 
2-3). When the reaction was conducted in DMF at 100 °C, completion was achieved in 5 min with a slightly 
higher regioselectivity (91:9 para:ortho) noted (Table 10, entry 4). Encouraged by the results obtained, the 
conversion in CH3CN was studied at 170 °C. Remarkably, the reaction was complete after only 30 sec 
giving virtually identical regioselectivity to before (90:10 para:ortho) (Table 10, entry 5). Indeed, it was 
discovered that full conversion could be achieved in as little as 10 sec without impacting the regioselectivity 
of the reaction (Table 10, entries 6-7). In conclusion, it is clear that a balance between time and temperature 
is critical to achieving good results in this Friedel-Crafts cyclisation. Lessening reaction duration and 






Table 10: Optimisation of Friedel-Crafts cyclisation of 3,4-dimethoxyphenylalanine derivative 154c 
    
Entry Solvent Temp (ºC) Time Regioisomer ratio 
1 CH3CN 150 2 min 91:9 
2 CH3CN 130 5 min 88:12 
3 CH3CN 100 30 min 88:12 
4 DMF 100 5 min 91:9 
5 CH3CN 170 30 sec 90:10 
6 CH3CN 170 20 sec 90:10 
7 CH3CN 170 10 sec 91:9 
 
 Friedel-Crafts Cyclisation of 4-Nitrophenylalanine 
The cyclisation of the 4-nitrophenylalanine substrate 154e was attempted using potassium iodide (1.1 equiv.) 
and 2,6-lutidine (2 equiv.) in CH3CN (1 M) at 170 °C. Despite complete consumption of 154e, only a 20% 
yield of the cyclised species 156d was obtained (Table 11, entries 1). Repeating the reaction in DMF allowed 
it to be carried out over reduced time and at significantly lower temperature, leading to a 30% isolated yield 
of 156d (Table 11, entries 2). Unfortunately, all further attempts to optimise this reaction proved 
unsuccessful. 
Table 11: Attempted cyclisation of 4-nitrophenylalanine derivative 154e 
 
Entry Solvent Temp (ºC) Time Yield (%) Unknown side product 
1 CH3CN 170 30 min 20% 15% 








 Investigating Additives in the Friedel-Crafts Cyclisation 
The question that presents itself is whether this interesting cyclisation proceeds via a transient acyl iodide 
or not, and also whether 2,6-lutidine has a significant role in the reaction. To be able to answer these 
questions, three experiments were undertaken. Firstly, the cyclisation reaction of compound 154a was 
performed in the absence of potassium iodide. Under these conditions, the reaction did not reach 
completion even after 30 min of microwave irradiation at 150 °C (Table 12, entries 1) (cf. 100% conversion 
after 5 min with KI – Table 1, entry 1). Secondly, an experiment was conducted without the addition of 
2,6-lutidine (Table 12, entries 2). In the absence of base, only trace amounts of the desired product 156a 
were observed after 30 min of microwave irradiation and mostly starting material was observed by 1H 
NMR analysis. Finally, when the reaction was carried out without any additives (neither potassium iodide 
nor 2,6-lutidine added), only very slight conversion to cyclised product was detected in spite of the reaction 
time being 2 h (Table 12, entries 3). In conclusion, we can emphasise that both potassium iodide and 2,6-
lutidine have major roles in the Friedel-Crafts cyclisation. KI is used as an activating agent, facilitating the 
formation of a transient and highly reactive carbamoyl iodide under the reaction conditions, which, in turn, 
accelerates the rate of the ring closing reaction. 2,6-Lutidine also appears to be vital to the reaction as it acts 
to neutralise any HCl and HI generated in the cyclisation, providing another driving force for the forward 
reaction. 
Table 12: Investigation of Friedel-Crafts cyclisation without additives 
 
Entry KI (eq.) 2,6-Lutidine (eq.) Time 
1 – 2.0 30 min 
2 1.1 – 30 min 
3 – – 2 h 
 
 In situ ReactIR Studies and Mechanistic Proposal 
ReactIR was a vital technique to determine whether the intramolecular Friedel-Crafts acylation goes 
through an acyl iodide intermediate or not. Initially, we investigated the cyclisation reaction using the 4-
Nitrophenylalanine derivative 154e as a model substrate due to the slow cyclisation reaction between the 
phenyl ring, the nucleophilicity of which is reduced by the electron-withdrawing NO2, and the chloroformyl 
functionality. As a result, the conversion of the chloroformyl group to iodoformyl would be faster and 
could be detected into the reaction mixture. The reaction was monitored for 10 hours at 70 °C in dry 
acetonitrile. However, the cyclisation reaction did not proceed at all after 10 h, and decomposition of N-






At that point we decided to switch to electron-rich rings which can spontaneously cyclise under thermal 
condition. Instead, we chose 3,4-dimthoxypheyl derivative 154c as it is the fastest substrate in performing 
the cyclisation reaction in the microwave reactor and could be possible to easily cyclise under thermal 
conditions as shown below in Scheme 50. Hence, we thermally conducted the substrate 154c in dry 
acetonitrile at 70 °C and allowed to stabilise for 20 minutes prior to analysis. In situ IR analysis was initiated, 
2,6-lutidine (60 µL, 2 equiv.) was added to the solution, followed by potassium iodide (0.049 g, 1.1 equiv.).  
 
Scheme 50: Thermally promoted Friedel-Crafts cyclisation of 154c 
At the beginning of the reaction, 154c showed two absorptions at 1745 and 1712 cm-1 which corresponds 
to (NCOCl, NCONR2) respectively. Over a period of 4 hours, these absorptions shifted to new absorptions 
regions at 1716 and 1663 cm-1 which corresponds to (5-membered ring NCONR2, 6-membered ring of 
NCONR2) respectively as shown below in Figure 10. This suggests a direct conversion of 154c to 156c with 
no detectable intermediate. In this case, if a carbamoyl iodide does form, it does so only transiently. 
 








 Tryptophan synthesis – Challenges and Solutions 
 Benzylation Reaction 
Tryptophan represented an attractive substrate for investigation because of the biological activity of the 
indole functional group. The commercially available tryptophan 177 has three functional groups that 
required manipulation to be able to obtain the targeted final product 156n. The initial challenge was to form 
the corresponding tryptophan-derived carbamoyl chloride to facilitate the subsequent Friedel-Crafts 
cyclisation. In order to form the imine precursor 182, a chemoselective condensation reaction between the 
primary amino group of tryptophan and the pivaldehyde reagent was required. As a result, it was important 
to protect both the carboxylic acid functional group and the indole nitrogen, the latter with a protecting 
group stable towards acid, as acidic conditions would be required to subsequently remove the Boc group 
to reveal the required primary amine of structure 181. Subsequent condensation of 181 is therefore possible 
to selectively from the Schiff base 182. Surprisingly, initial attempts to double benzylate the tryptophan 
derivative 177 using the reported procedures gave poor results.115,116 The reaction of 177 with NaH for 30 
min followed by the addition of excess benzyl bromide yielded 179 in only 47% yield alongside 28% of the 
monobenzylated species 179, suggesting that the substrate had not been completely deprotonated. To 
overcome this challenge, 177 was left to react with NaH for 3 h before the addition of benzyl bromide. 
Satisfyingly, these conditions allowed the isolation of 178 in 95% yield (Table 13, entries 1-2). 
Table 13: Effect of deprotonation time on 178 formation 
 
Entry Method Yield of 178 (%) Yield of 1-40 (%) 
1 NaH → 30 min → BnBr 47% 28% 
2 NaH → 3 h → BnBr 95% – 
 Amide Formation Reaction 
In order to prepare the required amide from ester 178, a solution of MeNH2 in EtOH was added and the 
mixture stirred overnight to afford the desired N-methylamide 180. The product was sparingly soluble in 
all eluents trialled, which created difficulties for the purification. As a consequence, there appeared to be 
significant loss of material during column chromatography leading to only 54% pure 180 isolated (Table 
14, entry 1). The major impurity detected by NMR analysis was benzyl alcohol. As a result, attempts were 
made in subsequent runs to remove this impurity by washing the crude product with cold ethanol, instead 
of performing chromatography. This approach was successful to an extent, giving pure 180 in moderate 
yield (60%) (Table 14, entry 2). When a less polar (diethyl ether) was used in the trituration, the yield 
improved to 75% (Table 14, entry 3). When a binary mixture of pentane:ether (50:50) was employed, the 






was performed using 70:30 pentane:ether, affording the desired N-methylamide 180 in 96% yield (Table 14, 
entry 5). 
Table 14: Optimisation of amidation of tryptophan derivative 178 
 
Method  Yield (%) 
column 54% 
cold ethanol wash 60% 
100% ether wash 75% 
pentane:ether (50:50) 80% 
pentane:ether (70:30) 96% 
 Boc-deprotection Reaction 
Several attempts were made to perform Boc deprotection of tryptophan derivative 180 in order to generate 
the free amine 181. Contrary to literature, using varying amounts of TFA in dichloromethane gave poor 
isolated yields of 181 (Table 15, entries 1-2). Disappointedly, when 100% TFA was applied to the 180, there 
was no conversion to the anticipated product 181 (Table 15, entry 3). Gratifyingly, however, it was found 
that 181 could be readily formed by refluxing with acetyl chloride in methanol. The yield of 181 after basic 
aqueous work-up in this case was 99% without the need for further purification (Table 15, entry 4). 
Table 15: Improved deprotection of Boc-protected tryptophan derivative 180 
 
Method Yield (%) Comments 
20% TFA in CH2Cl2 29% After flash chromatography 
50 % TFA in CH2Cl2 25% After flash chromatography 
100 % TFA -–- After flash chromatography 
Acetyl chloride in MeOH 99% No purification needed 
 
 Synthesis of Cyclised Tryptophan Derivative 
This intermolecular condensation step was carried out in dichloromethane in the presence of magnesium 
sulfate as a drying agent, for 2 days to afford 182 in excellent yield. Treatment of 182 with phosgene solution 






a compound assigned the structure 156n directly in 70% yield as a single diastereoisomer as given below in 
Scheme 51.  
 
Scheme 51: Synthesis of L-tryptophan derivative 156n 
 
1H NMR spectrum of 156n showed an interesting splitting pattern for protons (H-5, H-9). The 
diastereotopic nature of protons H-9 due to their presence adjacent to a chiral centre (C-5), caused them 
to appear as doublet of doublet. 1D 1H NMR (Figure 11) was not enough to elucidate which regioisomer 
was formed from this cyclisation, so we used HMBC to confirm the structure of the product.   
 







HMBC showed long range correlation between the protons and carbons of compound 156n were observed 
as depicted in Figure 12. The spectrum exhibits correlations between the β-protons, 9, and three quaternary 
centres (13, 14, 10), and the α-carbon (5) and the C=O (4). In the light of observation above, we concluded 
that the product is 156n as the HMBC can only detect 2-3 bond correlations between neighbouring carbons 
and the proton of interest. On the other hand, in 184 the correlation between proton (H-9) and carbon (C-
14) would not be observed as the nuclei are 4-bonds apart and correlation cannot be detected by HMBC. 
 
Figure 12: Proposed structures for cyclic tryptophan derivative 
 
Figure 13: HMBC NMR of trans tryptophan derivative 156n 
          
Two plausible mechanisms for intramolecular cyclisation of the tryptophan intermediate 183 were proposed 
and are given in Scheme 52. Apparently, the formation of 156n occurs through Pictet-Spengler50,117 like 
cyclisation. Pathway A involves nucleophilic attack of the indole moiety at position 2 on to the electrophilic 
chloroformyl group synchronised with extensive delocalisation of the nitrogen lone pair into the fused 






Subsequent deprotonation by chloride ion and rearomatisation of intermediate 185 would form the final 
targeted compound 156n as shown in Scheme 8. Alternatively, Pathway B could involve the nucleophilic 
attack of the indole moiety from position 3 onto the electrophilic chloroformyl group to form the spiro 
intermediate 186 which undergoes a ring expansion (via a 1,2-acyl shift) and subsequent rearomatisation to 
produce the final observed product 156n.  
 
Scheme 52: Proposed mechanistic routes for the synthesis of tryptolactam skeleton 156n 
 
 Scope of Cyclisation of a Range of trans N-Chloroformylimidazolidinones  
The exploratory work on the cyclisation reaction was then applied to a wide range of substrates to give 
synthetically useful quantities of the lactam products. The original optimised reaction conditions were 
slightly modified by using fewer equivalents of 2,6-lutidine (1.1 equiv. instead of 2 equiv.), which facilitated 
the reaction on a wide range of N-chloroformyl imidazolidinones. Notably, the reaction time was dependent 
on the identity of the functional group substituted on the aromatic ring of the trans N-chloroformyl 
imidazolidinones. As mentioned above, when strong electron-donating groups (namely two methoxy 
groups) were substituted on the aromatic ring, the reaction was complete within 30 sec in microwave reactor 
and in excellent yield. On the other hand, with a strongly electron withdrawing NO2 substituent, the reaction 
took 30 min. 156 lactam motifs can be formed from their corresponding trans N-chloroformyl 
imidazolidinones precursors 154 in good to excellent yields as indicated below in Scheme 53. The scope 
includes not only electron-rich carbocyclic, neutral carbocyclic, electron-deficient carbocyclic lactams 156a-
j, but also heterocyclic lactams 156k-n. Pleasingly, five and seven-membered ring-containing products 156h 
and 156i were also accessible via this methodology albeit in modest yields (38% and 42%, respectively). For 






Additionally, we managed to scale up the cyclisation of trans N-Chloroformyl imidazolidinones, 
demonstrating that the reaction can be performed on 1-10 gm scale. Specifically, 156b can be smoothly 
formed on a 10 g scale at 1 M in 10 sec. On 2−5 g scale 156c, 156e-g were straightforwardly synthesized at 
0.5−1 M, however, 156k-m were synthesised on 1 g scale at 0.15 M (see experimental).  
 












 Diastereoselective Alkylation of the Benzolactam Motifs  
Alkylation of the benzolactams 156a-g at the α-position was attempted with the intention of generating 
unusual quaternary amino acid derivatives, compounds of pharmaceutical relevance which are otherwise 
challenging to synthesize. An additional benefit of the α,α-disubstitution is that it allows hydrolysis of these 
products to form enantiomerically enriched amino acid derivatives without the risk of racemisation. Initially, 
we carried out several attempts at diastereoselective alkylation. We found that double alkylation (α,β 
positions to the imidazolidinone carbonyl group) was the main outcome of treating the phenylalanine-
derived benzolactam 156a with LDA (2 equiv.) first at 0 °C, then quenching it with methyl iodide (10 equiv.) 
as shown below in Scheme 54. It is noteworthy that changing the addition order of electrophile and 
substrate 156a led to messy crude NMRs and significantly reduced yields, attributed to degradation of 
starting materials. Decreasing the number of equivalents of added electrophiles also gave similarly poor 
results.  
 
Scheme 54: LDA promoted alkylation of benzolactam 156a 
Surprisingly, when a mixture of an electrophile and benzolactam 156a was treated with LDA at –78 °C and 
subsequent warming to rt, β-alkylation occurred instead of the expected α-alkylation. A completely 
diastereoselective β-alkylation of an indigo-violet solution of deprotonated benzolactam occurred when 
either methyl iodide or ethyl iodide were used. NOE experiments and X-ray techniques confirmed the 
relative stereochemistry of products 188a, 188b (appendix 2). However, the diastereoselectivity of the 
reaction dropped (70:30 dr) when benzyl bromide was employed as the electrophile.118 Pleasingly, synthesis 
of the structurally interesting multicyclic product 188d was also possible and X-ray techniques confirmed 
the relative stereochemistry of product 188d (appendix 2). After several attempts at its formation, we found 
that the order of reactant addition, as well as staggered addition of LDA was critical. The target product 
formed in a high yield (86%) by treating 156a first with 1,3-dibromopropane and then with two portions 
of 2 equiv. of LDA at −78 °C (second portion added one hour after the first). One rationale for preferential 
β-alkylation over α-alkylation in these examples could be related to the presence of the nearby amide 
carbonyl group which controls the deprotonation process by coordination to the lithium counter ion, 
favouring removal of the accessible β-proton over the more sterically encumbered (though more 







Scheme 55: Diastereoselective β-alkylation of benzolactam motifs 
We next turned our attention to the use of weaker bases with the aim of achieving α-alkylation. Potassium 
hexamethyldisilazide (KHMDS) had been used to great effect previously in the group for the migration of 
N-to-C aryl migration and so this was trialled first.110 Alkylation of the phenylalanine-derived species 156a 
was investigated by the addition of methyl iodide (1.5 equiv.) in THF (0.1 M) at −78 ºC, followed by addition 
of KHMDS; however, under these conditions, no reaction was observed (Table 16, entry 1). It was thought 
that the temperature may not have been sufficient to allow deprotonation of the starting material by this 
hindered base, and so another attempt was made involving initial addition of methyl iodide (3 equiv.) and 
the same amount of base to the substrate 156a at −78 ºC, before the solution was warmed to 0 ºC and left 
to react. Once again, there was no conversion to anticipated product (Table 16, entry 2). Disappointingly, 
addition of 18-crown-6 (2 equiv.) into this system did not offer any improvement at either −78 ºC or rt 
(Table 16, entries 3-4). Furthermore, the reaction was also attempted using the stronger base NaH at 0 ºC, 
but this was unsuccessful (Table 16, entry 5). 






 Deuteration Studies 
As a result of the unsuccessful trials conducted previously, it was important to be certain that KHMDS was 
basic enough to deprotonate the α-carbon of substrate 156a. In order to determine this, the metallation 
Entry Base Temp (ºC) Reagent Results 
1 KHMDS -78 ºC MeI (1.5 equiv.) No reaction 
2 KHMDS -78 ºC to 0 ºC MeI (3 equiv.) No reaction 
3 KHMDS -78 ºC MeI (3 equiv.) + 18-crown-6 No reaction 
4 KHMDS -78 ºC to rt MeI (3 equiv.) + 18-crown-6 No reaction 






reaction of lactam 156a by KHMDS was performed at 0 ºC for 30 min. Upon addition of base the solution 
became deeply coloured, a feature typical of enolates. The reaction was quenched by addition of 2 ml of 
D2O as depicted in Scheme 56. Encouragingly, 67% conversion to deuterated product 191 was detected by 
NMR analysis of the crude mixture. Based on this deuteration experiment, we could conclude that KHMDS 
was indeed basic enough to deprotonate this position and that the addition order of the reagents was likely 
to blame for the failures in the above alkylation attempts. 
 
Scheme 56: Deuteration experiment of cyclised phenylalanine derivative 156a   
 
 Optimising Conditions for Methylation of Phenylalanine Derived 156a 
Selective α-methylation of 156a was eventually achieved by reacting the substrate first with KHMDS (1.2 
equiv.) at 0 ºC for 15 min in THF (0.1 M) followed by addition of methyl iodide (5 equiv.) and leaving the 
reaction mixture to stir for 3 h at 0 ºC, generating the desired product 189a as a single diastereomer with 
93% conversion by 1H NMR analysis of the crude reaction product. Curiously, there was still remaining 
starting material detected by NMR in the crude product mixture (Table 17, entry 1). The reaction was also 
successfully repeated using the cheaper base LiHMDS. NMR analysis of this reaction showed a marginal 
decrease in conversion to the methylated product (90%) (Table 17, entry 2). It was found that increasing 
the amount of either KHMDS or LiHMDS to 1.5 equiv. was effective, allowing 189a to be isolated in 95% 
and 91% yield, respectively (Table 17, entries 3-4). It is worth reiterating that the key solution to solving 
previous issues with the alkylation step was in the reagent addition sequence. We can confidently emphasize 
that KHMDS or LiHMDS were not basic enough to deprotonate the β-position, and it only selectively 
deprotonates the α-position.   
Table 17: Final optimisation of methylation of cyclised phenylalanine derivative 156a  
 
Entry Base Observation Yield (%) 
1 KHMDS (1.2 equiv.) 93% conversion + SM nd 
2 LiHMDS (1.2 equiv.) 90% conversion + SM nd 
3 KHMDS (1.5 equiv.) Reaction is completely finished 96% 






 α-Alkylations of other Benzolactams 
The optimised α-alkylation conditions were applied to a range of benzolactam derivatives 156 employing 
three different electrophiles: methyl iodide, allyl iodide and benzyl bromide. 156a, 156c, 156l, and 156n were 
all treated with KHMDS (1.5 equiv.) at 0 °C for 15 min in THF (0.1 M) followed by the addition of methyl 
iodide to afford the methylated products 189a, 189d, 189h and 189j in good to excellent yields (Scheme 57). 
It is worth noting that substrate 156b (the dimethoxyphenylalanine derivative) required more KHMDS (2 
equiv.) to be achieve complete methylation. Likewise, the α-allylation products 189b, 189e, 189f, 189i and  
could also be formed with similarly good to excellent yields (Scheme 57). In these cases 2 equiv. of KHMDS 
were also needed to give complete α-allylation of substrates 156b and 156c. The stereochemistry of 189f 
was confirmed by X-ray crystallography (appendix 2). Finally, α-benzylation of substrate 156a was also 
demonstrated, yielding the desired product 189c as a single diastereomer in 84% yield.  
 
Scheme 57: Diaseteroselective α-alkylation of benzolactam platforms 
 Selective α,β-Alkylations of Benzolactams of Derived Amino Acid  
With quaternization of the α-carbon successfully achieved, β-alkylation was attempted on the α-alkylated 
lactams 189a-c synthesized via method B. In a similar fashion to method A (Scheme 57), 193a-c were 
prepared by adding 2 equiv. of LDA to a degassed solution of starting materials 189a-c in THF (0.1 M) at 
– 78 °C for 15 min, followed by the electrophile (5 equiv.) and warming to rt and reacting for 2 h. These 






Additionally, a one-pot double alkylation process was developed to yield 193a-c in yields similar to or 
greater than those obtained by the stepwise alkylation approach. It should be noted that fine-tuning of the 
reaction conditions by changing number of equivalents of electrophiles and LDA was required in order to 
attain the target products diastereoselectively in high yields. It was found that a mere 1 equiv. of the first 
electrophile was sufficient to form the α-alkylated intermediate in appreciable quantity for the second part 
of this method. The quantity of electrophile was limited in these cases to avoid side reactions which could 
occur between the intermediate product and an excess of the first electrophile. In the second part of this 
procedure 3 equiv. of LDA and 10 equiv. of reacting electrophile were used. Additional LDA was needed 
to mitigate potential side reactions stemming from the KHMDS employed in the first part of this method 
(Scheme 58).  
 
Scheme 58: Diastereoselective α,β-alkylations of amino acid derived benzolactams 
 Hydrolysis of Alkylated Benzolactams  
Deprotection of the imidazolidinone function to reveal the masked amino acid functionality of the alkylated 
products is as important as introducing the chiral auxiliary itself during syntheses of the imidazolidinone 
skeletons in the first stage of this project. The dihydroisoquinolone products, cyclised derivatives of 
quaternary amino acids, are difficult to prepare by other methods – particularly in enantiomerically enriched 
form. 
With the many successes achieved in earlier stages of the project, the old English proverb “all that glistens 
is not gold” comes to mind when describing the hydrolysis of these compounds, as it proved to be not as 







  Optimisation of Imidazolidinone Hydrolysis 
To begin the hydrolysis study, the phenylalanine-derived benzolactam 189a was chosen as a model 
substrate. Unfortunately, reaction of 189a with 6 M HCl in a microwave reactor at either 120 °C or 150 °C 
for 6 h failed (Table 18, entries 1 and 2). It was observed that 189a appeared to be completely insoluble in 
aqueous HCl. Addition of EtOH (10%) proved to be beneficial not only in solubilising the starting material 
in aqueous HCl, but also for making a maximum boiling azeotrope mixture (having a higher boiling point 
solution). A benefit of this azeotrope mixture is the lower vapour pressure which in turn limits the pressure 
build up inside the sealed microwave vial. The desired dihydroisoquinolone product 194 was formed when 
substrate 189a was exposed to 6 M HCl (10% EtOH) at 170 °C for 6 h under microwave irradiation (79% 
yield) or by heating conventionally in a sealed tube for 72 h (75% yield) (Table 18, entries 3 and 4). 
Unfortunately, when these conditions were applied to other substrates 189a ,189c, 189d, 193a, 193b no 
traces of the desired hydrolysed products were observed (Table 18, entry 5).  
Table 18: Optimisation of imidazolidinone hydrolysis 
 
aTemperature in Celsius scale (°C). bN.R. = No reaction. 
Increasing the amount of EtOH to 20% or employing stronger acid (12 M HCl, 20% EtOH) at 170 °C for 
6 h was not successful for substrates 189a ,189c, 189d, 193a, 193b (Table 18, entry 6 and 7). Employing yet 
stronger acidic conditions (9 M HBr) at 150 °C (in the microwave reactor, and conventional heating) for 6 
h, gave no evidence of hydrolysis (Table 18, entries 8 and 9). Switching to 6 M HBr in acetic acid gave no 
reaction either (Table 18, entry 10). Reacting 189a, 189d with 7.6 M HI at 150 °C for 72 h also proved 
unsuccessful (Table 18, entry 11). It is worth mentioning that reactions with HBr or HI could not be 
performed at higher temperatures than stated due to overpressure in the sealed reaction vials. Pleasingly 
however, it was discovered that the alkylated benzolactams 189a, 189c, 189d, 189h, 193a, 188d could be 
Entry Conc  Substrate Reagent Time Tempa Yield 
1 0.05, 0.1 189a 6 M HCl 6 (µw) 120 N.R.b 
2 0.05, 0.1 189a  6 M HCl 6 (µw) 150 N.R. 
3 0.05 189a  6 M HCl, 10 % EtOH 6 (µw) 170 79%  
4 0.05 189a  6 M HCl, 10 % EtOH 72 (Δ) 170 75%  
5 0.05 189a, 189c-d, 193a-b 6 M HCl, 10 % EtOH 6 (µw) 170 N.R. 
6 0.05 189a, 189c-d, 193a-b 6 M HCl, 20 % EtOH 6 (µw) 170 N.R. 
7 0.1, 0.05 189a, 189c-d, 193a-b 12 M HCl, 20 % EtOH 6 (µw) 170 N.R. 
8 0.05 189a, 189c-d, 193a-b 9 M HBr 6 (µw) 150 N.R. 
9 0.05 189a, 189c-d, 193a-b 9 M HBr 72 (Δ) 150 N.R. 
10 0.05 189a, 189c-d, 193a-b 6 M HBr in acetic acid 6 (µw) 150 N.R. 
11 0.05 189a, 189d 7.6 M HI 72 (Δ) 150 N.R. 






cleanly deprotected by hydrolysis in 6 M HCl, 20% TFA at 170 °C for 4 h (Table 18, entry 12). The essential 
role of TFA is attributed to its ability to solubilise the hydrophobic (aromatic) portion of the benzolactam 
derivatives.124  An additional benefit of using TFA is that the reaction temperature can be increased to 180 
°C without apparent over pressuring of the microwave vial. 
 Hydrolysis of other Substrates  
With the successful hydrolysis conditions of entry 12 identified, a series of enantiomerically enriched 
dihydroisoquinolones 194, 195 were prepared (Scheme 59). 3-Carboxydihydroisoquinolones derived from 
α-alkylated phenylalanine, 3-fluorophenylalanine, and 2-thienylalanine derivatives 194a-d were isolated in 
high yield. Even hydrolysis of the more sterically hindered α,β-alkylated benzolactams 193a, 188d was 
demonstrated, affording the corresponding highly functionalised amino acid derivatives 195a, 195b in 
similarly high yields.   
 
Scheme 59: Hydrolysis to give dihydroisoquinolones 
 Conclusions 
To conclude, intramolecular Friedel−Crafts cyclisation of trans N-chloroformylimidazolidinones derived 
from aromatic amino acids is possible under mild conditions utilising potassium iodide as an activating 
agent. Further functionalisation by diastereoselective alkylation followed by hydrolysis of the 
imidazolidinone auxiliary gave a range of enantiopure dihydroisoquinolone structures bearing a quaternary 
centre at the α-position. Our achieved protocol is economical, requires relatively short synthesis times, and 
is accessible to a wide variety of modified amino acids. It employs cheap, readily available, and bench-stable 
starting materials and affords the desired products with excellent selectivity. However, this method is 
limited to commercially available enantiopure aromatic amino acids bearing nucleophilic aromatic 






 Future Work 
The practical and operationally simple method of ammonia-free Birch reduction125 could be applies to the 
range of benzolactams 193 and followed by regioselective α-alkylation with benzyl bromides. These 
reductive alkylated products 196 could undergo Grewe cyclisation under acidic conditions using excess of 
trifluoromethanesulfonic acid to form bridged cyclohexene analogues of the benzolactam motifs 197 
(Scheme 60).126–128 Formation of a stable allyl cation intermediate after protonation of the diene should 
favour formation of the bridged 6-membered product over an alternative 5-membered fused system (not 
shown) resulting from the opposite regioselectivity of diene protonation (proximal to the aryl group). 
 
Scheme 60: Proposed application of Birch reduction–alkylation–Grewe cyclisation to form 197 
Amide activation is a famous method that is a major area of interest for chemists all over the world.129–140 
Hung et al. has reported an effective facile one pot tandem methodology including the reductive alkylation 
of lactams 189f, 189g with Grignard reagents.141 The method utilized a combination of triflic anhydride and 
2,6-di-tert-butyl-4-methyl-pyridine (DTBMP) to activate the amide system. Treatment of the previous 
mixture with Grignard reagents to achieve benzylation in presence of lithium aluminium hydride as a 
reducing agent (Scheme 61).142,143 The application of this methodology on our lactam motifs will get a key 
reductive benzylated substrates 198 ready for further Birch reduction, and Grewe cyclisation to form 4 
fused six-membered rings 199 in a fashion very similar to codeine and morphine family.144   
 






3 Dihydroisoquinolones by Alkylation of N-Chloroformylimidazolidinones 
 
Abstract 
This chapter describes the remarkable behaviour of the enolates of N-chloroformylimidazolidinones 
derived from wide range of α-amino acids. These well-behaved enolates undergo diastereoselective 
C-quaternarisation with benzylic bromides, followed by intramolecular Friedel-Crafts acylative 
reaction (Bischler−Napieralski-type) and acid-catalysed hydrolysis to access functionalised 
dihydroisoquinolones possessing stereochemical configuration complementary to those synthesised 
previously (chapter 2).  
 
 
          
The contents of this chapter have been communicated in:145 
       Abas, H. ‡; Amer, M. M. ‡; Olaizola, O.; Clayden, J. Org. Lett. 2019, 21, 1908. (‡ Joint first authorship) 
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Mostafa M. Amer, and Jonathan Clayden. X-ray diffraction analysis was performed by Dr. Hazel 







 Aim of the Project 
In the previous chapter we described a synthesis of dihydroisoquinolone derivatives 194, 195 that was 
somewhat limited to species derived from commercially available aromatic amino acids. As aromatic 
functionalities are integral to our intramolecular Friedel-Crafts cyclisation methodology and, in an attempt 
to widen the scope of dihydroisoquinolone products available to us, we decided to explore the possibility 
of alkylating the N-chlorofomylimidazolidinones 154 directly, prior to Friedel-Crafts cyclisation. In spite of 
our initial reservations concerning the stability of the N-chloroformyl function on exposure to strong base, 
we discover that N-chlorofomylimidazolidinones derivatives 154 can indeed be deprotonated cleanly to 
form remarkably stable enolates 200 which are amenable to successive alkylation and cyclisation procedures. 
This approach can be considered as a complementary method to our earlier procedure which enables us to 
access dihydroisoquinolones 203 possessing opposite stereogenic centres to those synthesised previously 
(Scheme 62).55,145 
 













 Diastereoselective Alkylation of trans N-Chloroformylimidazolidinones  
As before, the trans L-phenylalanine derived substrate 154a was used as a model substrate for our 
investigation into diastereoselective alkylation. 154a was treated with LDA (2 equiv.) in THF at rt for 15 
min followed by addition of allyl bromide (3 equiv.) and left to stir for 3 h. Unfortunately, the reaction did 
not give the desired allylated product, it instead led to only degradation of 154a (Table 19, entry 1). The 
same results were observed when KHMDS (1 equiv.) or LiHMDS (1 equiv.) were used as alternative bases 
(Table 19, entries 2 and 3). Based on these previous trials, kinetic deprotonation of 154a at low temperature 
was attempted as it was thought the enolate may be too unstable at rt. Gratifyingly, addition of LDA (2 
equiv.) to a solution of 154a in THF at -100 °C for 15 min followed by the addition of allyl bromide, led to 
formation of 204 with excellent diastereoselectivity, albeit in poor yield (Table 19, entry 4). It was notable 
that no starting material was not recovered, instead degrading over the course of the reaction. Encouraged 
by this promising early result, exchanging LDA for KHMDS (2 equiv.) at −78 °C gave the desired product 
204 in 80% yield with no erosion in diastereoselectivity (Table 19, entry 5). Decreasing the amount of 
KHMDS significantly was also possible, even leading to increased product yield (86%) (Table 19, entry 6).  
Table 19: Diastereoselective alkylation of trans N-chloroformylimidazolidinones 154a 
 
Entry Base Equiv. Temp (ºc) Yield (%), dr 
1 LDA 2 equiv. rt 0a 
2 KHMDS 1 equiv. rt 0a 
3 LiHMDS 1 equiv. rt 0a 
4 LDA 2 equiv. -100 20, >95:5 
5 KHMDS 2 equiv. -78 80, >95:5 
6 KHMDS 1.2 equiv. -78 86, >95:5 
 Scope of Diastereoselective Benzylation and Alkylation  
 Benzylation of trans L-Alanine N-Chloroformylimidazolidinone  
With the aim of extending the alkylation protocol to different amino acid derivatives, we synthesized trans 
N-chloroformylimidazolidinone 154o derived from enantiopure L-alanine 152o in three steps. 154o was 
successfully reacted with wide range of benzyl bromide analogues bearing different functional groups using 
the above method to provide the corresponding α,α-disubstituted species 205a-m in moderate to high 
yields (Scheme 63). Neutral, electron-rich, and electron-poor arenes were well tolerated in this 
diastereoselective alkylation procedure, enabling us to access a broad range of quaternary N-






It was found that some benzylations gave better yields when the addition sequence of electrophile and 
KHMDS were altered (see experimental section). The reaction yields were best when KHMDS was added 
dropwise into a degassed solution of substrate 154o and reacting electrophile to give 205b, 205c, 205g, 
205h, 205j, 205k and 205m. On the other hand, when the remaining electrophiles were used, better results 
were obtained when KHMDS was mixed first with substrate 154o for 10-15 min, followed by electrophile 
addition. Relative stereochemistry was determined for product 205a by NOE experiments, suggesting the 
approaching electrophiles reacted with the trans N-chloroformylimidazolidinone from the opposite face to 
the bulky t-butyl group in a completely diastereoselective fashion.  
 
Scheme 63: Scope of diastereoselective alkylation of alanine derived imidazolidinone 154oiv   
 
 






 Benzylation and Alkylation of other trans N-Chloroformylimidazolidinones  
Trans N-chloroformylimidazolidinones derived from amino acids other than L-alanine were also subjected 
to our benzylation and alkylation procedures. They reacted cleanly in each case with substituted benzyl and 
alkyl bromides to produce the corresponding α-alkylated derivatives. Benzylated imidazolidinones derived 
from L-phenylalanine 206a, 206b, L-valine 206c, L-leucine 206d, L-phenylglycine 206e, and L-tryptophan 
206g, 206h were obtained in good yields. Similarly, alkylated L-phenylalanine derivatives 206f, 206i-j were 
prepared in good yields as shown below in Scheme 64. 206i and 206j were hydrogenated to reduce the 
double bond functionality to avoid possible side reactions which could happen in the subsequent step 
(Friedel-Crafts cyclisation). NOE experiments were used to elucidate the stereochemistry of compound 
206f (appendix 2). Once again, it was found that the order of electrophile/KHMDS addition is critical to 
achieving efficient alkylation. KHMDS must be added first to a degassed solution of starting materials in 
order to obtain products 206a, 206c, 206e, 206f, 206i and 206j in high yield. Interestingly, the remainder 
of the desired quaternary imidazolidinones 206b, 206d, 206g, 206h gave better results when the opposite 
sequence of electrophile and base addition was employed (See experimental section).   
 
Scheme 64: Scope of diastereoselective alkylation of 154v 
 






 Cyclisation of Alkylated N-Chloroformylimidazolidinones 
With alkylated imidazolidinones products synthesised, we attempted intramolecular Friedel-Crafts 
acylation. We found that this transformation could be achieved by applying either the optimal conditions 
described in the previous chapter or via alternative Lewis acidic conditions to form the desired benzolactam 
skeletons (Scheme 65). It was found that the cyclisation of quaternary imidazolidinones 205 took 2 h at 150 
°C to go to completion which is significantly slower than that of their tertiary equivalents which took only 
2-5 min (discussed in chapter 2). Refluxing the α-benzylated imidazolidinones with AlCl3 (3 equiv.) in DCE 
for 16 h gave the desired products in satisfactory yields. Interestingly, deactivated arenes were tolerated 
alongside more conventional neutral and electron-rich benzyl species.  
 
Scheme 65: Cyclisation of quaternary N-chloroformylimidazolidinones 205 
The yields of the electron-rich cyclisations 207a-f were excellent employing either mild (method A), or 
harsher conditions (method B). On the other hand, the yields of electron-deficient cyclisations 207g-h were 
poor to moderate yields under the KI conditions (method A), specifically the 4-bromo and 2-






conditions (method B) were used, excellent isolated yields were obtained (93% and 86% respectively). 
Likewise, 2-cyano and 4-trichloromethylbenzolactam products 207m, 207i can be formed only via method 
B in 58% and 72% yields respectively. Formation of the 4-fluorophenylalanine-derived product 207h can 
be achieved by both methods, although the yield was moderate (44%) in the case of KI condition (method 
A), and near-quantitative with AlCl3 conditionsvi (method B) as illustrated in Scheme 65. X-ray 
crystallography was used to unambiguously assign the stereochemistry of product 207f. Based on X-ray 
technique, it was concluded that the amino acid sidechain α to carbonyl of the imidazolidinone lies on the 
same face as t-butyl group (protecting group). The resulting compounds are the opposite enantiomers of 
their analogues obtained by the previous method (discussed in the previous chapter). 
 Cyclisation of other Alkylated N-Chloroformylimidazolidinones 
In order to thoroughly examine the scope of the methodology, it was important to test the Friedel-Crafts 
cyclisation on α-benzylated N-chloroformylimidazolidinones derived from the aromatic amino acids L-
phenylalanine and L-phenylglycine. The main purpose of this was to investigate which nucleophilic arene, 
trans or cis relative to the t-butyl group, would cyclise preferentially to form the respective lactam product. 
As expected, 206a-e cyclised via their trans benzyl groups to give 208a-e in moderate to high yields (Scheme 
66). This attributed to the lower steric hindrance induced by t-Bu group in case of cyclisation of the aryl 
substituents trans to the tert-butyl group to from less strained benzolactam products. On the other hand, 
cyclisation of the aryl substituents cis to the tert-butyl group may not be possible due to the steric hindrance 
induced by the t-Bu group leading to strained benzolactam products.   
 
Scheme 66: Cyclisation of quaternary N-chloroformylimidazolidinones 206  
 







Finally, benzylated N-chloroformyl imidazolidinones derived from L-valine 206c and L-leucine 206d 
underwent acylative cyclisation to give the corresponding benzolactam products in 64% and 84% yield 
respectively (Scheme 66). These two benzolactam skeletons are not accessible via our earlier method 
(Chapter 2). According to that route, reaction of the benzolactam 156a derived from L-phenylalanine with 
isopropyl bromide and isobutyl bromide in presence of KHMDS at 0 °C failed and did not yield any of the 
corresponding alkylated benzolactams. 
 
 Hydrolysis of the Imidazolidinone Auxiliary 
 The imidazolidinone functions of these benzolactams can be cleanly hydrolysed using our previously 
optimised conditions (6 M HCl, 20% TFA). The corresponding dihydroisoquinolone products 209a-f were 
afforded in moderate to high isolated yields (Scheme 67).  It is worth reiterating that 20% TFA was critical 
to achieving efficient hydrolysis. We managed to access both enantiomers of the dihydroisoquinolone 
products via the first (discussed in previous chapter) and second routes (discussed in this chapter). 
 
 












In summary, efficient alkylation of a wide range of stable trans N-chloroformylimidazolidinones has been 
demonstrated. The resulting alkylated skeletons were cyclised by intramolecular nucleophilic carbonylative 
cyclisation onto carbamoyl chloride functionality and hydrolysed to give the desired dihydroisoquinolones 
with the opposite stereochemistry to the dihydroisoquinolones synthesised via the previous route (chapter 
2). This procedure is complementary to our previous synthesis of dihydroisoquinolones: the methodology 
is no longer limited to the commercially available aromatic amino acids, as it enabled us to start with any 
enantiopure amino acid and introduce the arene as an incoming electrophile.  
Choice of the Friedel-Crafts reaction promoters is critical in the synthesis of both enantiomers of the 
product 2-carboxydihydroisoquinolones. However, this protocol requires relatively longer reaction times 
for the intramolecular cyclisation (it needs hours) compared to the previous method (which needs only a 





















 Future Work 
Research in the abovementioned projects has shown the robustness of the methodologies that we 
established based on alkylation of the remarkably stable enolate of trans N-chloroformylimidazolidinones 
derived from a wide range of amino acids. However, there has not yet been investigation into the reaction 
of these enolates 200 with sulfonyl electrophiles 210 to form medicinally-relevant sultam skeletons 212.146 
It noteworthy that the phenyl ring has to bear electron-donating groups-rendering it more nucleophilic 
toward cyclisation reaction- to offset the deficiency that could result from sulphonyl function group 
(Scheme 68).  
 
Scheme 68: Proposed route for the formation of highly functionalised sultam derivatives 212  
Future efforts will aim to establish an alternative route toward the synthesis of sultam platforms 215. This 
will involve the reaction between the nucleophilic imines 153 and the electrophilic sulfuryl chloride reagent 
to form imidazolidinone sulfonyl chloride intermediates derived from wide range of amino acids. The 
resulting sulfonyl chloride skeletons 213 will be cyclised by intramolecular Friedel-Crafts attack onto the 
sulfonyl chloride functionality and the products will be alkylated with versatile electrophiles to give the 
desired sultam skeletons 214. The hydrolysis of the alkylated sultam motifs will deliver the sultam platform 
215 bearing a quaternary centre as shown below in Scheme 69.  
 
Scheme 69: Alternative route for the formation of highly functionalised sultam motifs 215 
 
In precedent literature, Macmillan et al reported a robust synthesis of imidazolidinone catalysts which have 






However, there are very few examples of selective, scalable syntheses of functionalised derivatives. N-
chloroimidazolidinones therefore could serve as key precursors for establishing an efficient synthesis of 
Macmillan-type catalysts in order to access a large library of catalysts which would be valuable as the side 
chain of the amino acid has been shown to be influential on the enantioselectivity.147  Herein, we managed 
to form the less sterically hindered cis Cbz derivative starting from the N-chloroimidazolidone derivative of 
L-phenyl alanine 154a by treating it with a pre-reacted mixture of NaH (1.1 equiv.) and benzyl alcohol (1.1 
equiv.) in dry THF for 30 min at 0° C) at room temperature for 1 h. The use of the benzyloxide anion 
provided epimerization of the amino acid α-stereocenter, giving from L-phenylalanine the 
diastereoisomerically pure cis imidazolidinone derivative of D-phenylalanine 216.  The yield was 63% yield 
and the relative stereochemistry of 216 was determined by the X-ray crystal structure (Figure 14), confirmed 
using 1D NOE studies (appendix 2). Subsequent hydrogenolysis of the Cbz protected group should be 
possible to synthesize the corresponding cis Macmillan organocatalyst 217. The synthesized trans 
imidazolidinones 154 of many amino acids could potentially be converted to cis catalysts 219 through a Cbz 
protected imidazolidinone intermediate 218 as presented below in Scheme 70.  
 
Scheme 70: Suggested route for the formation of cis Macmillan organocatalyst motifs 
 
 







4 Dihydropyridinones via Aliphatic Bischler-Napieralski Cyclisation  
 
Abstract 
This chapter describes the first intramolecular aliphatic Bischler–Napieralski-type reaction of the 
alkylated N-chloroformylimidazolidinones derived from enantiopure L-alanine. The methodology 
entails the reaction of the remarkably stable enolate of N-chloroformylimidazolidinones with a range 
of allylic bromides. Subsequent intramolecular acylation and acid-catalysed hydrolysis led to the 
formation of 3,4-dihydropyridinones and enantio-enriched pipecolic acid derivatives which are 
embedded in biologically relevant compounds. 
 
 
          
The contents of this chapter have been communicated in:148 
       Amer, M. M.; Olaizola, O.; Carter, J.; Abas, H.; Clayden, J. Org. Lett. 2020, 22, 253−256.  
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Mostafa M. Amer, Jonathan Clayden and Hossay Abas. X-ray diffraction analysis was performed by 








 L-Pipecolic acid and Dihydropyridin-2-one in Biologically Relevant Compounds 
L-Pipecolic acid is a non-proteinogenic, cyclic α-amino acid present in nature. L-Pipecolic acid 220 can be 
found in human physiology fluids as well as in plants and fungi and is considered as  a secondary metabolite 
of L-lysine.149,150 Examples of bioactive derivatives of L-pipecolic acid include rapamycin 221, a specific 
inhibitor of mTOR, palinavir 222, which targets human immunodeficiency virus (HIV) proteases, and the 
small molecule direct thrombin inhibitor argatroban 223, which acts as an anticoagulant (Figure 15).151–155 
 
Figure 15: Biologically relevant pipecolic acid derivatives 
 
Another important 6-membered nitrogen heterocycle is the dihydropyridin-2-one scaffold 224, which is 
found embedded in several naturally occurring alkaloids and constitutes the core of many other biologically 
active compounds. Examples of dihydropyridin-2-one-containing drugs and natural products include 
Dutasteride 225, an FDA-approved 5α-reductase inhibitor for the treatment of enlarged prostate 
glands,156,157 Setrobuvir 226,  an experimental drug candidate (Phase II) used alongside interferon for the 
treatment of hepatitis C,158 and Piperlongumine 227, which belongs to the Piperaceae family of natural 








Figure 16: Bioactive dihydropyridin-2-one derivatives 
 
 Synthesis of Pipecolic Acid Derivatives 
Novel methods have been established to synthesise homochiral pipecolic acid and substituted 
dihydropyridin-2-one scaffolds due to their presence in important bioactive compounds.161–164 The most 
widely used methods have been based on chiral pool approaches, however, asymmetric catalysis protocols 
have emerged as efficient approaches toward the synthesis of enantioenriched pipecolic acid derivatives.165 
This section describes different approaches including chiral pool strategies from α-amino acids, the use of 
Williams lactone, self-regeneration of stereocentres protocol (SRS)), ring closing metathesis (RCM) and 
finally, the first synthesis toward dihydropyridin-2-ones via intramolecular ring rearrangement reactions. 
These selected synthetic methodologies enable access to a wide range of pipecolic acid and dihydropyridin-












 Chiral Pool Synthetic Strategies from α-Amino Acids  
The synthesis of homochiral pipecolic acid derivatives has been reported using inexensive, enantiopure 
amino acids as starting materials. In particular, the synthesis of 4-substituted pipecolic acids was 
straightforward when aspartic acid was employed as a useful chiral-pool precursor. In 1996, Murray and 
Starkey introduced a facile protocol for the synthesis of pipecolic acid derivatives from the cheap, 
commercially available aspartic acid derivative 228a-b.166 They applied a condensation reaction between 
aspartic acid derivative 228a-b and Meldrum's acid in the presence of isopropenyl chloroformate and 
DMAP to provide 4-ketopiperidone 229a-b. Subsequent ketone reduction, mesylation and elimination 
produced the α,β-unsaturated pipecolic acid derivative 230 (Scheme 71, steps (1)-(2)). In 2009, Stephen 
Hanessian and co-workers introduced an additional chiral center at C-4. After installing various substituents 
at C-4 (R1) via Suzuki-Miyaura cross-coupling with enol triflate 231, diastereoselective hydrogenation of 
alkene 232 gave final products 233. (Scheme 71, steps (3)-(5)).167 
 













Golubev and co-workers designed a methodology starting from L-aspartic acid to synthesize 4-oxo-, cis-4-
hydroxy-, and trans-4-hydroxy-L-pipecolic acids 237, 239 and 240 through the employment of 
hexafluoroacetone as a masking reagent. The L-pipecolic acid derivatives produced via this method 
constitute substructures of the virginiamycin natural products which exhibit promising antibiotic activities. 
The crucial step involved intramolecular aza-Michael cyclisation of the enone 235 to obtain 
hexafluoroacetone-protected 4-oxo-L-pipecolic acid 236 in moderate yield (55-60%). 236 was then 
deprotected to form 4-oxo-L-pipecolic acid 237 in quantitative yield (Scheme 72).168 Sodium borohydride 
reduction of intermediate 236 gave 238 in high diastereoselectivity which was easily hydrolysed to cis-4-
hydroxy-L-pipecolic acid 239.  
Finally, the epimeric trans -4-hydroxy-L-pipecolic acid 240 was synthesized via alcohol inversion with formic 
acid under Mitsunobu conditions followed by concomitant hydrolysis of the ester and hemiaminal ether 
functionalities.   
 
Scheme 72: Synthesis of 4-hydroxy pipecolic acids 
 
Bailey and co-workers developed a synthetic pathway for the preparation of 5-substitued pipecolic acid 
derivatives from L-glutamic acid derivative 241.169 Treating 241 with ethyl chloroformate gave a mixed 
anhydride crude product which was reacted with diazomethane to afford 242 in excellent yield (82%). The 
key cyclisation step was achieved by a rhodium-catalysed N-H insertion reaction of 242 to furnish protected 
5-oxopipecolic acid 243. Diastereoselective ketone reduction, followed by ester saponification and 
hydrogenolysis of the Cbz group yielded the target 5-hydroxypipecolic acid 244 in quantitative yield 








Scheme 73: Route to cis-5-hydroxy-L-pipecolic acid 244 
 
 Asymmetric Induction from Williams Lactone 
The Funk group reported a short (5 steps) and facile synthesis of trans-4-hydroxy-L-pipecolic acid 239 
exploiting Williams’ lactone 245 as a chiral auxiliary (Scheme 74).171 Williams’ lactone 245 underwent 
diastereoselective alkylation with alkyl bromide 246 to afford the dioxin-containing product 247 in 86% 
yield.  Retro-cycloaddition of the dioxin ring (150 °C, toluene) with loss of formaldehyde formed a vinyl 
ketone intermediate (not shown). Boc deprotection under neutral conditions via transcarbamation and 
methanolysis (TMSOTf, lutidine, MeOH) revealed the secondary amine which triggered the desired 
intramolecular aza-Michael addition to the vinyl ketone to give lactone 248 in 59% over two steps. 
Subsequent diastereoselective reduction of the carbonyl group, followed by deprotection of Williams’ 
lactone auxiliary by hydrogenolysis furnished the targeted L-pipecolic acid 239 in 80% yield (Scheme 74). 
 
Scheme 74: Asymmetric induction utilising Williams lactone 
 
 α-Alkylpipecolic Acids  
In 1989, Seebach et al reported an operationally simple method for the synthesis of enantiopure α-
alkylpipecolic acids utilizing the self-regeneration of stereocentres protocol (SRS).21,172 Initially, it was found 
that sequential alkylation of commercially available glycine-derived imidazolidinone 58 with an alkyl iodide 
(methyl, ethyl iodide) and 1-bromo-4-chlorobutane afforded 250 (a, b) in 96% and 78% yields respectively 
(Scheme 75). Subsequent Boc deprotection of 250 gave the corresponding free imidazolidinones 251 (a, b) 
which underwent intramolecular nucleophilic substitution reactions to from the fused 6-membered ring in 
252 (a, b) (86%, 89% yield). 253 (a, b) were then hydrolysed under acidic conditions to afford the target 






rare method to access synthetically challenging pipecolic acids bearing a quaternary centre at the α-carbon, 
one drawback of this methodology is that highly functionalised pipecolic acids are difficult to access.  
 
Scheme 75: Double alkylation of Boc-BMI to give α-alkylpipecolic acids 
Rutjes and Schoemaker synthesised enantiopure α-alkylpipecolic acid derivatives 258 and 260 in a practical 
and succinct (4 steps) process employing a ring closing metathesis as a key step. The required bis-alkene 
precursors 256 and 259 were prepared from allylalanine derivative 255 by reaction with allyl bromide or 
acryloyl chloride in acceptable yields of 45%, 68% respectively over three steps. Heating 256 and 259 at 
reflux with 5 mol% of Grubbs catalyst 257 (0.05 M in CH2Cl2) gave the corresponding L-pipecolic esters 
258 and 260, respectively, in 54% and 92% yields (Scheme 76). It is nothworthy that the required 
enantiopure allylalanine starting material 254 was synthesised via an enzymatic resolution method.173  
 








In 2020, Das et al reported the synthesis of N-aryl-piperidin-2-ones 262 with mono- or multi-alkyl 
substitution from aminocyclopentanones 261 via a ring expansion mediated by the hypervalent iodine 
reagent PIFA. The key step in the proposed mechanism (Scheme 77) was a 1,2-acyl shift of the 
cyclopentanone carbonyl group on to the oxidised aniline nitrogen.174 
 
























 Aim of the Project   
Previous chapters have described the intramolecular KI-promoted Friedel-Crafts acylation of N-
chloroformylimidazolidinones derived from aromatic amino acids such as L-phenylalanine which offers a 
robust synthesis of substituted 3,4-dihydroisoquinolones 203 (previous chapter).145 Moreover, we recently 
discovered that benzylation of the N-chloroformylimidazolidinones of a range of non-aromatic amino acids 
followed by our KI-assisted cyclisation allows access to an even wider range of 3,4-dihydroisoquinolones 
(Scheme 78, a). In this chapter, we show that our previously described intramolecular Friedel-Crafts 
acylation can be readily extended to alkenyl nucleophiles, providing access to α,β-unsaturated piperidin-2-
ones 265 and highly functionalized pipecolic acid derivatives bearing a quaternary centre (Scheme 78, b).148  
 











Following our previously optimised alkylation strategy,109 the enolate of L-alanine derived N-
chloroformylimidazolidinone could be formed upon treatment with KHMDS and trapped with allylic 
electrophiles at −78 °C. However, the yields of these allylic products were insufficient and required 
optimisation. Initially, we investigated the reaction using allyl bromide as the electrophile. It was observed 
that the yield increased upon decreasing the interval time between the addition of the base and the 
electrophile as shown below in Table 20. It was noted that treatment of the substrate 154o with KHMDS 
for 10 min followed by the addition of allyl bromide gave only 37% isolated yield (Table 20, entry 1). 
Unfortunately, changing the addition sequence of electrophile and KHMDS led mainly to the 
decomposition of starting material (Table 20, entry 2). It was found that shortening the time between the 
addition of KHMDS and the electrophile to 5 min had a significant effect, increasing the isolated yield of 
266a to 65% (Table 20, entry 3). After investigating variables such as reaction time, temperature and mode 
of addition, we developed optimised reaction conditions which involved treating N-
chloroformylimidazolidinone 154o with KHMDS (1.2 equiv.) for 2 min at −78 °C followed by the addition 
of allyl bromide (Table 20, entry 4).  






With the optimised reaction conditions in hand, we began examining the scope of the reaction with a variety 
of differently substituted allyl bromides (Scheme 79).vii The enolate reacted successfully with allyl bromides 
bearing a wide variety of functional groups and substitution patterns (i.e. where R1 or R2 ≠ H) to give 
products 266a-k in high yields. The tolerance of this reaction system toward a trimethylsilyl group (R1 = 
SiMe3) was of particular interest, as this moiety provides a versatile synthetic handle for downstream 
manipulations (Scheme 79). In line with our previous observations, the addition of the electrophile was 
diastereoselective, with the electrophile reacting anti to the bulky t-butyl moiety, as evidenced by NOE 
analysis (none of the cis-allylated diastereomer was observed by 1H NMR analysis).    
 
vii 266b-c, 266g were synthesised by J. Carter. 
    266i-k were synthesised by O. Olaizola.  
Entry Addition of electrophile  Isolated yield (%) 
1 10 mins after KHMDS 37 
2 Before KHMDS - 
3 5 mins after KHMDS 65 







Scheme 79: Diastereoselective allylation of N-chloroformylimidazolidone 154o 
 Optimisation of Aliphatic Cyclisationviii 
In 2009, Takemoto and co-workers developed an intramolecular electrophilic carbamoylation of 
alkenylchloroformamides 268 to obtain quinolone derivatives 269. They developed a one-pot procedure 
involving treatment of N-benzylanilines 267 with triphosgene (0.4 equiv.) to form the corresponding 
carbamoyl chlorides 268 followed by the addition of catalytic amount of HBr (30 mol%) in N-
methylpyrrolidone at 150 °C under microwave irradiation as depicted below in Scheme 80. Moreover, 2-
pyridinones 270, 7-membered 271 and 5-membered rings 272, 273 were accessed through their protocol.175 
 







Scheme 80: Formation of α,β-unsaturated lactams from alkenylchloroformaides  
Inspired by the methodology established by Takemoto et al, and with the intention of expanding the scope 
of our intramolecular cyclisation from aromatic-derived amino acids to aliphatic (allylic) substrates, we 
applied the previous optimal conditions on 266a precursor as shown below in Table 21. Surprisingly, the 
expected conjugated product 274a was formed together with the unconjugated adduct 275a in a ratio of 
41:59 as determined by 1H NMR analysis (Table 21, entry 1). Separation of the two isomers was possible 
by column chromatography. The isomers could be readily differentiated by their characteristic 1H NMR 
shifts and splitting patterns and the structures were further confirmed using X-ray crystallography (Figure 
17). Looking to improve the isolated yield of the desired product 274a, we explored varying the equivalents 
and nature of the base. Donohoe et al. reported the use of DBU to isomerise unconjugated double bonds 
into conjugation in a related heterocycle 277 (Scheme 81),176 therefore we explored the use of DBU as base 
in our reaction (Table 21, entries 1 and 2). 
Table 21: Optimisation of cyclocarbonylation of 266a 
 
              
Entry 
Base (equiv.) Crude ratio 
(A:B) 
Isolated yield 274a 
(%) 
Isolated yield 275a 
(%)  1 2,6-Lutidine (1.1) 41:59 45 50 
2 DBU (1.1) 63:37 34 21 
3 DBU (3.0) 77:23 19 19 
4a 2,6-Lutidine (1.1) 
Then DBU (5.0) 
85:15 43 --- 
5b 2,6-Lutidine (1.1) 
Then DBU (5.0) 
85:15 39 --- 
6 2,6-Lutidine (1.1) 
Then DBU (3.0) 
41:59 45c, 43d 50c 
a Treated with DBU (2 h, 150 °C) before workup. b Treated with DBU (2 h, 150 °C) after workup.  







Scheme 81: Isomerization of dihydropyridones 276 
Whilst the ratio of 274a : 275a in the crude material increased to 63:37 when DBU was used in place of 
2,6-lutidine, the isolated yields decreased to 34% and 21% respectively (Table 21, entry 2).  Increasing the 
amount of DBU to 3 equiv. gave a small improvement on the crude ratio (77:23, 274a : 275a) but led to 
even lower isolated yields (19% of 274a and 19% of 275a) (Table 21, entry 3). These results suggested that, 
although DBU could improve the ratio of the desired conjugated adduct, 2,6-lutidine was the superior base 
in the cyclisation step. We therefore looked to employ a stepwise protocol, and conducted the reaction 
using 2,6-lutidine to initiate the cyclisation step, followed by treatment of the resulting mixture of cyclised 
isomers with DBU to promote isomerisation to 274a. In this one-pot tandem procedure, pleasingly all of 
the unconjugated species isomerised to the conjugated isomer, however the isolated yield was still low at 
43% (Table 21, entry 4). It was thought that an aqueous workup between the two steps might lead to a 
cleaner reaction and improve the yield (Table 21, entry 5). However, the outcome of this experiment was 
comparable. Ultimately, it was discovered that separation of 274a from 275a (following column 
chromatography) after the first step followed by treatment of isomer 275a with DBU (3 equiv.) furnished 

















As expected, the 1H NMR spectrum of 274a showed that the alkenyl protons (H-1, H-6) of the conjugated 
product 274a are more deshielded compared to those (H-6, H-5) of the unconjugated product 275a. On 
the other hand, the diastereotopic methylene protons (H-5) of the conjugated isomer 274a are less 
deshielded than those (H-1) in the unconjugated isomer 275a. In unconjugated isomer 275a, the presence 
of the electron-withdrawing carbonyl group in the α position to the methylene protons shifted the chemical 
shift downfield. Conversely, in conjugated isomer 274a, the presence of the carbonyl group in the γ position 
to the methylene protons would have a marginal electron-withdrawing effect which in turn shifted the 
chemical shift of the methylene protons upfield. 
 
Figure 18: 1H NMR spectra for isomeric products 274a, 275a 
The formation of these two isomers stems from the generation of the carbocation 278 as a result of the 
intramolecular cyclisation. Subsequent competing deprotonation at either vicinal C−H group leads to the 
two isomeric products observed (Scheme 82). 
 
Scheme 82: Formation of possible isomers from the cyclisation of 266a 
    









 Few Attempts for the Cyclisation of Aliphatic Skeletonsix 
We next investigated more substituted allyl derivatives at the terminal position of the double bond to 
explore what effect this would have on the reactivity and regioselectivity of the reaction (Scheme 83). In 
case of R1 = Ph, the cyclisation conditions revealed a new competitive reaction (Scheme 84 (a)), compound 
266i, which arises following the ring closure at the internal position of the alkene and proceeds via the 
formation of the stabilized carbocation on the benzylic carbon, which in turn forms a five-membered ring 
upon loss of a proton. In this case, there were two possible alkene isomers formed, depending on which 
proton was removed and the two products were detected in a 70:30 proportion of (281:280) by 1H NMR 
analysis of the crude reaction mixture. These isomers were separable by column chromatography, however 
identification of the structures of the two compounds proved challenging using NMR analysis alone. 
Fortunately, an X-ray crystal structure was obtained for the major product 281, which allowed us to assign 
it as the five-membered lactam with E-alkene stereochemistry. In light of the results obtained, it is clear 
that the use of a phenyl group at the terminal end of the double bond favours formation of the five-
membered ring instead of the six-membered ring. This is perhaps unsurprising as formation of the five-
membered lactam proceeds via a resonance-stabilized benzylic carbocation intermediate 279 as shown in 
pathway a (Scheme 83). In contrast, potential products 283 and 284 from pathway b were not formed 
during the reaction as this route proceeds through a less stable (cyclic) secondary carbocation 280 which is 
stabilized only by hyperconjugation.   
 
Scheme 83: Suggested pathways for the intramolecular cyclisation of 266i  
Unfortunately, the cyclisation reaction of 266j (R1 = Me) gave three different products. It is worth noting 
that one of the products was the six-membered lactam ring. Although two of the products could not be 
separated, using 2D NMR experiments we were able to deduce the structure of all three products: 285a, 
285b and 285c in a ratio of 29:48:23 (Scheme 84, (b)). Interestingly, products 285b and 285c were isolated 
as a single diastereoisomer, however, we are yet to confirm the stereochemistry. For comparison, the 
cyclisation of 266a was also carried out using Lewis acidic conditions (AlCl3 in hot dichloroethane).145 
Interestingly, the reaction not only generated the unconjugated isomer 275a, but also a β-chloro 6-
membered lactam 286 (Scheme 84, (c)). Here, it appeared that the Cl- generated following the initial 
 






cyclization event underwent a 1,4-addition into the lactam, with the attack taking place on the opposite face 
of the methyl and t-Bu substituents. The relative stereochemistry was confirmed using 1D NOE studies 
(See Experimental section).  
 
Scheme 84: Cyclization of terminally substituted allyl substituents 
We were also interested to explore whether a trimethylsilyl group at the terminal carbon of the allyl group 
would promote the exclusive formation of six-membered rings via the formation of a stabilized β-silyl 
carbocation by hyperconjugation. The β-silyl carbocation is reported to be 38 kJ mol-1 more stable than that 
of the corresponding β-carbo carbocation as shown below in Figure 19.177 However, this six-membered ring 
was not exclusively formed; the isolated ratio of six to five-membered ring formation was 3:1 (Scheme 84 
(d)). Furthermore, the six-membered product was formed as a mixture of desilylated and silylated 
conjugated products 274a, 287a with the former being the major of the two, as expected given that the silyl 













 Scope of the Allylic Cyclisation 
In order to examine the scope of the aliphatic Friedel Crafts cyclization we looked to cyclize those trans-
imidazolidinones which had been alkylated with functionalized substituents on the alkene 266a-h. As 
discussed above, we found that the aliphatic Bischler-Napieralski cyclisation using 2,6-lutidine formed the 
two cyclized isomers (method A), and subsequent isomerization to the conjugated isomer took place upon 
treatment with DBU (method B (Scheme 85). It was notable that the conjugated and unconjugated 
regioisomers were typically formed in approximately the same ratio following method A. These two isomers 
were easily separable by chromatography and the unconjugated isomer 275 was then treated with excess 
DBU to further increase the yield of the conjugated isomer 274 (Scheme 85). With respect to the diversity 
of the R2 substituent, a series of styrenyl precursors were explored and the reaction worked well for neutral, 
electron-donating and halogen-bearing phenyl rings, with the corresponding products being obtained in 
satisfactory yields. When we studied the influence of a methyl group at the internal carbon of the allyl group 
on the cyclisation reaction, the six-membered lactam was exclusively formed, albeit as a mixture of the 
conjugated, unconjugated, and exo isomers (Scheme 85). The three regioisomers were separated by 
chromatography with a combined isolated yield of 100% (ratio of 24:53:23) as shown below in Scheme 85. 
The isomerization of the (isolated) major isomer 275b, with an internal, unconjugated olefin, provided the 
corresponding desired conjugated isomer 274b in 67% yield.    
 






When R2  = phenyl or 4-fluorophenyl or 3,4-dichlorophenyl, the two regioisomers are obtained in ratio of 
(38:62) and total yield of (66%), (37:63), and total yield of (65%), (37:63), and total yield of (85%). The 
isomerization of the major isomers provides the corresponding desired conjugated isomers 274c-e in good 
to excellent yields (Scheme 85).x The total combined yields (from step A and B) of conjugated isomer were 
(60%), (56%), (72%) respectively. Furthermore, when R2 is 3-methoxyphenyl or 4-bromobiphenyl or 
naphthyl, the ratio from the 1H NMR for crude material was comparable. The ratio and total yields were 
(40:60) (95%), (43:57) (68%), (42:58) (98%) respectively. Again, the isomerization was a perfect protocol to 
boost the formation of the desired isomers 274f-h. The total combined yields (from step A and B) of 
conjugated isomer were (89%), (65%), (95%) respectively.  
 Functionalisation of Pipecolic Acid Scaffolds 
We began investigating functionalisation of the embedded dihydropyridinone core which is fused to the 
imidazolidinone auxiliary. According to precedent literature, 3,4-dihydropyridin-3-ones 274, 275, and 288 
offer multiple possibilities for functionalisation of the reactive electrophilic alkene.178 
 Hydrogenation of Pipecolic Acid Scaffolds 
Firstly, we were able to perform a chemoselective reduction of the double bond rooted in 
dihydropyridinone core of 274a, 274b, 274d precursors by hydrogenation with 10% Pd/C in the presence 
of two drops of acetic acid in methanol for 18 h at rt. Consequently, 289a, 289b and 289c were efficiently 
formed in excellent yields (Scheme 86). It was observed for 274b that reduction of the alkene was 
completely diastereoselective by 1H NMR analysis of the crude reaction product (>99:1 dr). The relative 
stereochemistry of 289b was proved by NOE experiments. However, the reduction of 274d produced a 
mixture of diastereomers in a ratio of 70:30 by 1H NMR analysis of the crude reaction mixture. The relative 
stereochemistry of 289c was also confirmed by X-ray crystallography (appendix 2). 
 
 
Scheme 86: Hydrogenation of the dihydropyridinone scaffold 274  
 






Next, we successfully accomplished a chemoselective reduction of the amide of the dihydropyridinone core 
289a using borane dimethyl sulfide complex to afford the corresponding reduced product 290xi in 70% 
yield (Scheme 87).179  
 
Scheme 87: Chemoselective reduction of the lactam 289a 
 
 Hydroxylation of Pipecolic Acid Scaffolds 
Additionally, Upjohn dihydroxylation of the electron-poor alkene functionality proceeded in a completely 
diastereoselective manner for substrates 274b, 275b and 288b to provide vicinal diols 291a, 291b and 291c 
in good to excellent isolated yields (Scheme 88). The relative stereochemistry of 291a was determined by 
NOE analysis. Unfortunately, attempted dihydroxylation of 274d and 274e (where R2 = 4-fluorophenyl or 
3,4-dichlorophenyl) failed when either the previous conditions or OsO4,180–182 K4Fe(CN)6,183 K2CO3,183,184 
t-BuOH to H2O, 1:1 at 60 °C were used,185,186 returning only unreacted starting materials. This observation 
can be explained by the fact that the top and bottom faces of the targeted double bond are sterically 
hindered by the presence of R2 (aromatic substituent), and bulky t-Bu group as this six-membered ring is 
slightly non-planar puckered shaped, beside that the double bond is less reactive for the aromatic substrates 
because of increased conjugation and the electron-withdrawing halogen substituents.  
 










 Michael Addition 
4.3.3.3.1 Optimisation of Michael Addition on Pipecolic Acidxii 
Initially, 274a was heated at reflux with potassium thioacetate (1 equiv.) in dry MeCN for 17 h (Table 22, 
entry 1). There was no reaction observed and the starting material was recovered. Subsequently, 274a was 
treated with potassium thioacetate (1 equiv.) in dry MeCN (Table 22, entry 2), and in dry (MeCN:MeOH 
1:1) (Table 22, entry 3) for 4 h at elevated temperature (150 °C) under microwave irradiation. No Michael 
addition adduct was observed, however the corresponding unconjugated isomer 275a was observed (Table 
22, entries 2, 3). Another trial was made under the same conditions in the presence of 18-crown-6 as an 
additive in order to increase the reactivity of the thioacetate anion by chelating with the potassium counter 
ion, however no product observed (Table 22, entry 4). At this point, we turned our attention to use Lewis 
acid or protic acids to activate the Michael acceptor by enhancing the electrophilic character of the carbonyl 
group to increase reactivity with potassium thioacetate. Therefore, employing AlCl3 (1 equiv.) or TFA (1 
equiv.) in two attempts under the same conditions, there was no conversion to the anticipated product 
(Table 22, entries 6, 7). Pleasingly, when 274a was heated at reflux in MeCN with both TFA (1 equiv.) and 
AlCl3 (3 equiv.) for 30 min at 100 °C, followed by the addition of potassium thioacetate (5 equiv.) and 
stirring for 24 h, 292a was produced in an excellent isolated yield (85%) with good diastereoselectivity 
(88:12 dr). The diastereoselectivity of the Michael addition was determined by 1H NMR analysis of the 
crude reaction product. Interestingly, when 274a was heated at reflux in neat thioacetic acid for 24 h, the 
other diastereomer 292b was formed selectivity in moderate yield (55%) alongside with a side product 293 
in 15% yield (Table 22, entry 9).    
Table 22: Optimisation of the Michael addition reaction of 274a 
 
Entry Reagent additive Temp (°C) Time (h) 
Isolated Yield 
dr (a : b) 
1a KSAc (1 equiv.) --- 85 (Δ) 17 --- 
2a KSAc (1 equiv.) --- 150 (μw) 4 --- 
3b KSAc (1 equiv.) --- 150 (μw) 4 --- 
4c KSAc (5 equiv.) --- 150 (μw) 4 --- 
5a KSAc (1 equiv.) 18-crown-6 (1.2 equiv.) 150 (μw) 4 --- 
6a KSAc (1 equiv.) AlCl3 (1 equiv.) 85 (Δ) 17 --- 
7a KSAc (1 equiv.) TFA (1 equiv.) 85 (Δ) 17 --- 
8a KSAc (5 equiv.) TFA (1 equiv.), AlCl3 (3 equiv.) 100 (Δ) 24 85% (88 : 12) 
9d AcSH --- 100 (Δ) 24 55% (0 : 100) 
a These experiments were carried out in dry MeCN. b This experiment was carried out in dry MeCN; MeOH 
c This experiment was carried out in dry DMF. d This experiment was carried out in neat thioacetic acid. 
 






After several attempts mentioned above, we developed an operationally simple protocol to carry out a 
conjugate addition of thioacetate to the unsaturated alkene of 274a as summarised below in Scheme 89, 
allowing access to both diastereomers of the product. In conclusion,  when 274a was heated at reflux in 
MeCN with TFA and AlCl3 for 30 min at 100 °C, followed by the addition of potassium thioacetate and 
stirring for 24 h, 292a was produced in an excellent isolated yield (85%) with good diastereoselectivity 
(88:12 dr). The diastereoselectivity of the Michael addition reaction was determined by 1H NMR analysis 
of the crude reaction product.  
 
Scheme 89: Optimal Michael addition reaction of 274a   
We found that the major isomer was formed due to the facial approach of thioacetate anion to electrophilic 
double bond in the lactam scaffold. In precedent literature, Sotomayor and co-workers observed similar 
behaviour for the conjugate addition to benzo[a]quinolizinones skeleton.187,188 The rational explanation for 
diastereoselective formation of the trans isomer is due to the conjugate addition of the incoming thioacetate 
from the opposite face to the methyl substituent α to the five-membered amide nitrogen. It is difficult to 
rationalise the diastereodivergence from these two sets of reactions conditions. Obviously AlCl3 and TFA 
could be playing important roles. Presumably, it is also possible that one of these reactions is under 
thermodynamic control (i.e., reversible) while the other is under kinetic control. This means the incoming 
thioacetate will end up in an equatorial position, avoiding unfavourable 1,3-diaxial interactions with  the 
axial methyl group (through transition state A) leading to less sterically hindered, more stable, more 
favoured than being in axial to axial interaction between thioacetate and methyl group (through disfavoured 







Figure 20: Conjugate addition of thioacetate via 1,3-syn diaxial interactions to form intermediate A 
 
On the other hand, when 274a was refluxing with thioacetic acid for 24 h at 100 °C, surprisingly, the cis 
isomer was formed as the sole product in acceptable yield (55%), along with a dithioester as a side product 
in 15% yield. The side product was identified by the greater downfield chemical shift of thiocarbonyl 
functional group at δ = 230 ppm in the 13C NMR.xiii The formation of the side product 293 was due to 
possible nucleophilic reaction between thioacetate anion and thioacetic acid to finally form the dithioacetate 
nucleophilic anion 294 (Scheme 90). 
 
Scheme 90: Formation of dithioacetate anion 294 from disproportionation reaction 
 Hydrolysis of Cyclised Skeletons 
Products 274d, 274g, 274e of the cyclofunctionalization contain an embedded dihydropyridinone core, 
fused to the imidizadolidinone masking group which plays no further role in the synthesis. We managed to 
reveal the dihydropyridinone core by utilizing the optimal conditions of hydrolysis that we have achieved 
before. Thus, substrates with 4-fluorophenyl and 4-bromobiphenyl substituents on the dihydropyridinone 
core were examined and the corresponding products 295a and 295b were obtained in 68% and 70% yields 
respectively as illustrated below in Scheme 91. Finally, attempts to hydrolyse 274e (dichlorophenyl) 
surprisingly led to the amide analogue 295c in satisfactory yield (75%).  
 







Scheme 91: Hydrolysis to form pipecolic acid derivatives 295 
 
Interestingly, we investigated the practicality of our optimal hydrolysed conditions by applying them on 
substrates with a less bulky methyl substituent on the dihydropyridinone core 274b, 289b (Scheme 92). It 
was observed that the hydrolysis reaction proceeded smoothly, and purification using column 
chromatography was easier than substrates bearing the arene substituents. We noted that hydrolysed 
platform 296b was cleanly formed in excellent yield (88%) and did not need chromatographic purification 
(Scheme 92). 
 
Scheme 92: Hydrolysis to form pipecolic acid derivatives 296 
 
 Conclusion 
Indeed, we have developed an effective methodology for accessing 3,4-dihydropyridinone, and pipecolic 
acid derivatives. The method includes firstly allylation of trans N-chloroformylimidazolidinone derived from 
enantiopure L-alanine with various selection of substituted allyl bromides followed by intramolecular 
Friedel-crafts cyclisation which corresponds to aliphatic Bischler−Napieralski reaction. Subsequent 
derivatisation, and hydrolysis on the produced products provides 3,4- dihydropyridinone, and pipecolic acid 






 Future Work 
 Various Functionalisation of the α,β-Unsaturated Lactam 
Taking advantage of alkylation of the dienolate of 274a followed by chemoselective carbonyl reduction of 
the six membered lactam motifs would give the corresponding reduced skeleton 298.142 This motif may 
undergo Grewe cyclisation under acidic conditions to access fused tetracyclic scaffolds 299 which contain 
a combination of bridged and fused ring systems that is embedded in many naturally occurring alkaloids 
and constitutes the core of the biologically relevant morphinan class of compounds as shown below in 
Scheme 93.189 It’s also possible that you would also get fused 5-memebered product 300 from the Grewe 
cyclisation shown below.126–128 
 
Scheme 93: Proposed synthesis of fused tetracyclic scaffolds 299 and 300 
Yet to be explored in the aliphatic Bischler Napieralski cyclisation is the possibility of cascade cyclisation 
reactions where, rather than elimination of a proton after intramolecular cyclisation, a second tethered 
nucleophile undergoes intramolecular attack on to the intermediate carbocation. For example, if a silyl-
protected alcohol is tethered to the aryl ring via a methylene linker, capture of the intermediate carbocation 
302 by oxygen with concomitant elimination of the silyl electrofuge would form a benzotetrahydrofuran 
spirofused to the 3,4-dihydropyridinone skeleton 303 (Scheme 94). Alternatively, performing the reaction 
with substrates derived from O-protected serine 305 (rather than alanine) could produce oxygen-bridged 
products 306 via a similar cascade mechanism. In the latter case, direct acylation of the protected oxygen 
could potentially compete with alkene attack but tuning of the protecting group should be possible to direct 
the reaction toward the desired cascade process. These products will be interesting substrates for hydrolysis 
to form enantiopure, highly functionalised, quaternary amino acids with spiro- and bridged ring systems 







Scheme 94: Synthesis of 304 and 306 via cascade elimination-cyclisation reactions 
Amide activation can be another route which enables the introduction of additional heterocycles.129–134 In 
the future, it can be investigated the option of introducing a thiazolidine ring through the reaction of 
iminium triflates with 2-mercaptoethyl amine as shown below in Scheme 95. Charette et al. has a similar 
protocol in precedent literature for the formation of thiazolines from secondary and tertiary aryl amides.191 
In this method, triflic anhydride may be used to activate the lactam carbonyl group in presence of a base 
such as pyridine which used a scavenger for the acid formed throughout the reaction. It is important to 
note that the addition of triflic anhydride must be in a stepwise and slow manner at -10 °C to prevent the 
side reaction between trifilic anhydride and pyridine which stops the reaction at this stage.192 Treatment of 
highly electrophilic activated amide species with 2-mercaptoethyl amine led to the formation of 
corresponding thiazolidine.143,193 
 







The imidazolinone-fused 3,4-dihydropyridin-3-ones 274 are potential substrates to install benzyl 
functionality at the 5-position via regioselective γ-alkylation of the derived dienolates. Subsequent 
diastereoselective functionalisation of the alkene in the α,β-unsaturated lactam moiety would then provide 
access to pipecolic acid derivatives 311 with 4 contiguous stereogenic centres (Scheme 96). Moreover, 
dihydroxylation and epoxidation as potential methods to access the compounds with 4-continous 
stereocentres. Exemplary transformations to functionalise the alkene include aminochlorination,194–196 
dihydroxylation and epoxidation. 
 
Scheme 96: Potential protocol to form highly functionalised pipecolic acid motifs 311   
 
  Application of Michael Addition on α,β-Unsaturated Lactam  
As discussed earlier in chapter 4, we established a facile methodology for the formation of Michael addition 
adduct from 3,4-dihydropyridone precursor fused with imidazolidinone auxiliary. We can utilise this state-
of-art protocol to synthesize an analogue of natural product pulcherrimine 314.148 The naturally occurring 
sulfur-containing amino acid 315 is found in the ovaries of the sea urchin Hemicentrotus pulcherrimus.197 
Treatment of 292b with benzyl (R)-oxirane-2-carboxylate reagent in presence of sodium methoxide will 
form an α-hydroxy carboxylic derivative 312 which may be amenable to lactam reduction using boron 
trihydride in dimethyl sulphide solution and finally the hydrolysis to achieve the targeted analogue of 
pulcherrimine 314 (Scheme 97).198–201 
 






















 General Information 
Where specified, reactions requiring anhydrous conditions were executed under dry nitrogen or argon 
atmospheres in glassware that was dried using either a combination of vacuum and heat-gun, oven, or flame 
drying. Reaction mixtures were stirred magnetically. Air- and moisture-sensitive liquids and solutions were 
transferred via syringe or cannula into the reaction vessels through rubber septa. All reagents were 
purchased at highest commercial quality and used as received (unless specified otherwise). Solvents were 
purchased at the highest commercial quality and used as received (unless specified otherwise). Anhydrous 
CH2Cl2, Et2O, THF and MeCN were collected under argon from an Anhydrous Engineering alumina-
column drying system. Anhydrous pyridine stored over 3 Å molecular sieves was purchased from Acros. 
Pet ether (grade 40-60) where used for column chromatographic techniques. All reaction temperatures 
described below −10 °C were achieved using acetone/dry ice cooling baths. n-Butyllithium (n-BuLi) was 
used as a solution in hexanes (2.5 M from Sigma-Aldrich). Lithium diisopropylamide (LDA) was used as a 
solution in THF/heptane/ethylbenzene (2.0 M from Sigma-Aldrich) or freshly prepared immediately prior 
to use. Potassium bis(trimethylsilyl)amide (KHMDS) were used as a solution in THF (1.0 M from Sigma-
Aldrich). Et3N and 2,6-lutidine were stored over KOH. Potassium iodide (KI) was dried in a vacuum oven 
(T = 80 °C) prior to use 
 Analytical Information 
Rf: TLC was performed on aluminium backed silica plates (0.2 mm, 60 F254) which were developed using 
standard visualising agents: UV fluorescence (254 and 366 nm), phosphomolybdic acid, vanillin, potassium 
permanganate and Seebach stain. 
Chromatography: Flash chromatography was performed on an automated Biotage IsoleraTM Spektra Four 
using gradient elution on pre-packed silica gel Biotage® SNAP Ultra columns. 
m.p.: Melting points (mp), expressed in °C, were measured on a Kofler hotstage melting point apparatus 
and are uncorrected. 
IR: IR spectra were recorded from neat compounds applied as thin films on a Perkin Elmer (Spectrum 
One) FT-IR spectrometer (ATR sampling accessory). Only absorbances of interest (neat, νmax expressed in 
cm−1) are reported. In situ IR measurements were performed using a Mettler Toledo ReactIR 15 instrument 
equipped with a 6.3 mm AgX DiComp probe and iC IR software. 
NMR: Spectra were recorded on Varian VNMR (400 MHz or 500 MHz) instruments, and Bruker (400 
MHz or 500 MHz). Chemical shifts (δ) are quoted in parts per million (ppm) downfield of trimethylsilane. 
Spectra were calibrated using the residual solvent peaks for CDCl3 (δH: 7.26 ppm; δC: 77.16 ppm) or CD3OD 
(δH: 3.31 ppm; δC: 49.00 ppm) as appropriate. Coupling constants (J) are quoted in Hz and are rounded to 






(quin.), multiplet (m), broad (br.) or some combination thereof. 2D NMR experiments COSY, HSQC and 
HMBC were used in assigning NMR spectra where necessary. 
MS: Low resolution mass spectra were recorded by the technical staff at the University of Bristol on a 
Bruker Daltronics MicrOTOF 2 mass spectrometer (ESI), with only molecular ions of interest ([M]+, [M + 
H]+, [M + Na]+) reported.  
HRMS: High resolution mass spectra were recorded by the technical staff at the University of Bristol on a 
Bruker Daltronics MicrOTOF 2 mass spectrometer (ESI, positive ion mode). 
Optical Rotations: ([α]D
T ) Optical rotations were measured on a Bellingham and Stanley Ltd. ADP220 
polarimeter using a cell with a pathlength of 0.25 dm with the solvent quoted and concentration (c) given 
in g/100 mL. 
Naming of Compounds: Compound names are those generated by ChemBioDraw 16.0 software 
(PerkinElmer), following the IUPAC nomenclature. 
X-Ray Sample Preparation: Crystals suitable for X-ray were grown by dissolving the sample in a dense 
solvent (CH2Cl2) in which it is reasonably soluble which is then placed inside a second chamber containing 
a less dense solvent (Hexane or n-Pentane). The solvents slowly mixed together, altering the polarity of the 
solution in which the sample is dissolved, leading to crystallisation (Figure 1-1). The resulting crystals are 





















 General Procedures 
General Procedure 1: Synthesis of O-Methyl Ester Hydrochloride 
The amino acid (1.0 equiv.) was dissolved in methanol (0.5 M) before thionyl chloride (2.0 equiv.) was 
added dropwise. The solution was stirred at reflux for 18 h (reaction monitored by TLC). The solvent was 
removed under reduced pressure before diethyl ether was added to the crude product. The suspended solid 
was filtered, dissolved in CH2Cl2 and concentrated under reduced pressure to give the purified product. 
General Procedure 2: Synthesis of N-methylamide 
MeNH2 solution (33% in EtOH, 7.0 equiv.) was added to the amino ester hydrochloride (1.0 equiv.) and 
the mixture was stirred at rt for 1-2 days. The solvent was removed under reduced pressure and the solid 
remainder was dissolved in CHCl3 and washed with aqueous K2CO3 solution (3.8 M). The aqueous layer 
was extracted with CHCl3 three times. The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was used without further purification. 
General Procedure 3: Synthesis of imine precursors  
To a solution of N-methylamide (1.0 equiv.) in dry CH2Cl2 (1.0 M) at rt under N2, was added MgSO4 (2.5 
equiv.) followed by pivaldehyde (1.2 equiv.) and the reaction mixture was left to stir for 2 – 18 h. The 
reaction mixture was isolated by filtration and washed with CH2Cl2. The mixture was concentrated under 
reduced pressure. The crude product was used without further purification. 
General Procedure 4: Synthesis of Trans N-chloroformylimidazolidinone  
To a solution of imine (1.0 equiv.) in dry THF (0.5 M) at rt under N2, was added phosgene solution (15% 
wt. in toluene, 1.5 equiv.) dropwise over approximately 30 min (a suspension is typically observed 10-15 
min after addition). The reaction mixture was allowed to stir for 2 h at rt before pyridine (2.0 equiv.) was 
added dropwise. The reaction mixture was then stirred at rt for a further 16 h before quenching with a few 
drops of aqueous HCl (1.0 M). The mixture was concentrated under reduced pressure, diluted with CH2Cl2 
and washed with aqueous HCl (1.0 M). The aqueous solution was further extracted with CH2Cl2. The 
combined organic solutions were washed with brine, dried over MgSO4 and filtered before concentrating 
under reduced pressure. The crude material was purified by flash column chromatography to yield the 
desired trans N-chloroformylimidazolidinone. 
Note: Regarding big scale reactions, the reaction temperature must be maintained at rt on the addition of 
phosgene solution onto the imine solution. Addition of phosgene solution onto the imine solution at higher 








General Procedure 5: Lactamisation of Trans N-chloroformylimidazolidinone 
N-Chloroformylimidazolidinone (1.0 equiv.) was dissolved in dry MeCN (0.15 M) in a microwave vial 
before the addition of potassium iodide (1.1 equiv.) and 2,6-lutidine (1.1 equiv.). The vial was heated in a 
microwave reactor with the temperature and reaction duration depending on the substrate. The reaction 
mixture was washed with aqueous HCl (1.0 M, 3 times) and brine (3 times). The resulting solution was dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude material was purified by flash 
column chromatography to yield the desired lactam. 
General Procedure 6: Diastereoselective β-alkylation of the cyclised product 
Cyclised product (1.0 equiv.) was dissolved in anhydrous THF (0.1 M overall) before addition of the 
electrophile. The mixture was degassed for 10-15 min by bubbling N2 to the solution (unless otherwise 
indicated) and cooled to -78 ºC. In a separate flask, LDA was prepared; anhydrous THF and DIPA were 
cooled to 0 ºC, n-BuLi was added dropwise and stirred for 10 minutes. The LDA solution was added 
dropwise to the cooled reaction mixture and a colour change was observed. The reaction mixture was 
allowed to warm to rt over approximately 2 hours and left to stir for between 18 – 24 hours at rt. The 
reaction was quenched with distilled water and extracted three times with EtOAc. The combined organic 
layers were dried over MgSO4, filtered and reduced in vacuo. The crude product obtained was purified by 
flash column chromatography. 
General Procedure 7:  Diastereoselective α-alkylation of lactam 
Lactam (1.0 equiv.) was dissolved in dry THF (0.1 M overall) in a flame-dried flask at 0 °C under N2 and 
degassed for 10-15 min by bubbling N2 to the solution, then KHMDS solution (1.0 M in THF, 1.5 equiv.) 
was added dropwise and left to stir for 30 min at 0 °C. To the reaction mixture, the electrophile (5.0 equiv.) 
unless otherwise indicated was added and left to stir at rt for 3 h. The reaction mixture was washed with 
aqueous HCl (1.0 M, 3 × 10 mL) and brine (3 × 10 mL). The resulting solution was dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude material was purified by flash column 
chromatography to yield the desired alkylated product. 
General Procedure 8: Diastereoselective β-alkylation of the cyclised product 
α-Alkylated cyclised product (1.0 equiv.) was dissolved in anhydrous THF (0.1 M) before addition of the 
electrophile. The mixture was degassed (unless otherwise indicated) and cooled to -78 ºC under N2, then 
LDA solution (2.0 M in THF, 0.52 mL, 1.1 mmol, 2.0 equiv.) was added dropwise and left to stir for 15 
min at –78 °C. To the reaction mixture electrophile (5.0 equiv.) was added and left to stir at rt for 2 h. The 
reaction mixture was washed with aqueous HCl (1.0 M, 3 × 1 mL) and brine (3 × 1 mL). The resulting 
solution was dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 






General Procedure 9: Hydrolysis of alkylated lactam 
Alkylated lactam (1.0 equiv.) was dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio, 0.05 M) in a 
microwave vial. The vial was heated in a microwave reactor with the temperature and reaction duration 
depending on the substrate (2-5 h). The reaction mixture was concentrated under reduced pressure. The 
crude material was purified by flash column chromatography to yield the desired hydrolysed product. 
General Procedure 10: Alkylation of carbamoyl chloride with addition of electrophile AFTER KHMDS 
To a solution of trans-carbamoyl chloride (1.0 equiv.) in dry THF (0.1 M – 0.2 M) was added KHMDS  
(1.1 equiv., 1.0 M in THF) at -78 °C dropwise and stirred for 5 mins. Then, the electrophile  
(1.1 equiv.) was added. After stirring for 2 h at -78 °C, the reaction was quenched with water and extracted 
with EtOAc (x 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude material was purified by flash column chromatography 
(FCC) (SiO2; pet. ether/EtOAc) to afford the desired quaternary imidazolidinone.  
General Procedure 11: Alkylation of carbamoyl chloride with addition of electrophile BEFORE KHMDS 
To a solution of trans-carbamoyl chloride (1.0 equiv.) and the electrophile (1.1 equiv.) in dry THF  
(0.1 M – 0.2 M) was added KHMDS (1.1 equiv., 1.0 M in THF) at -78 °C dropwise. After stirring for 2 h 
at -78 °C, the reaction was quenched with water and extracted with EtOAc (x 3). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude material was purified by automated FCC (SiO2; pet. ether/EtOAc) to afford the desired quaternary 
imidazolidinone.  
General Procedure 12: Cyclization onto chloroformyl group using method A 
 
To a solution of N-chloroformylimidazolidinone (1.0 equiv.) in dry MeCN (0.1 M) was added KI (1.1 equiv.) 
and 2,6-lutidine (1.1 equiv.). The reaction mixture was then sealed and heated in the microwave reactor at 
150 °C for 2-4 h. The reaction was quenched with HCl (1.0 M) and extracted with EtOAc (x 3). The 
combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude material was purified by automated FCC (SiO2; pet. ether/EtOAc) to afford 
the desired 3,4-dihydroisoquinolone.  
 
General Procedure 13: Cyclization onto chloroformyl group using method B 
To a solution of N-chloroformylimidazolidinone (1.0 equiv.) in 1,2-dichloroethane (0.1 M) was added AlCl3 
(3.0 equiv.). The reaction mixture was then sealed and heated in an oil bath at 80 °C for 18 h. The reaction 
was quenched with HCl (1.0 M) and extracted with CH2Cl2 (x 3). The combined organic layers were washed 






purified (if required) by automated FCC (SiO2; pet. ether/EtOAc) to afford the desired 3,4-
dihydroisoquinolone.  
General Procedure 14: Synthesis of α-methyl arenes 
Methyltriphosphonium bromide (1.2 equiv.) was dissolved in THF (0.8 M) and cooled to 0 °C. To the 
resulting white suspension was added KOtBu (1 M in THF, 1.2 equiv.) or n-BuLi (2.5 M in THF, 1.1 equiv.) 
dropwise to give a yellow suspension which stirred at 0 °C for 45 min. A solution of aromatic ketone (1 
equiv.) in THF (0.8 M) was added dropwise to the reaction mixture. An orange mixture resulted and after 
stirring overnight (16 h) this became red. The mixture was filtered by gravity filtration and washed with 
petroleum ether (3x 15 mL). The mother liquor was concentrated under reduced pressure. 
General Procedure 15: Bromonation of α-methyl arenes 
To a solution of α-methyl styrene (1.0 equiv.) in dry THF (0.3 M) were added N-bromosuccinimide (1.05 
equiv.) and p-TsOH (0.1 equiv.). The mixture was heated to 120 °C in the microwave for 3 h to give a 
brown solution. The reaction mixture was cooled to rt, then taken up in petroleum ether and washed with 
water (3x 15 mL). The combined organic phases were dried over MgSO4 and concentrated under reduced 
pressure. 
General Procedure 16: Lactamisation of alkylated trans N-chloroformylimidazolidinone utilising DBU 
N-Chloroformylimidazolidinone (1.0 equiv.) was dissolved in dry MeCN (0.2 M) in a microwave vial before 
the addition of potassium iodide (1.1 equiv.) and DBU (3.0 equiv.). The vial was heated in a microwave 
reactor to 150 °C for 2 h. The reaction mixture was quenched with aqueous HCl (1.0 M). The reaction 
mixture was partitioned between H2O and EtOAc. The aqueous phase was further extracted with EtOAc 
(x2) and the combined organic phases were washed with brine, dried over MgSO4, filtered and the solvent 
was removed under reduced pressure. The crude product was purified by flash column chromatography to 
yield the desired lactam. 
General Procedure 17: Isomerisation of unconjugated isomer 275 to conjugated isomer 274  
The unconjugated isomer 275 (1.0 equiv.) was dissolved in dry MeCN (0.2 M) in a microwave vial before 
the addition of DBU (3.0 equiv.). The vial was heated in a microwave reactor to 150 °C for 2 h. The reaction 
mixture was quenched with aqueous HCl (1.0 M). The reaction mixture was partitioned between H2O and 
EtOAc. The aqueous phase was further extracted with EtOAc (x2) and the combined organic phases were 
washed with brine, dried over MgSO4, filtered and the solvent was removed under reduced pressure. The 














 Experimental Data 
Esters 
Methyl (S)-2-amino-3-(3,4-dimethoxyphenyl)propanoate hydrochloride (152c) 
According to general procedure 1, a solution of (S)-2-amino-3-(3,4-
dimethoxyphenyl)propanoic acid (5.00 g, 22.2 mmol) in dry methanol (44.5 
mL, 0.5 M) was cooled to 0 °C before thionyl chloride (4.85 mL, 66.6 
mmol) was added. The title compound was formed (6.00 g, 98%) as a 
colourless solid without further purification. 1H NMR (500 MHz, CD3OD) δ 6.93 (d, J = 8.2 Hz, 1H, H-
9), 6.88 (dd, J = 19.2, 2.0 Hz, 1H, H-10), 6.81 (ddd, J = 21.5, 8.2, 2.1 Hz, 1H, H-6), 4.27 (ddd, J = 35.9, 7.6, 
5.7 Hz, 1H, H-2), 3.83 (s, 3H, H-15), 3.82 (s, 3H, H-13), 3.81 (s, 3H, H-17), 3.24 (ddd, J = 20.0, 14.5, 5.7 
Hz, 1H, H-4), 3.11 (ddd, J = 14.5, 7.6, 2.8 Hz, 1H, H-4). 13C NMR (125 MHz, CD3OD) δ 171.3 (C-3), 
150.9 (C-7), 150.2 (C-8), 127.9 (C-5), 123.0 (C-6), 114.0 (C-10), 113.4 (C-9), 56.5 (C-15, C-17), 55.2 (C-2), 
53.7 (C-13), 36.9 (C-4); HRMS (ESI+) C12H17NO4 [M + H]+ calculated: 240.1230, found: 240.1238. 
Methyl (S)-2-amino-3-(3-fluorophenyl)propanoate hydrochloride (152d) 
According to general procedure 1, a solution of (S)-2-amino-3-(3-
fluorophenyl)propanoic acid (2.00 g, 10.9 mmol) in dry methanol (21.8 mL, 
0.5 M) was cooled to 0 °C before thionyl chloride (2.40 mL, 32.7 mmol) was 
added. The title compound was formed (2.50 g, 98%) as a colourless solid 
without further purification. 1H NMR (500 MHz, CD3OD) δ 7.45 – 7.37 (m, 1H), 7.13 – 7.02 (m, 3H), 
4.37 (dd, J = 7.3, 6.3 Hz, 1H, H-1), 3.83 (s, 3H, H-6), 3.32 – 3.28 (m, 1H, H-3), 3.22 (dd, J = 14.4, 7.3 Hz, 
1H, H-3). 13C NMR (125 MHz, CD3OD) δ 168.9 (C-2), 163.1 (d, 1JC-F = 245.5 Hz, C-9), 136.7 (d, 3JC-F = 
7.5 Hz, C-7), 130.6 (d, 3JC-F = 8.3 Hz, C-11), 125.0 (d, 4JC-F = 2.9 Hz, C-12), 115.9 (d, 2JC-F = 22.0 Hz, C-8), 
114.4 (d, 2JC-F = 21.2 Hz, C-10), 53.6 (C-1), 52.3 (C-6), 35.6 (d, 4JC-F = 1.8 Hz, C-3); HRMS (ESI+)  















Methyl (S)-2-amino-3-(4-nitrophenyl)propanoate hydrochloride (152e) 
According to general procedure 1, a solution of (S)-2-amino-3-(4-
nitrophenyl)propanoic acid (2.00 g, 8.80 mmol) in dry methanol (17.5 mL, 
0.5 M) was cooled to 0 °C and thionyl chloride (1.90 mL, 26.3 mmol) was 
added. The title compound was formed (2.27 g, 99%) as a pale yellow solid 
without further purification. 1H NMR (400 MHz, DMSO) δ 8.18 (d, J = 8.7 Hz, 2H, H-7, H-9), 7.58 (d, J 
= 8.7 Hz, 2H, H-6, H-10), 4.35 (dd, J = 7.6, 5.8 Hz, 1H, H-2), 3.67 (s, 3H, H-13), 3.37 (d, J = 5.8 Hz, 1H, 
H-4), 3.29 (dd, J = 14.0, 7.6 Hz, 1H, H-4). 13C NMR (100 MHz, CDCl3) δ 169.0 (C-3), 146.9 (C-8), 143.2 
(C-5), 131.0 (C-7, C-9), 123.6 (C-6, C-10), 52.8 (C-2), 52.7 (C-13), 35.3 (C-4); HRMS (ESI+)  C10H12N2NaO4 
[M + Na]+ calculated: 225.0869, found: 225.0879. Data in agreement with reported values.208 
(S)-2-Amino-3-(4-(benzyloxy)phenyl)-N-methylpropanamide hydrochloride (152f) 
According to general procedure 1, a solution of 3-(naphth-1-yl)-L-alanine 
(5.00 g, 23.2 mmol) in dry methanol (60 mL, 0.5 M) was cooled to 0 °C and 
acetyl chloride (16 mL, 90 mmol) was added. The title compound was formed 
(6.10 g, 99%) as a colourless solid without further purification. 1H NMR (500 
MHz, CD3OD) δ 8.07 (d, J = 8.4 Hz, 1H, H-Ar), 7.92 (dd, J = 8.3, 1.3 Hz, 1H, 
H-Ar), 7.86 (d, J = 7.9 Hz, 1H, H-Ar), 7.60 (ddd, J = 8.4, 6.8, 1.3 Hz, 1H, H-Ar), 7.53 (ddd, J = 8.0, 6.8, 
1.1 Hz, 1H, H-Ar), 7.48 – 7.41 (m, 2H, H-Ar), 4.38 (t, J = 7.5 Hz, 1H, H-2), 3.77 (dd, J = 14.4, 7.0 Hz, 1H, 
H-4), 3.65 (s, 3H, H-8), 3.61 (dd, J = 14.4, 7.5 Hz, 1H, H-4). 13C NMR (125 MHz, CD3OD) δ 170.5 (C-3), 
135.5 (C-Ar, C-Ar), 132.9 (C-Ar), 131.4 (C-Ar), 130.1 (C-Ar), 129.8 (C-Ar), 129.2 (C-Ar), 127.8 (C-Ar), 
127.1 (C-Ar), 126.5 (C-Ar), 123.8 (C-Ar), 54.6 (C-2), 53.5 (C-8), 34.9 (C-4); HRMS (ESI+)  C14H16NO2 [M 
+ H]+ calculated: 230.1175, found 230.1169. Data in agreement with reported values.209 
 
Methyl (S)-2-amino-3-(naphthalen-2-yl)propanoate hydrochloride (152g) 
According to general procedure 1, a solution of 3-(naphth-2-yl)-L-alanine 
(2.00 g, 9.30 mmol) in dry methanol (24 mL, 0.5 M) was cooled to 0 °C and 
acetyl chloride (6.4 mL, 90 mmol) was added. The title compound was formed 
(2.45 g, 99%) as a pale brown solid without further purification. 1H NMR 
(500 MHz, CD3OD) δ 8.00 – 7.81 (m, 3H, H-Ar), 7.78 (d, J = 1.8 Hz, 1H, H-
Ar), 7.53 – 7.44 (m, 2H, H-Ar), 7.39 (dd, J = 8.4, 1.8 Hz, 1H, H-Ar), 4.44 (dd, J = 7.5, 6.2 Hz, 1H, H-2), 
3.80 (s, 3H, H-8), 3.45 (dd, J = 14.4, 6.2 Hz, 1H, H-4), 3.36 (dd, J = 14.4, 7.4 Hz, 1H, H-4). 13C NMR (125 
MHz, CD3OD) δ 169.1 (C-3), 133.6 (C-17), 132.9 (C-16), 131.4 (C-14), 128.6 (C-Ar), 128.2 (C-Ar), 127.4 
(C-Ar), 127.3 (C-Ar), 126.5 (C-Ar), 126.1 (C-Ar), 125.9 (C-Ar), 53.8 (C-2), 52.3 (C-8), 36.2 (C-4). Data in 






Methyl (S)-2-amino-4-phenylbutanoate hydrochloride (152h) 
According to general procedure 1, a solution of L-homophenylalanine (5.00 
g, 28.0 mmol) in dry methanol (50 mL, 0.5 M) was cooled to 0 °C and acetyl 
chloride (14 mL, 90 mmol) was added. The title compound was formed (6.40 
g, 97%) as a colourless solid without further purification. 1H NMR (400 MHz, 
MeOD) δ 7.34 – 7.09 (m, 5H, H-Ar), 4.04 (t, J = 6.4 Hz, 1H, H-1), 3.79 (s, 3H, 
H-6), 2.90 – 2.58 (m, 2H, H-7), 2.35 – 1.95 (m, 2H, H-8); HRMS (ESI+) C11H16NO2 [M + H]+ calculated: 
194.1175, found: 194.1181. 
 
Methyl (S)-2-amino-3-(furan-2-yl)propanoate hydrochloride (152j) 
According to general procedure 1, a solution of 3-(2-furyl)-L-alanine (1.00 g, 6.45 
mmol) in dry methanol (12 mL, 0.5 M) was cooled to 0 °C and acetyl chloride 
(6.40 mL, 90.0 mmol) was added. The title compound was formed (1.00 g, 75%) 
as a yellow solid without further purification. 1H NMR (500 MHz, CD3OD) δ 
7.49 (s, 1H, H-10), 6.41 – 6.36 (m, 1H, H-11), 6.31 (d, J = 3.2 Hz, 1H, H-12), 4.36 (t, J = 5.3 Hz, 1H, H-2), 
3.85 (s, 3H, H-8), 3.34 (q, J = 5.3, 4.7 Hz, 2H, H-4). 13C NMR (125 MHz, CD3OD) δ 168.6 (C-3), 147.8 
(C-5), 143.0 (C-10), 110.3 (C-11), 108.9 (C-12), 52.4 (C-8), 51.8 (C-2), 28.4 (C-4); HRMS (ESI+)  C8H12NO3 
[M + H]+ calculated: 170.0811, found 170.0813. 
Methyl (S)-2-amino-3-(thiophen-2-yl)propanoate hydrochloride (152k) 
According to general procedure 1, a solution of 3-(2-thienyl)-L-alanine (2.00 g, 
11.7 mmol) in dry methanol (24 mL, 0.50 M) was cooled to 0 °C and acetyl 
chloride (6.40 mL, 90 mmol) was added. The title compound was formed (2.58 g, 
96%) as a yellow solid without further purification. 1H NMR (500 MHz, CD3OD) 
δ 7.38 (dd, J = 4.5, 1.9 Hz, 1H, H-10), 7.03 (d, J = 4.7 Hz, 2H, H-11, H-12), 4.37 (t, J = 5.9 Hz, 1H, H-2), 
3.87 (s, 3H, H-8), 3.52 (d, J = 5.9 Hz, 2H, H-4); 13C NMR (125 MHz, CD3OD) δ 169.9 (C-3), 136.1 (C-5), 
129.3 (C-11), 128.6 (C-12), 127.1 (C-10), 55.1 (C-2), 53.8 (C-8), 31.2 (C-4); HRMS (ESI+)  C8H12NO2S [M 
+ H]+ calculated: 186.0583, found 186.0584. 
Methyl (S)-2-amino-3-(thiophen-3-yl)propanoate hydrochloride (152l) 
According to general procedure 1, a solution of 3-(3-thienyl)-L-alanine (2.00 g, 
11.7 mmol) in dry methanol (24 mL, 0.5 M) was cooled to 0 °C and acetyl chloride 
(6.4 mL, 90 mmol) was added. The title compound was formed (2.58 g, 96%) as a 
yellow solid without further purification. 1H NMR (500 MHz, CD3OD) δ 7.43 
(dd, J = 4.8, 2.7 Hz, 1H, H-11), 7.28 (d, J = 2.7 Hz, 1H, H-9), 6.99 (d, J = 4.7 Hz, 






CD3OD) δ 170.3 (C-3), 135.1 (C-5), 129.1 (C-12), 128.0 (C-11), 125.4 (C-9), 54.6 (C-2), 53.8 (C-8), 31.7 (C-
4); HRMS (ESI+) C8H12N2O2S [M + H]+ calculated: 186.0583, found 186.0588. 
Methyl (S)-2-aminopent-4-enoate hydrochloride (152n) 
According to general procedure 1, a solution of (S)-2-aminopent-4-enoic acid (1.00 g, 
8.70 mmol) in dry methanol (17.5 mL, 0.5 M) was cooled to 0 °C and thionyl chloride 
(1.89 mL, 26.0 mmol) was added. The title compound was formed (1.36 g, 95%) as a 
colourless solid without further purification. 1H NMR (400 MHz, CD3OD) δ 5.79 (ddt, 
J = 17.2, 10.1, 7.2 Hz, 1H, H-7), 5.37 – 5.21 (m, 2H, H-8), 4.22 – 4.09 (m, 1H, H-2), 3.84 (s, 3H, H-9), 2.81 
– 2.59 (m, 2H, H-6). 13C NMR (100 MHz, CD3OD) δ 170.3 (C-3), 131.6 (C-7), 121.6 (C-8), 53.7 (C-9), 
53.5 (C-2), 49.8 (C-9), 35.7 (C-6); HRMS (ESI+) C6H12NO2 [M + H]+ calculated: 130.0859, found: 
130.0862. Data in agreement with reported values.44 
 
Benzyl 1-benzyl-Nα-(tert-butoxycarbonyl)-L-tryptophanate (178) 
To a cooled (0 °C) solution of (tert-butoxycarbonyl)-L-tryptophan 
(1.00 g, 3.29 mmol, 1.00 equiv.) in DMF (3.3 mL, 1.0 M) was added 
sodium hydride (60% suspension in mineral oil, 0.40 g, 9.8 mmol, 3.0 
equiv.). The solution was stirred for 30 minutes at 0 °C before benzyl 
bromide (1.4 mL, 3.6 equiv.) was added dropwise. The reaction 
mixture was warmed to rt and allowed to stir for 18 h. The reaction 
mixture was quenched with saturated aqueous NH4Cl (10 mL) and 
diluted with EtOAc (10 mL) before the organic layer was separated. The aqueous layer was extracted with 
EtOAc (3 × 10 mL) and the combined organic layers were washed with brine (3 × 15 mL), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude product was purified by flash column 
chromatography (SiO2, pet.ether/EtOAc, 9:1) yielding the title compound (1.45 g, 90%) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.9 Hz, 1H, H-20), 7.32 – 7.19 (m, 9H, H-23, H-24, H-25, H-
26, H-27, H-32, H-33, H-35, H-36), 7.21 – 7.06 (m, 2H, H-18, H-19), 7.03 (d, J = 7.4 Hz, 2H, H-17, H-34), 
6.67 (s, 1H, H-13), 5.18 (s, 2H, H-30), 5.05 (q, J = 12.2 Hz, 2H, H-11), 4.76 – 4.61 (m, 1H, H-9), 3.36 – 
3.21 (m, 2H, H-21), 1.42 (s, 9H, H-5, H-6, H-7); 13C NMR (100 MHz, CDCl3) δ 172.0 (C-10), 156.0 (C-2), 
155.2 (C-16), 137.4 (C-31), 136.5 (C-12), 135.4 (C-15), 128.7 (C-24, C-26), 128.5 (C-32, C-34, C-36), 128.3 
(C-17), 127.6 (C-33, C-35), 127.0 (C-13), 126.7 (C-23, C-27), 121.9 (C-18), 119.4 (C-19), 119.1 (C-20), 109.7 
(C-25), 109.2 (C-22), 79.8 (C-4), 67.0 (C-11), 54.5 (C-9), 49.8 (C-30), 28.3 (C-5, C-6, C-7), 27.9 (C-21); 











According to general procedure 2, L-phenylalanine ethyl ester hydrochloride 
(5.00 g, 23.2 mmol) was dissolved in MeNH2 solution (20.2 mL, 162 mmol, 33% 
in EtOH, 7.0 equiv.) in a 50 mL round bottom flask and the reaction was stirred 
at rt for 2 h. The title compound was formed (4.00 g, 97%) as a colourless solid 
without further purification. 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.20 (m, 5H, H-6, H-7, H-8, H-9, H-
10), 3.61 (dd, J = 9.5, 3.9 Hz, 1H, H-2), 3.30 (dd, J = 13.7, 3.9 Hz, 1H, H-4), 2.82 (d, J = 5.0 Hz, 3H, H-
13), 2.7 (dd, J = 13.7, 9.5 Hz, 1H, H-4), 1.36 (s, 2H, H-1); 13C NMR (100 MHz, CDCl3) δ 174.6 (C-3), 
137.8 (C-5), 129.1 (C-6, C-10), 128.5 (C-8), 126.6 (C-7, C-9), 56.3 (C-2), 40.9 (C-4), 25.6 (C-13); HRMS 
(ESI+) C10H14N2O [M + H]+ calculated: 179.1179, found: 179.1185. Data in agreement with reported 
values.210 
(S)-2-Amino-3-(4-(benzyloxy)phenyl)-N-methylpropanamide (166b) 
According to general procedure 2, MeNH2 solution (2.26 mL, 33.2 
mmol, 33% in EtOH, 7.0 equiv.) was added to a suspension of 
methyl ester hydrochloride (0.55 g, 1.7 mmol) in absolute ethanol 
(3.40 mL, 0.5 M) and the reaction was stirred at rt for 2 days. The 
title compound was formed (0.48 g, 98%) as a colourless solid 
without further purification. Rf = 0.13 (EtOAc/methanol = 49:1); 1H NMR (400 MHz, CDCl3) δ 7.45 – 
7.27 (m, 5H, H-17, H-18, H-19, H-20, H-21), 7.12 (d, J = 8.6 Hz, 2H, H-10, H-12), 6.92 (d, J = 8.6 Hz, 2H, 
H-9, H-13), 4.87 (s, 2H, H-15), 3.55 (dd, J = 9.2, 4.1 Hz, 1H, H-2), 3.19 (dd, J = 13.9, 4.1 Hz, 1H, H-7), 
2.80 (d, J = 5.0 Hz, 3H, H-6), 2.64 (dd, J = 13.9, 9.2 Hz, 1H, H-7), 1.34 (s, 2H, H-1); 13C NMR (100 MHz, 
CDCl3) δ 175.29 (C-3), 158.1 (C-11), 137.4 (C-8, C-16), 130.7 (C-9, C-13), 129.0 (C-17, C-21), 128.3 (C-19), 
127.8 (C-18, C-20), 115.4 (C-10, C-12), 70.40 (C-15), 57.0 (C-2), 40.60 (C-7), 26.2 (C-6); HRMS (ESI+)  
C17H21N2 O2 [M + H]+ Calculated: 285.1598, found: 285.1593. 
 
(S)-2-Amino-3-(3,4-dimethoxyphenyl)-N-methylpropanamide (166c) 
According to general procedure 2, methyl ester hydrochloride 152c (6.00 
g, 21.8 mmol) was dissolved in MeNH2 solution (38.00 mL, 304.6 mmol, 
33% in EtOH, 14 equiv.) and left to stir at rt for 2 days. The title compound 
was formed (4.70 g, 90%) as a yellow solid without further purification. 1H 
NMR (400 MHz, CDCl3) δ 6.77 (s, 1H, H-6), 6.74 – 6.68 (m, 2H, H-9, H-10), 3.83 (s, 6H, H-15, H-17), 
3.55 (dd, J = 9.1, 4.0 Hz, 1H, H-2), 3.15 (dd, J = 13.8, 4.0 Hz, 1H, H-4), 2.79 (d, J = 5.0 Hz, 3H, H-13), 
2.63 (dd, J = 13.8, 9.1 Hz, 1H, H-4), 1.37 (br. s, 2H, H-1); 13C NMR (100 MHz, CDCl3) δ 174.9 (C-3), 
149.1 (C-7), 147.9 (C-8), 130.3 (C-5), 121.4 (C-10), 112.1 (C-6), 111.1 (C-9), 56.5 (C-2), 55.8 (C-15, C-17), 







According to general procedure 2, methyl ester hydrochloride 152d (2.50 g, 
10.6 mmol) was dissolved in MeNH2 solution (18.50 mL, 148.4 mmol, 33% in 
EtOH, 14 equiv.) and left to stir at rt for 2 days. The title compound was 
formed (1.92 g, 99%) as a yellow oil without further purification. 1H NMR 
(400 MHz, CDCl3) δ 7.30 – 7.27 (m, 1H, H-Ar), 7.26 – 7.23 (m, 1H, H-Ar), 7.01 – 6.96 (m, 1H, H-Ar), 6.96 
– 6.88 (m, 1H, H-Ar), 3.59 (dd, J = 9.3, 4.0 Hz, 1H, H-1), 3.26 (dd, J = 13.8, 4.0 Hz, 1H, H-3), 2.81 (d, J = 
5.0 Hz, 3H, H-6), 2.70 (dd, J = 13.8, 9.3 Hz, 1H, H-3), 1.34 (br. s, 2H, H-14); 13C NMR (100 MHz, CDCl3) 
δ 174.4 (C-2), 164.2 (C-9), 161.7 (C-9), 140.6 (C-7), 140.5 (C-7), 130.2 (C-11), 130.1 (C-11), 124.9 (C-12), 
124.9 (C-12), 116.2 (C-8), 116.0 (C-8), 113.8 (C-10), 113.6 (C-10), 56.3 (C-1), 40.7 (C-3), 25.8 (C-6); HRMS 
(ESI+) C10H14FN2O [M + H]+ calculated: 197.1084, found: 197.1088. 
 
(S)-2-Amino-N-methyl-3-(4-nitrophenyl)propanamide (153e) 
According to general procedure 2, methyl ester hydrochloride 152e (2.27 
g, 8.71 mmol) was dissolved in MeNH2 solution (15.0 mL, 122 mmol, 33% 
in EtOH, 14 equiv.) and left to stir at rt for 2 days. The title compound was 
formed (1.92 g, 99%) as a pale yellow solid without further purification. 1H 
NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.7 Hz, 2H, H-7, H-9), 7.38 (d, J = 8.7 Hz, 2H, H-6, H-10), 7.21 ( 
br. s, 1H, H-12), 3.65 (dd, J = 8.7, 4.2 Hz, 1H, H-2), 3.33 (dd, J = 13.8, 4.2 Hz, 1H, H-4), 2.91 (dd, J = 13.8, 
8.7 Hz, 1H, H-4), 2.81 (d, J = 5.0 Hz, 4H, H-13), 1.31 (br. s, 2H, H-1); 13C NMR (100 MHz, CDCl3) δ 
173.8 (C-3), 147 (C-8), 145.9 (C-5), 130.2 (C-6, C-10), 123.8 (C-7, C-9), 56.1 (C-2), 40.9 (C-4), 26.0 (C-13); 




According to general procedure 2, Methyl ester hydrochloride 152f (6.00 g, 
22.6 mmol) was dissolved in MeNH2 solution (44.0 mL, 158 mmol, 33% in 
EtOH, 7.0 equiv.). The reaction was left to stir at rt for 2 days. The title 
compound was formed (5.00 g, 97%) as a brown solid without further 
purification. 1H NMR (500 MHz, CDCl3) δ 8.22 (dd, J = 8.6, 1.2 Hz, 1H, H-Ar), 7.86 (dd, J = 8.0, 1.4 Hz, 
1H, H-Ar), 7.77 (d, J = 8.2 Hz, 1H, H-Ar), 7.55 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H, H-Ar), 7.50 (ddd, J = 8.0, 
6.8, 1.2 Hz, 1H, H-Ar), 7.40 (dd, J = 8.0, 7.0 Hz, 1H, H-Ar), 7.32 (dd, J = 7.0, 1.2 Hz, 1H, H-Ar), 3.99 (dd, 
J = 14.1, 3.6 Hz, 1H, H-2), 3.76 (dd, J = 10.3, 3.6 Hz, 1H, H-4), 2.89 – 2.85 (m, 1H, H-4), 2.84 (d, J = 4.9 
Hz, 3H, H-13), 1.51 (s, 2H, H-1); 13C NMR (125 MHz, CDCl3) δ 175.2 (C-3), 134.5 (C-16), 134.2 (C-15), 
132.0 (C-14), 128.9 C-Ar), 127.8 (C-Ar), 127.6 (C-Ar), 126.5 (C-Ar), 126.0 (C-Ar), 125.4 (C-Ar), 124.0 (C-








According to general procedure 2, methyl ester hydrochloride 152g (2.50 
g, 9.41 mmol) was dissolved in MeNH2 solution (8.0 mL, 66 mmol, 33% in 
EtOH, 7.0 equiv.). The reaction was left to stir at rt for 2 days. The title 
compound was formed (2.00 g, 96%) as a yellow solid without further 
purification. 1H NMR (500 MHz, CDCl3) δ 7.85 – 7.77 (m, 3H, H-Ar), 7.67 – 7.63 (m, 2H, H-Ar), 7.51 – 
7.42 (m, 2H, H-Ar), 7.37 (dd, J = 8.4, 1.8 Hz, 1H, H-Ar), 3.70 (dd, J = 9.4, 4.0 Hz, 1H, H-2), 3.44 (dd, J = 
13.7, 4.0 Hz, 1H, H-4), 2.89 – 2.84 (m, 1H, H-4), 2.83 (d, J = 5.0 Hz, 3H, H-13), 1.46 (br. s, 2H, H-1); 13C 
NMR (125 MHz, CDCl3) δ 174.9 (C-3), 135.6 (C-11), 133.6 (C-10), 132.5 (C-5), 128.6 (C-Ar), 128.1 (C-
Ar), 127.8 (C-Ar), 127.6 (C-Ar), 127.4 (C-Ar), 126.3 (C-Ar), 125.8 (C-Ar), 56.4 (C-2), 41.3 (C-8), 26.0 (C-4); 
HRMS (ESI+)  C14H17N2O [M + H]+ calculated: 229.1335, found: 229.1341. 
 
(S)-2-Amino-N-methyl-2-phenylacetamide (166i) 
According to general procedure 2, methyl (S)-2-amino-2-phenylacetate (4.40 g, 21.8 
mmol) was dissolved in MeNH2 solution (21.6 mL, 153 mmol, 33% in EtOH, 7.0 equiv.). 
The reaction was left to stir at rt for 2 days. The title compound was formed (3.10 g, 
87%) as a yellow oil without further purification. 1H NMR (400 MHz, CDCl3) δ 7.34- 
7.23 (m, 5H, H-9, H-11, H-8, H-12, H-10), 4.42 (s, 1H, H-2), 2.72 (d, J = 5.0 Hz, 3H, 
H-7), 1.84 (s, 2H, H-1); 13C NMR (100 MHz, CDCl3) δ 173.7 (C-3), 141.2 (C-6), 128.7 (C-8, C-12), 127.8 
(C-10), 126.9 (C-9, C-11), 59.8 (C-2), 26.0 (C-7); HRMS (ESI+) C9H13N2O [M + H]+ calculated: 165.1022, 
found: 165.1024. Data in agreement with reported values.211 
(S)-2-Amino-N-methyl-4-phenylbutanamide (166h) 
According to general procedure 2, methyl ester hydrochloride 152h (6.0 g, 26 
mmol) was dissolved in MeNH2 solution (22.8 mL, 183 mmol, 33% in EtOH, 
7.0 equiv.). The reaction was left to stir at rt for 2 days. The title compound 
was formed (4 g, 80%) as a colourless solid without further purification. 1H 
NMR (400 MHz, CDCl3) δ 7.32 – 7.23 (m, 2H, H-Ar), 7.24 – 7.13 (m, 3H, H-Ar), 3.35 (dd, J = 8.2, 4.4 
Hz, 1H, H-2), 2.80 (d, J = 4.9 Hz, 3H, H-8), 2.72 (dt, J = 9.5, 6.2 Hz, 2H, H-5), 2.19 (dddd, J = 14.0, 9.5, 
6.2, 4.4 Hz, 1H, H-4), 1.87 – 1.72 (m,1H, H-4), 1.45 (br. s, 2H, H-1); HRMS (ESI+)  C11H17N2O [M + H]+ 













According to general procedure 2, methyl ester hydrochloride 152j (1.30 g, 6.30 
mmol) was dissolved in MeNH2 solution (5.50 mL, 44.3 mmol, 33% in EtOH, 
7.0 equiv.) and left to stir at rt for 2 days. The title compound was formed (1.10 
g, 95%) as a pale yellow solid without further purification. 1H NMR (500 MHz, 
CDCl3) δ 7.35 (br. s, 1H, H-7), 7.27 (dd, J = 1.8, 0.8 Hz, 1H, H-10), 6.24 (dd, J = 3.2, 1.9 Hz, 1H, H-11), 
6.05 (dd, J = 3.1, 0.9 Hz, 1H, H-12), 3.57 (dd, J = 9.0, 3.9 Hz, 1H, H-2), 3.18 (ddd, J = 15.0, 3.9, 0.8 Hz, 
1H, H-4), 2.86 – 2.67 (m, 4H, H-8, H-4), 1.52 (br. s, 2H, H-1); 13C NMR (125 MHz, CDCl3) δ 174.4 (C-
3), 152.3 (C-5), 141.8 (C-10), 110.3 (C-11), 107.4 (C-12), 54.5 (C-2), 33.6 (C-4), 25.8 (C-8); HRMS (ESI+)  
C8H12N2O2Na [M + Na]+ calculated: 191.0791, found 191.0799. 
 
(S)-2-Amino-N-methyl-3-(thiophen-2-yl)propanamide (166k) 
According to general procedure 2, methyl ester hydrochloride 152k (2.50 g, 11.3 
mmol) was dissolved in MeNH2 solution (9.8 mL, 79 mmol, 33% in EtOH, 7.0 
equiv.) in a 150 mL round bottom flask and the reaction was stirred at rt for 2 h. 
The title compound was formed (1.90 g, 95%) as a colourless solid without further 
purification. 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 1H, H-7), 7.18 (dd, J = 5.1, 1.1 Hz, 1H, H-10), 6.95 
(dd, J = 5.1, 3.4 Hz, 1H, H-11), 6.86 (d, J = 2.4 Hz, 1H, H-12), 3.59 (dd, J = 8.7, 4.0 Hz, 1H, H-2), 3.41 
(ddd, J = 14.8, 4.0, 0.9 Hz, 1H, H-4), 3.04 (dd, J = 14.8, 8.7 Hz, 1H, H-4), 2.81 (d, J = 5.0 Hz, 3H, H-8), 
1.62 (br. s, 2H, H-1); 13C NMR (125 MHz, CDCl3) δ 174.2 (C-3), 140.1 (C-5), 127.2 (C-11), 126.7 (C-12), 
124.7 (C-10), 56.5 (C-2), 35.4 (C-4), 26.0 (C-8); HRMS (ESI+) C8H13N2OS [M + H]+ calculated: 185.0740, 
found 185.0743. 
(S)-2-Amino-N-methyl-3-phenylpropanamide (166l) 
According to general procedure 2, methyl ester hydrochloride 152l (2.50 g, 11.3 
mmol) was dissolved in MeNH2 solution (9.8 mL, 79 mmol, 33% in EtOH, 7.0 
equiv.) in a 150 mL round bottom flask and the reaction was stirred at rt for 2 h. 
The title compound was formed (1.90 g, 95%) as a yellow oil without further 
purification. 1H NMR (500 MHz, CDCl3) δ 7.31 (s, 1H, H-7), 7.20 (dd, J = 4.9, 2.9 Hz, 1H, H-11), 6.96 
(ddt, J = 2.9, 1.4, 0.7 Hz, 1H, H-9), 6.88 (dd, J = 4.9, 1.4 Hz, 1H, H-12), 3.51 (dd, J = 8.7, 4.2 Hz, 1H, H-
2), 3.10 (ddd, J = 14.2, 4.2, 0.9 Hz, 1H, H-4), 2.76 (dd, J = 14.2, 8.7 Hz, 1H, H-4), 2.71 (d, J = 5.0 Hz, 3H, 
H-8), 1.71 (s, 2H, H-1); 13C NMR (125 MHz, CDCl3) δ 174.8 (C-3), 138.0 (C-5), 128.2 (C-12), 126.0 (C-
11), 122.4 (C-9), 55.6 (C-2), 35.4 (C-4), 25.8 (C-8); HRMS (ESI+) C8H13N2OS [M + H]+ calculated: 











According to general procedure 2, methyl ester hydrochloride 152n (1.36 g, 8.20 mmol) 
was dissolved in MeNH2 solution (14.3 mL, 115 mmol, 33% in EtOH, 14 equiv.) in 50 
mL round bottom flask. The reaction was left to stir at rt for 2 days. The title compound 
was formed (0.70 g, 70%) as a yellow oil without further purification. 1H NMR (500 
MHz, CDCl3) δ 7.37 (br. s, 1H, H-4), 5.70 – 5.53 (m, 1H, H-8), 5.03 (q, J = 1.4 Hz, 1H, 
H-9), 5.01 (ddd, J = 5.9, 2.5, 1.4 Hz, 1H, H-9), 3.29 (dd, J = 8.5, 3.9 Hz, 1H, H-2), 2.69 (dd, J = 5.0, 2.0 
Hz, 3H, H-5), 2.48 (dddt, J = 13.7, 6.6, 3.9, 1.4 Hz, 1H, H-7), 2.23 – 2.08 (m, 1H, H-7), 1.63 (br. s, 2H, H-
1); 13C NMR (125 MHz, CDCl3) δ 175.0 (C-3), 134.4 (C-8), 118.5 (C-9), 53.9 (C-2), 39.4 (C-7), 25.7 (C-5); 
HRMS C6H13N2O [M + H]+ calculated: 129.1014, found: 129.1022. 
tert-Butyl (S)-(3-(1-benzyl-1H-indol-3-yl)-1-(methylamino)-1-oxopropan-2-yl)carbamate (180) 
According to general procedure 2, Ester 178 (0.900 g, 1.86 mmol) 
was dissolved in MeNH2 solution (1.62 mL, 13 mmol, 33% in EtOH, 
7.0 equiv.) in a 25 mL round bottom flask. The reaction was left to 
stir at rt for 2 days. The title compound was formed (0.65 g, 83%) as 
a colourless solid without further purification. 1H NMR (500 MHz, 
CDCl3) δ 7.66 (d, J = 7.8 Hz, 1H, H-Ar), 7.31 – 7.24 (m, 4H, H-Ar), 
7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, H-Ar), 7.13 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, H-Ar), 7.10 – 7.08 (m, 2H, 
H-Ar), 6.98 (br. s, 1H, H-Ar), 5.74 (br. s, 1H, H-1), 5.30 – 5.23 (m, 2H, H-24), 5.22 – 5.16 (m, 1H, H-12), 
4.49 – 4.29 (m, 1H, H-2), 3.30 (dd, J = 15.1, 5.4 Hz, 1H, H-14), 3.14 (dd, J = 14.6, 7.8 Hz, 1H, H-14), 2.61 
(d, J = 4.8 Hz, 3H, H-13), 1.41 (s, 9H, H-7, H-8, H-9); 13C NMR (125 MHz, CDCl3) δ 172.3 (C-3), 155.6 
(C-10), 141.1 (C-Ar), 137.6 (C-Ar), 136.7 (C-Ar), 128.9 (C-Ar), 128.6 (C-Ar), 128.2(C-Ar), 127.8 (C-Ar), 
127.7 (C-Ar), 127.2(C-Ar), 127.1(C-Ar), 126.9 (C-Ar), 126.9 (C-Ar), 122.2(C-Ar), 119.6 (C-Ar), 119.3 (C-
Ar), 110.2 (C-Ar), 109.9 (C-Ar), 80.1 (C-6), 55.4 (C-2), 50.0 (C-24), 28.7 (C-14), 28.4 (C-7, C-8, C-9), 26.2 
(C-13); HRMS (ESI+) C24H29N3O3Na [M + Na]+ 430.2107, found 430.2104. Data in agreement with 
reported values.110 
(S)-2-Amino-3-(1-benzyl-1H-indol-3-yl)-N-methylpropanamide (181)  
According to general procedure 2, to a solution of N-methylamide 180 
(0.30 g, 0.74 mmol, 1.0 equiv.) in methanol (2.76 mL, 0.25 M) was added 
acetyl chloride (0.26 mL, 3.7 mmol, 5.0 equiv.) dropwise at 0 °C and the 
reaction mixture was left to stir for 3 hours at rt. The title compound was 
formed as a pale yellow solid (0.21 g, 97%) without further purification. 1H 
NMR (500 MHz, CDCl3) δ 7.60 – 7.55 (m, 1H, H-10), 7.28 – 7.19 (m, 4H, 
H-9, H-11, H-12, H-13), 7.13 – 7.08 (m, 2H, H-17, H-19), 7.06 – 7.00 (m, 1H, H-18), 6.89 (d, J = 7.0 Hz, 
2H, H-16, H-20), 5.46 (s, 2H, H-14), 3.70 (dd, J = 14.5, 4.4 Hz, 1H, H-2), 3.44 (dd, J = 14.5, 4.4 Hz, 1H, 






NMR (125 MHz, CDCl3) δ 173.7 (C-3), 141.0 (C-13), 137.9 (C-7), 137.3 (C-15), 128.7 (C-7, C-19), 127.1 
(C-18), 126.8 (C-5), 125.6 (C-16, C-20), 122.0 (C-11), 119.6 (C-12), 118.5 (C-10), 109.8 (C-9), 108.6 (C-6), 
53.5 (C-2), 48.1 (C-14), 26.2 (C-4), 25.9 (C-23). Data in agreement with reported values.110,210 
Imines 
(S)-2-((2,2-Dimethylpropylidene)amino)-N-methyl-3-phenylpropanamide (153a) 
According to general procedure 3, to a solution of N-methylamide 166a (3.80 
g, 21.3 mmol, 1.0 equiv.) in dry CH2Cl2 (21.3 mL, 1.0 M) was added MgSO4 (3.80 
g) followed by pivaldehyde (2.78 mL, 25.6 mmol, 1.2 equiv.) in a 100 mL round 
bottom flask and the reaction mixture was left to stir at rt for 2 h. The title 
compound was formed (4.72 g, 96%) as a colourless solid without further 
purification. 1H NMR (400 MHz, CDCl3) δ 7.20 – 6.97 (m, 5H, H-11, H-12, H-13, H-14, H-15), 6.94 (s, 
1H, H-7), 6.76 (s, 1H, H-5), 3.65 (dd, J = 10.6, 3.0 Hz, 1H, H-2), 3.31 (dd, J = 13.4, 3.0 Hz, 1H, H-4), 2.81 
(d, J = 5.0 Hz, 3H, H-9), 2.69 (dd, J = 13.4, 10.6 Hz, 1H, H-4), 0.82 (s, 9H, H-16, H-17, H-18); 13C NMR 
(100 MHz; CDCl3) δ 174.3 (C-3), 173.4 (C-5), 137.6 (C-10), 130.0 (C-11, C-15), 128.1 (C-13), 126.3 (C-12, 
C-14), 74.3 (C-2), 40.8 (C-4), 36.1 (C-6), 26.5 (C-16, C-17, C-18), 25.9 (C-9); HRMS (ESI+)  C15H22N2O 
[M + H]+ calculated: 247.1805, found: 247.1798. Data in agreement with reported values.24 
(S)-3-(4-(Benzyloxy)phenyl)-2-((2,2-dimethylpropylidene)amino)-N-methylpropanamide (153b) 
According to general procedure 3, N-methylamide 166b (0.35 g, 1.2 
mmol) was dissolved in dry CH2Cl2 (1.23 mL, 1.0 M) before the addition 
of anhydrous MgSO4 (0.35 g) followed by the addition of pivaldehyde 
(0.16 mL, 1.5 mmol, 1.2 equiv.). The reaction mixture was left to stir at 
rt for 2 h. The title compound was formed (0.40 g, 95%) as a white solid 
without further purification. 1H NMR (400 MHz,CDCl3) δ 7.42 – 7.27 
(m, 5H, H-22, H-23, H-24, H-25, H-26), 6.97 (d, J = 8.4 Hz, 2H, H-15, H-17), 6.88 (s, 1H, H-8), 6.85 (d, J 
= 8.4 Hz, 2H, H-14, H-18), 5.02 (s, 2H, H-20), 3.65 (dd, J = 10.4, 3.0 Hz, 1H, H-2), 3.28 (dd, J = 13.5, 3.0 
Hz, 1H, H-4), 2.85 (d, J = 5.0 Hz, 3H, H-7), 2.69 (dd, J = 13.5, 10.4 Hz, 1H, H-4), 0.89 (s, 9H, H-10, H-
11, H-12); 13C NMR (100 MHz, CDCl3) δ 174.0 (C-8), 173.3 (C-3), 157.1 (C-16), 136.8 (C-21), 130.8 (C-
14, C-18), 129.7 (C-13), 127.6 (C-23, C-25), 127.1 (C-24), 114.34 (C-22, C-26), 74.24 (C-15, C-17), 69.7 (C-











According to general procedure 3, to a solution of N-methylamide 166c (1.40 
g, 7.14 mmol) in dry CH2Cl2 (14 mL, 0.5 M) was added MgSO4 (1.40 g, 2.5 equiv.) 
followed by pivaldehyde (0.94 mL, 8.6 mmol, 1.2 equiv.). The reaction mixture 
was left to stir at rt for 2 h. The reaction mixture was filtered and washed with 
CH2Cl2 (10 mL) to afford the title compound (1.80 g, 95%) as a colourless oil 
without further purification. (unstable product used immediately in the next step, 
it degraded over the NMR analysis time). 1H NMR (400 MHz, CDCl3) δ 6.85 (s, 1H, H-11), 6.72 (d, J = 
8.1 Hz, 1H, H-Ar), 6.63 (d, J = 2.0 Hz, 1H, H-Ar), 6.56 (dd, J = 8.1, 2.0 Hz, 1H, H-Ar), 3.82 (d, J = 6.1 
Hz, 6H, H-21, H-22), 3.65 (dd, J = 10.3, 3.0 Hz, 1H, H-2), 3.26 (dd, J = 13.5, 3.0 Hz, 1H, H-4), 2.84 (d, J 
= 5.0 Hz, 3H, H-18), 2.68 (dd, J = 13.5, 10.3 Hz, 1H, H-4), 0.89 (s, 9H, H-13, H-14, H-15); HRMS (ESI+) 
C17H27N2O3 [M + H]+ calculated: 307.2016, found: 307.2017. 
 
(S)-2-((2,2-Dimethylpropylidene)amino)-3-(3-fluorophenyl)-N-methylpropanamide (153d) 
According to general procedure 3, to a solution of N-methylamide 166d (1.40 
g, 7.14 mmol) in dry CH2Cl2 (14 mL, 0.5 M) was added MgSO4 (1.40 g, 2.5 
equiv.) followed by pivaldehyde (0.94 mL, 8.6 mmol, 1.2 equiv.). The reaction 
mixture was left to stir at rt for 2 h. The reaction mixture was filtered and washed 
with CH2Cl2 (10 mL) to afford the title compound (1.80 g, 95%) as a colourless 
oil without further purification. 1H NMR (400 MHz, CDCl3) δ 7.19 (td, J = 7.9, 
6.0 Hz, 1H, H-9), 6.90 – 6.81 (m, 4H, H-8, H-10, H-11, H-17), 6.75 (dt, J = 9.8, 2.1 Hz, 1H, H-6), 3.66 (dd, 
J = 10.5, 3.1 Hz, 1H, H-2), 3.32 (dd, J = 13.4, 3.1 Hz, 1H, H-4), 2.84 (d, J = 5.0 Hz, 3H, H-18), 2.74 (dd, J 
= 13.4, 10.5 Hz, 1H, H-4), 0.88 (s, 9H, H-13, H-14, H-15); 13C NMR (100 MHz, CDCl3) δ 174.9 (C-3), 
173.1 (C-11), 162.9 (d, J = 245.4 Hz, C-7), 140.4 (d, J = 7.3 Hz, C-5), 129.7 (d, J = 8.3 Hz, C-9), 125.7 (d, J 
= 2.9 Hz, C-10), 117.0 (d, J = 21.0 Hz, C-6), 113.4 (d, J = 21.0 Hz, C-8), 74.2 (C-2), 40.7 (d, J = 1.8 Hz, C-
4), 36.4 (C-12), 26.7 (C-13, C-14, C-15), 26.0 (C-18); HRMS (ESI+) C15H22FN2O [M + H]+ calculated: 
265.1711, found: 265.1718. 
 
(S)-2-((2,2-Dimethylpropylidene)amino)-N-methyl-3-(4-nitrophenyl)propanamide (153e) 
According to general procedure 3, N-methylamide 166e (0.50 g, 2.7 mmol) 
was dissolved in dry CH2Cl2 (2.7 mL, 1.0 M) before the addition of anhydrous 
MgSO4 (0.5 g) followed by the addition of pivaldehyde (0.29 mL, 3.2 mmol, 
1.2 equiv.). The reaction mixture was left to stir at rt for 2 h. The reaction 
mixture was filtered and washed with CH2Cl2 (10 mL) to afford the title 
compound (0.40 g, 95%) as a pale yellow solid without further purification. 1H NMR (400 MHz, CDCl3) 
δ 8.09 (d, J = 8.7 Hz, 2H, H-7, H-9), 7.23 (d, J = 8.7 Hz, 2H, H-6, H-10), 6.97 (s, 1H, H-11), 6.70 (s, 1H, 






1H, H-4), 2.82 (d, J = 5.0 Hz, 3H, H-18), 0.89 (s, 9H, H-13, H-14, H-15); 13C NMR (100 MHz, CDCl3) δ 
175.3 (C-11), 172.3 (C-3), 146.7 (C-8), 145.6 (C-5), 130.8 (C-6, C-10), 123.3 (C-7, C-9), 73.7 (C-2), 40.7 (C-
4), 36.5 (C-12), 26.6 (C-14, C-15, C-16), 25.9 (C-18); HRMS (ESI+) C15H21N3O3 [M + H]+ calculated: 
292.1655, found: 292.1664. 
 
(S)-2-((2,2-Dimethylpropylidene)amino)-N-methyl-3-(naphthalen-1-yl)propanamide (153f) 
According to general procedure 3, N-methylamide 166f (4.65 g, 20.4 mmol) 
was dissolved in dry CH2Cl2 (8 mL, 0.5 M) before the addition of anhydrous 
MgSO4 (7.0 g) followed by the addition of pivaldehyde (2.78 mL, 24.4 mmol, 
1.2 equiv.) in a 25 mL round bottom flask. The reaction mixture was left to stir 
at rt for 2 h. The title compound was formed (1.30 g, 89%) as a colourless solid 
without further purification. 1H NMR (400 MHz, CDCl3) δ 8.22 (dd, J = 8.4, 
1.1 Hz, 1H, H-Ar), 7.83 (d, J = 7.6 Hz, 1H, H-Ar), 7.71 (d, J = 8.2 Hz, 1H, H-Ar), 7.54 (ddd, J = 8.4, 6.9, 
1.5 Hz, 1H, H-Ar), 7.47 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H, H-Ar), 7.34 (dd, J = 8.2, 7.0 Hz, 1H, H-Ar), 7.14 (d, 
J = 6.7 Hz, 1H, H-Ar), 7.01 (s, 1H, H-6), 6.44 (s, 1H, H-4), 3.96 (dd, J = 13.7, 2.7 Hz, 1H, H-12), 3.86 (dd, 
J = 10.8, 2.7 Hz, 1H, H-2), 3.07 (dd, J = 13.7, 10.8 Hz, 1H, H-12), 2.92 (d, J = 5.0 Hz, 3H, H-8), 0.71 (s, 
9H, H-9, H-10, H-11); 13C NMR (125 MHz, CDCl3) δ 174.4 (C-4), 173.9 (C-3), 134.0 (C-Ar), 133.8 (C-Ar), 
132.2 (C-Ar), 128.8 (C-Ar), 128.8 (C-Ar), 127.5 (C-Ar), 126.2 (C-Ar), 125.7 (C-Ar), 125.1 (C-Ar), 124.6 (C-
Ar), 73.4 (C-2), 37.9 (C-12), 36.3 (C-5), 26.5 (C-9, H-10, H-11), 26.1 (C-8); HRMS (ESI+) C19H25N2ONa 
[M + Na]+ calculated: 319.1780, found: 319.1788. 
(S)-2-((2,2-Dimethylpropylidene)amino)-N-methyl-3-(naphthalen-2-yl)propanamide (153g) 
According to general procedure 3, N-methylamide 166g (2.0 g, 8.8 mmol) 
was dissolved in dry CH2Cl2 (18 mL, 0.5 M) before the addition of anhydrous 
MgSO4 (2.0 g) followed by the addition of pivaldehyde (1.20 mL, 10.6 mmol, 
1.2 equiv.) in a 50 mL round bottom flask. The reaction mixture was left to 
stir at rt for 2 h. The title compound was formed (2.36 g, 91%) as a yellow oil 
without further purification. 1H NMR (500 MHz, CDCl3) δ 7.67 – 7.59 (m, 
2H, H-Ar), 7.59 – 7.54 (m, 2H, H-Ar), 7.32 (s, 1H, H-Ar), 7.29 – 7.23 (m, 1H, H-Ar), 7.09 (dd, J = 8.0, 1.9 
Hz, 1H, H-Ar), 6.79 – 6.71 (m, 1H, H-6), 6.63 (s, 1H, H-4), 3.62 (dd, J = 10.4, 3.0 Hz, 1H, H-2), 3.33 (dd, 
J = 13.3, 3.0 Hz, 1H, H-12), 2.77 (dd, J = 13.3, 10.4 Hz, 1H, H-12), 2.71 (d, J = 5.0 Hz, 3H, H-8), 0.64 (s, 
9H, H-9, H-10, H-11); 13C NMR (125 MHz, CDCl3) δ 174.6 (C-4), 173.5 (C-3), 135.3 (C-17), 133.4 (C-20), 
132.3 (C-14), 129.0 (C-Ar), 128.3 (C-Ar), 127.9 (C-Ar), 127.7 (C-Ar), 127.6 (C-Ar), 126.1 (C-Ar), 125.5 (C-








According to general procedure 3, N-methylamide 166i (1.0 g, 6.3 mmol) was 
dissolved in dry CH2Cl2 (6 mL, 1.0 M) before the addition of anhydrous MgSO4 
(1.0 g) followed by the addition of pivaldehyde (0.66 mL, 7.6 mmol, 1.2 equiv.) 
in a 25 mL round bottom flask. The reaction mixture was left to stir at rt for 2 h. 
The title compound was formed (1.30 g, 89%) as colourless solid without further 
purification. 1H NMR (400 MHz, CDCl3) δ 7.58 (s, 1H, H-5), 7.39 – 7.34 (m, 2H, H-15, H-16), 7.32 – 7.27 
(m, 2H, H-13, H-17), 7.26 – 7.21 (m, 1H, H-15), 7.01 (br. s, 1H, H-7), 4.72 (s, 1H, H-2), 2.82 (d, J = 5.0 
Hz, 3H, H-9), 1.09 (s, 9H, H-10, H-11, H-12); 13C NMR (100 MHz, CDCl3) δ 174.6 (C-3), 172.2 (C-5), 
139.8 (C-4), 128.4 (C-13, C-17), 127.5 (C-15), 126.8 (C-14, C-16), 76.3 (C-2), 36.7 (C-6), 26.7 (C-10, C-11, 
C-12), 26.0 (C-9); HRMS (ESI+) C14H21N2O [M + H]+ calculated: 233.1648, found: 233.1656. Data in 
agreement with reported values.24 
(S)-2-((2,2-Dimethylpropylidene)amino)-3-(furan-2-yl)-N-methylpropanamide (153j) 
According to general procedure 3, N-methylamide 166j (1.0 g, 6.0 mmol) was 
dissolved in dry CH2Cl2 (12 mL, 0.5 M) before the addition of anhydrous MgSO4 
(1.0 g) followed by the addition of pivaldehyde (0.78 mL, 7.2 mmol, 1.2 equiv.). 
The reaction mixture was left to stir at rt for 2 h. The title compound was formed 
(0.99 g, 70%) as a pale yellow solid without further purification. 1H NMR (500 
MHz, CDCl3) δ 7.28 (dd, J = 1.8, 0.8 Hz, 1H, H-15), 6.98 (s, 1H, H-5), 6.95 (s, 1H, H-7), 6.23 (dd, J = 3.2, 
1.9 Hz, 1H, H-16), 5.97 (d, J = 3.1 Hz, 1H, H-17), 3.83 (dd, J = 10.8, 3.1 Hz, 1H, H-2), 3.34 (dd, J = 14.7, 
3.1 Hz, 1H, H-4), 2.86 (d, J = 5.0 Hz, 3H, H-9), 2.79 (dd, J = 14.7, 10.8 Hz, 1H, H-4), 0.94 (s, 9H, H-11, 
H-12, H-13); 13C NMR (125 MHz, CDCl3) δ 175.0 (C-5), 173.1 (C-3), 151.9 (C-10), 141.5 (C-15), 110.2 (C-
16), 108.2 (C-17), 71.5 (C-2), 36.4 (C-6), 33.4 (C-4), 26.7 (C-11, C-12, C-13), 26.1 (C-9); HRMS (ESI+) 
C13H21N2O2 [M + H]+ calculated: 237.1597, found: 237.1599. 
(S)-2-((2,2-Dimethylpropylidene)amino)-N-methyl-3-(thiophen-2-yl)propanamide (153k) 
According to general procedure 3, to a solution of N-methylamide 166k (1.90 
g, 10.3 mmol, 1.0 equiv.) in dry CH2Cl2 (10 mL, 1.0 M) was added MgSO4 (2.0 g) 
followed by pivaldehyde (1.34 mL, 12.4 mmol, 1.2 equiv.) in a 50 mL round 
bottom flask and the reaction mixture was left to stir at rt for 2 h. The title 
compound was formed (2.38 g, 95%) as a colourless solid without further 
purification. 1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 5.1 Hz, 1H, H-17), 7.03 (s, 1H, H-5), 6.89 – 6.80 
(m, 2H, H-16, H-7), 6.69 (d, J = 3.4 Hz, 1H, H-15), 3.69 (dd, J = 10.1, 3.1 Hz, 1H, H-2), 3.46 (dd, J = 14.5, 
3.1 Hz, 1H, H-4), 3.03 (dd, J = 14.5, 10.1 Hz, 1H, H-4), 2.82 (d, J = 5.0 Hz, 3H, H-9), 0.92 (s, 9H, H-11, 
H-12, H-13); 13C NMR (125 MHz, CDCl3) δ 175.0 (C-3), 172.9 (C-5), 139.7 (C-10), 126.8 (C-15), 126.7 (C-
16), 124.2 (C-17), 74.2 (C-2), 36.4 (C-6), 35.1 (C-4), 26.7 (C-11, C-12, C-13), 26.0 (C-9); HRMS (ESI+) 







According to general procedure 3, to a solution of N-methylamide 166l (0.86 g, 
4.7 mmol, 1.0 equiv.) in dry CH2Cl2 (9.5 mL, 0.5 M) was added MgSO4 (0.80 g, 2.0 
equiv.) followed by pivaldehyde (0.62 mL, 5.6 mmol, 1.20 equiv.) in a 25 mL round 
bottom flask and the reaction mixture was left to stir at rt for 2 h. The title 
compound was formed (0.86 g, 88%) as a colourless solid without further 
purification (unstable compound, used immediately in the next step). 1H NMR (400 MHz, CDCl3) δ 7.24 
– 6.90 (m, 1H, H-16), 6.93 (s, 1H, H-5), 6.89 – 6.84 (m, 3H, H-14, H-17, H-7), 3.70 (d, J = 14.3 Hz, 1H, 
H-2), 3.31 (d, J = 14.3 Hz, 1H, H-4), 2.90 – 2.79 (m, 4H, H-9, H-4), 0.92 (s, 9H, H-11, H-12, H-13); HRMS 
(ESI+) C13H21N2OS [M + H]+ calculated: 253.1369, found: 253.1379. 
(R)-2-((2,2-Dimethylpropylidene)amino)-N-methylpent-4-enamide (153n) 
According to general procedure 3, N-methylamide 166n (0.50 g, 3.3 mmol) was 
dissolved in dry CH2Cl2 (3 mL, 1.0 M) before the addition of MgSO4 (0.5 g) 
followed by the addition of pivaldehyde (0.45 mL, 4 mmol, 1.2 equiv.). The 
reaction mixture was left to stir at rt for 2 h. The title compound was formed 
(0.40 g, 95%) as a pale yellow oil without further purification. 1H NMR (400 MHz, CDCl3) δ 7.33 (s, 1H, 
H-5), 6.83 (br. s, 1H, H-7), 5.61 – 5.40 (m, 1H, H-10), 5.02 – 4.80 (m, 2H, H-11), 3.48 (dd, J = 9.2, 3.5 Hz, 
1H, H-2), 2.77 (dd, J = 4.9, 1.2 Hz, 3H, H-9), 2.59 (dddt, J = 13.5, 8.1, 3.5, 1.3 Hz, 1H, H-4), 2.23 (dddd, J 
= 13.5, 9.2, 8.1, 1.3 Hz, 1H, H-4), 1.00 (d, J = 1.1 Hz, 9H, H-12, H-13, H-14); 13C NMR (100 MHz, CDCl3) 
δ 174.3 (C-5), 173.4 (C-3), 133.9 (C-10), 118.3 (C-11), 71.9 (C-2), 39.1 (C-4), 36.6 (C-6), 26.9 (C-12, C-13, 
C-14), 25.8 (C-9); HRMS (ESI+) C11H21N2O [M + H]+ calculated: 197.1654, found: 197.1648. 
(S)-3-(1-Benzyl-1H-indol-3-yl)-2-((2,2-dimethylpropylidene)amino)-N-methylpropanamide (182) 
According to general procedure 3, N-methylamide 181 (0.10 g, 0.34 
mmol) was dissolved in dry CH2Cl2 (0.3 mL, 1.0 M) before the addition 
of anhydrous MgSO4 (0.1 g) followed by the addition of pivaldehyde (50 
μL, 0.4 mmol, 1.2 equiv.). The title compound was formed (0.12 g, 96%) 
as a colourless solid without further purification. 1H NMR (400 MHz, 
CDCl3) δ 7.62 (ddd, J = 7.7, 1.2, 0.7 Hz, 1H, H-Ar), 7.26 – 7.18 (m, 5H, 
H-Ar), 7.11 (td, J = 8.2, 7.6, 1.3 Hz, 1H, H-Ar), 7.08 – 7.03 (m, 3H, H-
Ar), 6.90 (d, J = 5.2 Hz, 1H, H-7), 6.79 (d, J = 5.8 Hz, 2H, H-4), 5.19 (d, J = 5.2 Hz, 2H, H-18), 3.75 (dd, 
J = 10.1, 3.1 Hz, 1H, H-2), 3.44 (ddd, J = 14.3, 3.1, 0.9 Hz, 1H, H-3), 2.90 (dd, J = 14.3, 10.1 Hz, 1H, H-
3), 2.81 (d, J = 5.0 Hz, 3H, H-8), 0.72 (s, 9H, H-26, H-27, H-28); 13C NMR (100 MHz, CDCl3) δ 173.9 (C-
5), 173.6 (C-4), 137.6 (C-Ar), 136.6 (C-Ar), 128.8 (C-Ar), 128.5 (C-Ar), 127.7 (C-Ar), 127.2 (C-Ar), 126.9 
(C-Ar), 121.8 (C-Ar), 119.8 (C-Ar), 119.1 (C-Ar), 111.2 (C-Ar), 109.6 (C-Ar), 73.7 (C-2), 49.9 (C-18), 36.2 







(2S,5S)-5-Benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154a) 
According to general procedure 4, imine 153a (0.75 g, 3.2 mmol, 1.0 equiv.) was 
dissolved in dry THF (6.65 mL, 0.5 M) in a flame-dried flask and phosgene 
solution (15% wt. in toluene, 6.7 mL, 8.1 mmol, 2.5 equiv.) was added. The 
reaction mixture was stirred at rt for 2 h before pyridine (0.50 mL, 6.5 mmol, 2.0 
equiv.) was added. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to yield the title compound (0.800 g, 82%) as a colourless 
solid. Rf = 0.17 (pet.ether/EtOAc, 6:1); m.p. 95-97 °C; [𝛂]𝐃
𝟐𝟒 = -24° (c = 1 in CHCl3); IR (neat, cm-1): νmax 
= 3030, 2939 (C-H), 1747 (C=O carbamoyl chloride), 1719 (C=O amide); 1H NMR (500 MHz, CDCl3) 
(0.55:0.45 rotamers) δ 7.28 – 7.21 (m, 3H, H-15, H-16, H-17), 7.17 (dd, J = 7.6, 2.0 Hz, 2H, H-14, H-18), 
4.73 (s, 0.55H, H-4), 4.60 (s, 0.45H, H-4), 4.46 (d, J = 4.0 Hz, 0.55H, H-2), 4.43 (d, J = 4.0 Hz, 0.45H, H-
2), 3.88 (dd, J = 14.3, 4.0 Hz, 0.45H, H-1), 3.74 (dd, J = 14.3, 4.0 Hz, 0.55H, H-1), 3.35 (d, J = 14.3 Hz, 
0.45H, H-1’), 3.28 (d, J = 14.3 Hz, 0.55H, H-1’), 2.88 (s, 1.65H, H-3), 2.74 (s, 1.35H, H-3), 1.00 (s, 4.95H, 
H-19, H-20, H-21), 0.93 (s, 4.05H, H-19, H-20, H-21); 13C NMR (125 MHz, CDCl3) δ 170.1 (C-6), 169.5 
(C-6), 147.5 (C-10), 146.3 (C-10), 134.6 (C-13), 134.3 (C-13), 130.4 (C-14, C-18), 130.3 (C-14, C-18), 128.7 
(C-15, C-17), 128.5 (C-15, C-17), 127.8 (C-16), 127.5 (C-16), 83.7 (C-4), 83.1 (C-4), 63.8 (C-2), 63.0 (C-2), 
42.0 (C-7), 42.0 (C-7), 37.0 (C-1), 33.1 (C-1), 32.33 (C-9), 27.0 (C-19, C-20, C-21), 26.8 (C-19, C-20, C-21); 




According to general procedure 4, imine 153b (0.20 g, 0.57 
mmol) was dissolved in dry THF (1.13 mL, 0.5 M) in a 10 mL 
flame-dried flask and phosgene solution (15% wt. in toluene, 1.10 
mL, 1.42 mmol, 2.5 equiv.) was added. The reaction mixture was 
stirred at rt for 2 h before pyridine (0.10 mL, 1.1 mmol, 2.0 equiv.) 
was added. The residue was purified by column chromatography 
(SiO2, pet.ether/EtOAc, 6:1) to afford the title compound (0.17 g, 
74%) as a colourless solid. Rf = 0.13 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟓 = +8° (c = 1 in CHCl3); m.p. 152–
153 °C; IR (neat, cm-1): νmax = 3030, 2967 (C-H), 1739 (C=O carbamoyl chloride), 1707 (C=O amide); 1H 
NMR (500 MHz, CDCl3) (0.55:0.45 rotamers) δ 7.45 – 7.34 (m, 4H, H-23, H-24, H-26, H-27), 7.35 – 7.28 
(m, 1H, H-25), 7.09 (d, J = 8.0 Hz, 2H, H-15, H-19), 6.86 (d, J = 8.0 Hz, 2H, H-16, H-18), 5.03 (s, 2H, H-
21), 4.67 (s, 0.55H, H-2), 4.58 (s, 0.45H, H-2), 4.40 (br. s, 0.55H, H-5), 4.41 (br. s, 0.45H, H-5), 3.75 (dd, J 






3.27 (d, J = 14.3 Hz, 0.55H, H-13’), 2.80 (s, 1.65H, H-29), 2.75 (s, 1.35H, H-29), 0.97 (s, 4.95H, H-7, H-8, 
H-9), 0.92 (s, 4.05H, H-7, H-8, H-9); 13C NMR (125 MHz, CDCl3) δ 169.8 (C4), 169.3 (C-4), 158.0 (C-17), 
157.9 (C-17), 147.2 (C-10), 146.1 (C-10), 137.0 (C-22), 136.9 (C-22), 131.2 (C-15, C-19), 131.1 (C-15, C-19), 
128.6 (C-23, C-27), 128.0 (C-25), 127.6 (C-24, C-26), 126.5 (C-14), 126.1 (C-14), 114.8 (C-16, C-18), 114.6 
(C-16, C-18), 83.4 (C-2), 82.8 (C-2), 70.0 (C-21), 63.7 (C-5), 62.8 (C-5), 41.7 (C-6), 41.6 (C-6), 35.8 (C-13), 
32.0 (C-29), 31.9 (C-29), 26.7 (C-7, C-8, C-9), 26.4 (C-7, C-8, C-9); HRMS (ESI+) C23H27ClN2NaO3 [M + 
Na]+ calculated: 437.1602, found: 437.1605. Data in agreement with reported values.110 
(2S,5S)-2-(tert-Butyl)-5-(3,4-dimethoxybenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride 
(154c) 
According to general procedure 4, imine 153c (5.39 g, 17.6 mmol) was 
dissolved in dry THF (35 mL, 0.5 M) in a 150 mL flame-dried flask and 
phosgene solution (15% wt. in toluene, 33.6 mL, 44.0 mmol, 2.5 equiv.) was 
added. The reaction mixture was stirred at rt for 2 h before pyridine (1.45 
mL, 35.2 mmol, 2.0 equiv.) was added. The residue was purified by column 
chromatography (SiO2, pet.ether/EtOAc, 1:2) to afford the title compound 
(4.50 g, 83%) as a beige solid. Rf = 0.19 (pet.ether/EtOAc, 1:2); [𝛂]𝐃
𝟐𝟒 = -
20° (c = 1 in CHCl3); m.p. 140-141 °C; IR (neat, cm-1): νmax = 2963 (C-H), 2937 (C-H), 1740 (C=O 
carbamoyl chloride), 1708 (C=O amide), 1590; 1H NMR (400 MHz, CDCl3) (0.55:0.45 rotamers) δ 6.90 – 
6.55 (m, 3H), 4.73 (s, 0.55H, H-4), 4.62 (s, 0.45H, H-4), 4.39 (d, J = 14.0 Hz, 1H, H-2), 3.83 (s, 6H, H-24, 
H-25), 3.67 (dd, J = 14.0, 3.5 Hz, 0.57H, H-1), 3.66 (dd, J = 31.3, 14.0 Hz, 0.43H, H-1), 3.29 (d, J = 15.3 
Hz, 0.43H, H-1’), 3.21 (d, J = 14.0 Hz, 0.57H, H-1’), 2.87 (s, 1.65H, H-9), 2.75 (s, 1.35H, H-9), 1.00 (s, 
4.95H, H-20, H-21, H-22), 0.92 (s, 4.05H, H-20, H-21, H-22); 13C NMR (100 MHz, CDCl3) δ 169.8 (C-6), 
168.9 (C-6), 148.5 (C-10), 148.3 (C-10), 148.0, 147.4, 146.1, 126.7, 126.3, 122.5, 113.1, 110.9, 83.5 (C-4), 
82.9 (C-4), 63.9 (C-2), 62.9 (C-2), 55.8 (C-24, C-25), 41.7 (C-1), 36.1 (C-7), 32.3 (C-9), 32.2 (C-9), 26.8 (C-













(2S,5S)-2-(tert-Butyl)-5-(3-fluorobenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154d) 
According to general procedure 4, imine 153d (1.76 g, 6.66 mmol) was dissolved 
in dry THF (13 mL, 0.5 M) in a 100 mL flame-dried flask and phosgene solution 
(15% wt. in toluene, 13.0 mL, 16.6 mmol, 2.5 equiv.) was added. The reaction 
mixture was stirred at rt for 2 h before pyridine (1.00 mL, 13.3 mmol, 2.0 equiv.) 
was added. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to afford the title compound (1.70 g, 82%) as a colourless 
solid. Rf = 0.18 (pet.ether/EtOAc, 6:1); [𝛂]𝐃
𝟐𝟓 = -32° (c = 1 in CHCl3); m.p. 96-
97 °C; IR (neat, cm-1): νmax = 2969 (C-H), 1739 (C=O carbamoyl chloride), 1709 (C=O amide), 1615; 1H 
NMR (500 MHz, CDCl3) (0.6:0.4 rotamers) δ 7.26 – 7.15 (m, 1H, H-Ar), 7.01 – 6.84 (m, 3H, H-Ar), 4.77 
(br. s, 0.60H, H-7), 4.68 (br. s, 0.4H, H-7), 4.49 – 4.37 (m, 1H, H-2), 3.92 – 3.82 (m, 0.4H, H-4), 3.73 (dd, 
J = 14.1, 4.5 Hz, 0.6H, H-4), 3.36 (d, J = 14.1 Hz, 0.4H, H-4), 3.27 (d, J = 14.1 Hz, 0.6H, H-4), 2.91 (s, 
1.8H, H-22), 2.80 (s, 1.2H, H-22), 1.01 (s, 5.4H, H-19, H-20, H-21), 0.94 (s, 3.6H, H-19, H-20, H-21); 13C 
NMR (125 MHz, CDCl3) δ 169.7 (C-3), 169.2 (C-3’), 162.8 (d, J = 245.8 Hz, C-16), 147.2 (C-9’), 146.2 (C-
9), 137.0 (d, J = 7.3 Hz, C-12), 136.6 (d, J = 7.8 Hz, C-12’), 130.0 (d, J = 7.5 Hz, C-14), 129.8 (d, J = 7.9 
Hz, 14’), 126.0 (C-13), 125.9 (C-13’), 116.9 (d, J = 21.5 Hz, C-17), 114.6 (d, J = 21.2 Hz, C-14’), 114.3 (d, J 
= 21.0 Hz, C-14), 83.6 (C-7), 83.0 (C-7’), 63.3 (C-2), 62.4 (C-2’), 41.9 (C-8’), 41.7 (C-8), 36.4 (C-4), 32.6 (C-
22’), 32.2 (C-22), 26.8 (C-19, C-20, C-21), 26.6 (C-19’, C-20’, C-21’); HRMS (ESI+) C16H21ClFN2O2 [M + 
H]+ calculated: 327.1270, found: 327.1260. 
(2S,5S)-2-(tert-Butyl)-3-methyl-5-(4-nitrobenzyl)-4-oxoimidazolidine-1-carbonyl chloride (154e) 
According to general procedure 4, imine 153e (0.21 g, 0.76 mmol) was 
dissolved in dry THF (1.43 mL, 0.5 M) in a 10 mL flame-dried flask, then 
phosgene solution (15% wt. in toluene, 1.45 mL, 1.89 mmol, 2.5 equiv.) was 
added. The reaction mixture was stirred at rt for 2 h. To the reaction mixture, 
pyridine (60 μL, 1.5 mmol, 2.0 equiv.) was added and left to stir for 30 min. 
The residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 
6:1) to afford the title compound (0.21 g, 80%) as a colourless solid. Rf = 0.16 (pet.ether/EtOAc, 4:1); 
[𝛂]𝐃
𝟐𝟓 = -8° (c = 1 in CHCl3); m.p. 129-130 °C; IR (neat, cm-1): νmax = 2969 (C-H), 1738 (C=O carbamoyl 
chloride), 1708 (C=O amide), 1520, 1344 (N-O); 1H NMR (400 MHz, CDCl3) (0.65:0.35 rotamers) δ 8.09 
(d, J = 8 Hz, 2H, H-15, H-17), 7.36 (d, J = 8 Hz, 2H, H-14, H-18), 4.76 (s, 0.65H, H-4), 4.68 (s, 0.35H, H-
4), 4.49 (br. s, 1H, H-2), 3.98 (d, J = 16 Hz, 0.35H, H-1), 3.86 (dd, J = 12, 4 Hz, 0.65H, H-1), 3.48 (d, J = 
12 Hz, 0.35H, H-1’), 3.38 (d, J = 16 Hz, 0.65H, H-1’), 2.90 (s, 1.95H, H-9), 2.78 (s, 1.05H, H-9), 0.99 (s, 
5.85H, H-19, H-20, H-21), 0.93 (s, 3.15H, H-19, H-20, H-21); 13C NMR (100 MHz, CDCl3) δ 169.1 (C-6), 
147.2 (C-16), 146.1 (C-10), 142.4 (C-13), 131.0 (C-15, C-17), 123.3 (C-14, C-18), 83.5 (C-4), 82.9 (C-4), 62.9 
(C-2), 62.0 (C-2), 41.7 (C-7), 41.5 (C-7), 32.6 (C-1), 32.0 (C-9), 26.7 (C-19, C-20, C-21), 26.5 (C-19, C-20, 








According to general procedure 4, imine 153f (1.27 g, 4.29 mmol) was dissolved 
in dry THF (8.5 mL, 0.5 M), phosgene solution (15% wt. in toluene, 15.0 mL, 10.7 
mmol, 2.5 equiv.) was added dropwise. The reaction mixture was stirred at rt for 
2 h. To the reaction mixture, pyridine (0.70 mL, 8.6 mmol, 2.0 equiv.) was added 
and left to stir for 30 min. The residue was purified by column chromatography 
(SiO2, pet.ether/EtOAc, 2:1) to yield the title compound (1.13 g, 74%) as a beige 
solid. Rf = 0.31 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟓 = -48° (c = 1 in CHCl3); m.p. 
108-109 °C; IR (neat, cm-1): νmax = 3045, 2968 (C-H), 1720 (C=O carbamoyl chloride), 1712 (C=O amide); 
1H NMR (500 MHz, CDCl3) (rotameric mixture) δ 8.27 (s, 1H, H-Ar), 7.83 (d, J = 8.1 Hz, 1H, H-Ar), 7.75 
(d, J = 7.8 Hz, 1H, H-Ar), 7.54 (t, J = 7.7 Hz, 1H, H-Ar), 7.47 (t, J = 7.5 Hz, 1H, H-Ar), 7.43 – 7.34 (m, 
2H, H-Ar), 5.20 – 4.48 (m, 1H, H-2), 4.68 – 4.47 (m, 1H, H-5), 4.06 (dd, J = 14.9, 2.7 Hz, 1H, H-14), 4.16 
– 3.49 (m, 1H, H-14), 3.17 – 2.25 (m, 3H, H-6), 0.99 (s, 9H, H-11, H-12, H-13); 13C NMR (125 MHz, 
CDCl3) (major rotamer) δ 170.1 (C-4), 146.2 (C-7), 133.9 (C-Ar), 132.3 (C-Ar), 131.7 (C-Ar), 128.7 (C-Ar), 
128.2 (C-Ar), 127.9 (C-Ar), 126.1 (C-Ar), 125.6 (C-Ar), 125.1 (C-Ar), 124.2 (C-Ar), 83.2 (C-2), 61.9 (C-5), 
41.8 (C-10), 32.1 (C-6), 31.0 (C-14), 26.8 (C-11, C-12, C-13); HRMS (ESI+) C20H24ClN2O2 [M + H]+ 




According to general procedure 4, imine 153g (2.28 g, 7.70 mmol) was dissolved 
in dry THF (15 mL, 0.5 M), phosgene solution (15% wt. in toluene, 15.0 mL, 19.3 
mmol, 2.5 equiv.) was added dropwise. The reaction mixture was stirred at rt for 
2 h. To the reaction mixture, pyridine (1.25 mL, 15 mmol, 2.0 equiv.) was added 
and left to stir for 30 min. The residue was purified by column chromatography 
(SiO2, pet.ether/EtOAc, 2:1) to yield the title compound (2 g, 73%) as a yellow 
oil. Rf = 0.31 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟓 = -24°  (c = 1 in CHCl3); m.p. 145-
146 °C; IR (neat, cm-1): νmax = 3056, 2968 (C-H), 1717 (C=O carbamoyl chloride), 1711 (C=O amide); 1H 
NMR (500 MHz, CDCl3) δ 7.83 – 7.76 (m, 2H, H-Ar), 7.76 – 7.70 (m, 1H, H-Ar), 7.67 (s, 1H, H-Ar), 7.50 
– 7.41 (m, 2H, H-Ar), 7.33 – 7.26 (m, 1H, H-Ar), 4.63 (s, 0.6H, H-2), 4.57 – 4.46 (m, 1.4H, H-2, H-5), 4.04 
(dd, J = 14.4, 5.3 Hz, 0.4H, H-15), 3.92 (dd, J = 14.3, 5.3 Hz, 0.6H, H-15), 3.53 (d, J = 14.3 Hz, 0.4H, H-
15), 3.43 (d, J = 14.3 Hz, 0.6H, H-15), 2.83 (s, 3H, 1.8H, H-6), 2.70 (s, 1.2H, H-6), 0.99 (s, 5.4H, H-12, H-
13, H-14), 0.91 (s, 3.6H, H-12, H-13, H-14); 13C NMR (125 MHz, CDCl3) δ 169.9 (C-4), 169.5 (C-4), 147.3 
(C-Ar), 146.4 (C-7), 133.5 (C-7), 132.7 (C-Ar), 132.0 (C-Ar), 131.6 (C-Ar), 129.4 (C-Ar), 129.3 (C-Ar), 128.3 






(C-2), 63.9 (C-5), 62.9 (C-5), 41.8 (C-15), 41.7 (C-15), 36.9 (C-11), 33.0 (C-6), 32.2 (C-6), 26.8 (C-12, C-13, 
C-14), 26.5 (C-12, C-13, C-14); HRMS (ESI+) C20H24ClN2O2 [M + H]+ calculated: 359.1520, found: 
359.1534. 
 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-phenylimidazolidine-1-carbonyl chloride (154i) 
According to general procedure 4, imine 153i (0.57 g, 2.6 mmol) was dissolved in 
dry THF (5 mL, 0.5 M), phosgene solution (15% wt. in toluene, 5.0 mL, 6.6 mmol, 
2.5 equiv.) was added dropwise. The reaction mixture was stirred at rt for 2 h. To 
the reaction mixture, pyridine (0.45 mL, 5.3 mmol, 2.0 equiv.) was added and left 
to stir for 30 min. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 2:1) to yield the title compound (0.22 g, 72%) as a colourless 
solid. Rf = 0.15 (pet. ether/EtOAc 3:1); [𝛂]𝐃
𝟐𝟒 = -24° (c = 1 in CHCl3); m.p. 170-171 °C; IR (neat, cm-1):  
νmax = 2970 (C-H), 1718, 1710 (C=O); 1H NMR (400 MHz, CDCl3) (rotameric mixture) δ 7.43 – 7.31 (m, 
3H, H-Ar), 7.24 – 7.17 (m, 2H, H-Ar), 5.45 (s, 0.78H, H-2), 5.37 (s, 0.22H, H-2), 5.06 (s, 0.22H, H-5), 5.03 
(s, 0.78H, H-5), 3.14 (s, 0.66H, H-9), 3.08 (s, 2.34H, H-9), 1.15 (s, 1.98H, H-18, H-19, H-20), 1.10 (s, 7.02H, 
H-18, H-19, H-20); 13C NMR (100 MHz, CDCl3) δ 169.0 (C-4), 148.7 (C-10), 137.7 (C-8), 129.2 (C-13, C-
17), 129.0 (C-15), 128.8 (C-14, C-16), 82.7 (C-2), 66.0 (C-5), 41.5 (C-7), 32.4 (C-9), 26.3 (C-18, C-19, C-20); 
HRMS (ESI+) C15H20ClN2O2 [M + H]+ calculated: 295.1208, found: 295.1207. Data in agreement with 
reported values.110 
(2S,5S)-2-(tert-butyl)-3-methyl-4-oxo-5-phenethylimidazolidine-1-carbonyl chloride (154h) 
According to general procedure 4, imine 153h (2.90 g, 11.2 mmol) was dissolved in 
dry THF (23 mL, 0.5 M), phosgene solution (15% wt. in toluene, 16 mL, 28 mmol, 
2.5 equiv.) was added dropwise. The reaction mixture was stirred at rt for 2 h. To the 
reaction mixture, pyridine (1.86 mL, 22.3 mmol, 2.0 equiv.) was added and left to stir 
for 30 min. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to yield the title compound (2.90 g, 82%) as a colourless solid. 
Rf = 0.13 (pet. ether/EtOAc 6:1); [𝛂]𝐃
𝟐𝟓 = -24° (c = 1 in CHCl3); m.p. 82-83 °C, IR 
(neat, cm-1): νmax = 3026, 2968 (C-H), 1737 (C=O carbamoyl chloride), 1710 (C=O amide); 1H NMR (500 
MHz, CDCl3, 50 °C) (rotameric mixture) δ 7.27 (t, J = 7.5 Hz, 3H, H-18, H-20), 7.21 – 7.16 (m, 3H, H-17, 
H-19, H-20), 5.15 (s, 1H, H-2), 4.25 (br. s, 1H, H-5), 3.00 (s, 3H, H-7), 2.78 (br. s, 1H, H-15), 2.58 – 2.31 
(m, 3H, H-14, H-15), 1.06 (s, 9H, H-11, H-12, H-13); 13C NMR (125 MHz, CDCl3, 50 °C) δ 170.0 (C-4), 
145.7 (C-6), 140.4 (C-16), 128.7 (C-18, C-20), 128.6 (C-17, C-21), 126.3 (C-19), 83.6 (C-2), 61.8 (C-5), 41.6 
(C-10), 32.7 (C-15), 32.1 (C-7), 29.6 (C-14), 26.8 (C-11, C-12, C-13); HRMS (ESI+) C17H23ClN2O2 [M + 









According to general procedure 4, imine 153j (0.84 g, 3.6 mmol, 1.0 equiv.) was 
dissolved in dry THF (7.0 mL, 0.5 M) in a flame-dried flask and phosgene solution 
(15% wt. in toluene, 6.72 mL, 8.92 mmol, 2.5 equiv.) was added. The reaction 
mixture was stirred at rt for 2 h before pyridine (0.59 mL, 7.2 mmol, 2.0 equiv.) 
was added. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to afford the title compound (0.83 g, 83%) as a beige solid. 
Rf = 0.2 (pet.ether/EtOAc, 6:1); [𝛂]𝐃
𝟐𝟓 = +16° (c = 1 in CHCl3); m.p. 123-125 °C; IR (neat, cm-1): νmax = 
2968 (C-H), 1738, 1709 (C=O); 1H NMR (400 MHz, CDCl3) (0.55:0.45 rotamers) δ 7.30 (s, 1H, H-19), 
6.29 – 6.23 (m, 1H, H-17), 6.16 – 6.07 (m, 1H, H-18), 4.87 (s, 0.55H, H-2), 4.81 (s, 0.45H, H-2), 4.39 – 4.27 
(m, 1H, H-5), 4.00 (dd, J = 15.4, 5.5 Hz, 0.55H, H-14), 3.88 (dd, J = 15.4, 5.1 Hz, 0.45H, H-14), 3.43 (d, J 
= 15.4 Hz, 0.55H, H-14’), 3.29 (d, J = 15.4 Hz, 0.45H, H-14’), 2.97 (s, 1.65H, H-6), 2.91 (s, 1.35H, H-6), 
1.02 (s, 4.95H, H-11, H-12, H-13), 0.96 (s, 4.05H, H-11, H-12, H-13); 13C NMR (125 MHz, CDCl3) δ 169.9 
(C-4), 169.6 (C-4), 149.2 (C-7), 148.7 (C-7), 147.4 (C-16), 146.2 (C-16), 142.7, 142.3, 110.5, 110.4, 109.6, 
109.3, 83.7 (C-2), 82.9 (C-2), 61.7 (C-5), 60.8 (C-5), 41.6 (C-10), 41.5 (C-10), 32.5 (C-6), 32.5 (C-6), 30.2 (C-
14), 26.7 (C-11, C-12, C-13), 26.4 (C-11, C-12, C-13); HRMS (ESI+) C14H20ClN2O3 [M + H]+ calculated: 
299.1156, found: 229.1160. 
(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-(thiophen-2-ylmethyl)imidazolidine-1-carbonyl chloride 
(154k) 
According to general procedure 4, imine 153k (2.10 g, 8.53 mmol, 1.0 equiv.) 
was dissolved in dry THF (16 mL, 0.5 M) in a flame-dried flask and phosgene 
solution (15% wt. in toluene, 16 mL, 21 mmol, 2.5 equiv.) was added. The reaction 
mixture was stirred at rt for 2 h before pyridine (1.34 mL, 16.7 mmol, 2.0 equiv.) 
was added. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to afford the title compound (1.90 g, 73%) as a colourless 
solid. Rf = 0.14 (pet.ether/EtOAc, 6:1); [𝛂]𝐃
𝟐𝟓 = -16° (c = 1 in CHCl3); m.p. 119-120 °C; IR (neat, cm-1): 
νmax = 2968 (C-H), 1738, 1709 (C=O); 1H NMR (500 MHz, CDCl3) (0.55:0.45 rotamers) δ 7.16 – 7.07 (m, 
1H, H-19), 6.87 (t, J = 4.1 Hz, 1H, H-18), 6.83 (d, J = 3.5 Hz, 1H, H-17), 4.81 (s, 0.55H, H-4), 4.76 (s, 
0.45H, H-4), 4.40 – 4.28 (m, 1H, H-2), 4.14 (dd, J = 15.4, 4 Hz, 0.45H, H-1), 4.04 (dd, J = 15.4, 4 Hz, 
0.55H, H-1), 3.56 (d, J = 15.4 Hz, 0.45H, H-1), 3.39 (d, J = 15.4 Hz, 0.55H, H-1), 2.94 (s, 1.65H, H-9), 2.85 
(s, 1.35H, H-9), 0.99 (s, 4.95H, H-14, H-15, H-16), 0.92 (s, 4.05H, H-14, H-15, H-16); 13C NMR (125 MHz, 
CDCl3) δ 169.5 (C-6), 169.1 (C-6), 146.8 (C-10), 146.0 (C-10), 135.2 (C-13), 134.6 (C-13), 128.6 (C-19), 
128.4 (C-19), 126.9 (C-18), 126.6 (C-18), 125.5 (C-17), 125.1 (C-17), 83.6 (C-4), 83.0 (C-4), 63.1 (C-2), 61.9 
(C-2), 41.6 (C-7), 41.4 (C-7), 32.4 (C-9), 31.4 (C-1), 27.8 (C-1), 26.7 (C-19, C-20, C-21), 26.4 (C-19, C-20, 








According to general procedure 4, imine 153l (0.58 g, 2.3 mmol) was dissolved 
in dry THF (4.6 mL, 0.5 M) in a 10 mL flame-dried flask and phosgene solution 
(15% wt. in toluene, 4.4 mL, 5.8 mmol, 2.5 equiv.) was added. The reaction 
mixture was stirred at rt for 2 h before pyridine (0.37 mL, 4.6 mmol, 2.0 equiv.) 
was added. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 6:1) to afford the title compound (0.56 g, 78%) as a colourless 
solid. Rf = 0.26 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟓 = -32° (c = 1 in CHCl3); m.p. 103-104 °C; IR (neat, cm-
1): νmax = 2967 (C-H), 1741, 1712 (C=O); 1H NMR (500 MHz, CDCl3) (0.58:0.42 rotamers) δ 7.25 – 7.17 
(m, 1H, H-18), 7.07 (d, J = 9.4 Hz, 1H, H-20), 6.86 (d, J = 4.7 Hz, 1H, H-17), 4.78 (s, 0.58H, H-4), 4.69 (s, 
0.42H, H-4),4.46 – 4.31 (m, 1H, H-2), 3.99 (dd, J = 16, 4 Hz, 0.47H, H-1), 3.84 (dd, J = 16, 4 Hz, 0.53H, 
H-1), 3.27 (dd, J = 16, 4 Hz, 0.46H, H-1), 3.24 (dd, J = 16, 4 Hz, 0.53H, H-1), 2.92 (s, 1.74H, H-9), 2.81 (s, 
1.26H, H-9), 0.98 (s, 5.22H, H-19, H-20, H-21), 0.92 (s, 3.78H, H-19, H-20, H-21); 13C NMR (125 MHz, 
CDCl3) δ 170.0 (C-6), 169.6 (C-10), 147.0 (C-10), 146.2, 134.2, 133.7, 129.1, 128.7, 125.8, 125.3, 124.6, 83.7 
(C-4), 82.9 (C-4), 63.3 (C-2), 62.3 (C-2), 41.7 (C-7), 41.5 (C-7), 32.3 (C-9), 31.5 (C-1), 27.8 (C-1), 26.8 (C-
14, C-15, C-16), 26.5 (C-14, C-15, C-16); HRMS (ESI+) C14H19ClN2O2S [M + H]+ calculated: 315.0929, 
found: 315.0928. 
(2S,5S)-5-Allyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154n) 
According to general procedure 4, imine 153n (2.85 g, 14.5 mmol) was dissolved 
in dry THF (29 mL, 0.5 M), and phosgene solution (15% wt. in toluene, 28.0 mL, 
36.3 mmol, 2.5 equiv.) was added. The reaction mixture was stirred at rt for 2 h. To 
the reaction mixture, pyridine (2.3 mL, 29 mmol, 2.0 equiv.) was added and left to 
stir for 30 min. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 4:1) to afford the title compound (3.20 g, 84%) as a pale yellow solid. Rf = 0.32 
(pet.ether/EtOAc = 4:1); [𝛂]𝐃
𝟐𝟓 = -72° (c = 1 in CHCl3); m.p. 98-100 °C; IR (neat, cm-1): νmax = 3086, 2969 
(C-H), 1741, 1708 (C=O); 1H NMR (400 MHz, CDCl3) (0.55:0.45 rotamers) δ 5.48 – 5.33 (m, 1H, H-14), 
5.26 – 5.17 (m, 1H, H-14), 5.17 – 5.03 (m, 2H, H-2, H-13), 4.20 (d, J = 13.1 Hz, 1H, H-5), 3.45 – 3.15 (m, 
1H, H-12), 3.02 (s, 3H, H-8), 2.71 (dd, J = 21.3, 12.5 Hz, 1H, H-12), 1.05 (s, 4.95H, H-15, H-16, H-17), 
1.00 (s, 4.05H, H-15, H-16, H-17); 13C NMR (100 MHz, CDCl3) δ 169.9 (C-4), 169.7 (C-4), 147.7 (C-9), 
145.6 (C-9), 130.2 (C-13), 129.6 (C-13), 121.6 (C-14), 121.1 (C-14), 83.9 (C-2), 83.0 (C-2), 62.2 (C-5), 61.0 
(C-5), 41.5 (C-7), 41.3 (C-7), 35.2 (C-8), 32.2 (C-12), 31.5 (C-12), 29.9 (C-8), 26.7 (C-15, C-16, C-17), 26.4 










According to general procedure 5, N-chloroformylimidazolidinone 154a (2.50 g, 
8.10 mmol) was dissolved in dry MeCN (8.0 mL, 1.0 M) in a 10 mL microwave vial 
before the addition of potassium iodide (1.5 g, 8.9 mmol, 1.1 equiv.) followed by the 
addition of 2,6-lutidine (1.00 mL, 16.2 mmol, 2.0 equiv.). The reaction was complete 
after 2 min at 150 °C in a microwave reactor. The residue was purified by column 
chromatography (SiO2, pet.ether/EtOAc, 1:2) to yield the title compound (2.1 g, 
95%) as a colourless solid. Rf = 0.14 (pet.ether/EtOAc = 1:2); [𝛂]𝐃
𝟐𝟓 = -284° (c = 1 in CHCl3); m.p. 158-
161 °C; IR (neat, cm-1): νmax = 2964, 2928, 2874 (C-H), 1705, 1661 (C=O); 1H NMR (500 MHz, CDCl3) δ 
7.93 (dd, J = 7.6, 1.4 Hz, 1H, H-12), 7.46 (td, J = 7.5, 1.5 Hz, 1H, H-11), 7.37 (tt, J = 7.5, 1.1 Hz, 1H, H-
10), 7.24 (d, J = 7.5 Hz, 1H, H-9), 5.39 (d, J = 0.9 Hz, 1H, H-3), 4.44 (ddt, J = 13.3, 5.5, 0.8 Hz, 1H, H-1), 
3.24 (dd, J = 13.3, 5.5 Hz, 1H, H-15), 3.09 (d, J = 0.6 Hz, 3H, H-8), 3.01 – 2.77 (m, 1H, H-15), 1.06 (s, 9H, 
H-18, H-19, H-20); 13C NMR (125 MHz, CDCl3) δ 171.7 (C-5), 162.5 (C-16), 135.1 (C-13), 132.4 (C-11), 
130.1 (C-14), 127.9 (C-12), 127.7 (C-10), 127.4 (C-9), 81.0 (C-3), 56.6 (C-1), 40.5 (C-6), 32.0 (C-8), 30.4 (C-




According to general procedure 5, N-Chloroformylimidazolidinone 154c (2.00 
g, 7.05 mmol) was dissolved in dry MeCN (5.5 mL, 1.0 M) in a 10 mL microwave 
vial before the addition of potassium iodide (1.00 g, 5.39 mmol, 1.1 equiv.) 
followed by the addition of 2,6-lutidine (90.0 μL , 5.93 mmol, 1.1 equiv.). The 
reaction was complete after 10 sec at 150 °C in a microwave reactor. The residue 
was purified by column chromatography (SiO2, pet.ether/EtOAc, 4:1) to afford 
the title compound (1.70 g, 95%) as a colourless solid. Rf = 0.1 
(pet.ether/EtOAc, 4:1); [𝛂]𝐃
𝟐𝟓 = -196° (c = 1 in CHCl3); m.p. 124-125 °C; IR (neat, cm-1): νmax = 2962 (C-
H), 1701, 1654 (C=O); 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H, H-13), 6.68 (s, 1H, H-16), 5.36 (d, J = 
1.0 Hz, 1H, H-4), 4.45 (dd, J = 13.3, 5.8 Hz, 1H, H-2), 3.93 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.15 (dd, J 
= 15.5, 5.8 Hz, 1H, H-1), 3.11 – 3.05 (m, 3H, H-8), 2.88 (ddd, J = 15.5, 13.3, 1.0 Hz, 1H, H-1), 1.07 (s, 9H, 
H-23, H-24, H-25); 13C NMR (100 MHz, CDCl3) δ 171.9 (C-6), 162.3 (C-9), 152.3 (C-15), 148.5 (C-14), 
128.5 (C-11), 122.4 (C-12), 110.4 (d, J = 3.8 Hz, C-13), 109.7 (d, J = 3.4 Hz, C-16), 81.0 (d, J = 4.9 Hz, C-
4), 56.6 (C-2), 56.3 (C-19, C-21), 40.5 (C-22), 32.0 (C-8), 29.9 (C-1), 26.7 (C-23, C-24, C-25); HRMS (ESI+) 









According to general procedure 5, N-chloroformylimidazolidinone 154d (2.30 g, 7.05 
mmol) was dissolved in dry MeCN (7 mL, 1 M) in a 10 mL microwave vial before the 
addition of potassium iodide (1.28 g, 7.76 mmol, 1.1 equiv.) followed by the addition 
of 2,6-lutidine (90 μL, 7.8 mmol, 1.1 equiv.). The reaction was complete after 2 min at 
150 °C in a microwave reactor. The residue was purified by column chromatography 
(SiO2, pet.ether/EtOAc, 3:1) to afford the title compound (1.80 g, 90%) as a colourless 
solid. Rf = 0.16 (pet.ether/EtOAc, 4:1); [𝛂]𝐃
𝟐𝟓 = -268° (c = 1 in CHCl3); m.p. 174-175 
°C; IR (neat, cm-1): νmax = 2965 (C-H), 1702, 1660 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 8.6, 
5.7 Hz, 1H, H-12), 7.03 (tdd, J = 8.5, 2.5, 0.9 Hz, 1H, H-11), 6.94 (ddd, J = 8.6, 2.6, 1.1 Hz, 1H, H-9), 5.35 
(d, J = 0.9 Hz, 1H, H-3), 4.44 (dd, J = 15.8, 5.5 Hz, 1H, H-1), 3.22 (dd, J = 15.8, 5.5 Hz, 1H, H-15), 3.08 
(s, 3H, H-8), 2.90 (ddd, J = 15.8, 13.2, 1.2 Hz, 1H, H-15), 1.05 (s, 9H, H, 18, H-19, H-20); 13C NMR (125 
MHz, CDCl3) δ 171.4 (C-5), 165.1 (d, 1JC-F = 253.5 Hz, C-10), 161.6 (C-16), 137.9 (d, 3JC-F = 9.0 Hz, C-14), 
130.7 (d, 3JC-F = 9.4 Hz, C-12), 126.3 (d, 4JC-F = 2.9 Hz, C-14), 114.9 (d, 2JC-F = 21.9 Hz, C-11), 114.4 (d, 2JC-
F = 22.4 Hz, C-9), 81.0 (C-3), 56.4 (C-1), 40.4 (C-6), 32.0 (C-8), 30.4 (d, 4JC-F = 1.6 Hz, C-15), 26.7 (C-18, 




According to general procedure 5, N-chloroformylimidazolidinone 154e 
(200 mg, 0.57 mmol) was dissolved in dry MeCN (0.56 mL, 1.0 M) in a 2 mL 
microwave vial before the addition of potassium iodide (100 mg, 0.62 mmol, 
1.1 equiv.) followed by the addition of 2,6-lutidine (130 μL, 1.14 mmol, 1.1 
equiv.). The reaction was complete after 30 min at 170 °C in a microwave 
reactor. The residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 1:1) to afford the 
title compound (34 mg, 20%) as a bright yellow oil. Rf = 0.33 (pet.ether/EtOAc, 1:1); [𝛂]𝐃
𝟐𝟑 = -240° (c = 
1 in CHCl3); IR (neat, cm-1): νmax = 2965 (C-H), 1702, 1660 (C=O), 1520, 1344 (N-O); 1H NMR (500 
MHz, CDCl3) δ 8.78 (d, J = 2.5 Hz, 1H, H-14), 8.31 (dd, J = 8.3, 2.4 Hz, 1H, H-12), 7.46 (dd, J = 8.3, 1.1 
Hz, 1H, H-11), 5.41 (s, 1H, H-3), 4.48 (dd, J = 13.2, 5.4 Hz, 1H, H-1), 3.41 (dd, J = 16.2, 5.4 Hz, 1H, H-
7), 3.11 (s, 3H, H-6), 2.98 (ddd, J = 16.2, 13.2, 1.3 Hz, 1H, H-7), 1.08 (s, 9H, H-18, H-19, H-20); 13C NMR 
(125 MHz, CDCl3) δ 170.8 (C-5), 160.4 (C-10), 147.9 (C-13), 141.9 (C-9), 131.4 (C-8), 128.8 (C-11), 126.9 
(C-12), 123.4 (C-14), 81.3 (C-3), 56.2 (C-1), 40.5 (C-17), 32.1 (C-6), 30.5 (C-7), 26.6 (C-18, C-19, C-20); 









According to general procedure 5, N-chloroformylimidazolidinone 
154b (0.30 g, 0.73 mmol) was dissolved in dry MeCN (0.73 mL, 1.0 M) 
in a 2 mL microwave vial before the addition of potassium iodide (0.13 
g, 0.70 mmol, 1.1 equiv.) followed by the addition of 2,6-lutidine (93 μL 
, 0.79 mmol, 1.1 equiv.). The reaction was complete after 5 min at 150 
°C in a microwave reactor. The residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 
1:1) to afford the title compound (0.22 g, 76%) as a colourless solid. Rf = 0.33 (pet.ether/EtOAc, 1:1); 
[𝛂]𝐃
𝟐𝟑 = -208° (c = 1 in CHCl3); m.p. 165-166 °C; IR (neat, cm-1): νmax = 3030, 2966 (C-H), 1706, 1661 
(C=O); 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 2.7 Hz, 1H, H-3), 7.46 – 7.41 (m, 2H, H-25, H-28), 
7.38 (dd, J = 8.3, 6.6 Hz, 2H, H-26, H-28), 7.35 – 7.30 (m, 1H, H-27), 7.16 (dd, J = 8.3, 1.0 Hz, 1H, H-6), 
7.08 (dd, J = 8.3, 2.8 Hz, 1H, H-1), 5.39 (s, 1H, H-11), 5.14 – 5.06 (m, 2H, H-23), 4.43 (dd, J = 15.5, 5.5 
Hz, 1H, H-21), 3.20 (dd, J = 15.5, 5.5 Hz, 1H, H-10), 3.09 (s, 3H, H-14), 2.84 (dd, J = 14.7, 13.1 Hz, 1H, 
H-10), 1.06 (s, 9H, H-17, H-18, H-19); 13C NMR (125 MHz, CDCl3) δ 171.7 (C-13), 162.4 (C-7), 158.4 (C-
2), 136.6 (C-24), 131.0 (C-4), 128.7 (C-26, C-28), 128.6 (C-6), 128.2 (C-27), 127.6 (C-25, C-29), 127.4 (C-5), 
120.2 (C-1), 112.7 (C-3), 81.0 (C-11), 70.4 (C-23), 56.8 (C-9), 40.5 (C-16), 32.0 (C-14), 29.6 (C-10), 26.7 (C-




According to general procedure 5, N-chloroformylimidazolidinone 154f (2.50 g, 
6.96 mmol) was dissolved in dry MeCN (7 mL, 1 M) in a 10 mL microwave vial before 
the addition of potassium iodide (1.27 g, 7.70 mmol, 1.1 equiv.) followed by the 
addition of 2,6-lutidine (0.90 mL, 7.7 mmol, 1.1 equiv.). The reaction was complete 
after 5 min at 150 °C in a microwave reactor. The residue was purified by column 
chromatography (SiO2, pet.ether/EtOAc, 1:2) to afford the title compound (2.1 g, 
93%) as a colourless solid. Rf = 0.13 (pet.ether/EtOAc = 1:2); [𝛂]𝐃
𝟐𝟓 = -256° (c = 1 
in CHCl3); m.p. 153-154 °C; IR (neat, cm-1): νmax = 3053, 2966 (C-H), 1703, 1658 (C=O); 1H NMR (500 
MHz, CDCl3) δ 8.12 – 8.07 (m, 1H, H-Ar), 8.02 (d, J = 8.6 Hz, 1H, H-Ar), 7.93 – 7.89 (m, 1H, H-Ar), 7.85 
(dd, J = 8.6, 1.1 Hz, 1H, H-Ar), 7.65 – 7.56 (m, 2H, H-Ar), 5.45 (d, J = 1.0 Hz, 1H, H-3), 4.55 (ddt, J = 
13.3, 6.0, 0.8 Hz, 1H, H-1), 4.01 (dd, J = 16.3, 6.0 Hz, 1H, H-11), 3.15 (d, J = 0.6 Hz, 3H, H-7), 3.04 (ddd, 
J = 16.3, 13.3, 1.2 Hz, 1H, H-11), 1.11 (s, 9H, H-22, H-23, H-24); 13C NMR (125 MHz, CDCl3) δ 172.0 






(2 × C-Ar), 124.4 (C-Ar), 123.9 (C-Ar), 81.2 (C-3), 56.3 (C-1), 40.5 (C-9), 32.1 (C-7), 26.7 (C-22, C-23, C-




According to general procedure 5, N-chloroformylimidazolidinone 154g (2.5 g, 
8.1 mmol) was dissolved in dry MeCN (8.0 mL, 1.0 M) in a 10 mL microwave vial 
before the addition of potassium iodide (1.5 g, 8.9 mmol, 1.1 equiv.) followed by 
the addition of 2,6-lutidine (1.0 mL, 16 mmol, 2 equiv.). The reaction was 
complete after 5 min at 150 °C in a microwave reactor. The residue was purified 
by column chromatography (SiO2, pet.ether/EtOAc, 1:2) to yield the title 
compound (2.1 g, 95%) as a colourless solid. Rf = 0.13 (pet.ether/EtOAc = 1:2); 
[𝛂]𝐃
𝟐𝟓 = -400° (c = 1 in CHCl3); m.p. 153-154 °C; IR (neat, cm-1): νmax = 2966 (C-H), 1704, 1655 (C=O); 
1H NMR (500 MHz, CDCl3) δ 8.97 (d, J = 8.6 Hz, 1H, H-Ar), 7.91 (d, J = 8.2 Hz, 1H, H-Ar), 7.82 (dd, J 
= 8.2, 1.3 Hz, 1H, H-Ar), 7.59 (ddd, J = 8.5, 6.8, 1.3 Hz, 1H, H-Ar), 7.52 – 7.47 (m, 1H, H-Ar), 7.32 (d, J 
= 8.3 Hz, 1H, H-Ar), 5.56 (s, 1H, H-3), 4.42 (dd, J = 13.4, 5.0 Hz, 1H, H-1), 3.32 (dd, J = 15.7, 5.0 Hz, 1H, 
H-9), 3.12 (s, 3H, H-6), 3.07 (dd, J = 15.7, 13.4 Hz, 1H, H-9), 1.09 (s, 9H, H-22, H-23, H-24); 13C NMR 
(125 MHz, CDCl3) δ 171.5 (C-5), 163.1 (C-12), 135.0 (C-Ar), 133.3 (C-Ar), 132.7 (C-Ar), 130.8 (C-Ar), 
128.4 (C-Ar), 128.1 (C-Ar), 126.1 (C-Ar), 126.0 (C-Ar), 125.8 (C-Ar), 125.1 (C-Ar), 80.3 (C-3), 56.4 (C-1), 
40.1 (C-8), 32.1 (C-6), 31.9 (C-9), 26.4 (C-22, C-23, C-24); HRMS (ESI+) C20H23N2O2 [M + H]+ calculated: 
323.1754, found: 323.1768. 
(3S,11aS)-3-(tert-butyl)-2-methyl-2,3,11,11a-tetrahydro-1H-benzo[e]imidazo[1,5-a]azepine-
1,5(10H)-dione (156i) 
According to general procedure 5, N-chloroformylimidazolidinone 154h (0.20 
g, 0.62 mmol, 1.0 equiv.) was dissolved in dry MeCN (0.65 mL, 1.0 M) in a 2 mL 
microwave vial before the addition of potassium iodide (0.11 g, 0.68 mmol, 1.1 
equiv.) followed by the addition of 2,6-lutidine (0.08 mL, 0.68 mmol, 2.0 equiv.). 
The reaction was complete after 10 min at 150 °C in a microwave reactor. The 
residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 4:1) to yield the title compound 
(0.06 g, 35%) as a pale yellow foam. [𝛂]𝐃
𝟐𝟑 = -164° (c = 1 in CHCl3); Rf = 0.08 (pet.ether/EtOAc = 4:1); 
IR (neat, cm-1): νmax = 2964 (C-H), 1707, 1630 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.98 (dd, J = 7.7, 1.4 
Hz, 1H, H-3), 7.37 (td, J = 7.7, 1.4 Hz, 1H, H-2), 7.28 (d, J = 7.7 Hz, 1H, H-1), 7.21 (d, J = 7.7 Hz, 1H, H-
6), 5.72 (s, 1H, H-12), 4.03 (dd, J = 8.7, 1.7 Hz, 1H, H-9), 3.29 – 3.14 (m, 2H, H-11), 3.08 (s, 3H, H-15), 
2.69 (dtd, J = 14.7, 4.8, 1.7 Hz, 1H, H-10), 2.05 (dtt, J = 14.7, 8.7, 4.8 Hz, 1H, H-10), 0.98 (s, 9H, H-19, H-






130.8 (C-2), 130.0 (C-6), 126.4 (C-1), 80.1 (C-12), 60.3 (C-18), 40.5 (C-9), 34.1 (C-11), 32.1 (C-15), 31.8 (C-
10), 26.5 (C-19, C-20, C-21); HRMS (ESI+) C17H23N2O2 [M + H]+ calculated: 287.1754, found: 287.1759. 
 
(3S,8aS)-3-(tert-Butyl)-2-methyl-2,3,8,8a-tetrahydroimidazo[1,5-a]pyridine-1,5-dione (156j) 
According to general procedure 5, N-chloroformylimidazolidinone 154n (0.20 g, 
0.77 mmol) was dissolved in dry MeCN (5.0 mL, 0.15 M) in a 10 mL microwave vial 
before the addition of potassium iodide (0.14 g, 0.85 mmol, 1.1 equiv.) followed by 
the addition of 2,6-lutidine (0.96 mL, 0.85 mmol, 1.1 equiv.). The reaction was heated 
in a microwave reactor for 10 min at 150 °C. The residue was purified by column 
chromatography (SiO2, pet.ether/EtOAc, 6:1) to afford the title compound (0.18 g, 65%) as a colourless 
solid. Rf = 0.28 (pet.ether/EtOAc, 1:4); [𝛂]𝐃
𝟐𝟎 = -12° (c = 1 in CHCl3); m.p. 108-110 °C; IR (neat, cm-1): 
νmax = 2962, 2917 (C-H), 1707, 1672 (C=O). 1H NMR (400 MHz, CDCl3) δ 6.57 – 6.47 (m, 1H, H-13), 
5.99 (dd, J = 9.9, 3.0 Hz, 1H, H-12), 5.22 (s, 1H, H-2), 4.35 (dd, J = 13.0, 7.1 Hz, 1H, H-5), 3.05 (s, 3H, H-
8), 2.73 (dt, J = 16.7, 7.1 Hz, 1H, H-11), 2.32 (dd, J = 16.7, 13.0 Hz, 1H, H-11), 1.03 (s, 9H, H-14, H-15, 
H-16); 13C NMR (100 MHz, CDCl3) δ 171.9 (C-4), 161.0 (C-9), 136.6 (C-13), 125.3 (C-12), 80.7 (C-2), 55.6 
(C-5), 40.2 (C-7), 31.8 (C-8), 26.5 (C-14, C-15, C-16), 25.6 (C-11); HRMS (ESI+) C12H18N2O2Na [M + 
Na]+ 245.1266, found 245.1262. 
(6S,8aS)-6-(tert-Butyl)-7-methyl-6,7,8a,9-tetrahydrofuro[2,3-d]imidazo[1,5-a]pyridine-4,8-dione 
(156k) 
According to general procedure 5, N-chloroformylimidazolidinone 154j (0.20 g, 
0.70 mmol) was dissolved in dry MeCN (4.5 mL, 0.15 M) in a 10 mL microwave vial 
before the addition of potassium iodide (0.13 g, 0.74 mmol, 1.1 equiv.) followed by 
the addition of 2,6-lutidine (0.15 mL, 1.3 mmol, 2.0 equiv.). The reaction was 
complete after 5 min at 150 °C in a microwave reactor. The residue was purified by 
column chromatography (SiO2, pet.ether/EtOAc, 6:1) to afford the title compound 
(0.11 g, 63%) as a brown solid. Rf = 0.4 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟓 = +108° (c = 1 in CHCl3); m.p. 
126-128 °C; IR (neat, cm-1): νmax = 2966 (C-H), 1706 (C=O), 1673 (C=O); 1H NMR (500 MHz, CDCl3) δ 
7.35 – 7.32 (m, 1H, H-12), 6.76 – 6.56 (m, 1H, H-13), 5.21 (s, 1H, H-4), 4.61 (dd, J = 12.2, 8.3 Hz, 1H, H-
2), 3.30 (dd, J = 12.2, 8.3 Hz, 1H, H-3), 3.04 (s, 3H, H-9), 2.99 – 2.88 (m, 1H, H-3), 1.04 (s, 9H, H-17, H-
18, H-19); 13C NMR (125 MHz, CDCl3) δ 171.3 (C-6), 159.9 (C-15), 155.7 (C-11), 143.4 (C-12), 115.8 (C-
10), 108.1 (C-13), 80.7 (C-4), 56.4 (C-2), 40.5 (C-5), 32.1 (C-9), 26.8 (C-17, C-18, C-19), 24.6 (C-3); HRMS 










According to general procedure 5, N-chloroformylimidazolidinone 154k (0.20 g, 
0.64 mmol) was dissolved in dry MeCN (4.3 mL, 0.15 M) in a 10 mL microwave vial 
before the addition of potassium iodide (0.12 g, 0.70 mmol, 1.1 equiv.) followed by 
the addition of 2,6-lutidine (0.15 mL, 1.3 mmol, 2.0 equiv.). The reaction was 
complete after 5 min at 150 °C in a microwave reactor. The residue was purified by 
column chromatography (SiO2, pet.ether/EtOAc, 6:1) to afford the title compound 
(0.18 g, 65%) as a brown solid. Rf = 0.14 (pet.ether/EtOAc, 6:1); [𝛂]𝐃
𝟐𝟓 = -204° (c = 1 in CHCl3); m.p. 
169-170 °C; IR (neat, cm-1): νmax = 3090, 2967 (C-H), 1698 (C=O), 1682 (C=O); 1H NMR (500 MHz, 
CDCl3) δ 7.37 (d, J = 5.2 Hz, 1H, H-16), 7.15 (dd, J = 5.2, 1.1 Hz, 1H, H-15), 5.29 (s, 1H, H-4), 4.60 (dd, 
J = 13.0, 6.7 Hz, 1H, H-2), 3.43 (dd, J = 16.5, 6.7 Hz, 1H, H-1), 3.08 (s, 3H, H-8), 2.97 (ddd, J = 16.5, 13.0, 
1.1 Hz, 1H, H-1), 1.07 (s, 9H, H-18, H-19, H-20); 13C NMR (125 MHz, CDCl3) δ 171.3 (C-6), 158.9 (C-9), 
142.0 (C-12), 132.9 (C-16), 126.1 (C-13), 124.3 (C-15), 80.8 (C-4), 57.5 (C-2), 40.6 (C-17), 32.1 (C-8), 26.8 




According to general procedure 5, N-Chloroformylimidazolidinone 154l (40 mg, 
0.13 mmol) was dissolved in dry MeCN (0.85 mL, 0.15 M) in a 1 mL microwave vial 
before the addition of potassium iodide (20 mg, 0.14 mmol, 1.1 equiv.) followed by 
the addition of 2,6-lutidine (30 μL, 0.25 mmol, 2.0 equiv.). The reaction was 
complete after 5 min at 150 °C in a microwave reactor. The residue was purified by 
column chromatography (SiO2, pet.ether/EtOAc, 6:1) to yield the title compound 
(30 mg, 63%) as a colourless solid. Rf = 0.17 (pet.ether/EtOAc = 6:1); [𝛂]𝐃
𝟐𝟑 = -176° (c = 1 in CHCl3); 
m.p. 171-172 °C; IR (neat, cm-1): νmax = 3087, 2977 (C-H), 1701 (C=O), 1687 (C=O); 1H NMR (500 MHz, 
CDCl3) δ 7.48 (d, J = 4.9 Hz, 1H, H-17), 6.89 (d, J = 4.9 Hz, 1H, H-16), 5.23 (s, 1H, H-4), 4.54 (dd, J = 
13.1, 7.0 Hz, 1H, H-2), 3.29 (dd, J = 16.4, 7.0 Hz, 1H, H-1), 3.04 (s, 3H, H-9), 2.78 (dd, J = 16.4, 13.1 Hz, 
1H, H-1), 1.04 (s, 9H, H-13, H-14, H-15); 13C NMR (125 MHz, CDCl3) δ 171.6 (C-6), 158.1 (C-10), 140.8 
(C-19), 131.5 (C-17), 131.3 (C-12), 126.6 (C-16), 80.8 (C-4), 57.3 (C-2), 40.5 (C-7), 32.0 (C-9), 26.7 (C-13, 











According to general procedure 4, imine 182 (0.16 g, 0.40 mmol) was 
dissolved in dry THF (0.9 mL, 0.5 M) in a 10 mL flame-dried flask, 
phosgene solution (15% wt. in toluene, 0.9 mL, 1.0 mmol, 2.5 equiv.) was 
added dropwise. The reaction mixture was stirred at rt for 2 h. To the 
reaction mixture, pyridine (0.80 mL, 0.88 mmol, 2.0 equiv.) was added and 
left to stir for 30 min. The residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 4:1) 
to afford the title compound (0.10 g, 70%) as a yellow foam. [𝛂]𝐃
𝟐𝟓 = -256° (c = 1 in CHCl3); IR (neat, cm-
1): νmax = 2969 (C-H), 1718, 1704 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.60 (d, J = 8.0 Hz, 1H, H-17), 
7.37 (d, J = 8.4 Hz, 1H, H-20), 7.30 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H, H-19), 7.26 – 7.13 (m, 6H, H-18, H-23, 
H-24, H-25, H-26, H-27), 5.82 (d, J = 15.8 Hz, 1H, H-21), 5.73 (d, J = 15.8 Hz, 1H, H-21), 5.33 (s, 1H, H-
2), 4.65 (dd, J = 13.2, 7.2 Hz, 1H, H-5), 3.53 (dd, J = 16.2, 7.2 Hz, 1H, H-9), 3.11 (s, 3H, H-6), 3.00 (dd, J 
= 16.2, 13.2 Hz, 1H, H-9), 1.04 (s, 9H, H-28, H-29, H-30); 13C NMR (125 MHz, CDCl3) δ 172.1 (C-4), 
157.7 (C-11), 139.0 (C-15), 138.3 (C-22), 128.7 (C-23, C-27), 127.4 (C-25), 127.1 (C-24, C-26), 126.4 (C-10), 
125.4 (C-19), 124.4 (C-14), 120.8 (C-18), 120.6 (C-17), 116.3 (C-13), 111.1 (C-20), 80.3 (C-2), 58.0 (C-5), 
47.8 (C-21), 40.6 (C-8), 32.1 (C-6), 26.8 (C-28, C-29, C-30), 23.3 (C-9); HRMS (ESI+) C25H28N3O2 [M + 




According to general procedure 6, lactam 156a (52 mg, 0.19 mmol, 1.0 equiv.) was 
dissolved in THF (1.3 mL) and degassed by bubbling N2 into the solution. The 
solution was cooled to –78 °C before dropwise addition of methyl iodide (0.12 mL, 
1.90 mmol, 10.0 equiv.). LDA solution (2 M in THF, 1.5 equiv.) was added dropwise. 
Upon addition of LDA, the reaction mixture turned red before becoming yellow (24 
h later) when the reaction was quenched. Purification by flash column 
chromatography (SiO2, 1.5:1, pet.ether:EtOAc) yielded the title compound (0.03 g, 60%) as a pale yellow 
oil. Rf = 0.26 (pet.ether/EtOAc 1:1); [𝛂]𝐃
𝟐𝟎= -303° (c = 1, CHCl3); m.p. 150-154 °C; IR (neat, cm-1): νmax 
= 2964, 2925 (C-H), 1708, 1662 (C=O); 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 7.2 Hz, 1H, H-15), 
7.47 (t, J = 7.2 Hz, 1H, H-14), 7.38 (t, J = 7.5 Hz, 1H, H-13), 7.23 (d, J = 7.5 Hz, 1H, H-12), 5.41 (s, 1H, 
H-2), 4.52 (d, J = 4.6 Hz, 1H, H-5), 3.39 – 3.30 (m, 1H, H-8), 3.11 (s, 2H, H-7), 1.06 (s, 9H, H-18, H-19, 
H-20), 1.03 (d, J = 6.9 Hz, 3H, H-21); 13C NMR (100 MHz, CDCl3) δ 170.4 (C-4), 162.5 (C-11), 142.1 (C-










According to general procedure 6, lactam 156a (50 mg, 0.21 mmol, 1.0 equiv.) was 
dissolved in THF (1.4 mL) and ethyl iodide (0.17 mL, 2.1 mmol, 10 equiv.) was added. 
The mixture was degassed and cooled to –78 °C. LDA solution (2 M in THF, 1.25 
equiv.) was added dropwise. Upon addition of LDA, the reaction mixture turned dark 
red. The reaction was complete after 3 h (yellow solution). Purification by flash column 
chromatography (SiO2, 1.5:1, pet.ether:EtOAc) yielded the title compound (35 mg, 
56%) as a pale yellow solid. Rf = 0.24 (pet.ether/EtOAc 1.5:1); [𝛂]𝐃
𝟐𝟎 = -252.8° (c = 1, CHCl3); m.p. 125–
127 °C; IR (neat, cm-1): νmax = 2967, 2931, 2875 (C-H), 1707 (C=O), 1663 (C=O); 1H NMR (400 MHz, 
CDCl3) δ 7.92 (d, J = 7.4 Hz, 1H, H-15), 7.45 (t, J = 7.4 Hz, 1H, H-14), 7.39 (t, J = 7.3 Hz, 1H, H-13), 7.20 
(d, J = 7.3 Hz, 1H, H-12), 5.38 (s, 1H, H-2), 4.54 (d, J = 4.0 Hz, 1H, H-5), 3.10 (s, 3H, H-7), 3.03 (dt, J = 
7.5, 4.0 Hz, 1H, H-8), 1.70 – 1.55 (m, 1H, H-18), 1.21 – 1.12 (m, 1H, H-18), 1.04 (s, 9H, H-19, H-20, H-
21), 0.66 (t, J = 7.5 Hz, 3H, H-22); 13C NMR (100 MHz, CDCl3) δ 170.5 (C-4), 162.9 (C-11), 139.6 (C-10), 
131.6 (C-14), 129.8 (C-9), 128.3 (C-12), 128.1 (C-15), 127.8 (C-13), 80.7 (C-2), 61.3 (C-5), 40.9 (C-8), 40.8 
(C-6), 31.9 (C-7), 26.6 (C-19, C-20, C-21), 23.0 (C-18), 10.9 (C-22); HRMS (ESI+) C18H24N2O2Na [M + 
Na]+ 323.1735, found 323.1731. 
 (3aR,6S,12bR)-6-(tert-butyl)-5-methyl-1,2,3,5,6,12b-hexahydro-4H,8H-cyclopenta[c]imidazo[1,5-
b]isoquinoline-4,8-dione (188d) 
Lactam 156a (100 mg, 0.37 mmol) was dissolved in dry THF (3.7 mL, 0.1 M) and 1,3-
dibromopropane (0.37 mL, 3.7 mmol, and 10 equiv.) was added. The mixture was 
degassed and cooled to –78 °C. LDA solution (2.0 M in THF, 0.37 mL, 0.74 mmol, 
2.0 equiv.) was added dropwise and left to stir for 30 min at –78 °C, then the second 
portion of LDA solution (2.0 M in THF, 0.37 mL, 0.74 mmol, 2.0 equiv.) was added 
dropwise at –78 °C and left to stir for at rt for 2 h. The reaction mixture was washed 
with aqueous HCl (1.0 M, 3 × 1 mL) and brine (3 × 1 mL). The resulting solution was dried over MgSO4, 
filtered and concentrated under reduced pressure. The residue was chromatographed (SiO2, 
pet.ether/EtOAc, 4:1) to yield the title compound (100 mg, 86%) as a colourless solid. Rf = 0.47 
(pet.ether/EtOAc 4:1); [𝛂]𝐃
𝟐𝟎 = +33° (c = 1 in CHCl3); m.p. 145-147 °C; IR (neat, cm-1): νmax = 2957, 2872 
(C-H), 1694 (C=O), 1665 (C=O); 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 7.7 Hz, 1H, H-11), 7.54 (t, J 
= 7.4 Hz, 1H, H-10), 7.43 (d, J = 7.8 Hz, 1H, H-8), 7.35 (t, J = 7.5 Hz, 1H, H-9), 5.40 (s, 1H, H-3), 3.63 
(d, J = 5.8 Hz, 1H, H-14), 3.06 (s, 3H, H-7), 2.87 (ddt, J = 12.7, 5.8, 3.5 Hz, 1H, H-20), 2.30 (dd, J = 12.7, 






0.97 (s, 9H, H-17, H-18, H-19); 13C NMR (100 MHz, CDCl3) δ 174.1 (C-5), 164.4 (C-15), 142.0 (C-12), 
133.1 (C-10), 130.5 (C-13), 128.3 (C-11), 127.4 (C-8), 126.9 (C-9), 80.1 (C-3), 69.2 (C-1), 44.4 (C-14), 41.2 
(C-6), 39.9 (C-21), 33.0 (C-7), 31.0 (C-20), 27.2 (C-17, C-18, C-19), 20.9 (C-22); HRMS (ESI+) 
C19H24N2O2Na [M + Na]+ 335.1735, found 335.1729. 
(3S,10aS)-3-(tert-butyl)-2,10a-dimethyl-2,3,10,10a-tetrahydroimidazo[1,5-b]isoquinoline-1,5-dione 
(189a) 
According to general procedure 7, lactam 156a (0.20 g, 0.73 mmol) was dissolved 
in dry THF (7.0 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C, then KHMDS 
solution (2.0 M in THF, 0.55 mL, 1.1 mmol, 1.5 equiv.) was added. The reaction 
mixture was stirred at rt for 1 h. To the reaction mixture methyl iodide (0.25 mL, 3.7 
mmol, and 5.0 equiv.) was added and left to stir for 30 min. The residue was purified 
by column chromatography (SiO2, pet.ether/EtOAc, 1.5:1) to yield the title 
compound (0.19 g, 91%) as a colourless solid. Rf = 0.26 (pet.ether/EtOAc 1.5:1); [𝛂]𝐃
𝟐𝟓 = +8° (c = 1 in 
CHCl3); m.p. 117–118 °C, IR (neat, cm-1): νmax = 3068, 2968 (C-H), 1710, 1670 (C=O); 1H NMR (500 
MHz, CDCl3) δ 8.22 (dd, J = 7.8, 1.4 Hz, 1H, H-12), 7.57 (td, J = 7.5, 1.5 Hz, 1H, H-11), 7.46 (tt, J = 7.6, 
1.1 Hz, 1H, H-10), 7.39 (dd, J = 7.0, 1.9 Hz, 1H, H-9), 5.50 (s, 1H, H-3), 3.48 (d, J = 15.9 Hz, 1H, H-15), 
3.18 (d, J = 15.9 Hz, 1H, H-15), 3.17 (s, 3H, H-8), 1.43 (s, 3H, H-18), 1.12 (s, 9H, H-19, H-20, H-21); 13C 
NMR (125 MHz, CDCl3) δ 173.5 (C-5), 164.5 (C-16), 137.0 (C-13), 132.7 (C-11), 130.6 (C-14), 129.3 (C-
9), 128.4 (C-12), 127.2 (C-10), 80.5 (C-3), 61.8 (C-1), 40.7 (C-6), 35.9 (C-15), 32.9 (C-8), 27.3 (C-19, C-20, 
C-21), 25.9 (C-18); HRMS (ESI+) C17H23N2O2 [M + H]+ calculated: 287.1754, found 287.1761. 
(3S,10aR)-10a-Allyl-3-(tert-butyl)-2-methyl-2,3,10,10a-tetrahydroimidazo[1,5-b]isoquinoline-1,5-
dione (189b) 
According to general procedure 7, lactam 156a (100 mg, 0.37 mmol) was dissolved 
in dry THF (3.7 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under N2, then 
KHMDS solution (1.0 M in THF, 0.55 mL, 0.55 mmol, 1.5 equiv.) was added 
dropwise and left to stir for 30 min at 0 °C. To the reaction mixture allyl bromide 
(0.16 mL, 1.8 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue 
was purified by column chromatography (SiO2, pet.ether/EtOAc, 3:1) to yield the 
title compound (110 mg, 98%) as a colourless oil. Rf = 0.28 (pet.ether/EtOAc 3:1); [𝛂]𝐃
𝟐𝟓 = +36° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax = 3079, 2966 (C-H), 1709, 1772 (C=O); 1H NMR (400 MHz, CDCl3) δ 8.16 
(dd, J = 7.9, 1.3 Hz, 1H, H-13), 7.49 (td, J = 7.5, 1.5 Hz, 1H, H-14), 7.38 (t, J = 7.5 Hz, 1H, H-15), 7.28 (d, 
J = 7.6 Hz, 1H, H-16), 5.64 – 5.48 (m, 1H, H-18), 5.29 (s, 1H, H-4), 5.10 – 5.04 (m, 1H, H-19), 4.99 (ddd, 
J = 17.2, 2.7, 1.5 Hz, 1H, H-19), 3.41 (d, J = 16.1 Hz, 1H, H-1), 3.11 (d, J = 16.1 Hz, 1H, H-1), 3.03 (s, 3H, 
H-8), 2.53 (dd, J = 13.8, 7.0 Hz, 1H, H-17), 2.35 (dd, J = 13.8, 8.1 Hz, 1H, H-17), 1.03 (s, 9H, H-21, H-22, 






130.6 (C-11), 129.3 (C-16), 128.6 (C-13), 127.3 (C-15), 120.5 (C-19), 82.1 (d, J = 3.1 Hz, C-4), 65.8 (C-2), 
42.5 (C-17), 40.9 (C-20), 35.4 (C-1), 32.7 (C-8), 27.5 (C-21, C-22, C-23); HRMS (ESI+) C19H25N2O2 [M + 
H]+ calculated: 313.1911, found 313.1910. 
(3S,10aR)-10a-Benzyl-3-(tert-butyl)-2-methyl-2,3,10,10a-tetrahydroimidazo[1,5-b]isoquinoline-1,5-
dione (189c) 
According to general procedure 7, lactam 156a (0.40 g, 1.47 mmol) was dissolved 
in dry THF (14.7 mL, 0.1 M) in a 25 mL flame-dried flask at 0 °C under N2, then 
KHMDS solution (1.0 M in THF, 2.2 mL, 2.2 mmol, 1.5 equiv.) was added dropwise 
and left to stir for 30 min at 0 °C. To the reaction mixture benzyl bromide (0.87 mL, 
7.4 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue was 
purified by column chromatography (SiO2, pet.ether/EtOAc, 2:1) to yield the title 
compound (0.19 g, 84%) as a colourless oil. Rf = 0.23 (pet.ether/EtOAc 2:1). [𝛂]𝐃
𝟐𝟓 = +172° (c = 1 in 
CHCl3); m.p. 85-86 °C; IR (neat, cm-1): νmax = 3060, 2964 (C-H), 1709, 1670 (C=O); 1H NMR (400 MHz, 
CDCl3) δ 8.27 (dd, J = 7.8, 1.4 Hz, 1H, H-Ar), 7.53 (td, J = 7.5, 1.4 Hz, 1H, H-Ar), 7.43 (t, J = 7.6 Hz, 1H, 
H-Ar), 7.35 (d, J = 7.5 Hz, 1H, H-Ar), 7.31 – 7.22 (m, 3H, H-Ar), 7.08 – 7.03 (m, 2H, H-Ar), 4.52 (s, 1H, 
H-11), 3.50 (d, J = 16.0 Hz, 1H, H-10), 3.22 (d, J = 16.0 Hz, 1H, H-10), 3.07 (d, J = 13.5 Hz, 1H, H-21), 
2.79 (d, J = 13.5 Hz, 1H, H-21), 2.41 (s, 3H, H-20), 0.92 (s, 9H, H-16, H-17, H-18); 13C NMR (100 MHz, 
CDCl3) δ 171.5 (C-13), 164.3 (C-7), 137.2 (C-Ar), 135.1 (C-Ar), 133.0 (C-Ar), 130.7 (C-Ar), 130.1 (2 × C-
Ar), 129.3 (C-Ar), 128.8 (C-Ar), 128.3 (2 × C-Ar), 127.5 (C-Ar), 127.3 (C-Ar), 82.2 (C-11), 67.6 (C-9), 43.7 
(C-21), 40.8 (C-15), 36.0 (C-10), 32.5 (d, J = 2.8 Hz, C-20), 27.6 (C-16, C-17, C-18); HRMS (ESI+) 
C23H26N2O2 [M + H]+ calculated: 363.2067, found 363.2076. 
(3S,10aR)-3-(tert-Butyl)-7,8-dimethoxy-2,10a-dimethyl-2,3,10,10a-tetrahydroimidazo[1,5-
b]isoquinoline-1,5-dione (189g) 
According to general procedure 7, lactam 156b (100 mg, 0.3 mmol) was 
dissolved in dry THF (3 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under 
N2, then KHMDS solution (1.0 M in THF, 0.6 mL, 0.6 mmol, 2 equiv.) was added 
dropwise and left to stir for 30 min at 0 °C. To the reaction mixture methyl iodide 
(0.19 mL, 3.0 mmol, and 10 equiv.) was added and left to stir at rt for 3 h. The 
residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 1:1) to 
yield the title compound (100 mg, 97%) as a colourless oil. [𝛂]𝐃
𝟐𝟓 = +4° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax = 3079, 2965 (C-H), 1698 (C=O), 1662 (C=O); 1H NMR (400 MHz, CDCl3) 
δ 7.59 (s, 1H, H-13), 6.71 (s, 1H, H-16), 5.35 (s, 1H, H-4), 3.91 (s, 3H, H-20), 3.91 (s, 3H, H-21), 3.31 (d, J 
= 15.8 Hz, 1H, H-1), 3.05 (s, 3H, H-8), 2.95 (d, J = 15.8 Hz, 1H, H-1), 1.33 (s, 3H, H-17), 1.00 (s, 9H, H-
23, H-24, H-25); 13C NMR (100 MHz, CDCl3) δ 173.7 (C-6), 164.5 (C-9), 152.6 (C-15), 148.0 (C-14), 130.8 






(C-1), 32.9 (C-8), 27.3 (C-23, C-24, C-25), 25.7 (C-17); HRMS (ESI+) C19H27N2O4 [M + H]+ calculated: 
347.1965, found 347.1970. 
(3S,10aR)-10a-Allyl-3-(tert-butyl)-7,8-dimethoxy-2-methyl-2,3,10,10a-tetrahydroimidazo[1,5-
b]isoquinoline-1,5-dione (189f) 
According to general procedure 7, lactam 156b (180 mg, 0.54 mmol) was 
dissolved in dry THF (5.6 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under 
N2, then KHMDS solution (1.0 M in THF, 1.1 mL, 1.1 mmol, 2 equiv.) was added 
dropwise and left to stir for 15 min at 0 °C. To the reaction mixture allyl bromide 
(0.23 mL, 2.7 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The 
residue was purified by column chromatography (SiO2, pet.ether/EtOAc, 2:1) to 
yield the title compound as a colourless solid (190 mg, 91%). Rf = 0.24 
(pet.ether/EtOAc 2:1); [𝛂]𝐃
𝟐𝟓 = +64° (c = 1 in CHCl3); m.p. 133-134 °C; IR (neat, cm-1): νmax = 3075, 2963 
(C-H), 1705 (C=O), 1664 (C=O); 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H, H-13), 6.70 (s, 1H, H-16), 
5.62 – 5.45 (m, 1H, H-18), 5.25 (s, 1H, H-4), 5.04 (dd, J = 10.2, 2.0 Hz, 1H, H-19), 4.98 (dd, J = 17.2, 2.0 
Hz, 1H, H-19), 3.92 (s, 3H, H-22), 3.92 (s, 3H, H-23), 3.33 (dt, J = 15.9, 1.5 Hz, 1H, H-1), 2.99 (s, 3H, H-
8), 2.98 (d, J = 15.9 Hz, 1H, H-1), 2.59 (dd, J = 13.7, 8.2 Hz, 1H, H-17), 2.31 (dd, J = 13.7, 8.2 Hz, 1H, H-
17), 1.00 (s, 9H, H-25, H-26, H-27); 13C NMR (100 MHz, CDCl3) δ 172.4 (C-6), 164.3 (C-9), 152.6 (C-15), 
148.0 (C-14), 131.3 (C-18), 130.8 (C-11), 123.1 (C-12), 120.4 (C-19), 111.3 (C-16), 110.6 (C-13), 82.1 ( C-4), 
66.1 (C-2), 56.2 (C-22), 56.2 (C-23), 42.2 (C-17), 40.8 (C-24), 35.1 (C-1), 32.7 (C-8), 27.5 (C-25, C-26, C-
27); HRMS (ESI+) C21H29N2O4 [M + H]+ calculated: 373.2122, found 373.2142. 
(3S,10aR)-3-(tert-butyl)-8-fluoro-2,10a-dimethyl-2,3,10,10a-tetrahydroimidazo[1,5-b]isoquinoline-
1,5-dione (189d) 
According to general procedure 7, lactam 156c (100 mg, 0.34 mmol) was dissolved 
in dry THF (3.4 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under N2, then 
KHMDS solution (1.0 M in THF, 0.52 mL, 0.52 mmol, 1.5 equiv.) was added 
dropwise and left to stir for 30 min at 0 °C. To the reaction mixture methyl iodide 
(0.1 mL, 1.7 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue 
was purified by column chromatography (SiO2, pet.ether/EtOAc, 3:1) to yield the 
title compound (73 mg, 70%) as a yellow oil. Rf = 0.22 (pet.ether/EtOAc 3:1); [𝛂]𝐃
𝟐𝟓 
= +12° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2967 (C-H), 1707 (C=O), 1670 (C=O); 1H NMR (400 
MHz, CDCl3) δ 8.14 (dd, J = 8.6, 5.8 Hz, 1H, H-13), 7.07 – 7.01 (m, 1H, H-14), 6.99 (dd, J = 8.6, 2.4 Hz, 
1H, H-16), 5.38 (s, 1H, H-4), 3.37 (d, J = 16.0 Hz, 1H, H-1), 3.08 (s, 3H, H-8), 3.08 (d, J = 16.3 Hz, 2H, 
H-1), 1.35 (s, 3H, H-17), 1.02 (s, 9H, H-20, H-21, H-22); 13C NMR (100 MHz, CDCl3) δ 173.3 (C-6), 165.3 
(d, 1JC-F = 254.2 Hz, C-15), 163.8 (C-9), 140.2 (d, 3JC-F = 9.1 Hz, C-11), 131.2 (d, 3JC-F = 9.6 Hz, C-13), 127.0 






2), 40.8 (C-19), 36.2 (d, 4JC-F = 1.3 Hz, C-1), 33.0 (C-8), 27.4 (C-20, C-21, C-22), 25.9 (C-17); HRMS (ESI+) 
C17H22FN2O2 [M + H]+ calculated: 305.1669, found 305.1660. 
(3S,10aR)-10a-allyl-3-(tert-butyl)-8-fluoro-2-methyl-2,3,10,10a-tetrahydroimidazo[1,5-
b]isoquinoline-1,5-dione (189e) 
According to general procedure 7, lactam 156c (300 mg, 1 mmol) was dissolved in 
dry THF (10 mL, 0.1 M) in a 25 mL flame-dried flask at 0 °C under N2, then KHMDS 
solution (1.0 M in THF, 2.0 mL, 2.0 mmol, 2 equiv.) was added dropwise and left to 
stir for 30 min at 0 °C. To the reaction mixture allyl bromide (0.45 mL, 5.0 mmol, 
and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue was purified by 
column chromatography (SiO2, pet.ether/EtOAc, 4:1) to yield the title compound 
(240 mg, 91%) as a colourless oil. Rf = 0.31 (pet.ether/EtOAc 4:1). [𝛂]𝐃
𝟐𝟑 = +32° (c 
= 1 in CHCl3); IR (neat, cm-1): νmax = 3079, 2966 (C-H), 1709 (C=O), 1673 (C=O); 1H NMR (400 MHz, 
CDCl3) δ 8.14 (dd, J = 8.7, 5.8 Hz, 1H, H-12), 7.07 – 6.97 (m, 1H, H-11), 6.96 (dd, J = 9.4, 2.6 Hz, 1H, H-
9), 5.52 (dddd, J = 16.9, 10.2, 8.1, 6.9 Hz, 1H, H-22), 5.25 (s, 1H, H-3), 5.05 (dd, J = 10.2, 1.5 Hz, 1H, H-
23), 4.97 (dd, J = 17.0, 1.5 Hz, 1H, H-23), 3.36 (d, J = 16.2 Hz, 1H, H-15), 3.07 (d, J = 16.2 Hz, 1H, H-15), 
2.99 (s, 3H, H-8), 2.48 (dd, J = 13.6, 6.8 Hz, 1H, H-18), 2.33 (dd, J = 13.6, 8.1 Hz, 1H, H-18), 0.99 (s, 9H, 
H-19, H-20, H-21); 13C NMR (100 MHz, CDCl3) δ 171.9 (C-5), 165.4 (d, 1JC-F = 254.4 Hz, C-10), 163.5 
(C-16), 140.1 (d, 3JC-F = 8.9 Hz, C-14), 131.2 (d, 3JC-F = 9.6 Hz, C-12), 130.9 (C-22), 126.9 (d, 4JC-F = 3.0 Hz, 
C-13), 120.7 (C-23), 116.2 (d, 2JC-F = 22.4 Hz, C-9), 114.5 (d, 2JC-F = 21.7 Hz, C-11), 82.1 (d, J = 2.0 Hz, C-
3), 65.7 (C-1), 42.5 (C-18), 40.8 (C-6), 35.6 (d, 4JC-F = 1.5 Hz, C-15), 32.7 (C-8), 27.5 (C-19, C-20, C-21); 
HRMS (ESI+) C19H24FN2O2 [M + H]+ calculated: 331.1816, found 331.1810. 
(6S,8aR)-6-(tert-Butyl)-7,8a-dimethyl-6,7,8a,9-tetrahydroimidazo[1,5-a]thieno[2,3-d]pyridine-4,8-
dione (189h) 
According to general procedure 7, lactam 156l (100 mg, 0.36 mmol) was dissolved 
in dry THF (3.6 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under N2, then 
KHMDS solution (1.0 M in THF, 0.54 mL, 0.54 mmol, 1.5 equiv.) was added 
dropwise and left to stir for 15 min at 0 °C. To the reaction mixture methyl iodide 
(0.11 mL, 1.8 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue 
was purified by column chromatography (SiO2, pet.ether/EtOAc, 2:1) to yield the 
title compound (85 mg, 85%) as a yellow oil. Rf = 0.13 (pet.ether/EtOAc 2:1); [𝛂]𝐃
𝟐𝟑 = +12° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax = 3082, 2965 (C-H), 1705 (C=O), 1667 (C=O amide); 1H NMR (400 MHz, 
CDCl3) δ 7.43 (d, J = 5.3 Hz, 1H, H-16), 7.12 (dd, J = 5.3, 0.9 Hz, 1H, H-15), 5.33 (s, 1H, H-4), 3.30 (d, J 
= 16.4 Hz, 1H, H-1), 3.16 (d, J = 16.4 Hz, 1H, H-1), 3.06 (s, 3H, H-8), 1.43 (s, 2H, H-11), 1.01 (s, 9H, H-






(C-16), 124.0 (C-15), 80.1 (d, J = 2.6 Hz, C-4), 63.9 (C-2), 40.8 (C-17), 33.0 (C-8), 32.3 (C-1), 27.3 (C-18, C-




According to general procedure 7, lactam 156l (100 mg, 0.36 mmol) was dissolved 
in dry THF (3.6 mL, 0.1 M) in a 10 mL flame-dried flask at 0 °C under N2, then 
KHMDS solution (1.0 M in THF, 0.54 mL, 0.54 mmol, 1.5 equiv.) was added 
dropwise and left to stir for 15 min at 0 °C. To the reaction mixture allyl bromide 
(0.11 mL, 1.8 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. The residue 
was purified by column chromatography (SiO2, pet.ether/EtOAc, 4:1) to yield the 
title compound (86 mg, 78%) as a yellow oil. Rf = 0.29 (pet.ether/EtOAc 4:1); [𝛂]𝐃
𝟐𝟑 = +44° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax = 3082, 2965 (C-H), 1707 (C=O), 1669 (C=O amide); 1H NMR (400 MHz, 
CDCl3) δ 7.45 (d, J = 5.2 Hz, 1H, H-15), 7.13 (dd, J = 5.3, 0.9 Hz, 1H, H-14), 5.56 (dddd, J = 16.5, 12.5, 
8.2, 6.8 Hz, 1H, H-17), 5.22 (s, 1H, H-4), 5.10 – 5.04 (m, 1H, H-18), 5.04 – 4.97 (m, 1H, H-18), 3.31 (dd, J 
= 16.5, 1.0 Hz, 1H, H-1), 3.18 (d, J = 16.5 Hz, 1H, H-1), 3.00 (s, 3H, H-8), 2.72 (dd, J = 13.6, 6.8 Hz, 1H, 
H-16), 2.37 (dd, J = 12.5, 8.2 Hz, 1H, H-16), 1.00 (s, 9H, H-20, H-21, H-22); 13C NMR (100 MHz, CDCl3) 
δ 171.6 (C-6), 161.5 (C-9), 145.2 (C-12), 134.5 (C-11), 131.1 (C-17), 126.1 (C-15), 124.0 (C-14), 120.7 (C-
18), 81.7 (d, J = 5.3 Hz, C-4), 67.7 (C-2), 42.4 (C-16), 40.9 (C-19), 32.8 (C-8), 31.7 (C-1), 27.5 (C-20, C-21, 
C-22); HRMS (ESI+) C17H23N2O2S [M + H]+ calculated: 319.1474, found 319.1486. 
(3S,11aR)-6-benzyl-3-(tert-butyl)-2,11a-dimethyl-2,3,11,11a-tetrahydro-1H-
imidazo[1',5':1,6]pyrido[3,4-b]indole-1,5(6H)-dione (189j) 
According to general procedure 7, lactam 156n (0.15 g, 0.37 mmol) was 
dissolved in dry THF (3.67 mL, 0.1 M) in a 10 mL flame-dried flask at 0 
°C under N2, then KHMDS solution (1.0 M in THF, 0.55 mL, 0.56 mmol, 
1.5 equiv.) was added dropwise and left to stir for 15 min at 0 °C. To the 
reaction mixture methyl iodide (0.12 mL, 1.9 mmol, and 5 equiv.) was 
added and left to stir at rt for 3 h. The residue was purified by column chromatography (SiO2, 
pet.ether/EtOAc, 4:1) to yield the title compound (0.15 g, 95%) as a yellow oil. Rf = 0.15 (pet.ether/EtOAc 
4:1); [𝛂]𝐃
𝟐𝟑 = -40° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3064, 2967 (C-H), 1706 (C=O), 1658 (C=O); 1H 
NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.1 Hz, 1H, H-5), 7.37 (d, J = 8.4 Hz, 1H, H-2), 7.31 (ddd, J = 8.4, 
6.9, 1.2 Hz, 1H, H-1), 7.25 – 7.16 (m, 4H, H-6, H-27, H-29, H-31), 7.10 – 7.06 (m, 2H, H-28, H-30), 6.00 
(d, J = 15.9 Hz, 1H, H-25), 5.80 (d, J = 15.9 Hz, 1H, H-25), 5.37 (s, 1H, H-14), 3.35 (d, J = 16.1 Hz, 1H, 
H-13), 3.23 (d, J = 16.1 Hz, 1H, H-13), 3.08 (s, 3H, H-24), 1.49 (s, 3H, H-18), 1.02 (s, 9H, H-20, H-21, H-






31), 127.6 (C-8), 127.3 (C-29), 126.6 (C-28, C-30), 125.6 (C-1), 125.3 (C-4), 120.9 (C-6), 120.6 (C-5), 119.3 
(C-9), 111.2 (C-2), 80.1 (d, J = 2.7 Hz, C-14), 64.4 (C-12), 47.9 (C-25), 41.0 (C-19), 33.0 (C-24), 28.8 (C-13), 




According to general procedure 8, alkylated lactam 189a (0.15 g, 0.52 mmol) was 
dissolved in dry THF (5.0 mL, 0.1 M) in a 10 mL flame-dried flask at –78 °C under 
N2, then LDA solution (2.0 M in THF, 0.52 mL, 1.1 mmol, 2.0 equiv.) was added 
dropwise and left to stir for 15 min at –78 °C. To the reaction mixture ethyl iodide 
(0.20 mL, 2.6 mmol, and 5.0 equiv.) was added and left to stir at rt for 2 h. The 
residue was chromatographed (SiO2, pet.ether/EtOAc, 2:1) to yield the title 
compound (0.13 g, 87%) as a colourless oil. Rf = 0.29 (pet.ether/EtOAc 2:1); [𝛂]𝐃
𝟐𝟓 = +4° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax = 3064, 2968 (C-H), 1706 (C=O), 1672 (C=O); 1H NMR (400 MHz, CDCl3) δ 8.14 
(d, J = 7.5 Hz, 1H, H-13), 7.46 (t, J = 7.5 Hz, 1H, H-14), 7.36 (t, J = 7.5 Hz, 1H, H-15), 7.23 (d, J = 7.5 
Hz, 1H, H-16), 5.27 (s, 1H, H-4), 3.08 (s, 3H, H-8), 2.91 (dd, J = 10.7, 3.4 Hz, 1H, H-1), 1.88 (dtd, J = 14.5, 
7.4, 3.4 Hz, 1H, H-18), 1.66 (tdd, J = 14.5, 7.4, 3.4 Hz, 1H, H-18), 1.30 (s, 3H, H-17), 1.11 (s, 9H, H-21, 
H-22, H-23), 1.03 (t, J = 7.4 Hz, 3H, H-19); 13C NMR (100 MHz, CDCl3) δ 173.2 (C-6), 165.6 (C-9), 141.2 
(C-12), 132.1 (C-14), 130.2 (C-16), 129.3 (C-11), 128.7 (C-13), 127.2 (C-15), 79.8 (d, J = 2.6 Hz, C-4), 66.9 
(C-2), 47.5 (C-1), 40.2 (C-20), 32.5 (C-8), 28.2 (C-21, C-22, C-23), 26.9 (C-17), 25.5 (C-18), 12.5 (C-19); 
HRMS (ESI+) C19H27N2O2 [M + H]+ calculated: 315.2067, found 315.2075. 
(3S,10S,10aR)-10a-benzyl-3-(tert-butyl)-2,10-dimethyl-2,3,10,10a-tetrahydroimidazo[1,5-
b]isoquinoline-1,5-dione (193b) 
According to general procedure 8, alkylated lactam 189c (0.12 g, 0.33 mmol) 
was dissolved in dry THF (3.25 mL, 0.1 M) in a 10 mL flame-dried flask at –78 
°C under N2, then LDA solution (2.0 M in THF, 0.65 mL, 0.65 mmol, 2.0 equiv.) 
was added dropwise and left to stir for 15 min at –78 °C. To the reaction mixture 
methyl iodide (0.10 mL, 1.6 mmol, and 5.0 equiv.) was added and left to stir at rt 
for 2 h. The residue was chromatographed (SiO2, pet.ether/EtOAc, 3:1) to yield 
the title compound (0.13 g, 87%) as a colourless solid. Rf = 0.5 (pet.ether/EtOAc 3:1); [𝛂]𝐃
𝟐𝟓 = +152° (c 
= 1 in CHCl3); m.p. 165-166 °C; IR (neat, cm-1): νmax = 3030, 2969 (C-H), 1705 (C=O), 1673 (C=O); 1H 
NMR (500 MHz, CDCl3) δ 8.29 (dd, J = 7.8, 1.3 Hz, 1H, H-3), 7.56 (tt, J = 7.5, 1.0 Hz, 1H, H-1), 7.45 – 
7.41 (m, 1H, H-2), 7.35 (d, J = 7.5 Hz, 1H, H-6), 7.32 – 7.24 (m, 3H, H-23, H-24, H-25), 7.12 – 7.02 (m, 
2H, H-22, H-26), 4.32 (s, 1H, H-11), 3.39 (q, J = 7.1 Hz, 1H, H-10), 3.10 (d, J = 13.6 Hz, 1H, H-20), 2.84 






18); 13C NMR (125 MHz, CDCl3) δ 170.8 (C-13), 165.0 (C-7), 143.5 (C-4), 135.0 (C-21), 133.1 (C-1), 130.3 
(C-22, C-26), 129.2 (C-5), 128.9 (C-6), 128.7 (C-3), 128.2 (C-23, C-25), 127.5 (C-24), 127.3 (C-2), 81.5 (C-
11), 72.0 (C-9), 45.9 (C-20), 40.6 (C-10), 40.2 (C-15), 31.9 (C-28), 28.3 (C-16, C-17, C-18), 18.9 (C-27); 




According to general procedure 8, alkylated lactam 189b (100 mg, 0.32 mmol) 
was dissolved in dry THF (3.2 mL, 0.1 M) in a 10 mL flame-dried flask at –78 °C 
under N2, then LDA solution (2.0 M in THF, 0.32 mL, 0.64 mmol, 2.0 equiv.) was 
added dropwise and left to stir for 15 min at –78 °C. To the reaction mixture allyl 
iodide (0.14 mL, 1.6 mmol, and 5.0 equiv.) was added and left to stir at rt for 3 h. 
The residue was chromatographed (SiO2, pet.ether/EtOAc, 4:1) to yield the title 
compound (80 mg, 75%) as a colourless oil. Rf = 0.29 (pet.ether/EtOAc 4:1). [𝛂]𝐃
𝟐𝟓 = +144° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax = 3071, 2965 (C-H), 1738, 1704 (C=O), 1674 (C=O), 1602; 1H NMR (400 
MHz, CDCl3) δ 8.17 (d, J = 7.5 Hz, 1H, H-11), 7.44 (td, J = 7.5, 1.2 Hz, 1H, H-10), 7.36 (td, J = 7.5, 1.2 
Hz, 1H, H-9), 7.17 (dd, J = 7.5, 1.2 Hz, 1H, H-8), 5.94 – 5.72 (m, 1H, H-21), 5.64 – 5.46 (m, 1H, H-18), 
5.20 (s, 1H, H-3), 5.05 (t, J = 9.2 Hz, 2H, H-19, H-22), 4.94 (dd, J = 17.2, 9.2 Hz, 2H, H-19, H-22), 3.09 
(dd, J = 10.9, 3.2 Hz, 1H, H-14), 3.04 (s, 3H, H-7), 2.69 – 2.58 (m, 1H, H-20), 2.51 (dd, J = 14.0, 6.7 Hz, 
1H, H-17), 2.43 – 2.30 (m, 2H, H-17, H-20), 1.11 (s, 9H, H-24, H-25, H-26); 13C NMR (100 MHz, CDCl3) 
δ 171.7 (C-5), 165.2 (C-15), 140.5 (C-12), 135.5 (C-21), 132.1 (C-10), 131.1 (C-18), 130.5 (C-8), 129.3 (C-
13), 128.7 (C-11), 127.4 (C-9), 120.8 (C-19), 118.1 (C-22), 81.7 (d, J = 4.0 Hz, C-3), 70.6 (C-1), 45.3 (C-14), 
44.8 (C-17), 40.3 (C-23), 37.0 (C-20), 32.1 (C-7), 28.4 (C-24, C-25, C-26); HRMS (ESI+) C22H29N2O2 [M + 















(R)-3-Methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (194a) 
According to general procedure 9, alkylated lactam 189a (49 mg, 0.18 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (3.5 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 175 °C (11 bar) 
for 2 h. The crude material was purified by flash column chromatography to yield 
the title compound (33 mg, 94%) as a colourless oil. Rf = 0.09 (pet.ether/EtOAc 
3:1, 1% formic acid). [𝛂]𝐃
𝟐𝟑 = +180° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3251 (OH), 2976 (C-H), 1703 
(C=O acid), 1630 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H, H-1), 8.04 (d, J = 7.5 Hz, 1H, 
H-11), 7.59 – 7.49 (m, 1H, H-12), 7.40 (t, J = 7.5 Hz, 1H, H-13), 7.31 (d, J = 7.5 Hz, 1H, H-14), 3.43 (d, J 
= 15.9 Hz, 1H, H-7), 3.20 (d, J = 15.9 Hz, 1H, H-7), 1.57 (s, 3H, H-15); 13C NMR (125 MHz, CDCl3) δ 
177.6 (C-5), 166.8 (C-8), 136.4 (C-Ar), 133.4 (C-Ar), 128.8 (C-Ar), 128.1 (C-Ar), 127.7 (C-Ar), 127.2 (C-Ar), 
58.1 (C-6), 36.3 (C-7), 24.7 (C-15); HRMS (ESI+) C11H11NNaO3 [M + Na]+ calculated: 228.0631, found 
228.0621. 
(R)-3-Benzyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (194b) 
According to general procedure 9, alkylated lactam 189c (46 mg, 0.16 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (3.2 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 175 °C (12 bar) 
for 2.5 h. The crude material was purified by flash column chromatography to yield 
the title compound (26 mg, 85%) as a colourless foam. Rf = 0.06 (pet.ether/EtOAc 
3:1, 1% formic acid); [𝛂]𝐃
𝟐𝟑 = +12° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3230 
(OH), 2924 (C-H), 1704 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 9.19 (s, 1H, H-
4), 7.98 (dd, J = 7.5, 1.3 Hz, 1H, H-14), 7.51 (td, J = 7.5, 1.3 Hz, 1H, H-12), 7.38 – 7.31 (m, 1H, H-13), 
7.30 – 7.27 (m, 1H, H-Ar), 7.24 – 7.16 (m, 3H, H-Ar), 7.07 (dd, J = 7.6, 1.8 Hz, 2H, H-Ar), 3.43 (d, J = 
16.3 Hz, 1H, H-7), 3.29 (d, J = 16.3 Hz, 1H, H-7), 3.14 (d, J = 13.6 Hz, 1H, H-15), 3.08 (d, J = 13.6 Hz, 
1H, H-15); 13C NMR (125 MHz, CDCl3) δ 175.5 (C-5), 166.9 (C-3), 136.4 (C-Ar), 135.0 (C-Ar), 133.4 (C-
Ar), 130.3 (C-Ar), 128.5 (C-Ar), 128.4 (C-Ar), 128.1 (C-Ar), 127.5 (C-Ar), 127.4 (C-Ar), 127.3 (C-Ar), 61.9 











(R)-6-Fluoro-3-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (194c) 
According to general procedure 9, alkylated lactam 189d (30 mg, 0.1 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (2.0 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 180 °C (11 
bar) for 5 h. The crude material was purified by flash column chromatography to 
yield the title compound (16 mg, 78%) as a pale yellow oil. Rf = 0.3 
(pet.ether/EtOAc 1:1, 1% formic acid). [𝛂]𝐃
𝟐𝟑 = -12° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3212 (OH), 
2923 (C-H), 1736 (C=O acid), 1676 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 8.10 (dd, J = 8.6, 5.8 
Hz, 1H, H-11), 7.06 (td, J = 8.6, 2.5 Hz, 1H, H-12), 6.94 (dd, J = 8.6, 2.5 Hz, 1H, H-14), 6.25 (s, 1H, H-1), 
3.42 (d, J = 15.8 Hz, 1H, H-7), 3.12 (d, J = 15.8 Hz, 1H, H-7), 1.57 (s, 3H, H-15); 13C NMR (125 MHz, 
CDCl3) δ 173.8 (C-5), 165.1 (d, 1JC-F = 253.9 Hz, C-13), 164.5 (C-8), 138.9 (d, 3JC-F = 9.1 Hz, C-9), 131.2 (d, 
3JC-F = 9.7 Hz, C-11), 124.1 (d, 4JC-F = 2.9 Hz, C-10), 115.0 (d, 2JC-F = 21.9 Hz, C-12), 114.8 (d, 2JC-F = 22.3 
Hz, C-14), 58.9 (C-6), 37.8 (d, 4JC-F = 1.5 Hz, C-7), 26.0 (C-15); HRMS (ESI+) C16H19N2FO2 [M + H]+ 
calculated: 291.1402, found 291.1401.  
 
(R)-6-Methyl-4-oxo-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-6-carboxylic acid (194d) 
According to general procedure 9, alkylated lactam 189h (46 mg, 0.16 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (3.2 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 175 °C (12 bar) 
for 2.5 h. The crude material was purified by flash column chromatography to yield 
the title compound (26 mg, 85%) as a colourless oil. Rf = 0.06 (pet.ether/EtOAc 
3:1, 1% formic acid). [𝛂]𝐃
𝟐𝟒 = +4° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3238 (OH), 2924 (C-H), 1708 
(C=O acid), 1628 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 9.24 (s, 1H, H-1), 7.41 (d, J = 5.2 Hz, 1H, 
H-14), 7.20 (d, J = 5.2 Hz, 1H, H-13), 3.44 (d, J = 16.7 Hz, 1H, H-7), 3.35 (d, J = 16.7 Hz, 1H, H-7), 1.66 
(s, 3H, H-11); 13C NMR (125 MHz, CDCl3) δ 177.0 (C-5), 163.8 (C-8), 145.2 (C-10), 130.3 (C-9), 125.6 (C-
14), 124.3 (C-13), 59.8 (C-6), 32.5 (C-7), 25.1 (C-11); HRMS (ESI+) C9H10NSO3 [M + H]+ calculated: 
212.0376, found 212.0367. 
(3R,4S)-4-ethyl-3-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (195a) 
According to general procedure 9, alkylated lactam 193a (32 mg, 0.1 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (2.1 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 180 °C (11 bar) 
for 5 h. The crude material was purified by flash column chromatography to yield 
the title compound (15 mg, 65%) as a colourless oil. Rf = 0.06 (pet.ether/EtOAc 
3:1, 1% formic acid). [𝛂]𝐃
𝟐𝟒 = +168° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 3230 (OH), 2968, 2928 (C-






7.5, 1.4 Hz, 1H, H-11), 7.55 (td, J = 7.5, 1.4 Hz, 1H, H-12), 7.44 (td, J = 7.5, 1.4 Hz, 1H, H-13), 7.27 (s, 
1H, H-14), 3.01 (dd, J = 11.4, 2.2 Hz, 1H, H-7), 2.05 – 1.86 (m, 1H, H-16), 1.64 – 1.58 (m, 1H, H-16), 1.57 
(s, 3H, H-15), 0.83 (t, J = 7.4 Hz, 3H, H-17); 13C NMR (125 MHz, CDCl3) δ 177.1 (C-5), 166.6 (C-8), 140.6 
(C-10), 132.5 (C-12), 129.8 (C-14), 128.3 (C-11), 127.5 (C-13), 126.2 (C-9), 62.6 (C-6), 47.8 (C-7), 25.7 (C-
15), 25.4 (C-16), 11.6 (C-17); HRMS (ESI+) C13H16NO3 [M + H]+ calculated: 234.1125, found 282.1119. 
 
(3aR,9bR)-5-Oxo-1,2,3,4,5,9b-hexahydrocyclopenta[c]isoquinoline-3a-carboxylic acid (195a) 
According to general procedure 9, alkylated lactam 188d (30 mg, 0.1 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio, 0.05 M) in a microwave vial. 
The reaction was heated in a microwave reactor at 180 °C for 3 h. The crude 
material was purified by flash column chromatography to yield the title compound 
(22 mg, 80%) as a dark yellow oil. Rf = 0.04 (pet.ether/EtOAc 2:1, 1% formic 
acid). [𝛂]𝐃
𝟐𝟒 = -28° (c = 1 in CHCl3); IR (neat, cm-1): νmax 3230 (OH), 2954, 2873 (C-H), 1704 (C=O acid), 
1648 (C=O amide); 1H NMR (400 MHz, CD3OD) δ 7.90 (d, J = 7.5 Hz, 1H, H-11), 7.42 (td, J = 7.5, 1.2 
Hz, 1H, H-12), 7.29 (dd, J = 11.0, 4.1 Hz, 1H, H-13), 7.22 (d, J = 7.5 Hz, 1H, H-14), 3.56 (ddd, J = 12.2, 
9.0, 3.6 Hz, 1H, H-7), 2.49 – 2.31 (m, 1H, H-15), 2.31 – 2.22 (m, 1H, H-15), 2.16 – 2.05 (m, 1H, H-17), 
1.96 – 1.84 (m, 2H, H-17, H-16), 1.70 – 1.57 (m, 1H, H-16); 13C NMR (100 MHz, CD3OD) δ 175.5 (C-5), 
166.3 (C-8), 140.4 (C-Ar), 132.4 (C-Ar), 127.5 (C-Ar), 127.4 (C-Ar), 126.9 (C-Ar), 125.7 (C-Ar), 68.0 (C-6), 
48.4 (C-7), 37.7 (C-15), 34.6 (C-17), 23.0 (C-16); HRMS (ESI+) C13H14NO3 [M + H]+ 232.1102, found 
232.1103. 
Alkylated N-Chloroformylimidazolidinones 
 (2S,5S)-5-Benzyl-2-(tert-butyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (205a) 
The title compound 205a was prepared from L-alanine derived trans-carbamoyl 
chloride 154o (231 mg, 1.0 mmol, 1.0 equiv.), benzyl bromide (0.14 mL, 1.1 mmol, 
1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in THF (10 mL) according to 
general procedure 10. Colourless oil (208 mg, 65%); Rf = 0.43 (SiO2; pet. ether/Et2O 
80:20); [𝛂]𝐃
𝟐𝟓 = -40° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2971 (C–H), 1738 (C=O), 
1714 (C=O), 1241; 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 
0.54:0.46 ratio) δ 7.31 – 7.10 (m, 5H, H-Ar, rot. A+B), 4.54 (s, 0.54H, H-1, rot. A), 
4.46 (s, 0.46H, H-1, rot. B), 3.75 (d, J = 14.2 Hz, 0.46H, H-7A, rot. B), 3.61 (d, J = 13.9 Hz, 0.54H, H-7A, 
rot. A), 3.15 (d, J = 14.2 Hz, 0.46H, H-7B, rot. B), 3.07 (d, J = 13.9 Hz, 0.54H, H-7B, rot. A), 2.76 (s, 1.62H, 
H-16, rot. A), 2.69 (s, 1.38H, H-16, rot. B), 1.83 (s, 1.38H, H-8, rot. B), 1.75 (s, 1.62H, H-8, rot. A), 1.02 (s, 
4.86H, H-20 + H-21 + H-22, rot. A), 0.91 (s, 4.14H, H-20 + H-21 + H-22, rot. B); 13C NMR (100 MHz, 
CDCl3) δ 171.72 (C-3, rot. A/B), 171.70 (C-3, rot. A/B), 148.4 (C-17, rot. B), 146.9 (C-17, rot. A), 135.0 






C-14, rot. A+B), 128.3 (C-10 + C-14, rot. A+B), 127.7 (C-12, rot. A+B), 127.4 (C-12, rot. A+B), 82.8 (C-
1, rot. A), 82.7 (C-1, rot. B), 70.7 (C-4, rot. A), 68.5 (C-4, rot. B), 43.5 (C-7, rot. B), 41.0 (C-7, rot. A), 39.9 
(C-15, rot. B), 39.5 (C-15, rot. A), 31.9 (C-16, rot. B), 31.5 (C-16, rot. A), 27.7 (C-20 + C-21 + C-22, rot. 
A), 27.0 (C-20 + C-21 + C-22, rot. B), 23.7 (C-8, rot. B), 22.7 (C-8, rot. B); HRMS (ESI+) C17H23ClN2O2Na 





 The title compound 205b was prepared from L-alanine derived trans-
carbamoyl chloride 154o (100 mg, 0.43 mmol, 1.0 equiv.), 4-methylbenzyl 
bromide (88 mg, 0.47 mmol, 1.1 equiv.) and KHMDS (0.47 mL, 0.47 mmol, 
1.1 equiv.) in THF (4.3 mL) according to general procedure 11. Colourless 
oil (129 mg, 89%); Rf = 0.36 (SiO2; pet. ether/EtOAc 80:20); [𝛂]𝐃
𝟐𝟓 = -24° (c 
= 1 in CHCl3); IR (neat, cm-1): νmax = 2968 (C–H), 1738 (C=O), 1713 (C=O), 
1240; 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.52:0.48 ratio) δ 7.11 – 6.86 (m, 4H, H-
Ar, rot. A+B), 4.56 (s, 0.52H, H-2, rot. A), 4.47 (s, 0.48H, H-2, rot. B), 3.69 (d, J = 14.2 Hz, 0.48H, H-14A, 
rot. B), 3.56 (d, J = 14.0 Hz, 0.52H, H-14A, rot. A), 3.12 (d, J = 14.2 Hz, 0.48H, H-14B, rot. B), 3.01 (d, J = 
14.0 Hz, 0.52H, H-14B, rot. A), 2.77 (s, 1.56H, H-23, rot. A), 2.71 (s, 1.44H, H-23, rot. B), 2.30 – 2.27 (m, 
3H, H-22, rot. A+B), 1.81 (s, 1.44H, H-17, rot. B), 1.73 (s, 1.56H, H-17, rot. A), 1.01 (s, 4.68H, H-8 + H-
9 + H-10, rot. A), 0.91 (s, 4.32H, H-8 + H-9 + H-10, rot. A); 13C NMR (125 MHz, CDCl3) δ 171.9 (C-4, 
rot. A/B), 171.8 (C-4, rot. A/B), 148.5 (C-11, rot. A/B), 146.9 (C-11, rot. A/B), 137.2 (C-20, rot. A/B), 
136.9 (C-20, rot. A/B), 131.8 (C-15, rot. A/B), 131.5 (C-15, rot. A/B), 130.0 (C-19 + C-21, rot. A/B), 129.8 
(C-19 + C-21, rot. A/B), 129.0 (C-16 + C-18, rot. A/B), 128.9 (C-16 + C-18, rot. A/B), 82.8 (C-2, rot. 
A/B), 82.7 (C-2, rot. A/B), 70.7 (C-5, rot. A/B), 68.5 (C-5, rot. A/B), 43.1 (C-14, rot. B), 40.5 (C-14, rot. 
A), 39.9 (C-7, rot. A/B), 39.5 (C-7, rot. A/B), 31.9 (C-23, rot. A/B), 31.5 (C-23, rot. A/B), 27.6 (C-8 + C-
9 + C-10, rot. A), 26.9 (C-8 + C-9 + C-10, rot. B), 23.6 (C-17, rot. B), 22.6 (C-17, rot. A), 21.21 (C-22, rot. 

















The title compound 205c was prepared from L-alanine derived trans-
carbamoyl chloride 154o (100 mg, 0.43 mmol, 1.0 equiv.), 3,5-dimethylbenzyl 
bromide (94 mg, 0.47 mmol, 1.1 equiv.) and KHMDS (0.47 mL, 0.47 mmol, 
1.1 equiv.) in THF (4.3 mL) according to general procedure 11. Colourless 
solid (140 mg, 93%); m.p. 117 – 118 °C; Rf = 0.57 (SiO2; pet. ether/EtOAc 
80:20); [𝛂]𝐃
𝟐𝟓 = -36° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2964 (C–H), 
1739 (C=O), 1714 (C=O), 1241; 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.60:0.40 
ratio) δ 6.88 – 6.83 (m, 1H, H-20, rot. A+B), 6.81 – 6.72 (m, 2H, H-16 + H-18, rot. A+B), 4.51 (s, 0.60H, 
H-2, rot. A), 4.45 (s, 0.40H, H-2, rot. B), 3.64 (d, J = 14.1 Hz, 0.40H, H-14A, rot. B), 3.51 (d, J = 13.8 Hz, 
0.60H, H-14A, rot. A), 3.10 (d, J = 14.1 Hz, 0.40H, H-14B, rot. B), 3.00 (d, J = 13.8 Hz, 0.60H, H-14B, rot. 
A), 2.78 (s, 1.80H, H-24, rot. A), 2.74 (s, 1.20H, H-24, rot. B), 2.31 – 2.14 (m, 6H, H-22 + H-23, rot. A+B), 
1.81 (s, 1.20H, H-17, rot. B), 1.73 (s, 1.80H, H-17, rot. A), 1.01 (s, 5.40H, C-8 + C-9 + C-10, rot. A), 0.91 
(s, 3.60H, C-8 + C-9 + C-10, rot. B); 13C NMR (125 MHz, CDCl3) δ 172.1 (C-4, rot. B), 171.9 (C-4, rot. 
A), 148.5 (C-11, rot. B), 147.1 (C-11, rot. A), 137.8 (ArC), 137.7 (ArC), 134.8 (ArC), 134.5 (ArC), 129.1 
(ArC), 128.9 (ArC), 127.9 (ArC), 127.7 (ArC), 82.8 (C-2, rot. A), 82.8 (C-2, rot. B), 70.8 (C-5, rot. A), 68.4 
(C-5, rot. B), 43.4 (C-14, rot. B), 40.9 (C-14, rot. A), 40.0 (C-7, rot. B), 39.6 (C-7, rot. A), 31.9 (C-24, rot. 
B), 31.6 (C-23, rot. A), 27.6 (C-8 + C-9 + C-10, rot. A), 27.0 (C-8 + C-9 + C-10, rot. B), 23.7 (C-17, rot. 
B), 22.7 (C-17, rot. A), 21.32 (C-22 + C-23, rot. A/B), 21.30 (C-22 + C-23, rot. A/B); HRMS (ESI+) 























The title compound 205d was prepared from L-alanine derived trans-carbamoyl 
chloride 154o (231 mg, 1.0 mmol, 1.0 equiv.), 2-methylbenzyl bromide (0.15 mL, 
1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in THF (10 
mL) according to general procedure 10. Colourless oil (198 mg, 59%); Rf = 0.43 
(SiO2; pet. ether/Et2O 90:10); [𝛂]𝐃
𝟐𝟑 = -28° (c = 1 in CHCl3); IR (neat, cm-1): νmax 
= 2959 (C–H), 1738 (C=O), 1716 (C=O), 1241; 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers A:B in a 0.55:0.45 ratio) δ 7.11 – 6.92 (m, 3H, H-Ar, rot. A+B), 6.91 – 6.67 (m, 1H, 
H-Ar, rot. A+B), 4.74 (s, 0.45H, H-2, rot. B), 4.70 (s, 0.55H, H-2, rot. A), 3.62 (d, J = 15.1 Hz, 0.45H, H-
15A, rot. B), 3.51 (d, J = 15.0 Hz, 0.55H, H-15A, rot. A), 3.18 (d, J = 15.1 Hz, 0.45H, H-15B, rot. B), 3.08 
(d, J = 15.0 Hz, 0.55H, H-15B, rot. A), 2.71 (s, 1.65H, H-14, rot. A), 2.49 (s, 1.35H, H-14, rot. B), 2.29 (s, 
1.35H, H-23, rot. B), 2.28 (s, 1.65H, H-23, rot. A), 1.80 (s, 1.35H, H-16, rot. B), 1.70 (s, 1.65H, H-16, rot. 
A), 0.98 (s, 4.95H, H-11 + H-12 + H-13, rot. A), 0.89 (s, 4.05H, H-11 + H-12 + H-13, rot. B); 13C NMR 
(100 MHz, CDCl3) δ 172.1 (C-4, rot. A), 171.8 (C-4, rot. B), 148.6 (C-8, rot. B), 146.6 (C-8, rot. A), 138.2 
(C-18, rot. A), 137.9 (C-18, rot. B), 133.8 (C-17, rot. A), 133.6 (C-17, rot. B), 131.0 (C-19, rot. B), 130.9 (C-
19, rot. A), 128.5 (C-22, rot. B), 128.4 (C-22, rot. A), 127.0 (C-20, rot. B), 126.8 (C-20, rot. A), 125.6 (C-21, 
rot. B), 125.3 (C-21, rot. A), 82.9 (C-2, rot. B), 82.8 (C-2, rot. A), 69.8 (C-5, rot. A), 68.1 (C-5, rot. B), 40.1 
(C-7, rot. B), 39.6 (C-7, rot. A), 39.4 (C-15, rot. B), 36.8 (C-15, rot. A), 31.7 (C-14, rot. A), 31.5 (C-14, rot. 
B), 27.6 (C-11 + C-12 + C-13, rot. A), 27.0(C-11 + C-12 + C-13, rot. B), 24.5 (C-16, rot. B), 23.4 (C-16, 






















The title compound 205e was prepared from L-alanine derived trans-
carbamoyl chloride 154o (231 mg, 1.0 mmol, 1.0 equiv.), 3-methoxybenzyl 
bromide (0.15 mL, 1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 
1.1 equiv.) in THF (10 mL) according to the general procedure 10. 
Colourless solid (161 mg, 46%); m.p. = 30 - 32 °C; Rf = 0.50 (SiO2; pet. 
ether/Et2O 70:30); [𝛂]𝐃
𝟐𝟑 = -44° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 
2969 (C–H), 1737 (C=O), 1713 (C=O), 1264; 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 
0.55:0.45 ratio) δ 7.17 – 7.10 (m, 1H, H-19, rot. A+B), 6.81 – 6.67 (m, 3H, H-18 + H-20 + H-22, rot. A+B), 
4.58 (s, 0.55H, H-2, rot. A), 4.49 (s, 0.45H, H-2, rot. B), 3.78 (s, 1.65H, H-24, rot. A), 3.76 (s, 1.35H, H-24, 
rot. B), 3.70 (d, J = 14.1 Hz, 0.45H, H-15A, rot. B), 3.57 (d, J = 13.9 Hz, 0.55H, H-15A, rot. A), 3.12 (d, J = 
14.1 Hz, 0.45H, H-15B, rot. B), 3.04 (d, J = 13.9 Hz, 0.55H, H-15B, rot. A), 2.78 (s, 1.65H, H-14, rot. A), 
2.71 (s, 1.35H, H-14, rot. B), 1.81 (s, 1.35H, H-16, rot. B), 1.73 (s, 1.65H, H-16, rot. A), 1.01 (s, 4.95H, H-
11 + H-12 + H-13, rot. A), 0.91 (s, 4.05H, H-11 + H-12 + H-13, rot. B); 13C NMR (100 MHz, CDCl3) δ 
171.58 (C-4, rot. B), 171.56 (C-4, rot. A), 159.5 (C-21, rot. B), 159.4 (C-21, rot. A), 148.2 (C-8, rot. A), 146.8 
(C-8, rot. B), 136.3 (C-17, rot. A), 136.1 (C-17, rot. B), 129.1 (C-19, rot. B), 129.0 (C-19, rot. A), 122.3 (C-
18, rot. A), 122.1 (C-18, rot. B), 114.9 (C-22, rot. A), 114.8 (C-22, rot. B), 113.6 (C-20, rot. B), 113.5 (C-20, 
rot. A), 82.7 (C-2, rot. A), 82.6 (C-2, rot. B), 70.5 (C-5, rot. A), 68.3 (C-5, rot. B), 55.2 (C-24, rot. A), 55.1 
(C-24, rot. B), 43.3 (C-15, rot. B), 40.8 (C-15, rot. A), 39.8 (C-7, rot. B), 39.4 (C-7, rot. A), 31.8 (C-14, rot. 
B), 31.4 (C-14, rot. A), 27.6 (C-11 + C-12 + C-13, rot. A), 26.8 (C-11 + C-12 + C-13, rot. B), 23.6 (C-16, 
rot. B), 22.6 (C-16, rot. A); HRMS (ESI+) C18H25ClN2O3Na [M+Na]+ 375.1445, found 375.1463.  
(2S,5S)-2-(tert-butyl)-3,5-Dimethyl-5-(naphthalen-2-ylmethyl)-4-oxoimidazolidine-1-carbonyl 
chloride (205f) 
The title compound 205f was prepared from L-alanine derived trans-carbamoyl 
chloride 154o (231 mg, 1.0 mmol, 1.0 equiv.), 2-(bromomethyl)naphthalene 
(243 mg, 1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in 
THF (10 mL) according to general procedure 10. Colourless oil (241 mg, 
65%); Rf = 0.51 (SiO2; pet. ether/ Et2O 80:20); [𝛂]𝐃
𝟐𝟓 = -44° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax = 2971 (C–H), 1737 (C=O), 1712 (C=O), 1240; 1H NMR 
(400 MHz, CDCl3) (mixture of rotamers A:B in a 0.60:0.40 ratio) δ 7.75 – 7.67 
(m, 2H, H-Ar, rot. A+B), 7.65 (m, 1H, H-Ar, rot. A+B), 7.57 (m, 1H, H-Ar, rot. A+B), 7.42 – 7.32 (m, 2H, 
H-Ar, rot. A+B), 7.18 (m, 1H, H-Ar, rot. A+B), 4.35 (s, 0.60H, H-2, rot. A), 4.29 (s, 0.40H, H-2, rot. B), 
3.83 (d, J = 14.2 Hz, 0.40H, H-16A, rot. B), 3.71 (d, J = 13.9 Hz, 0.60H, H-16A, rot. A), 3.25 (d, J = 14.2 
Hz, 0.40H, H-16B, rot. B), 3.15 (d, J = 13.9 Hz, 0.60H, H-16B, rot. A), 2.63 (s, 1.80H, H-6, rot. A), 2.56 (s, 






13 + H-14, rot. A), 0.80 (s, 3.60H, H-12 + H-13 + H-14, rot. B); 13C NMR (100 MHz, CDCl3) δ 171.7 (C-
4, rot. B), 171.6 (C-4, rot. A), 148.2 (C-7, rot. B), 147.0 (C-7, rot. A), 133.3 (C-20, rot. A), 133.2 (C-20, rot. 
B), 132.6 (C-21, rot. B), 132.5 (C-21, rot. A), 132.4 (C-17, rot. A), 132.1 (C-17, rot. B), 129.3 (C-Ar), 129.0 
(C-Ar), 127.9 (C-Ar), 127.9 (C-Ar), 127.8 (C-Ar), 127.7 (C-Ar), 127.7 (C-Ar), 127.5 (C-Ar), 127.5 (C-Ar), 
126.2 (C-Ar), 126.0 (C-Ar), 125.9 (C-Ar), 125.8 (C-Ar), 82.6 (C-2, rot. A), 82.5 (C-2, rot. B), 70.8 (C-5, rot. 
A), 68.5 (C-5, rot. B), 43.5 (C-16, rot. B), 40.9 (C-16, rot. A), 39.8 (C-11, rot. B), 39.3 (C-11, rot. A), 31.8 
(C-6, rot. B), 31.4 (C-6, rot. A), 27.5 (C-12 + C-13 + C-14, rot. A), 26.8 (C-12 + C-13 + C-14, rot. B), 23.7 




 The title compound 205i was prepared from L-alanine derived trans-carbamoyl 
chloride 154o (150 mg, 0.65 mmol, 1.0 equiv.), 4-chlorobenzyl bromide (146 mg, 
0.72 mmol, 1.1 equiv.) and KHMDS (0.77 mL, 0.77 mmol, 1.2 equiv.) in THF (6 
mL) according to general procedure 10. Colourless foam (170 mg, 74%); Rf = 
0.23 (pet. ether/EtOAc 85:15); [𝛂]𝐃
𝟐𝟓 = -28° (c = 1 in CHCl3); IR (neat, cm-1): νmax 
= 2983 (C-H), 1736 (C=O), 1709 (C=O); 1H NMR (500 MHz, CDCl3) (mixture 
of rotamers A:B in a 0.57:0.43 ratio) δ 7.22 (dd, J = 8.6, 2.3 Hz, 2H, H-13, H-17, rot. A+B), 7.08 (t, J = 8.5 
Hz, 2H, H-14, H-16, rot. A+B), 4.59 (s, 0.57H, H-2, rot. A), 4.52 (s, 0.43H, H-2, rot. B), 3.72 (d, J = 14.2 
Hz, 0.43H, H-11A, rot. B), 3.59 (d, J = 14.0 Hz, 0.57H, H-11A, rot. A), 3.11 (d, J = 14.2 Hz, 0.43H, H-11B, 
rot. B), 3.02 (d, J = 14.0 Hz, 0.57H, H-11B, rot. A), 2.78 (s, 1.71H, H-23, rot. A), 2.72 (s, 1.29H, H-23, rot. 
B), 1.81 (s, 1.29H, H-10, rot. B), 1.73 (s, 1.71H, H-10, rot. A), 1.02 (s, 5.13H, H-20 + H-21 + H-22, rot. 
A), 0.92 (s, 3.87H, H-20 + H-21 + H-22, rot. B); 13C NMR (125 MHz, CDCl3) δ 171.5 (C-4, rot. B), 171.5 
(C-4, rot. A), 148.3 (C-7, rot. B), 146.9 (C-7, rot. A), 133.7 (C-12, rot. B), 133.5 (C-12, rot. A), 133.4 (C-15, 
rot. B), 133.3 (C-15, rot. B), 131.6 (C-13 + C-17, rot. A), 131.3 (C-13 + C-17, rot. B), 128.6 (C-14 + C-16, 
rot. A), 128.4 (C-14 + C-16, rot. A), 82.8 (C-2, rot. A), 82.7 (C-2, rot. B), 70.5 (C-5, rot. A), 68.3 (C-5, rot. 
B), 42.8 (C-11, rot. B), 40.2 (C-11, rot. A), 39.9 (C-19, rot. B), 39.4 (C-19, rot. A), 31.8 (C-23, rot. B), 31.5 
(C-23, rot. A), 27.7 (C-20 + C-21 + C-22, rot. A), 26.9 (C-20 + C-21 + C-22, rot. B), 23.7 (C-10, rot. B), 















The title compound 205j was prepared from L-alanine derived trans-
carbamoyl chloride 154o (100 mg, 0.43 mmol, 1.0 equiv.), 4-bromobenzyl 
bromide (118 mg, 0.47 mmol, 1.10 equiv.) and KHMDS (0.47 mL, 0.47 
mmol, 1.1 equiv.) in THF (4.3 mL) according to the general procedure 11. 
Colourless oil (158 mg, 92%); Rf = 0.46 (SiO2; pet. ether/EtOAc 80:20); 
[𝛂]𝐃
𝟐𝟒 = -20° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2968 (C–H), 1738 
(C=O), 1714 (C=O), 1351, 1241; 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.60:0.40 
ratio) δ 7.41 – 7.32 (m, 2H, H-19 + H-21, rot. A+B), 7.07 – 6.97 (m, 2H, H-16 + H-18, rot. A+B), 4.60 (s, 
0.60H, H-2, rot. A), 4.53 (s, 0.40H, H-2, rot. B), 3.71 (d, J = 14.2 Hz, 0.40H, H-14A, rot. B), 3.58 (d, J = 
14.0 Hz, 0.60H, H-14A, rot. A), 3.10 (d, J = 14.2 Hz, 0.40H, H-14B, rot. B), 3.01 (d, J = 14.0 Hz, 0.60H, H-
14B, rot. A), 2.79 (s, 1.80H, H-23, rot. A), 2.73 (s, 1.20H, H-23, rot. B), 1.82 (s, 1.20H, H-17, rot. B), 1.73 
(s, 1.80H, H-17, rot. A), 1.03 (s, 5.40H, H-8 + H-9 + H-10, rot. A), 0.92 (s, 3.60H, H-8 + H-9 + H-10, rot. 
B); 13C NMR (100 MHz, CDCl3) δ 171.5 (C-4, rot. B), 171.5 (C-4, rot. A), 148.3 (C-11, rot. B), 146.9 (C-
11, rot. A), 134.0 (C-15, rot. A), 133.8 (C-15, rot. B), 131.9 (C-16 + C-18, rot. A), 131.7 (C-16 + C-18, rot. 
B), 131.6 (C-19 + C-21, rot. B), 131.4 (C-19 + C-21, rot. A), 121.9 (C-20, rot. B), 121.6 (C-20, rot. A), 82.9 
(C-2, rot. A), 82.7 (C-2, rot. B), 70.4 (C-5, rot. A), 68.3 (C-5, rot. B), 42.9 (C-14, rot. B), 40.3 (C-14, rot. A), 
39.9 (C-7, rot. B), 39.5 (C-7, rot. A), 31.9 (C-23, rot. B), 31.5 (C-23, rot. A), 27.7 (C-8 + C-9 + C-10, rot. 
A), 27.0 (C-8 + C-9 + C-10, rot. B), 23.7 (C-17, rot. B), 22.7 (C-17, rot. A); HRMS (ESI+) C17H23BrClN2O2 
[M+H]+ 401.0626, found 401.0616. 
(2S,5S)-5-(2-bromobenzyl)-2-(tert-butyl)-3,5-Dimethyl-4-oxoimidazolidine-1-carbonyl  
chloride (205m) 
 The title compound 205m was prepared from L-alanine derived trans-carbamoyl 
chloride 154o (100 mg, 0.43 mmol, 1.0 equiv.), 2-bromobenzyl bromide (118 
mg, 0.47 mmol, 1.1 equiv.) and KHMDS (0.47 mL, 0.47 mmol, 1.1 equiv.) in 
THF (4.3 mL) according to general procedure 11. Colourless oil (125 mg, 
73%); Rf = 0.28 (SiO2; pet. ether/EtOAc 80:20); [𝛂]𝐃
𝟐𝟑 = -56° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax = 2980 (C–H), 1738 (C=O), 1716 (C=O), 1458, 1241; 1H 
NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.50:0.50 ratio) δ 7.57 – 7.52 (m, 1H, H-19, rot. 
A+B), 7.24 – 7.16 (m, 1H, H-21, rot. A+B), 7.11 – 7.01 (m, 1H, H-20, rot. A+B), 7.03 – 6.91 (m, 1H, H-
16, rot. A+B), 4.98 (s, 0.50H, H-2, rot. A), 4.91 (s, 0.50H, H-2, rot. B), 3.84 (d, J = 15.5 Hz, 0.50H, H-14A, 
rot. B), 3.76 (d, J = 15.1 Hz, 0.50H, H-14A, rot. A), 3.52 (d, J = 15.5 Hz, 0.50H, H-14B, rot. B), 3.39 (d, J = 
15.1 Hz, 0.50H, H-14B, rot. A), 2.87 (s, 1.50H, H-23, rot. A), 2.79 (s, 1.50H, H-23, rot. B), 1.87 (s, 1.50H, 
H-17, rot. B), 1.78 (s, 1.50H, H-17, rot. A), 1.08 (s, 4.50H, H-8 + H-9 + H-10, rot. A), 0.99 (s, 4.50H, H-8 






(C-11, rot. B), 146.4 (C-11, rot. A), 135.4 (C-15, rot. A/B), 135.1 (C-15, rot. A/B), 133.7 (C-19, rot. A/B), 
133.7 (C-19, rot. A/B), 129.7 (C-16, rot. A/B), 129.6 (C-16, rot. A/B), 128.7 (C-20, rot. A/B), 128.6 (C-20, 
rot. A/B), 127.3 (C-21, rot. A/B), 127.0 (C-21, rot. A/B), 126.5 (C-18, rot. A/B), 126.2 (C-18, rot. A/B), 
83.0 (C-2, rot. A), 82.9 (C-2, rot. B), 69.9 (C-5, rot. A), 67.1 (C-5, rot. B), 43.3 (C-14, rot. B), 40.5 (C-14, 
rot. A), 40.1 (C-7, rot. B), 39.7 (C-7, rot. A), 32.0 (C-23, rot. B), 31.7 (C-23, rot. A), 27.8 (C-8 + C-9 + C-
10, rot. A), 27.2 (C-8 + C-9 + C-10, rot. B), 24.7 (C-17, rot. B), 23.6 (C-17, rot. A); HRMS (ESI+) 
C17H23BrClN2O2 [M+H]+ 401.0626, found 401.0643. 
 
(S)-5,5-Dibenzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (206a) 
 The title compound 206a was prepared from L-phenylalanine derived trans-
carbamoyl chloride 154a (200 mg, 0.65 mmol, 1.0 equiv.), benzyl bromide (0.09 
mL, 0.71 mmol, 1.1 equiv.) and KHMDS (0.77 mL, 0.77 mmol, 1.2 equiv.) in 
THF (6.5 mL) according to general procedure 10. Colourless solid (217 mg, 
84%) as a colourless solid; Rf = 0.2 (pet. ether/EtOAc 85:15); m.p. 124 - 126 
°C, [𝛂]𝐃
𝟐𝟔 = -84° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2966 (C-H), 2927 (C-
H), 1738 (C=O), 1711 (C=O); 1H NMR (500 MHz, CDCl3) (mixture of rotamers A:B in a 0.51:0.49 ratio) 
δ 7.46 – 7.42 (m, 1H, H-Ar, rot. A+B), 7.39 – 7.34 (m, 1H, H-Ar, rot. A+B), 7.32 – 7.21 (m, 6H, H-Ar, rot. 
A+B), 7.21 – 7.18 (m, 1H, H-Ar, rot. A+B), 7.17 – 7.14 (m, 1H, H-Ar, rot. A+B), 4.25 (s, 0.49H, H-2, rot. 
B), 4.07 (s, 0.51H, H-2, rot. A), 3.83 – 3.43 (m, 3H), 3.22 (d, J = 14.1 Hz, 0.51H), 3.07 (d, J = 13.9 Hz, 
0.49H), 2.66 (s, 1.47H, H-8 rot. B), 2.59 (s, 1.53H, rot. A), 0.64 (s, 4.41H, H-10 + H-11 + H-12, rot. B), 
0.38 (s, 4.59H, H-10 + H-11 + H-12, rot. A); 13C NMR (125 MHz, CDCl3) δ 169.9 (C-4, rot. B), 169.7 (C-
4, rot. B), 149.3 (C-6, rot. A), 148.2 (C-6, rot. B), 135.8 (C-Ar), 134.5 (C-Ar), 134.2 (C-Ar), 131.4 (C-Ar), 
131.3 (C-Ar), 130.5 (C-Ar), 130.3 (C-Ar), 128.7 (C-Ar), 128.5 (C-Ar), 128.3 (C-Ar), 128.2 (C-Ar), 127.8 (C-
Ar), 127.6 (C-Ar), 127.5 (C-Ar), 127.5 (C-Ar), 82.8 (C-2, rot. A), 82.6 (C-2, rot. B), 75.8 (C-5, rot. B), 74.0 
(C-5, rot. A), 44.0 (CH2Ph), 42.0 (CH2Ph), 41.3 (CH2Ph), 40.7 (CH2Ph), 38.3 (C-9 rot. A), 38.3 (C-9 rot. B), 
31.3 (C-8 rot. A), 31.2 (C-8 rot. B), 27.3 (C-10 + C-11 + C-12, rot. A), 26.4 (C-10 + C-11 + C-12, rot. B). 




The title compound 206b was prepared from L-phenylalanine derived trans-
carbamoyl chloride 154a (250 mg, 0.81 mmol, 1.0 equiv.), 4-bromobenzyl bromide 
(223 mg, 0.89 mmol, 1.1 equiv.) and KHMDS (0.89 mL, 0.89 mmol, 1.1 equiv.) 
in THF (4 mL) according to general procedure 11. Colourless oil (285 mg, 74%); 
Rf = 0.61 (SiO2; pet. ether/EtOAc 70:30); [𝛂]𝐃
𝟐𝟒 = -48° (c = 1 in CHCl3); IR 






MHz, CDCl3) (mixture of rotamers A:B in a 0.55:0.45 ratio) δ 7.44 – 7.18 (m, 7H, H-Ar, rot. A+B), 7.04 
(dd, J = 13.4, 8.4 Hz, 2H, H-Ar, rot. A+B), 4.35 (s, 0.55H, H-2, rot. A), 4.16 (s, 0.45H, H-2, rot. B), 3.81 – 
3.39 (m, 3H, (2 x H-11, rot. A+B) + (H-12A, rot. A+B), 3.14 (d, J = 13.9 Hz, 0.45H, H-12B, rot. B), 2.98 
(d, J = 13.9 Hz, 0.55H, H-12B, rot. A), 2.70 (s, 1.65H, H-29, rot. A), 2.62 (s, 1.35H, H-29, rot. B), 0.69 (s, 
4.95H, H-8 + H-9 + H-10, rot. A), 0.40 (s, 4.05H, H-8 + H-9 + H-10, rot. A); 13C NMR (100 MHz, CDCl3) 
δ 169.8 (C-4, rot. A), 169.6 (C-4, rot. B), 149.3 (C-15, rot. B), 148.2 (C-15, rot. A), 135.6 (ArC), 135.5 (ArC), 
133.7 (ArC), 133.3 (ArC), 132.2 (ArC), 132.0 (ArC), 131.6 (ArC), 131.4 (ArC), 131.4 (ArC), 128.8 (ArC), 
128.6 (ArC), 127.7 (ArC), 127.6 (ArC), 122.0 (ArC), 121.7 (ArC), 82.8 (C-2, rot. B), 82.7 (C-2, rot. A), 75.2 
(C-5, rot. A), 73.6 (C-5, rot. B), 43.3 (C-12, rot. B), 42.2 (C-11, rot. A/B), 41.4 (C-11, rot. A/B), 39.9 (C-12, 
rot. A), 38.5 (C-7, rot. B), 38.4 (C-7, rot. A), 31.31 (C-29, rot. A/B), 31.28 (C-29, rot. A/B), 27.4 (C-8 + C-
9 + C-10, rot. A), 26.5 (C-8 + C-9 + C-10, rot. B); HRMS (ESI+) C23H26BrClN2NaO2 [M+Na]+ 499.0758, 
found 499.0754.  
(2S,5R)-5-Benzyl-2-(tert-butyl)-5-isopropyl-3-methyl-4-oxoimidazolidine-1-carbonyl  
chloride (206c) 
 The title compound 206c was prepared from L-valine derived trans-
carbamoyl chloride 154r (261 mg, 1.0 mmol, 1.0 equiv.), benzyl bromide (0.14 
mL, 1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in 
THF (10 mL) according to general procedure 10. Colourless solid (208 mg, 
54%); m.p: 119 – 124 °C; Rf = 0.37 (SiO2; pet. ether/Et2O 90:10); [𝛂]𝐃
𝟐𝟐 = -
48° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2957 (C–H), 1746 (C=O), 1705 (C=O); 1H NMR (400 MHz, 
CDCl3) (only one rotamer was observed) δ 7.45 – 6.91 (m, 5H, H-Ar), 4.60 (s, 1H, H-2), 3.58 (d, J = 13.9 
Hz, 1H, H-15A), 3.26 (d, J = 13.9 Hz, 1H, H-15B), 2.85 (s, 3H, H-14), 2.40 (hept, J = 7.0 Hz, 1H, H-16), 
1.27 (dd, J = 7.0, 4.7 Hz, 6H, H-17 + H-18), 1.07 (s, 9H, H-11 + H-12 + H-13); 13C NMR (125 MHz, 
CDCl3) δ 171.1 (C-4), 148.0 (C-8), 134.9 (C-19), 130.6, (C-Ar) 128.1 (C-Ar), 127.0 (C-Ar), 83.0 (C-2), 76.6 
(C-5), 38.2 (C-15), 36.2 (C-7), 34.1 (C-16), 31.2 (C-14), 28.0 (C-11 + C-12 + C-13), 19.6 (C-17/C-18), 19.1 
(C-17/C-18); HRMS (ESI+) C19H28ClN2O2 [M+H]+ 351.1834, found 351.1848. 
 
(2S,4R)-4-Benzyl-2-(tert-butyl)-4-isobutyl-1-methyl-5-oxopyrrolidine-3-carbonyl chloride (206d) 
The title compound 206d was prepared from L-leucine derived trans-
carbamoyl chloride 154p (275 mg, 1.0 mmol, 1.0 equiv.), benzyl bromide (0.14 
mL, 1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in 
THF (10 mL) according to general procedure 11. Colourless solid (327 mg, 
54%); m.p. 55 – 58 °C; Rf = 0.69 (SiO2; pet. ether/EtOAc 80:20); [𝛂]𝐃
𝟐𝟒 = -
32° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2958 (C–H), 1741 (C=O), 1710 
(C=O); 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.65:0.35 ratio) δ 7.28 – 6.98 (m, 5H, 






1H, H-19B, rot. A+B), 2.69 (s, 1.95H, H-14, rot. A), 2.59 (s, 1.05H, H-14, rot. B), 2.33 – 2.19 (m, 1H, H-
16, rot. A+B), 2.21 – 2.02 (m, 1.35H, (H-15A, rot. A+B) + (H-15B, rot. B)), 1.88 (dd, J = 14.6, 5.2 Hz, 
0.65H, H-15B, rot. A), 1.10 – 0.91 (m, 11.85H, (H-11 + H-12 + H-13, rot. A) + (H-17 + H-18, rot. A+B)), 
0.86 (s, 3.15H, H-11 + H-12 + H-13, rot. B); 13C NMR (100 MHz, CDCl3) δ 170.8 (C-4, rot. A), 170.7 (C-
4, rot. B), 149.0 (C-8, rot. B), 147.1 (C-8, rot. A), 134.9 (C-20, rot. A), 134.4 (C-20, rot. B), 130.3 (C-Ar, rot. 
A), 130.2 (C-Ar, rot. B), 128.2 (C-Ar, rot. B), 128.1 (C-Ar, rot. A), 127.5 (C-23, rot. B), 127.2 (C-23, rot. A), 
82.8 (C-2, rot. B), 82.7 (C-2, rot. A), 73.4 (C-5, rot. A), 71.6 (C-5, rot. B), 46.3 (C-19, rot. A), 46.2 (C-19, 
rot. B), 43.0 (C-15, rot. B), 39.2 (C-7, rot. B), 38.9 (C-15, rot. A), 38.8 (C-7, rot. A), 31.5 (C-14, rot. B), 31.2 
(C-14, rot. A), 27.8 (C-11 + C-12 + C-13, rot. A), 27.3 (C-11 + C-12 + C-13, rot. B), 25.1 (C-17/C-18, rot. 
A), 25.0 (C-17/C-18, rot. A), 24.8 (C-17/ C-18, rot. B), 24.7 (C-17/C-18, rot. B), 23.7 (C-16, rot. B), 23.6 
(C-16, rot. A); HRMS (ESI+) C20H30ClN2O2 [M+H]+ 365.1996, found 365.2008.   
 
(2S,5R)-5-Benzyl-2-(tert-butyl)-3-methyl-4-oxo-5-phenylimidazolidine-1-carbonyl chloride (206e) 
 The title compound 206e was prepared from L-phenyglycine derived trans-
carbamoyl chloride 154i (150 mg, 0.51 mmol, 1.0 equiv.), benzyl bromide (0.07 
mL, 0.56 mmol, 1.1 equiv.) and KHMDS (0.61 mL, 0.61 mmol, 1.2 equiv.) in 
THF (5 mL) according to general procedure 10. Colourless solid (157 mg, 
80%); m.p. 119 – 121 °C Rf = 0.4 (pet. ether/EtOAc 85:15); [𝛂]𝐃
𝟐𝟔 = +136° 
(c = 1 in CHCl3); IR (neat, cm-1): νmax = 3006 (C-H), 2902 (C-H), 1738 (C=O), 
1710 (C=O); 1H NMR (500 MHz, CDCl3) (mixture of rotamers A:B in a 0.82:0.18 ratio) δ 7.95 – 7.91 (m, 
1.64H, 2 x H-Ar, rot. A), 7.90 – 7.87 (m, 0.36H, 2 x H-Ar, rot. B), 7.49 – 7.45 (m, 0.36H, 2 x H-Ar, rot. B), 
7.44 – 7.39 (m, 1.64H, 2 x H-Ar, rot. A), 7.36 – 7.27 (m, 6H, 6 x H-Ar, rot. A+B), 4.88 (s, 0.82H, H-4, rot. 
A), 4.64 (s, 0.18H, H-4, rot. B), 4.02 (d, J = 14.2 Hz, 0.18H, H-1A, rot. B), 3.93 (d, J = 14.2 Hz, 0.18H, H-
1B, rot. B), 3.89 (d, J = 14.2 Hz, 0.82H, H-1A, rot. A), 3.58 (d, J = 14.2 Hz, 0.82H, H-1B, rot. A), 2.93 (s, 
2.46H, H-8, rot. A), 2.81 (s, 0.54H, H-8, rot. B), 0.96 (s, 1.62H, H-25 + H-26 + H-27, rot. B), 0.89 (s, 
7.38H, H-25 + H-26 + H-27, rot. A); 13C NMR (125 MHz, CDCl3) δ 169.8 (C-6, rot. A), 169.8 (C-6, rot. 
B), 150.1 (C-9, rot. B), 148.6 (C-9, rot. A), 139.0 (C-Ar, rot. A), 137.2 (C-Ar, rot. B), 134.7 (C-Ar, rot. A), 
134.2 (C-Ar, rot. B), 130.7 (C-Ar, rot. A), 130.4 (C-Ar, rot. B), 128.5 (C-Ar, rot. B), 128.4 (C-Ar, rot. A), 
128.4 (C-Ar, rot. A), 128.4 (C-Ar, rot. B), 128.0 (C-Ar, rot. A), 128.0 (C-Ar, rot. A), 128.0 (C-Ar, rot. A), 
127.9 (C-Ar, rot. A), 127.5 (C-Ar, rot. A), 127.3 (C-Ar, rot. A), 126.5 (C-Ar, rot. A), 83.7 (C-4, rot. A), 82.8 
(C-4, rot. B), 75.9 (C-2, rot. A), 73.6 (C-2, rot. B), 44.9 (C-1, rot. B), 43.9 (C-1, rot. A), 39.6 (C-24, rot. A), 
39.1 (C-24, rot. B), 31.8 (C-8, rot. A), 31.8(C-8, rot. B), 27.2 (C-25 + C-26 + C-27, rot. B), 27.0 (C-25 + C-










 (2S,5R)-5-Benzyl-2-(tert-butyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (206f) 
 The title compound 206f was prepared from L-phenylalanine derived trans-
carbamoyl chloride 154a (308 mg, 1.0 mmol, 1.0 equiv.), methyl iodide (71 μL, 
1.1 mmol, 1.1 equiv.) and KHMDS (1.1 mL, 1.1 mmol, 1.1 equiv.) in THF (10 
mL) according to general procedure 10. Colourless oil (199 mg, 62%); Rf = 0.50 
(SiO2; pet. ether/Et2O 50:50); [𝛂]𝐃
𝟐𝟓 = -172° (c = 1 in CHCl3); IR (neat, cm-1): 
νmax = 2962 (C–H), 1737 (C=O), 1712 (C=O); 1H NMR (400 MHz, CDCl3) 
(mixture of rotamers A:B in a 0.60:0.40 ratio) δ 7.45 – 7.14 (m, 5H, H-Ar, rot. A+B), 5.18 (s, 0.40H, H-2, 
rot. B), 5.12 (s, 0.60H, H-2, rot. A), 3.53 (d, J = 14.1 Hz, 0.60H, H-12A, rot. A), 3.35 (d, J = 14.1 Hz, 0.60H, 
H-12B, rot. A), 3.30 (br. s, 0.80H, (H-12A + H-12B, rot. B)), 3.02 (s, 1.20H, H-10, rot. B), 2.97 (s, 1.80H, H-
10, rot. A), 1.72 (s, 1.80H, H-13, rot. A), 1.60 (s, 1.20H, H-13, rot. B), 0.90 (s, 3.60H, H-14, H-15, H-16, 
rot. B), 0.61 (s, 5.40H, H-14, H-15, H-16, rot. B); 13C NMR (100 MHz, CDCl3) δ 171.73 (C-4, rot. B), 
171.69 (C-4, rot. A), 150.6 (C-6, rot. A), 147.5 (C-6, rot. B), 136.0 (C-17, rot. A), 135.8 (C-17, rot. B), 131.2 
(C-19 + C-21, rot. A), 131.1 (C-19 + C-21, rot. B), 128.6 (C-18 + C-22, rot. A), 128.4 (C-18 + C-22, rot. 
B), 127.5 (C-20, rot. A), 127.3 (C-20, rot. B), 82.7 (C-2, rot. B), 82.0 (C-2, rot. A), 69.4 (C-5, rot. B), 68.4 
(C-5, rot. A), 42.3 (C-12, rot. B), 41.8 (C-12, rot. A), 38.3 (C-9, rot. A+B), 31.7 (C-10, rot. A+B), 27.4 (C-
14 + C-15 + C-16, rot. B), 27.0 (C-13, rot. A), 26.4 (C-14 + C-15 + C-16, rot. A), 23.8 (C-13, rot. B); 





The title compound 207a was prepared from N-chloroformylimidazolidinone 205a 
(50 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine 
(19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave 
for 2 h, according to general procedure 12. Colourless oil (37 mg, 87%); Rf = 0.36 
(SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟓 = -248° (c = 1 in CHCl3); IR (neat, cm-1): 
νmax 2960 (C–H), 1705 (C=O), 1652 (C=O), 1354; 1H NMR (400 MHz, CDCl3) δ 
7.87 (dd, J = 7.5, 1.5 Hz, 1H, H-2), 7.46 (td, J = 7.5, 1.5 Hz, 1H, H-6), 7.41 – 7.34 (m, 1H, H-1), 7.25 – 
7.18 (m, 1H, H-5), 5.39 (s, 1H, H-11), 3.09 (s, 3H, H-14), 3.00 (br. m, 2H, H-10A + H-10B), 1.47 (s, 3H, H-
21), 1.12 (s, 9H, H-17 + H-18 + H-19); 13C NMR (100 MHz, CDCl3) δ 173.9 (C-13), 164.6 (C-7), 135.0 
(C-3), 132.4 (C-6), 130.0 (C-4), 128.1 (C-5), 128.0 (C-2), 127.8 (C-1), 81.3 (C-11), 61.2 (C-9), 38.9 (C-10), 
38.1 (C-16), 31.5 (C-14), 27.7 (C-17 + C-18 + C-19), 22.5 (C-21); HRMS (ESI+) C17H22N2O2Na [M+Na]+ 










Via Method A: 
The title compound 207b was prepared from N-chloroformylimidazolidinone 205b 
(27 mg, 0.08 mmol, 1.0 equiv.), KI (15 mg, 0.09 mmol, 1.1 equiv.) and 2,6-lutidine 
(10 µL, 0.09 mmol, 1.1 equiv.) in dry MeCN (0.8 mL) at 150 °C in the microwave for 
2 h, according to general procedure 12. Colourless oil (21 mg, 87%); Rf = 0.30 
(SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟓 = -264° (c = 1 in CHCl3); IR (neat, cm-1): νmax 
2964 (C–H), 1704 (C=O), 1660 (C=O), 1355; 1H NMR (400 MHz, CDCl3) δ 7.71 – 
7.65 (m, 1H, H-20), 7.30 – 7.22 (m, 1H, H-18), 7.11 (d, J = 7.6 Hz, 1H, H-17), 5.38 (s, 1H, H-2), 3.08 (s, 
3H, H-22), 2.95 (br. s, 2H, H-12A + H-12B), 2.38 (s, 3H, H-21), 1.45 (s, 3H, H-11), 1.11 (s, 9H, H-8 + H-9 
+ H-10); 13C NMR (100 MHz, CDCl3) δ 173.9 (C-4), 164.8 (C-15), 137.6 (C-Ar), 133.1 (C-18), 131.9 (C-
Ar), 129.8 (C-Ar), 128.4 (C-20), 128.0 (C-18), 81.2 (C-2), 61.2 (C-5), 38.5 (C-12), 38.1 (C-7), 31.5 (C-22), 
27.7 (C-8 + C-9 + C-10), 22.4 (C-11), 21.2 (C-21); HRMS (ESI+) C18H25N2O2 [M+H]+ 301.1916, found 
301.1701.  
Via Method B: 
The title compound 207b was prepared from N-chloroformylimidazolidinone 205b (35 mg, 0.10 mmol, 
1.0 equiv.), and AlCl3 (42 mg, 0.30 mmol, 3.0 equiv.) in 1,2-dichloroethane (1 mL) according to general 




Via Method A: 
The title compound 207c was prepared from N-chloroformylimidazolidinone 
205c (27 mg, 0.08 mmol, 1.0 equiv.), KI (14 mg, 0.09 mmol, 1.1 equiv.) and 2,6-
lutidine (10 µL, 0.09 mmol, 1.1 equiv.) in dry MeCN (0.8 mL) at 150 °C in the 
microwave for 2 h, according to general procedure 12. Colourless oil (16 mg, 
66%); Rf = 0.26 (SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟓 = -248° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax 2962 (C–H), 1707 (C=O), 1660 (C=O), 1356; 1H NMR (400 
MHz, CDCl3) δ 6.99 – 6.93 (br. m, 1H, H-19), 6.88 – 6.81 (br. m, 1H, H-17), 5.42 
(s, 1H, H-2), 3.07 (s, 3H, H-23), 2.93 (d, J = 15.0 Hz, 1H, H-12A), 2.85 (d, J = 15.0 Hz, 1H, H-12B), 2.53 (s, 
3H, H-21/H-22), 2.32 (s, 3H, H-21/H-22), 1.39 (s, 3H, H-11), 1.09 (s, 9H, H-8 + H-9 + H-10); 13C NMR 
(100 MHz, CDCl3) δ 174.1 (C-4), 165.4 (C-15), 141.7 (C-Ar), 139.4 (C-Ar), 135.7 (C-Ar), 131.6 (C-19), 126.6 
(C-17), 126.0 (C-Ar), 80.5 (C-2), 61.3 (C-5), 39.9 (C-12), 37.8 (C-7), 31.5 (C-23), 27.4 (C-8 + C-9 + C-10), 










Via Method B: 
The title compound 207c was prepared from N-chloroformylimidazolidinone 205c (42 mg, 0.12 mmol, 1.0 
equiv.), and AlCl3 (48 mg, 0.36 mmol, 3.0 equiv.) in 1,2-dichloroethane (1.2 mL) according to general 




The title compound 207d was prepared from N-chloroformylimidazolidinone 205d 
(51 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine 
(19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave 
for 4 h, according to general procedure 12. Colourless oil (40 mg, 89%); Rf = 0.34 
(SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟓 = -192° (c = 1 in CHCl3); IR (neat, cm-1): 
νmax 2972 (C–H), 1706 (C=O), 1669 (C=O), 1365; 1H NMR (400 MHz, CDCl3) δ 
7.76 – 7.54 (m, 1H, H-2), 7.25 (m, 1H, H-6), 7.22 – 7.15 (m, 1H, H-1), 5.31 (s, 1H, H-11), 3.12 (d, J = 15.5, 
1H, H-10A), 3.02 (s, 3H, H-21), 2.68 (d, J = 15.5 Hz, 1H, H-10B), 2.25 (s, 3H, H-22), 1.37 (s, 3H, H-14), 
1.05 (s, 9H, H-18 + H-19 + H-20); 13C NMR (100 MHz, CDCl3) δ 173.9 (C-13), 164.8 (C-7), 135.6 (C-5), 
133.7 (C-6), 133.3 (C-3), 129.9 (C-4), 127.0 (C-1), 125.6 (C-2), 81.2 (C-11), 60.8 (C-9), 37.9 (C-17), 35.3 (C-
10), 31.4 (C-21), 27.5 (C-18 + C-19 + C-20), 22.4 (C-14), 19.2 (C-22); HRMS (ESI+) C18H25N2O2 [M+H]+ 




The title compound 207e was prepared from N-chloroformylimidazolidinone 
205f (56 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-
lutidine (19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the 
microwave for 2 h, according to general procedure 12. Colourless oil (44 mg, 
87%); Rf = 0.47 (SiO2; pet. ether/EtOAc 80:20); [𝛂]𝐃
𝟐𝟒 = -324° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax 2970 (C–H), 1705 (C=O), 1666 (C=O), 1248, 798; 1H NMR 
(400 MHz, CDCl3) δ 8.76 (dd, J = 8.6, 1.1 Hz, 1H, H-25), 7.87 (d, J = 8.2 Hz, 1H, H-6), 7.80 – 7.75 (m, 
1H, H-22), 7.56 – 7.49 (m, 1H, H-24), 7.47 – 7.37 (m, 1H, H-23), 7.25 (d, J = 8.2 Hz, 1H, H-5), 5.49 (s, 1H, 
H-11), 3.14 (d, J = 15.3 Hz, 1H, H-10A), 3.05 (s, 3H, H-14), 3.01 (d, J = 15.3 Hz, 1H, H-10B), 1.37 (s, 3H, 
H-17), 1.09 (s, 9H, H-19 + H-20 + H-21); 13C NMR (100 MHz, CDCl3) δ 173.8 (C-13), 164.9 (C-7), 134.7 
(C-4), 133.4 (C-3), 132.6 (C-6), 130.7 (C-2), 128.3 (C-22), 127.9 (C-24), 126.0 (C-23), 125.8 (C-25), 125.7 
(C-5), 125.5 (C-1), 80.5 (C-11), 61.0 (C-9), 40.0 (C-10), 37.8 (C-18), 31.5 (C-14), 27.3 (C-19 + C-20 + C-









The title compound 207f was prepared from N-chloroformylimidazolidinone 205e 
(53 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine 
(19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave for 
2 h, according to general procedure 12. Colourless solid (36 mg, 76%); m.p. 144 – 
146 °C; Rf = 0.29 (SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟔 = -232° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax 2960 (C–H), 1704 (C=O), 1657 (C=O), 1362; 1258; 1H NMR 
(400 MHz, CDCl3) δ 7.81 (d, J = 8.6 Hz, 1H, H-2), 6.86 (ddd, J = 8.6, 2.6, 0.8 Hz, 
1H, H-1), 6.70 (dd, J = 2.6, 1.0 Hz, 1H, H-5), 5.34 (s, 1H, H-11), 3.85 (s, 3H, H-23), 3.07 (s, 3H, H-14), 
3.00 – 2.89 (m, 2H, H-10), 1.47 (s, 3H, H-17), 1.11 (s, 9H, H-19 + H-20 + H-21); 13C NMR (100 MHz, 
CDCl3) δ 173.9 (C-13), 164.3 (C-7), 162.8 (C-6), 137.1 (C-3), 130.0 (C-2), 122.6 (C-4), 113.3 (C-5), 113.0 
(C-1), 81.3 (C-11), 61.0 (C-9), 55.6 (C-23), 39.1 (C-10), 38.1 (C-18), 31.5 (C-14), 27.7 (C-19 + C-20 + C-
21), 22.5 (C-17); HRMS (ESI+) C18H25N2O3 [M+H]+ 317.1864 found 317.1859. An X-ray crystal structure, 
showing relative stereochemistry only, was obtained for this compound (CCDC 1895400 contains the 
supplementary crystallographic data for this paper. This data can be obtained from The Cambridge 




Via Method A: 
The title compound 207j was prepared from N-chloroformylimidazolidinone 205j 
(40 mg, 0.10 mmol, 1.0 equiv.), KI (18 mg, 0.11 mmol, 1.1 equiv.) and 2,6-lutidine 
(13 µL, 0.11 mmol, 1.1 equiv.) in dry MeCN (1 mL) at 150 °C in the microwave for 
4 h, according to general procedure 12. Colourless oil (5 mg, 15%); Rf = 0.13 (SiO2; 
pet. ether/Et2O 40:60); [𝛂]𝐃
𝟐𝟒 = -288° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2971 
(C–H), 1708 (C=O), 1663 (C=O), 1358; 1H NMR (400 MHz, CDCl3) δ 8.01 (br. s, 
1H, H-20), 7.64 – 7.55 (m, 1H, H-18), 7.12 (d, J = 8.1 Hz, 1H, H-17), 5.36 (s, 1H, H-2), 3.08 (s, 3H, H-22), 
2.98 (d, J = 15.4 Hz, 1H, H-12A), 2.92 (d, J = 15.4 Hz, 1H, H-12B), 1.45 (s, 3H, H-11), 1.11 (s, 9H, H-8 + 
H-9 + H-10); 13C NMR (100 MHz, CDCl3) δ 173.4 (C-4), 163.2 (C-15), 135.3 (C-Ar), 133.8 (C-Ar), 131.7 
(C-Ar), 131.1 (C-Ar), 129.7(C-Ar), 121.7 (C-Ar), 81.4 (C-2), 61.1 (C-5), 38.4 (C-12), 38.1 (C-7), 31.6 (C-22), 
27.7 (C-8 + C-9 + C-10), 22.5 (C-11); HRMS (ESI+) C17H22BrN2O2 [M+H]+ 365.0859, found 365.0860.  
 
Via Method B: 
The title compound 207j was prepared from N-chloroformylimidazolidinone 205j (20 mg, 0.05 mmol, 1.0 
equiv.), and AlCl3 (20 mg, 0.15 mmol, 3.0 equiv.) in 1,2-dichloroethane (0.5 mL) according to general 








Via Method A: 
The title compound 207k was prepared from N-chloroformylimidazolidinone 205m 
(40 mg, 0.10 mmol, 1.0 equiv.), KI (18 mg, 0.11 mmol, 1.1 equiv.) and 2,6-lutidine (13 
µL, 0.11 mmol, 1.1 equiv.) in dry MeCN (1 mL) at 150 °C in the microwave for 4 h, 
according to general procedure 12. Colourless oil (11 mg, 31%); Rf = 0.34 (SiO2; 
pet. ether/Et2O 20:80); [𝛂]𝐃
𝟐𝟑 = -252° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2960 (C–
H), 1710 (C=O), 1664 (C=O), 1373; 1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 7.6, 
1.2 Hz, 1H, H-20), 7.70 (dd, J = 8.1, 1.2 Hz, 1H, H-18), 7.27 – 7.20 (m, 1H, H-19), 5.36 (s, 1H, H-2), 3.51 
(d, J = 15.8 Hz, 1H, H-12A), 3.09 (s, 3H, H-22), 2.82 (d, J = 15.8 Hz, 1H, H-12B), 1.47 (s, 3H, H-11), 1.12 
(s, 9H, H-8 + H-9 + H-10); 13C NMR (100 MHz, CDCl3) δ 173.4 (C-4), 163.8 (C-15), 136.2 (C-18), 135.1 
(C-Ar), 131.9 (C-Ar), 128.9 (C-19), 127.3 (C-20), 123.6 (C-Ar), 81.4 (C-2), 60.9 (C-5), 38.6 (C-12), 38.1 (C-
7), 31.6 (C-22), 27.6 (C-8 + C-9 + C-10), 22.6 (C-11); HRMS (ESI+) C17H22BrN2O2 [M+H]+ 365.0859, 
found 365.0872.  
Via Method B: 
The title compound 207k was prepared from N-chloroformylimidazolidinone 205m (20 mg, 0.05 mmol, 
1.0 equiv.), and AlCl3 (20 mg, 0.15 mmol, 3.0 equiv.) in 1,2-dichloroethane (0.5 mL) according to general 




The title compound 207l was prepared from N-chloroformylimidazolidinone 205i 
(53 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine (19 
µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave for 4 
h, according to general procedure 12. Orange solid (26 mg, 54%); m.p: 101 – 103 
°C; Rf = 0.34 (SiO2; pet. ether/EtOAc 70:30); [𝛂]𝐃
𝟐𝟒 = -84° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2969 (C–H), 1706 (C=O), 1664 (C=O), 1421, 1358; 1H NMR (400 
MHz, CDCl3) δ 7.86 (d, J = 2.3 Hz, 1H, H-13), 7.42 (dd, J = 8.1, 2.3 Hz, 1H, H-11), 7.18 (d, J = 8.1 Hz, 
1H, H-10), 5.36 (s, 1H, H-7), 3.08 (s, 3H, H-14), 3.01 – 2.87 (m, 2H, H-5A + H-5B), 1.45 (s, 3H, H-18), 1.11 
(s, 9H, H-20 + H-21 + H-22); 13C NMR (100 MHz, CDCl3) δ 173.3 (C-9), 163.2 (C-2), 133.8 (C-1), 133.2 
(C-12), 132.2 (C-11), 131.3(C-6), 129.3 (C-10), 128.0 (C-13), 81.2 (C-7), 61.0 (C-4), 38.2 (C-5), 38.0 (C-19), 











The title compound 208a was prepared from N-chloroformylimidazolidinone 206a 
(60 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine (19 
µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave for 4 h, 
according to general procedure 12. Colourless solid (39 mg, 71%); m.p. 155 – 159 
°C; Rf = 0.28 (SiO2; pet. ether/EtOAc 70:30); [𝛂]𝐃
𝟐𝟓 = -172° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2960 (C–H), 1700 (C=O), 1661 (C=O), 1369; 1H NMR (400 MHz, 
CDCl3) δ 7.77 (dd, J = 7.6, 1.4 Hz, 1H, H-2), 7.32 (td, J = 7.5, 1.5 Hz, 1H, H-6), 7.25 – 7.21 (m, 1H, H-1), 
7.11– 7.02 (m, 5H, H-16 + H-17 + H-18 + H-19 + H-20), 6.95 – 6.92 (m, 1H, H-5), 5.43 (s, 1H, H-11), 
3.23 (d, J = 14.0 Hz, 1H, H-14A), 3.11 (m, 4H, H-10A + H-23), 3.05 (d, J = 14.0 Hz, 1H, H-14B), 2.90 (d, J 
= 15.8 Hz, 1H, H-10B), 1.24 (s, 9H, H-25 + H-26 + H-27); 13C NMR (100 MHz, CDCl3) δ 172.8 (C-13), 
165.1 (C-7), 135.1 (C-3), 134.7 (C-4), 132.2 (C-6), 130.5 (C-17 + C-19), 129.9 (C-15), 127.9 (C-16 + C-20), 
127.8 (C-5), 127.6 (C-2), 127.2 (C-1), 127.0 (C-18), 81.4 (C-11), 63.2 (C-9), 42.7 (C-14), 37.8 (C-24), 35.0 





The title compound 208b was prepared from N-chloroformylimidazolidinone 
206b (100 mg, 0.21 mmol, 1.0 equiv.), KI (38 mg, 0.23 mmol, 1.1 equiv.) and 2,6-
lutidine (27 µL, 0.23 mmol, 1.1 equiv.) in dry MeCN (1.4 mL) at 150 °C in the 
microwave for 4 h, according to general procedure 12. Yellow oil (37 mg, 40%); 
Rf = 0.33 (SiO2; pet. ether/EtOAc 50:50); [𝛂]𝐃
𝟐𝟓 = -100° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2956 (C–H), 1707 (C=O), 1664 (C=O), 1358; 1H NMR (400 
MHz, CDCl3) δ 7.87 (d, J = 2.0 Hz, 1H, H-19), 7.39 (dd, J = 8.1, 2.1 Hz, 1H, H-17), 7.15 – 6.96 (m, 5H, 
H-22 + H-23 + H-24 + H-25 + H-26), 6.77 (d, J = 8.0 Hz, 1H, H-16), 5.42 (s, 1H, H-2), 3.22 (d, J = 14.1 
Hz, 1H, H-11A), 3.15 – 3.01 (m, 5H, H-28 + H-11B + H-12A), 2.83 (d, J = 15.9 Hz, 1H, H-12B), 1.23 (s, 
9H, H-8 + H-9 + H-10); 13C NMR (100 MHz, CDCl3) δ 172.7 (C-4), 164.1 (C-15), 135.1 (C-Ar), 135.1 (C-
Ar), 133.7 (C-Ar), 131.7 (C-Ar), 130.6 (C-Ar), 130.6 (C-Ar), 129.6 (C-Ar), 128.2 (C-Ar), 127.3 (C-Ar), 121.1 
(C-Ar), 81.8 (C-2), 63.5 (C-5), 43.0 (C-11), 38.0 (C-7), 34.9 (C-12), 31.6 (C-28), 28.0 (C-8 + C-9 + C-10); 










The title compound 208c was prepared from N-chloroformylimidazolidinone 206c 
(52 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine 
(19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave for 
4 h, according to general procedure 12. Colourless solid (30 mg, 64%); m.p: 68 – 
73 °C; Rf = 0.36 (SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟒 = -200° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2964 (C–H), 1703 (C=O), 1660 (C=O), 1377; 1H NMR (400 MHz, 
CDCl3) δ 7.78 (dd, J = 7.6, 1.4 Hz, 1H, H-11), 7.37 (td, J = 7.5, 1.4 Hz, 1H, H-9), 7.26 (tt, J = 7.6, 1.2 Hz, 
1H, H-10), 7.15 – 7.11 (m, 1H, H-8), 5.34 (s, 1H, H-3), 3.30 (d, J = 16.2 Hz, 1H, H-14A), 2.98 (s, 3H, H-7), 
2.82 (d, J = 16.2 Hz, 1H, H-14B), 2.21 – 2.03 (m, 1H, H-17), 1.18 (d, J = 7.1 Hz, 3H, H-18/H-19), 1.08 (s, 
9H, H-21 + H-22 + H-23), 0.45 (d, J = 7.1 Hz, 3H, H-19/H-20); 13C NMR (100 MHz, CDCl3) δ 173.5 (C-
5), 165.9 (C-15), 136.1 (C-12), 132.5 (C-9), 130.4 (C-13), 127.5 (C-11), 127.4 (C-10), 126.4 (C-8), 81.2 (C-3), 
65.3 (C-1), 37.5 (C-20), 35.1 (C-17), 31.2 (C-14), 31.1 (C-7), 27.9 (C-21 + C-22 + C-23), 19.2 (C-18/C-19), 




The title compound 208d was prepared from N-chloroformylimidazolidinone 206d 
(55 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-lutidine 
(19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the microwave 
for 4 h, according to general procedure 12. Colourless oil (41 mg, 84%); Rf = 0.42 
(SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟒 = -208° (c = 1 in CHCl3); IR (neat, cm-1): 
νmax 2957 (C–H), 1703 (C=O), 1660 (C=O), 1364; 1H NMR (400 MHz, CDCl3) δ 
7.87 (dd, J = 7.5, 1.4 Hz, 1H, H-2), 7.45 (td, J = 7.5, 1.4 Hz, 1H, H-6), 7.35 (tt, J = 7.5, 1.4 Hz, 1H, H-1), 
7.23 – 7.18 (m, 1H, H-5), 5.36 (s, 1H, H-11), 3.24 (d, J = 15.7 Hz, 1H, H-10A), 3.06 (s, 3H, H-20), 2.99 (dd, 
J = 15.7, 1.3 Hz, 1H, H-10B), 1.93 (dtd, J = 13.2, 6.6, 4.9 Hz, 1H, H-15), 1.79 (ddd, J = 14.6, 4.9, 1.3 Hz, 
1H, H-14A), 1.67 (dd, J = 14.6, 6.6 Hz, 1H, H-14B), 1.14 (s, 9H, H-22 + H-23 + H-24), 0.86 (d, J = 6.6 Hz, 
3H, H-16/H-17), 0.81 (d, J = 6.6 Hz, 3H, H-16 or H-17); 13C NMR (100 MHz, CDCl3) δ 173.2 (C-13), 
164.5 (C-7), 135.1 (C-3), 132.4 (C-6), 129.8 (C-4), 127.8 (C-2), 127.6 (C-5), 127.5 (C-1), 81.1 (C-11), 63.0 
(C-9), 45.2 (C-14), 37.5 (C-21), 35.9 (C-10), 31.2 (C-20), 27.8 (C-22 + C-23 + C-24), 24.8 (C-16/C-17), 24.2 










The title compound 208e was prepared from N-chloroformylimidazolidinone 
206e (58 mg, 0.15 mmol, 1.0 equiv.), KI (27 mg, 0.17 mmol, 1.1 equiv.) and 2,6-
lutidine (19 µL, 0.17 mmol, 1.1 equiv.) in dry MeCN (1.5 mL) at 150 °C in the 
microwave for 4 h, according to general procedure 12. Colourless oil (33 mg, 
63%); Rf = 0.42 (SiO2; pet. ether/EtOAc 60:40); [𝛂]𝐃
𝟐𝟒 = -4° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2924 (C–H), 1704 (C=O), 1665 (C=O), 1354; 1H NMR (400 
MHz, CDCl3) δ 7.92 (dd, J = 7.2, 2.0 Hz, 1H, H-2), 7.46 – 7.38 (m, 2H, H-23 + H-25), 7.35 – 7.20 (m, 2H, 
H-1 + H-5), 7.14 – 7.01 (m, 3H, H-22 + H-24 + H-26), 6.86 (dt, J = 7.2, 1.4 Hz, 1H, H-6), 5.45 (s, 1H, H-
11), 3.36 (d, J = 15.3 Hz, 1H, H-10A), 3.22 (d, J = 15.3 Hz, 1H, H-10B), 3.05 (s, 3H, H-14), 0.80 (s, 9H, H-
18 + H-19 + H-20); 13C NMR (100 MHz, CDCl3) δ 171.8 (C-13), 165.3 (C-7), 138.9 (C-21), 133.6 (C-3), 
132.5 (C-1), 130.0 (C-4), 128.1 (C-22 + C-26), 127.9 (C-6), 127.7 (C-5), 127.7 (C-24), 127.6 (C-2), 125.6 (C-
23 + C-25), 81.2 (C-11), 65.4 (C-9), 41.5 (C-10), 38.0 (C-17), 31.5 (C-14), 26.9 (C-18 + C-19 + C-20); 
HRMS (ESI+) C22H25N2O2 [M+H]+ 349.1910 found 349.1905. 
 
Hydrolysed products 
(S)-3-Methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 209a 
The title compound 209a was prepared from dihydroisoquinolone 207a (28 mg, 
0.10 mmol) and TFA – 6.0 M HCl (1:4 ratio) (2 mL, 0.05 M) according to general 
procedure 9, heating for 4 h. Colourless oil (16.4 mg, 80%); Rf  = 0.20 (SiO2; pet. 
ether/1% HCOOH in EtOAc 60:40); [𝛂]𝐃
𝟐𝟐 = -152° (c = 1 in CHCl3); IR (neat, 
cm-1): νmax 3269 (O-H), 2922 (C–H), 1704 (C=O), 1632 (C=O), 1401; 1H NMR (500 MHz, CDCl3) δ 9.64 
(br. s, 1H, H-8), 8.04 (dd, J = 7.6, 1.4 Hz, 1H, H-2), 7.53 (td, J = 7.6, 1.4 Hz, 1H, H-6), 7.40 (tt, J = 7.6, 1.4 
Hz, 1H, H-1), 7.31 (d, J = 7.6 Hz, 1H, H-5), 3.43 (d, J = 15.9 Hz, 1H, H-10A), 3.20 (d, J = 15.9 Hz, 1H, H-
10B), 1.57 (s, 3H, H-11); 13C NMR (125 MHz, CDCl3) δ 177.4 (C-13), 166.6 (C-7), 136.3 (C-3), 133.3 (C-
6), 128.7 (C-5), 128.0 (C-2), 127.5 (C-1), 127.0 (C-4), 58.0 (C-9), 36.2 (C-10), 24.5 (C-11); HRMS (ESI+) 












(S)-3,7-Dimethyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 209b 
The title compound 209b was prepared from dihydroisoquinolone 207b (45 mg, 
0.16 mmol) and TFA – 6.0 M HCl (1:4 ratio) (3.2 mL, 0.05 M) according to 
general procedure 9, heating for 5 h. Beige foam (23 mg, 80%); Rf  = 0.30 
(SiO2; hex/1% HCOOH in EtOAc 80:20); [𝛂]𝐃
𝟐𝟔 = -176° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 3262 (O-H), 2924 (C–H), 1709 (C=O), 1639 (C=O); 1H NMR (500 MHz, CDCl3) δ 9.68 
(s, 1H, H-1), 7.84 (s, 1H, H-11), 7.33 (dd, J = 7.6, 1.8 Hz, 1H, H-13), 7.19 (d, J = 7.6 Hz, 1H, H-14), 3.37 
(d, J = 15.9 Hz, 1H, H-7A), 3.15 (d, J = 15.9 Hz, 1H, H-7B), 2.39 (s, 3H, H-16), 1.55 (s, 3H, H-15); 13C 
NMR (125 MHz, CDCl3) δ 177.6 (C-5), 167.0 (C-8), 137.5 (C-10), 134.1 (C-9), 133.4 (C-13), 128.7 (C-14), 
128.5 (C-11), 126.9 (C-12), 58.1 (C-6), 35.9 (C-7), 24.5 (C-15), 21.2 (C-16); HRMS (ESI+) C12H14NO3 [M 
+ H]+ 220.0968, found 220.0966.  
 
(S)-3,6,8-Trimethyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 209c 
The title compound 209c was prepared from dihydroisoquinolone 207c (36 mg, 
0.18 mmol) and TFA – 6.0 M HCl (1:4 ratio) (2.4 mL, 0.05 M) according to 
general procedure 9, heating for 4.5 h. Colourless oil (16 mg, 62%); Rf = 0.14 
(SiO2; hex/1% HCOOH in EtOAc 80:20); [𝛂]𝐃
𝟐𝟔 = -120° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 3253 (O-H), 2925 (C–H), 1710 (C=O), 1613 (C=O); 1H NMR 
(500 MHz, CDCl3) δ 9.50 (s, 1H, H-1), 6.97 (s, 1H, H-14), 6.92 (s, 1H, H-12), 3.37 (d, J = 15.6 Hz, 1H, H-
7+), 3.08 (d, J = 15.6 Hz, 1H, H-7B), 2.66 (s, 3H, H-16), 2.34 (s, 3H, H-17), 1.50 (s, 3H, H-15); 13C NMR 
(125 MHz, CDCl3) δ 177.6 (C-5), 167.9 (C-8), 142.8 (C-10), 141.4 (C-9), 137.6 (C-11), 132.3 (C-14), 127.6 
(C-12), 122.8 (C-13), 57.5 (C-6), 37.8 (C-7), 23.9 (C-15), 22.2 (C-16), 21.5 (C-17); HRMS (ESI+) C13H15NO3 
[M+H]+ 234.1125, found 234.1109. 
 
(S)-3,5-Dimethyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 209d 
The title compound 209d was prepared from dihydroisoquinolone 207d (30 mg, 
0.10 mmol) and TFA – 6.0 M HCl (1:4 ratio) (2.0 mL, 0.05 M) according to general 
procedure 9, heating for 4 h. White solid (14.9 mg, 68%); m.p: 200 – 201 °C; Rf 
= 0.17 (SiO2; pet. ether/1% HCOOH in EtOAc 60:40); [𝛂]𝐃
𝟐𝟐 = -276° (c = 1 in 
CHCl3); IR (neat, cm-1): νmax 3220 (O-H), 2920 (C–H), 1706 (C=O), 1622 (C=O), 749; 1H NMR (500 
MHz, CDCl3) δ 9.74 (br. s, 1H, H-3), 7.91 (dd, J = 7.2, 1.3 Hz, 1H, H-12), 7.40 (d, J = 7.2 Hz, 1H, H-10), 
7.29 (t, J = 7.8 Hz, 1H, H-11), 3.33 (d, J = 16.4 Hz, 1H, H-5A), 3.17 (d, J = 16.4 Hz, 1H, H-5B), 2.37 (s, 3H, 
H-16), 1.56 (s, 3H, H-13); 13C NMR (125 MHz, CDCl3) δ  177.6 (C-8), 167.0 (C-2), 136.3 (C-9), 134.9 (C-
10), 134.7 (C-1), 127.0 (C-6), 126.9 (C-11), 125.8 (C-12), 57.6 (C-4), 32.9 (C-5), 24.9 (C-13), 19.3 (C-16); 








(S)-3-Methyl-1-oxo-1,2,3,4-tetrahydrobenzo[h]isoquinoline-3-carboxylic acid 209e 
The title compound 209e was prepared from dihydroisoquinolone 207e (34 mg, 
0.10 mmol) and TFA – 6.0 M HCl (1:4 ratio) (2.0 mL, 0.05 M) according to 
general procedure 9, heating for 4 h. Colourless solid (10.2 mg, 43%); m.p. 
190 – 210 °C; Rf = 0.18 (SiO2; pet. ether/1% HCOOH in EtOAc 60:40); [𝛂]𝐃
𝟐𝟐 
= -120° (c = 1 in CHCl3); IR (neat, cm-1): νmax 3258 (O-H), 2922 (C–H), 1704 
(C=O), 1653 (C=O), 1440; 1H NMR (500 MHz, CDCl3) δ 9.69 (s, 1H, H-3), 9.36 (dd, J = 8.7, 1.1 Hz, 1H, 
H-19), 8.02 (d, J = 8.3 Hz, 1H, H-10), 7.87 (d, J = 8.0 Hz, 1H, H-16), 7.64 (ddd, J = 8.5, 6.8, 1.4 Hz, 1H, 
H-18), 7.53 (ddd, J = 8.5, 6.8, 1.4 Hz, 1H, H-17), 7.39 (d, J = 8.3 Hz, 1H, H-9), 3.66 (d, J = 16.2 Hz, 1H, 
H-5), 3.32 (d, J = 16.2 Hz, 1H, H-5), 1.62 (s, 3H, H-13); 13C NMR (125 MHz, CDCl3) δ 177.4 (C-8), 167.7 
(C-2), 137.4 (C-6), 134.1 (C-1), 133.5 (C-10), 131.4 (C-12), 128.5 (C-16), 128.2 (C-18), 126.5 (C-17), 126.4 
(C-19), 126.1 (C-9), 122.0 (C-11), 57.1 (C-4), 38.1 (C-5), 23.6 (C-13); HRMS (ESI+) C15H14NO3 [M+H]+ 
256.0968, found 256.0976. 
 
(S)-7-Fluoro-3-methyl-1-oxo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 209f 
The title compound 209f was prepared from dihydroisoquinolone 207h (49 mg, 
0.18 mmol) and TFA – 6.0 M HCl (1:4 ratio) (3.5 mL, 0.05 M) according to 
general procedure 9, heating for 7 h. Colourless oil (20 mg, 70%); Rf = 0.06 
(SiO2; hex /1% HCOOH in EtOAc 80:20); [𝛂]𝐃
𝟐𝟔 = -164° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 3248 (O-H), 2924 (C–H), 1710 (C=O), 1650 (C=O); 1H NMR (500 MHz, CDCl3) δ 9.71 
(s, 1H, H-1), 7.72 (dd, J = 8.5, 2.8 Hz, 1H, H-13), 7.29 (dd, J = 8.5, 5.1 Hz, 1H, H-14), 7.24 (td, J = 8.5, 2.8 
Hz, 1H, H-11), 3.36 (d, J = 16.1 Hz, 1H, H-7), 3.20 (dd, J = 16.1, 1.1 Hz, 1H, H-7), 1.56 (s, 3H, H-15);  13C 
NMR (125 MHz, CDCl3) δ 177.3 (C-5), 165.8 (C-8), 165.7 (C-8), 163.2 (C-12), 161.2 (C-12), 132.0 (C-9), 
131.9 (C-9), 130.6 (C-14) , 130.5 (C-14), 129.0 (C-10), 128.9 (C-10), 120.6 (C-11), 120.4 (C-11), 115.0 (C-


















Benzyl (2S,5S)-5-benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (216) 
In flask A, a solution of trans-N-chloroformylimidazolidinone 154a (200 
mg, 0.65 mmol, 1.0 equiv.) in THF (3 mL, 0.2 M) was degassed by 
bubbling with N2 for 15 min and cooled to 0 °C. In flask B, NaH (60% 
suspension in mineral oil, 39 mg, 0.71 mmol, 1.05 equiv.) was added to 
a solution of benzyl alcohol (0.14 ml, 0.71 mmol, 1.1 equiv.) in dry THF 
(2 mL) at 0 °C. The solution was stirred for 30 min at 0 °C. The content 
of flask A was added to flask B dropwise over 10 min at 0 °C. The reaction mixture was warmed to RT and 
allowed to stir for 1 h. The reaction was quenched with water (10 mL). The mixture was extracted with 
EtOAc (2 × 10 mL). The combined organic layers were washed with brine (2 × 10 mL), dried over MgSO4, 
filtered, and concentrated under reduced pressure. The residue was purified by automated FC (SiO2; pet. 
ether/EtOAc 8:1 → pet. ether/ EtOAc  3:1). The title compound 216 (150 mg, 63%) as a colourless semi-
solid. Rf = 0.06 (SiO2; pet. ether/ EtOAc  3:1); [𝛂]𝐃
𝟐𝟓 = +12 (c = 1 in CHCl3); IR (neat, cm-1): νmax 2968 
(C–H), 1738 (C=O), 1716 (C=O); 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 3H, ArH), 7.25 – 7.15 
(m, 7H, ArH), 5.07 (d, J = 11.7 Hz, 1H, H-22), 5.00 (s, 1H, H-4), 4.75 (s, 1H, H-22), 4.37 (t, J = 6.5 Hz, 
1H, H-2), 3.23 (dd, J = 13.7, 6.5 Hz, 1H, H-1), 3.07 – 2.93 (m, 4H, H-1, H-9), 1.05 (s, 9H, H-19, H-21, H-
22). 13C NMR (125 MHz, CDCl3) δ 171.2 (C-6), 156.8 (C-10), 138.1 (ArC), 135.7 (ArC), 130.2 (ArC), 129.6 
(ArC), 128.6 (ArC), 128.5 (ArC), 128.4 (ArC), 128.4 (ArC), 128.4 (ArC), 126.6 (ArC), 82.7 (C-4), 67.9 (C-
22), 62.0 (C-2), 39.9 (C-1), 37.6 (C-7), 31.5 (C-9), 26.8 (C-19, C-20, C-21). HRMS C23H29N2O3 [M + H]+ 
calculated: 381.2115, found: 381.2121. 
 
The relative stereochemistry was assigned by NOE experiments as indicated on the compound structure 
216 (See NOE section). NOE correlations were observed between H-1 and H-19, H-20, H-21 and between 
H-2 and H-4. There is no NOE correlation was observed between H-2 and H-19, H-20, H-21. There is no 
NOE correlation was observed between H-1 and H-4. The structure and relative stereochemistry were also 














Alkenyl reagents  
(3-Bromoprop-1-en-2-yl)benzene (263a) 
To a solution of α-methyl styrene (2.0 g, 17 mmol, 1.0 equiv.) in dry THF (50 ml, 0.3 
M) were added N-bromosuccinimide (3.16 g, 17.8 mmol, 1.05 equiv.) and p-TsOH 
(0.32 g, 1.7 mmol, 0.1 equiv.) according to general procedure 15. The residue was 
purified by gravity column chromatography (hexane). Pure fractions were combined 
and concentrated under reduced pressure to yield the title compound as a yellow oil (1.06 gm, 30% yield). 
1H NMR (400 MHz, CDCl3) δ 7.57 – 7.31 (m, 5H, H-1 + H-2 + H-3 + H-4 + H-6), 5.54 (d, J = 19.8 Hz, 
2H, H-8), 4.40 (s, 2H, H-9); Data in agreement with reported values.213 
 
1-(3-bromoprop-1-en-2-yl)-4-fluorobenzene (263b) 
To a solution of 1-fluoro-4-(prop-1-en-2-yl)benzene (1.0 g, 7.3 mmol, 1.0 equiv.) in 
dry THF (15 ml, 0.5 M) were added N-bromosuccinimide (1.5 g, 8.8 mmol, 1.2 
equiv.), p-TsOH (0.28 g, 1.5 mmol, 0.2 equiv.), and a colourless solution resulted 
according to general procedure 15. The residue was purified by gravity column 
chromatography (hexane). Pure fractions were combined and concentrated under reduced pressure to yield 
the title compound as a yellow oil (0.79 mg, 50% yield). 1H NMR (500 MHz, CDCl3) δ 7.47 (dd, J = 8.9, 
5.3 Hz, 2H, H-3, H-7), 7.11 – 6.97 (m, 2H, H-4, H-6), 5.49 (d, J = 13.0 Hz, 2H, H-10), 4.36 (s, 2H, H-1). 
13C NMR (125 MHz, CDCl3) δ 163.8 (C-5), 161.8 (C-5), 143.4 (C-9), 133.8 (C-2), 133.7 (C-2), 128.0 (C-3, 
C-7), 127.9 (C-3, C-7), 117.2 (C-10), 117.1 (C-10), 115.6 (C-4, C-6), 115.5 (C-4, C-6), 115.4 (C-4, C-6), 115.3 
(C-4, C-6), 34.3 (C-1). 
 
2-(Prop-1-en-2-yl)naphthalene (316) 
Methyltriphosphonium bromide (2.52 g, 7.05 mmol, 1.2 equiv.) was dissolved in 
THF (7.43 mL, 0.8 M) and cooled to 0 °C. To the resulting white suspension was 
added KOt-Bu (1 M in THF, 7.05 ml, 1.2 equiv.) dropwise to give a yellow 
suspension which stirred at 0 °C for 45 min. 1-(naphthalen-2-yl)ethan-1-one (1.0 g, 
5.9 mmol, 1.0 equiv.) in THF (8.4 mL, 0.8 M) was added dropwise according to general procedure 14,  
The residue was chromatographed (SiO2, pet.ether) to yield the title compound 316 as a colourless solid 
(758 mg, 77% yield). IR (neat, cm-1): νmax 2988, 2972, 2901; m.p. 58-60 °C; 1H NMR (400 MHz, CDCl3) δ 
7.89 – 7.76 (m, 4H, H-3 + H-6 + H-7 + H-10), 7.68 (dd, J = 8.6, 1.9 Hz, 1H, H-4), 7.46 (ddd, J = 6.6, 3.8, 
1.9 Hz, 2H, H-8 + H-9), 5.54 (s, 1H, H-13), 5.20 (s, 1H, H-13), 2.28 (s, 3H, H-12); 13C NMR (100 MHz, 
CDCl3) δ 143.1 (C-5), 138.5 (C-1), 133.5 (C-11), 132.9 (C-2), 128.4 (C-7 or C-10), 127.8 (C-7 or C-10), 127.6 
(C-3), 126.3 (C-8 or C-9), 126.0 (C-8 or C-9), 124.4 (C-6), 124.0 (C-4), 113.2 (C-13), 22.1 (C-12); HRMS 









N-bromosuccinimide (423 mg, 2.38 mmol, 2.0 equiv.) and p-TsOH (45 mg, 0.24 
mmol, 0.2 equiv.) were dissolved in dry THF (3.97 mL) to give a yellow solution. 
2-(prop-1-en-2-yl)naphthalene S5 (200 mg, 1.19 mmol, 1.0 equiv.) was added and 
a colourless solution resulted according to general procedure 15. The residue 
was chromatographed (SiO2, pet.ether) to yield the title compound as colourless oil (104 mg, 35% yield). 
IR (neat, cm-1): νmax 2988, 2972, 2901; 1H NMR (400 MHz, CDCl3) δ 7.96 – 7.76 (m, 4H, H-3 + H-6 + H-
7 + H-10), 7.61 (dd, J = 8.6, 1.9 Hz, 1H, H-4), 7.48 (td, J = 6.3, 5.9, 3.4 Hz, 2H, H-8 + H-9), 5.70 (s, 1H, 
H-13), 5.58 (s, 1H, H-13), 4.49 (s, 2H, H-12). Data in agreement with reported values.215 
 
1-(but-1-en-2-yl)-3-methoxybenzene (317)               
Methyltriphosphonium bromide (14.0 g, 39.6 mmol, 1.2 equiv.) was dissolved in THF 
(60 mL, 0.8 M) and cooled to 0 °C. To the resulting white suspension was added KOtBu 
(4.44 gm, 1.20 equiv.) dropwise to give a yellow suspension which stirred at 0 °C for 45 
min. 1-(3-methoxyphenyl)ethan-1-one (5.00 g, 33 mmol, 1.0 equiv.) in THF (8.4 mL, 0.8 
M) was added dropwise according to the general procedure 14. The residue was 
chromatographed (SiO2, pet.ether) to yield the title compound 317 as a colourless solid (3.00 gm, 61% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 8.0 Hz, 1H, H-4), 7.11 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H, H-
7), 7.05 (dd, J = 2.6, 1.7 Hz, 1H, H-5), 6.86 (ddd, J = 8.1, 2.6, 1.0 Hz, 1H, H-3), 5.41 (dd, J = 1.6, 0.8 Hz, 
1H, H-9), 5.13 (t, J = 1.6, 0.8 Hz, 1H, H-9), 3.85 (s, 3H, H-11), 2.22 – 2.14 (m, 3H, H-12). 13C NMR (125 
MHz, CDCl3) δ 159.6 (C-6), 143.3 (C-8), 142.9 (C-2), 129.3 (CH-Ar), 118.2 (CH-Ar), 112.8 (CH-Ar), 112.7 
(CH-Ar), 111.6 (C-9), 55.3 (C-11), 22.0 (C-1, C-12). 
 
1-(3-bromoprop-1-en-2-yl)-3-methoxybenzene (263d)      
To a solution of 1-methoxy-3-(prop-1-en-2-yl)benzene 317 (3.0 g, 20 mmol, 1.0 equiv.) 
in dry THF (15 ml, 1.5 M) were added N-bromosuccinimide (3.48 g, 19.8 mmol, 0.98 
equiv.), p-TsOH (0.77 g, 4.1 mmol, 0.20 equiv.), and added a colourless solution 
resulted according to general procedure 15. The residue was purified by column 
chromatography (hexane). Pure fractions were combined and concentrated under 
reduced pressure to yield the title compound as a yellow oil (2.5, 54% yield). 1H NMR (500 MHz, CDCl3) 
δ 7.31 (t, J = 8.0 Hz, 1H, H-4), 7.09 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H, H-7), 7.05 (dd, J = 2.6, 1.7 Hz, 1H, H-
5), 6.90 (ddd, J = 8.2, 2.6, 0.9 Hz, 1H, H-3), 5.57 (s, 1H, H-9), 5.50 (s, 1H, H-9), 4.38 (s, 2H, H-1), 3.84 (s, 
3H, H-11). 13C NMR (125 MHz, CDCl3) δ 159.8 (C-6), 144.3 (C-8), 139.2 (C-2), 129.6 (CH-Ar), 118.7 








Methyltriphosphonium bromide (10.0 g, 28.6 mmol, 1.1 equiv.) was dissolved in THF 
(45 mL, 1.0 M) and cooled to 0 °C. To the resulting white suspension was added n-
BuLi (11.5 mL, 2.5 M in THF, 1.1 equiv.) dropwise to give a yellow suspension which 
stirred at 0 °C for 45 min. 1-(3,4-dichlorophenyl)ethan-1-one (5.0 g, 26 mmol, 1.0 
equiv.) in THF (20 mL, 1.3 M) was added dropwise according to general procedure 14. The residue was 
chromatographed (SiO2, pet.ether) to yield the title compound 318 as a colourless solid (3.40 gm, 70% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 2.2 Hz, 1H, H-3), 7.39 (d, J = 8.4 Hz, 1H, H-6), 7.29 
(dd, J = 8.4, 2.1 Hz, 1H, H-7), 5.43 – 5.34 (m, 1H, H-10), 5.22 – 5.13 (m, 1H, H-10), 2.13 (s, 3H, H-1). 13C 
NMR (125 MHz, CDCl3) δ 141.3 (C-9), 141.2 (C-2), 132.4 (C-4), 131.3 (C-5), 130.8 (C-6), 127.6 (C-3), 
124.9 (C-7), 114.1 (C-10), 21.6 (C-1). 
 
4-(3-bromoprop-1-en-2-yl)-1,2-dichlorobenzene (263e) 
To a solution of 1,2-dichloro-4-(prop-1-en-2-yl)benzene 318 (2.18 g, 11.7 mmol, 
1.0 equiv.) in dry THF (8.00 ml, 1.5 M) were added N-bromosuccinimide (2.00 g, 
11.5 mmol, 0.98 equiv.), p-TsOH (0.44 g, 2.3 mmol, 0.2 equiv.), and a colourless 
solution resulted according to general procedure 15. The residue was purified by 
gravity column chromatography (hexane). Pure fractions were combined and concentrated under reduced 
pressure to yield the title compound as a colourless solid (2.3, 73% yield). 1H NMR (500 MHz, CDCl3) δ 
7.59 (d, J = 2.2 Hz, 1H, H-3), 7.46 (d, J = 8.4 Hz, 1H, H-6), 7.34 (dd, J = 8.4, 2.2 Hz, 2H, H-7), 5.57 (d, J 
= 7.4 Hz, 3H, H-10), 4.34 (s, 2H, H-1). 13C NMR (125 MHz, CDCl3) δ 142.4 (C-9), 137.8 (C-2), 132.8 (C-
4), 132.4 (C-5), 130.5 (C-6), 128.3 (C-3), 125.6 (C-7), 118.7 (C-10), 33.5 (C-1). 
 
4-bromo-4'-(prop-1-en-2-yl)-1,1'-biphenyl (319) 
Methyltriphosphonium bromide (4.29 g, 12.0 mmol, 1.1 equiv.) was dissolved 
in THF (22 mL, 0.5 M) and cooled to 0 °C. To the resulting white suspension 
was added n-BuLi (4.80 ml, 2.5 M in THF, 1.1 equiv.) dropwise to give a yellow 
suspension which stirred at 0 °C for 45 min. 1-(4'-bromo-[1,1'-biphenyl]-4-
yl)ethan-1-one (3.0 g, 11 mmol, 1.0 equiv.) in THF (11 mL, 1.0 M) was added 
dropwise according to general procedure 14. The residue was chromatographed (SiO2, pet.ether) to yield 
the title compound 319 as a colourless solid (1.94 gm, 65% yield). 1H NMR (500 MHz, CDCl3) δ 7.59 – 
7.51 (m, 6H, H-Ar), 7.49 – 7.44 (m, 2H, H-Ar), 5.57 – 5.35 (m, 1H, H-16), 5.24 – 4.98 (m, 1H, H-16), 2.19 
(s, 3H, H-1). 13C NMR (125 MHz, CDCl3) δ 142.8 (C-15), 140.7 (C-2), 139.8 (CH-Ar), 139.1 (CH-Ar), 








To a solution of 4-bromo-4'-(prop-1-en-2-yl)-1,1'-biphenyl 319 (1.22 g, 4.46 
mmol, 1.0 equiv.) in dry THF (3.0 ml, 1.5 M) were added N-
bromosuccinimide (0.81 g, 4.4 mmol, 0.98 equiv.), p-TsOH (0.17 g, 0.89 
mmol, 0.2 equiv.), and a colourless solution resulted according to general 
procedure 15. The residue was purified by column chromatography 
(hexane). Pure fractions were combined and concentrated under reduced pressure to yield the title 
compound as a colourless solid (0.99, 62% yield). 1H NMR (500 MHz, CDCl3) δ 7.61 – 7.55 (m, 6H, H-
Ar), 7.50 – 7.44 (m, 2H, H-Ar), 5.59 (d, J = 48.5 Hz, 2H, H-16), 4.43 (s, 2H, H-1). 13C NMR (125 MHz, 
CDCl3) δ 143.7 (C-15), 139.9 (C-Ar), 139.4 (C-Ar), 136.8 (C-Ar), 132.0 (CH-Ar), 128.7 (CH-Ar), 127.1 (CH-




(2S,5S)-5-Allyl-2-(tert-butyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (266a) 
Following general procedure 10, trans N-chloroformylimidazolidinone 154o (510 
mg, 2.19 mmol, 1.0 equiv.) was dissolved in dry THF (22 mL, 0.1 M) and the 
solution was cooled to -78 °C before the dropwise addition of KHMDS (2.62 ml, 
1.0 M in THF, 1.2 equiv.). The reaction was left to stir for 2 min at -78 °C. Allyl 
bromide (0.21 ml, 2.4 mmol, 1.1 equiv.) was added and the reaction mixture stirred 
at -78 °C for 2 h. The reaction mixture was quenched with aqueous HCl (1.0 M) and extracted with EtOAc 
(x2). The combined organic layers were washed with brine, dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. The crude material was purified by flash column chromatography (SiO2, 
pet.ether/EtOAc, 7:3) to afford the title compound (488 mg, 82%) as a pale yellow oil. Rf = 0.28 
(pet.ether/EtOAc = 7:3); [𝛂]𝐃
𝟐𝟑 = -72° (c = 1 in CHCl3); IR (neat, cm-1): νmax = 2972, 2901 (C-H), 1740, 
1715 (C=O); 1H NMR (400 MHz, CDCl3) (mixture of rotamers A:B in a 0.49:0.51 ratio) δ 5.46 – 5.29 (m, 
1H, H-12, rot. A + rot. B), 5.27 – 5.06 (m, 3H, H-13 + H-2, rot. A + rot. B), 3.17 (ddd, J = 50.9, 14.3, 8.6 
Hz, 1H, H-11, rot. B), 3.02 (d, J = 4.6 Hz, 3H, H-9, rot. A + rot. B), 2.59 (ddd, J = 69.1, 14.3, 6.0 Hz, 1H, 
H-11, rot. A), 1.65 (d, J = 27.8 Hz, 3H, H-15, rot. A + rot. B), 1.05 (d, J = 34.3 Hz, 9H, H-16 + H-17 + 
H-18, rot. A + rot. B). 13C NMR (100 MHz, CDCl3) δ 172.26 (C-4), 149.07 (C-6), 130.87 (C-12, rot. A), 
130.53 (C-12, rot. B), 121.35 (C-13, rot. A), 121.13 (C-13, rot. B), 83.39 (C-2, rot. B), 83.04 (C-2, rot. A), 
69.23 (C-5, rot. B), 66.92 (C-5, rot. A), 42.78 (C-11, rot. B), 39.89 (C-11, rot. A), 39.67 (C-14, rot. A), 39.23 
(C-14, rot. B), 31.93 (C-9, rot. A), 31.58 (C-9, rot. B), 27.64 (C-16 + C-17 + C-18, rot. B), 26.97 (C-16 + C-
17 + C-18, rot. A), 23.19 (C-15, rot. A), 22.46 (C-15, rot. B); HRMS (ESI+) C13H21ClN2O2 [M + H]+ 









chloride (266h)              
Following general procedure 10, The title compound 266h was prepared from 
trans N-chloroformylimidazolidinone 154o (150 mg, 0.64 mmol, 1.0 equiv.) and 
1-(3-bromoprop-1-en-2-yl)-3-methoxybenzene (0.18 mL, 1.1 mmol, 1.2 equiv.). 
Colourless oil (175 mg, 73%). Rf = 0.25 (SiO2; pet. Ether/ EtOAc 4:1). [𝛂]𝐃
𝟐𝟔 = 
-92° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2970 (C–H), 1739 (C=O), 1715 
(C=O), 1602; 1H NMR (500 MHz, CDCl3) δ 7.25 – 7.20 (m, 1H, H-Ar, rot. 
A+B), 6.90 – 6.82 (m, 1H, H-Ar, rot. A+B), 6.79 (tt, J = 2.7, 1.6 Hz, 1H, H-Ar, 
rot A+B), 6.77 – 6.76 (m, 1H, H-Ar, rot A+B), 5.39 – 5.36 (m, 0.92H, H-2, rot. B), 5.24 – 5.21 (m, 1.08H, 
H-2, rot. B), 4.70 (s, 0.46H, H-7, rot. B), 4.67 (s, 0.54H, H-7, rot. A), 3.84 (s, 3H, H-26, rot. A+B), 3.40 – 
3.39 (m, 0.46H, H-6B, rot. B), 3.39 – 3.37 (m, 0.54H, H-6B, rot. A), 3.36 – 3.34 (m, 0.54H, H-6A, rot. A), 
3.19 – 3.13 (m, 0.46H, H-6A, rot. B), 2.22 (s, 1.38H, H-11, rot. B), 2.16 (s, 1.62H, H-11, rot. A), 1.69 (s, 
1.62H, H-16, rot. A), 1.63 (s, 1.38H, H-16, rot. B), 0.98 (s, 4.14H, H-13, H-14, H-15, rot. B), 0.89 (s, 4.86H, 
H-13, H-14, H-15, rot. A). 13C NMR (125 MHz, CDCl3) δ 171.3 (C-9, rot. A), 171.0 (C-9, rot. B), 159.3 
(C-3, rot. B), 159.4 (C-3, rot. A), 148.6 (C-22, rot. A), 146.6 (C-22, rot. B), 143.6 (C-18, rot. B), 143.5 (C-
18, rot. A), 141.7 (C-1, rot. B), 141.4 (C-1, rot. A), 129.2 (CH-Ar, rot. B), 129.1 (CH-Ar, rot. A), 122.1 (CH-
Ar, rot. B), 121.8 (C-2, rot. A), 119.3 (C-2, rot. B), 119.3 (CH-Ar, rot. B), 114.1 (CH-Ar, rot. A), 113.7 (CH-
Ar, rot. B), 112.1 (CH-Ar, rot. B), 111.7 (CH-Ar, rot. A), 82.8 (C-7, rot. B), 82.5 (C-7, rot. A), 67.8 (C-5, 
rot. B), 64.9 (C-5, rot. A), 55.3 (C-26, rot. A+B), 44.3 (C-6, rot. A), 41.8 (C-6, rot. B), 39.5 (C-12, rot. A), 
39.3 (C-12, rot. B), 30.9 (C-11, rot. A), 30.7 (C-11, rot. B), 27.6 (C-13, C-14, C-15, rot. B), 26.9 (C-13, C-14, 
C-15, rot. A), 24.2 (C-16, rot. A), 23.1 (C-16, rot. B). HRMS (ESI+) C20H27ClN2O3 [M + H]+ calculated: 





















Following general procedure 10, The title compound 266d was prepared from trans 
N-chloroformylimidazolidinone 154o (200 mg, 1.0 mmol, 1.0 equiv.) and 1-(3-
bromoprop-1-en-2-yl)-4-fluorobenzene (0.22 mL, 1.2 equiv.). Colourless oil (180 
mg, 58%). Rf = 0.34 (SiO2; pet. Ether/ EtOAc 7/ 3). [𝛂]𝐃
𝟐𝟔 = -100° (c = 1 in CHCl3); 
IR (neat, cm-1): νmax 2971 (C–H), 1735 (C=O), 1710 (C=O), 1605; 1H NMR (500 
MHz, CDCl3) δ 7.28 – 7.22 (m, 2H, H-19, H-23, rot. A+B), 7.01 (t, J = 8.7 Hz, 2H, 
H-20, H-22, rot. A+B), 5.42 – 5.21 (m, 1H, H-2A, rot. A+B), 5.19 – 5.13 (m, 1H, 
H-2B rot. A+B), 4.73 (s, 0.45H, H-7, rot. B), 4.69 (s, 0.55H, H-7, rot. A), 3.37 – 3.35 (m, 1H, H-6A+B, rot. 
A), 3.45 – 3.31 (m, 0.55H, H-6 A+B, rot. A), 3.13 (dd, J = 14.5, 1.3 Hz, 0.45H, H-6A+B, rot. B), 2.25 (s, 1.35H, 
H-11), 2.18 (s, 1.65H, H-11), 1.70 (s, 1.65H, H-16), 1.63 (s, 1.35H, H-16), 1.00 (s, 4.05H, H-13, H-14, H-
15, rot. B), 0.90 (s, 4.95H, H-13, H-14, H-15, rot. A). 13C NMR (125 MHz, CDCl3) δ 171.3 (C-9, rot. A), 
171.0 (C-9, rot. B), 163.5 (C-3, rot. A), 163.5 (C-3, rot. B), 161.6 (C-3, rot. A), 161.5 (C-3, rot. B), 148.9 (C-
21, rot. A), 146.7 (C-21, rot. B), 142.8 (C-18, rot. B), 142.7 (C-18, rot. A), 136.6 (C-1, rot. A), 136.5 (C-1, 
rot. B), 136.3 (C-1, rot. A), 136.2 (C-1, rot. A), 128.9 (C-19/C-23, rot. B), 128.8 (C-19/C-23, rot. A+B), 
128.7 (C-19/C-23, rot. A+B), 128.6 (C-19/C-23, rot. B), 122.5 (C-2, rot. A), 122.0 (C-2, rot. B), 115.2 (C-
20/C-22, rot. A), 115.1 (C-20/C-22, rot. B), 115.0 (C-20/C-22, rot. A), 114.9 (C-20/C-22, rot. B), 82.9 (C-
7, rot. B), 82.5 (C-7, rot. A), 68.0 (C-5, rot. B), 65.0 (C-5, rot. A), 44.3 (C-6, rot. A), 41.8 (C-6, rot. B), 39.6 
(C-12, rot. A), 39.4 (C-12, rot. B), 31.0 (C-11, rot. A), 30.8 (C-11, rot. B), 27.7 (C-13, C-14, C-15, rot. A), 
27.0 (C-13, C-14, C-15, rot. A), 24.4 (C-16, rot. A), 23.3 (C-16, rot. B). HRMS (ESI+)  C19H24ClFN2O2 [M 





















1-carbonyl chloride (266f) 
Following general procedure 10, the title compound 266f was prepared from 
trans N-chloroformylimidazolidinone 154o (200 mg, 0.86 mmol, 1.0 equiv.) and 
4-bromo-4'-(3-bromoprop-1-en-2-yl)-1,1'-biphenyl (0.36 mL, 1.1 mmol, 1.2 
equiv.). Colourless oil (320 mg, 0.79 mmol, 80%).  
Rf = 0.47 (SiO2; pet. Ether/ EtOAc 4:1). [𝛂]𝐃
𝟐𝟔 = -32° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2970 (C–H), 1735 (C=O), 1713 (C=O), 1602; 1H NMR (500 
MHz, CDCl3) (mixture of rotamers A:B in a 0.53:0.47 ratio) δ 7.58 – 7.51 (m, 
4H, H-Ar), 7.47 – 7.42 (m, 2H, H-Ar), 7.38 – 7.33 (m, 2H, H-Ar), 5.45 – 5.25 
(m, 2H, H-2, rot. A + rot. B), 4.74 (s, 0.47H, H-7, rot. B), 4.72 (s, 0.53H, H-7, 
rot. A), 3.45 – 3.43 (m, 1H, H-6A+B, rot. A), 3.41 (d, J = 14.2 Hz, 0.55H, H-6 A+B, rot. A), 3.20 (d, J = 14.2 
Hz, 0.45H, H-6A+B, rot. B), 2.19 (s, 1.41H, H-11, rot. B), 2.10 (s, 1.59H, H-11, rot. A), 1.72 (s, 1.59H, H-
16, rot. A), 1.65 (s, 1.41H, H-16, rot. B), 0.99 (s, 4.23H, H-13, H-14, H-15, rot. B), 0.89 (s, 4.77H, H-13, H-
14, H-15, rot. A). 13C NMR (125 MHz, CDCl3) δ 171.3 (C-9, rot. A), 171.1 (C-9, rot. B), 148.9 (C-3, rot. 
A), 146.8 (C-3, rot. B), 143.4 (C-Ar, rot. B), 143.2 (C-Ar, rot. A), 139.9 (C-Ar, rot. A), 139.6 (C-Ar, rot. B), 
139.6 (C-Ar, rot. A), 139.5 (C-Ar, rot. B), 139.4 (C-Ar, rot. A), 139.2 (C-Ar, rot. B), 132.1 (CH-Ar, rot. A), 
132.1 (CH-Ar, rot. B), 128.6 (CH-Ar, rot. B), 128.5 (CH-Ar, rot. A), 127.6 (CH-Ar, rot. A), 127.6 (CH-Ar, 
rot. B), 126.6 (CH-Ar, rot. B), 126.6 (CH-Ar, rot. A), 122.6 (C-Ar, rot. A), 122.1 (C-Ar, rot. B), 121.9 (C-
Ar, rot. A), 121.8 (C-Ar, rot. B), 82.9 (C-7, rot. B), 82.5 (C-7, rot. A), 68.1 (C-5, rot. B), 65.0 (C-5, rot. A), 
44.4 (C-6, rot. A), 41.8 (C-6, rot. B), 39.6 (C-12, rot. A), 39.4 (C-12, rot. B), 30.9 (C-11, rot. A), 30.7 (C-11, 
rot. B), 27.7 (C-13, C-14, C-15, rot. B), 27.0 (C-13, C-14, C-15, rot. A), 24.4 (C-16, rot. A), 23.3 (C-16, rot. 




















Following general procedure 10, the title compound 266e was prepared from 
trans N-chloroformylimidazolidinone 154o (150 mg, 0.64 mmol, 1.0 equiv.) and 
4-(4-bromobut-1-en-2-yl)-1,2-dichlorobenzene (0.21 mL, 0.77 mmol, 1.2 
equiv.). Colourless oil (180 mg, 68%). Rf = 0.30 (SiO2; pet. Ether/ EtOAc 4:1). 
[𝛂]𝐃
𝟐𝟔 = -60° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2988 (C–H), 1730 (C=O), 
1710 (C=O), 1601; 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.3 Hz, 1H, H-
20, rot. A+B), 7.35 (dd, J = 3.3, 2.1 Hz, 1H, H-23, rot. A+B), 7.10 (ddd, J = 
10.4, 8.3, 2.1 Hz, 1H, H-19, rot. A+B), 5.43 (d, J = 1.1 Hz, 0.49H, H-2B, rot. B), 5.28 (d, J = 1.5 Hz, 0.51H, 
H-2A, rot. A), 5.24 (d, J = 1.2 Hz, 1H, H-2A+B, rot. A+B), 4.75 (s, 0.51H, H-7, rot. A), 4.72 (s, 0.49H, H-7, 
rot. B), 3.41 (dd, J = 22.4, 14.8 Hz, 1H, H-6A+B, rot. A+B), 3.33 – 3.27 (m, 0.49H, H-6B, rot. B), 3.07 (dd, 
J = 14.6, 1.3 Hz, 0.51H, H-6A, rot. A), 2.33 (s, 1.53H, H-11, rot. A), 2.25 (s, 1.47H, H-11, rot. B), 1.70 (s, 
1.47H, H-16, rot. B), 1.63 (s, 1.53H, H-16, rot. A), 1.01 (s, 4.59H, H-13, H-14, H-15, rot. A), 0.91 (s, 4.41H, 
H-13, H-14, H-15, rot. B). 13C NMR (125 MHz, CDCl3) δ 171.1 (C-9, rot. B), 170.9 (C-9, rot. A), 148.7 (C-
3, rot. A), 146.6 (C-3, rot. B), 141.9 (C-1, rot. A), 141.7 (C-1, rot. B), 140.6 (C-18, rot. A), 140.2 (C-18, rot. 
B), 132.3 (C-Ar, rot. A/B), 132.2 (C-Ar, rot. A/B), 131.9 (C-Ar, rot. A/B), 131.7 (C-Ar, rot. A/B), 130.0 
(C-20, rot. B), 130.1 (C-20, rot. A), 128.8 (C-23, rot. A), 128.9 (C-23, rot. B), 126.5 (C-19, rot. A+B), 123.4 
(C-2A+B, rot. A/B), 122.9 (C-2A+B, rot. A/B), 83.0 (C-7, rot. A), 82.6 (C-7, rot. B), 68.0 (C-5, rot. A), 65.0 
(C-5, rot. B), 44.0 (C-6, rot. B), 41.4 (C-6, rot. A), 39.7 (C-12, rot. B), 39.4 (C-12, rot. A), 31.0 (C-11, rot. 
B), 30.9 (C-11, rot. A), 27.7 (C-13, C-14, C-15, rot. A), 27.0 (C-13, C-14, C-15, rot. B), 24.3 (C-16, rot. B), 





















 (3S,8aS)-3-(tert-butyl)-2,8a-dimethyl-2,3,8,8a-tetrahydroimidazo[1,5-a]pyridine-1,5-dione (274a) 
The conjugated isomer 274a was prepared from (2S,4R)-4-allyl-2-(tert-butyl)-1,4-
dimethyl-5-oxopyrrolidine-3-carbonyl chloride 266a (41 mg, 0.15 mmol, 1.0 equiv.) 
according to general procedure 16. The reaction was finished after 2 h. Colourless 
solid (13 mg, 0.06 mmol, 39%). m.p.= 103 – 106 °C. Rf = 0.40 (SiO2; pet. Ether/ 
EtOAc 4/6). [𝛂]𝐃
𝟐𝟑 = -156° (c = 1 in CHCl3). ); IR (neat, cm-1): νmax 2978 (C–H), 
1704 (C=O), 1672 (C=O), 1389. 1H NMR (400 MHz, CDCl3) δ 6.44 (ddd, J = 9.8, 6.4, 2.3 Hz, 1H, H-6), 
5.95 (ddd, J = 9.8, 3.1, 0.6 Hz, 1H, H-1), 5.15 (s, 1H, H-7), 2.96 (s, 3H, H-17), 2.45 (ddd, J = 17.4, 6.4, 0.6 
Hz, 1H, H-5), 2.31 (dddd, J = 17.4, 3.1, 2.3, 0.6 Hz, 1H, H-5), 1.51 (s, 3H, H-11), 1.02 (s, 9H, H-14 + H-
15 + H-16). 13C NMR (100 MHz, CDCl3) δ 173.7(C-9), 163.0 (C-2), 136.3 (C-6), 125.2 (C-1), 80.9 (C-7), 
60.5 (C-4), 37.8 (C-13), 34.2 (C-5), 31.2 (C-17), 27.5 (C-14 + C-15 + C-16), 22.8 (C-11). HRMS (ESI+) 
C13H20N2O2Na [M + Na]+ 259.1416, found 259.1409. 
and; 
 (3S,8aS)-3-(tert-butyl)-2,8a-dimethyl-2,3,6,8a-tetrahydroimidazo[1,5-a]pyridine-1,5-dione (275a) 
The unconjugated 275a was prepared from (2S,4R)-2-(tert-butyl)-1,4-dimethyl-4-(2-
methylallyl)-5-oxopyrrolidine-3-carbonyl chloride 266a (41 mg, 0.15 mmol, 1.0 equiv.) 
according to general procedure 16. The reaction was finished after 2 h. (17 mg, 0.07 
mmol, 50%). m.p.= 107 – 109 °C. Rf = 0.70 (SiO2; pet. Ether/ EtOAc 4/6). [𝛂]𝐃
𝟐𝟒 
= -28° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2978 (C–H), 1706 (C=O), 1677 (C=O). 
1H NMR (400 MHz, CDCl3) δ 6.11 (dd, J = 9.2, 3.5 Hz, 1H, H-5), 5.82 (ddd, J = 9.2, 6.0, 2.1 Hz, 1H, H-
6), 5.13 (s, 1H, H-7), 3.03 – 2.79 (m, 6H, H-1 + H-17), 1.48 (s, 3H, H-11), 1.02 (s, 9H, H-14 + H-15 + H-
16). 13C NMR (101 MHz, CDCl3) δ 171.4 (C-9), 170.2 (C-2), 131.1 (C-5), 121.4 (C-6), 80.8 (C-7), 64.5 (C-
4), 37.2 (C-13), 33.3 (C-1), 31.3 (C-17), 27.5 (C-14 + C-15 + C-16), 24.8 (C-11). HRMS (ESI+) 
C13H20N2O2Na [M + Na]+ 259.1416, found 259.1414. 
 
Isomerisation of 275a to 274a 
Following general procedure 17, 275a (250 mg, 1.06 mmol, 1.0 equiv.) was dissolved in dry MeCN (5.0 
mL, 0.2 M) before the addition of DBU (475 μL, 3.17 mmol, 3.0 equiv.). The reaction was heated to 150 
°C in a microwave reactor for 2 h. The reaction was quenched with aqueous HCl (1.0 M). The crude product 
was purified by flash column chromatography (SiO2, pet.ether/EtOAc, 4:6) to yield 274a (162.6 mg, 65%) 










Following general procedure 16, the title compound 274b was prepared from 
(2S,4R)-4-allyl-2-(tert-butyl)-1,4-dimethyl-5-oxopyrrolidine-3-carbonyl chloride 266b 
(43 mg, 0.15 mmol, 1.0 equiv.). The reaction was finished after 2 h. Colourless solid 
(9 mg, 0.04 mmol, 24%). m.p.= 134 – 139 °C. Rf = 0.23 (SiO2; pet. Ether/ EtOAc 
4/6). [𝛂]𝐃
𝟐𝟒 = -168° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2974 (C–H), 1705 (C=O), 
1672 (C=O), 1380. 1H NMR (400 MHz, CDCl3) δ 5.78 (dd, J = 2.7, 1.4 Hz, 1H, H-
1), 5.17 (s, 1H, H-7), 3.01 (s, 3H, H-18), 2.41 (d, J = 16.0 Hz, 1H, H-5), 2.29 (d, J = 16.9 Hz, 1H, H-5), 1.93 
(t, J = 1.4 Hz, 3H, H-12), 1.54 (s, 3H, H-14), 1.07 (s, 9H, H-15 + H-16 + H-17). 13C NMR (100 MHz, 
CDCl3) δ 173.8 (C-9), 164.3 (C-2), 147.7 (C-6), 119.9 (C-1), 80.9 (C-7), 60.4 (C-4), 39.5 (C-5), 37.8 (C-13), 
31.2 (C-18), 27.5 (C-15 + C-16 + C-17), 23.2 (C-12), 22.8 (C-14). HRMS (ESI+) C14H22N2O2Na [M + Na]+ 
273.1573, found 273.1580. 
(3S,8aS)-3-(tert-butyl)-2,7,8a-trimethyl-2,3,6,8a-tetrahydroimidazo[1,5-a]pyridine-1,5-dione (275b) 
Following general procedure 16, the title compound 275b was prepared from 266b 
(43 mg, 0.15 mmol, 1.0 equiv.). The reaction was finished after 2 h. Colourless solid 
(18 mg, 0.07 mmol, 47%). m.p.= 90 – 94 °C. Rf = 0.60 (SiO2; pet. Ether/ EtOAc 
4/6). [𝛂]𝐃
𝟐𝟒 = -48° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2979 (C–H), 1705 (C=O), 
1679 (C=O), 1264, 782, 768. 1H NMR (400 MHz, CDCl3) δ 5.84 (ddd, J = 3.3, 1.6, 
0.6 Hz, 1H, H-5), 5.15 (s, 1H, H-7), 3.09 (ddd, J = 18.2, 3.3, 1.6 Hz, 1H, H-1), 2.98 
(s, 3H, H-18), 2.72 (d, J = 18.2 Hz, 1H, H-1), 1.78 (t, J = 1.5 Hz, 3H, H-12), 1.50 (s, 3H, H-14), 1.07 (s, 
9H, H-15 + H-16 + H-17). 13C NMR (100 MHz, CDCl3) δ 172.0 (C-9), 171.0 (C-2), 130.5 (C-6), 124.6 (C-
5), 80.8 (C-7), 64.3 (C-4), 38.2 (C-1), 37.2 (C-13), 31.2 (C-18), 27.4 (C-15 + C-16 + C-17), 24.9 (C-14), 21.7 




Following general procedure 16, the title compound 288b was prepared from 
(2S,4R)-4-allyl-2-(tert-butyl)-1,4-dimethyl-5-oxopyrrolidine-3-carbonyl chloride 266b 
(43 mg, 0.15 mmol, 1.0 equiv.). The reaction was finished after 2 h. Colourless oil (5 
mg, 0.02 mmol, 13%). Rf = 0.45 (SiO2; pet. Ether/ EtOAc 4/6). [𝛂]𝐃
𝟐𝟒 = -52° (c = 1 
in CHCl3); IR (neat, cm-1): νmax 2961 (C–H), 1706 (C=O), 1674 (C=O), 1363. 1H 
NMR (400 MHz, CDCl3) δ 5.27 (s, 1H, H-7), 5.11 – 4.97 (m, 2H, H-12), 3.30 (dq, J 
= 20.2, 2.1 Hz, 1H, H-1), 3.20 (dq, J = 20.2, 2.1 Hz, 1H, H-1), 3.02 (s, 3H, H-18), 2.67 (d, J = 13.9 Hz, 1H, 
H-5), 2.18 (d, J = 13.9 Hz, 1H, H-5), 1.47 (s, 3H, H-14), 1.04 (s, 9H, H-15 + H-16 + H-17). 13C NMR (100 






(C-1), 37.5 (C-13), 31.2 (C-18), 27.2 (C-15 + C-16 + C-17), 22.6 (C-14). HRMS (ESI+) C14H22N2O2Na [M 




Following general procedure 16, the title compound 274d was prepared 
from 266d (175 mg, 0.48 mmol, 1.0 equiv.). The reaction was finished after 
2 h. Colourless oil (39 mg, 25%). Rf = 0.13 (SiO2; pet. Ether/ EtOAc 4:1). 
[𝛂]𝐃
𝟐𝟔 = -28° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2962 (C–H), 1705 (C=O), 
1670 (C=O), 1600; 1H NMR (500 MHz, CDCl3) δ 7.51 – 7.46 (m, 2H, H-
19, H-23), 7.10 (dd, J = 8.9, 8.3 Hz, 2H, H-20, H-22), 6.25 (d, J = 2.8 Hz, 
1H, H-2), 5.24 (s, 1H, H-7), 3.06 (s, 3H, H-11), 2.93 (d, J = 16.5 Hz, 1H, H-6), 2.71 (ddd, J = 16.5, 2.8, 0.8 
Hz, 1H, H-6), 1.60 (d, J = 0.8 Hz, 3H, H-16), 1.10 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) 
δ 173.8 (C-3), 164.8 (C-21), 164.5 (C-9), 162.8 (C-21), 145.7 (C-1), 133.4 (C-18), 133.4 (C-18), 128.0 (C-19, 
C-23), 127.9 (C-19, C-23), 118.9 (C-2), 118.8 (C-2), 116.2 (C-20, C-21), 116.0 (C-20, C-21), 81.2 (C-7), 60.7 
(C-5), 38.0 (C-12), 37.1 (C-6), 31.5 (C-11), 27.6 (C-13, C-14, C-15), 22.8 (C-16). HRMS (ESI+) 




Following general procedure 16, the title compound 275d was prepared 
from 266d (175 mg, 0.48 mmol, 1.0 equiv.). The reaction was finished after 
2 h. Colourless oil (63 mg, 40%). Rf = 0.08 (SiO2; pet. Ether/ EtOAc 4:1). 
[𝛂]𝐃
𝟐𝟔 = -176° (c = 1 in CHCl3). IR (neat, cm-1): νmax 2958 (C–H), 1702 
(C=O), 1667 (C=O), 1613. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.31 (m, 
2H, H-19, H-23), 7.03 (t, J = 8.6 Hz, 2H, H-20, H-23), 6.40 (d, J = 3.3 Hz, 1H, H-6), 5.20 (s, 1H, H-7), 
3.44 (dd, J = 17.7, 3.3 Hz, 1H, H-2), 3.31 (d, J = 17.7 Hz, 1H, H-2), 3.02 (s, 3H, H-11), 1.61 (s, 3H, H-16), 
1.11 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) δ 171.6 (C-9), 170.6 (C-9), 163.8 (C-3), 161.8 
(C-3), 133.8 (C-21), 133.7 (C-21), 132.1 (C-1), 127.2 (C-20, C-22), 127.1 (C-20, C-22), 125.8 (C-18), 125.7 
(C-18), 115.8 (C-19, C-23), 115.6 (C-19, C-23), 81.0 (C-7), 64.8 (C-5), 37.4 (C-12), 36.2 (C-2), 31.5 (C-11), 
27.5 (C-13, C-14, C-15), 24.8 (C-16). HRMS (ESI+) C19H23FN2O2 [M + H]+ calculated: 331.1816, found 
331.1813. 
 
Isomerisation of 275d to 274d 
Following general procedure 17, 275d (73 mg, 0.22 mmol, 1.0 equiv.) was dissolved in dry MeCN (0.88 






by flash column chromatography (SiO2, pet.ether/EtOAc, 4:6) to yield 274d (57.0 mg, 78%) as a colourless 




Following general procedure 16, the title compound 274e was prepared 
from 266e (151 mg, 0.48 mmol, 1.0 equiv.). The reaction was finished after 
2 h. Colourless oil (73 mg, 53%). Rf = 0.09 (SiO2; pet. Ether/ EtOAc 4:1). 
[𝛂]𝐃
𝟐𝟔 = -192° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2972 (C–H), 1703 
(C=O), 1671 (C=O), 1605. 1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 2.2 
Hz, 1H, H-Ar), 7.48 (d, J = 8.5 Hz, 1H, H-Ar), 7.33 (dd, J = 8.5, 2.2 Hz, 
1H, H-Ar), 6.30 (d, J = 2.7 Hz, 1H, H-2), 5.24 (s, 1H, H-7), 3.06 (s, 3H, H-11), 2.88 (d, J = 16.6 Hz, 1H, 
H-6), 2.71 (dd, J = 16.6, 2.8 Hz, 1H, H-6), 1.60 (s, 3H, H-16), 1.10 (s, 9H, H-13, H-14, H-15).13C NMR 
(125 MHz, CDCl3) δ 173.4 (C-3), 163.9 (C-9), 144.3 (C-Ar), 137.1 (C-Ar), 134.0 (C-Ar), 133.4 (C-Ar), 130.9 
(CH-Ar), 127.9 (CH-Ar), 125.0 (CH-Ar), 120.2 (C-2), 81.1 (C-7), 60.5 (C-5), 37.9 (C-12), 36.7 (C-6) , 31.4 





Following general procedure 16, the title compound 275e was prepared 
from 266e (151 mg, 0.36 mmol, 1.0 equiv.). The reaction was finished after 
2 h. Colourless oil (43 mg, 31%). Rf = 0.21 (SiO2; pet. Ether/ EtOAc 4:1). 
[𝛂]𝐃
𝟐𝟔 = -20° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2970 (C–H), 1708 
(C=O), 1674 (C=O), 1605; 1H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 2.2 
Hz, 1H, H-Ar), 7.42 (d, J = 8.4 Hz, 1H, H-Ar), 7.20 (dd, J = 8.4, 2.2 Hz, 1H, H-Ar), 6.49 (dd, J = 3.3, 0.8 
Hz, 1H, H-6), 5.21 (s, 1H, H-7), 3.43 (dd, J = 17.8, 3.3 Hz, 1H, H-2), 3.28 (dd, J = 17.8, 0.7 Hz, 1H, H-2), 
3.03 (s, 3H, H-11), 1.62 (s, 3H, H-16), 1.12 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) δ 
171.3 (C-9), 170.2 (C-3), 137.6 (C-Ar), 133.1 (C-Ar), 132.5 (C-Ar), 131.2 (C-Ar), 130.7 (CH-Ar), 127.6 (CH-
Ar), 127.5 (CH-Ar), 124.7 (CH-Ar), 81.2 (C-7), 64.8 (C-5), 37.4 (C-12), 35.8 (C-2), 31.5 (C-11), 27.6 (C-13, 
C-14, C-15), 24.8 (C-16). HRMS (ESI+) C19H22Cl2N2O2 [M + H]+ calculated: 381.1131, found 381.1131. 
 
Isomerisation of 275e to 274e 
Following general procedure 17, 275e (92 mg, 0.29 mmol, 1.0 equiv.) was dissolved in dry MeCN (1.14 






by flash column chromatography (SiO2, pet.ether/EtOAc, 4:6) to yield 274e (69 mg, 75%) as a colourless 





Following general procedure 16, the title compound 274f was prepared 
from 266h (132 mg, 0.35 mmol, 1.0 equiv.). The reaction was finished after 
2 h. Colourless oil (50 mg, 0.02 mmol, 42%). Rf = 0.14 (SiO2; pet. Ether/ 
EtOAc 4:1). [𝛂]𝐃
𝟐𝟔 = -144° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2978 (C–
H), 1709 (C=O), 1668 (C=O), 1604. 1H NMR (500 MHz, CDCl3) δ 7.26 
(t, J = 8.0 Hz, 1H, H-20), 6.96 (ddd, J = 7.7, 1.7, 0.9 Hz, 1H, H-23), 6.89 (t, J = 2.1 Hz, 1H, H-21), 6.84 
(ddd, J = 8.0, 2.6, 0.9 Hz, 1H, H-19), 6.46 (d, J = 3.7 Hz, 1H, H-2), 5.21 (s, 1H, H-7), 3.80 (s, 3H, H-25), 
3.45 (dd, J = 17.8, 3.3 Hz, 1H, H-6), 3.35 (dd, J = 17.8, 3.3 Hz, 1H, H-6), 3.02 (s, 3H, H-11), 1.61 (s, 3H, 
H-16), 1.11 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) δ 171.7 (C-3), 170.8 (C-9), 159.9 (C-
22), 139.1 (C-1), 132.9 (C-18), 129.8 (C-20), 126.1 (C-2), 117.9 (C-23), 114.1 (C-19), 110.9 (C-21), 81.0 (C-
7), 64.8 (C-5), 55.4 (C-25), 37.4 (C-12), 36.1 (C-6), 31.5 (C-11), 27.5 (C-13, C-14, C-15), 24.8 (C-16). HRMS 





Following general procedure 16, the title compound 275f was prepared 
from 266h (132 mg, 0.35 mmol, 1.0 equiv.). The reaction was finished 
after 2 h. Colourless oil (64 mg, 53%). Rf = 0.07 (SiO2; pet. Ether/ EtOAc 
4:1). [𝛂]𝐃
𝟐𝟔 = -24° (c = 1 in CHCl3); IR (neat, cm-1): νmax 2968 (C–H), 1702 
(C=O), 1680 (C=O), 1610. 1H NMR (500 MHz, CDCl3) δ 7.32 (t, J = 8.0 
Hz, 1H, H-20), 7.08 (dd, J = 7.7, 0.9 Hz, 1H, H-23), 7.00 (t, J = 2.1 Hz, 1H, H-21), 6.93 (dd, J = 7.8, 2.1 
Hz, 1H, H-19), 6.30 (d, J = 2.7 Hz, 1H, H-6), 5.24 (s, 1H, H-7), 3.82 (s, 3H, H-25), 3.05 (s, 3H, H-11), 2.95 
(d, J = 16.6 Hz, 1H, H-2), 2.72 (dt, J = 16.6, 1.7 Hz, 1H, H-2), 1.60 (s, 3H, H-16), 1.10 (s, 9H, H-13, H-14, 
H-15). 13C NMR (125 MHz, CDCl3) δ 173.8 (C-9), 164.6 (C-3), 160.0 (C-Ar), 146.8 (C-Ar), 138.8 (C-1), 
130.0 (C-20), 119.2 (C-6), 118.5 (C-23), 115.6 (C-19), 111.5 (C-21), 81.1 (C-7), 60.7 (C-5), 55.5 (C-25), 38.0 
(C-12), 37.1 (C-2), 31.5 (C-11), 27.6 (C-13, C-14, C-15), 22.8 (C-16). HRMS (ESI+) C20H26N2O3 [M + H]+ 








Isomerisation of 275f to 274f 
Following general procedure 17, 275f (63 mg, 0.30 mmol, 1.0 equiv.) was dissolved in dry MeCN (1.20 
mL, 0.25 M) before the addition of DBU (130 μL, 0.73 mmol, 3.0 equiv.). The crude product was purified 
by flash column chromatography (SiO2, pet.ether/EtOAc, 4:6) to yield 274f (55.44 mg, 88%) as a colourless 




Following general procedure 16, the title compound 274g was 
prepared from 266f (274 mg, 0.54 mmol, 1.0 equiv.). The reaction 
was finished after 2 h. Colourless oil (71 mg, 28%). Rf = 0.17 (SiO2; 
pet. Ether/ EtOAc 4:1). [𝛂]𝐃
𝟐𝟔 = -168° (c = 1 in CHCl3); IR (neat, 
cm-1): νmax 2982 (C–H), 1705 (C=O), 1676 (C=O), 1605. 1H NMR 
(500 MHz, CDCl3) δ 7.63 – 7.55 (m, 6H, H-Ar), 7.47 (d, J = 8.5 
Hz, 2H, H-Ar), 6.37 (d, J = 2.8 Hz, 1H, H-2), 5.27 (s, 1H, H-7), 
3.07 (s, 3H, H-11), 3.02 (d, J = 16.6 Hz, 1H, H-6), 2.75 (dd, J = 16.6, 2.8 Hz, 1H, H-6), 1.62 (s, 3H, H-16), 
1.12 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) δ 173.8 (C-3), 164.6 (C-9), 146.1 (C-Ar), 
141.5 (C-Ar), 139.0 (C-Ar), 136.4 (C-1), 132.2 (CH-Ar), 128.7 (CH-Ar), 127.5 (CH-Ar), 126.6 (CH-Ar), 
122.3 (C-Ar), 119.0 (CH-Ar), 81.2 (C-7), 60.7 (C-5), 38.0 (C-12), 36.9 (C-6), 31.5 (C-11), 27.6 (C-13, C-14, 




Following general procedure 16, the title compound 275g was 
prepared from 266f (274 mg, 0.54 mmol, 1.0 equiv.). The reaction 
was finished after 2 h. Colourless oil (101 mg, 40%). Rf = 0.09 
(SiO2; pet. Ether/ EtOAc 4:1). [𝛂]𝐃
𝟐𝟔 = +8° (c = 1 in CHCl3); IR 
(neat, cm-1): νmax 2965 (C–H), 1710 (C=O), 1679 (C=O), 1604; 1H 
NMR (500 MHz, CDCl3) δ 7.53 (dd, J = 8.5, 1.8 Hz, 4H, H-Ar), 
7.47 – 7.39 (m, 4H, H-Ar), 6.52 (d, J = 3.2 Hz, 1H, H-6), 5.22 (s, 
1H, H-7), 3.48 (dd, J = 17.7, 3.2 Hz, 1H, H-2), 3.39 (d, J = 17.7 Hz, 1H, H-2), 3.03 (s, 3H, H-11), 1.63 (s, 
3H, H-16), 1.11 (s, 9H, H-13, H-14, H-15). 13C NMR (125 MHz, CDCl3) δ 171.5 (C-9), 170.6 (C-3), 139.8 
(C-Ar), 139.2 (C-Ar), 136.8 (C-1), 132.4 (C-Ar), 131.9 (CH-Ar), 128.5 (CH-Ar), 127.1 (CH-Ar), 126.0 (C-
Ar), 125.9 (CH-Ar), 121.8 (C-Ar), 80.9 (C-7), 64.7 (C-5), 37.3 (C-12), 35.8 (C-6), 31.4 (C-11), 27.5 (C-13, C-







Isomerisation of 275g to 274g 
Following general procedure 17, 275g (70 mg, 0.23 mmol, 1.0 equiv.) was dissolved in dry MeCN (0.90 
mL, 0.25 M) before the addition of DBU (100 μL, 0.68 mmol, 3.0 equiv.). The crude product was purified 
by flash column chromatography (SiO2, pet.ether/EtOAc, 4:6) to yield 274g (65 mg, 93%) as a colourless 





NMO (88.8 mg, 0.76 mmol, 2.0 equiv.) and osmium tetroxide (48 μL, 0.01 
mmol, 0.02 equiv.) were added to 274a (89.5 mg, 0.38 mmol, 1.0 equiv.) in dry 
MeCN (1.50 mL). The reaction stirred for 24 h at rt. The reaction was quenched 
with sat. Na2S2O3 (aq.). The reaction mixture was extracted with EtOAc (3x). 
The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was chromatographed (SiO2, pet ether/ EtOAc 1:9) to 
yield the title compound 291a as an off-white semi-solid (56.2 mg, 49% yield).  
Rf = 0.09 (EtOAc). [𝛂]𝐃
𝟐𝟓 = -4° (c = 1 in CHCl3); IR (neat, cm-1): νmax 3675, 3399 (br) (OH), 2970, 2922 
(C-H), 1683 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.07 (s, 1H, H-7), 4.42 – 4.35 (m, 1H, H-1), 4.02 – 3.97 
(m, 1H, H-6), 3.93 (d, J = 1.7 Hz, 1H, H-18), 3.04 (t, J = 1.7 Hz, 1H, H-19), 2.98 (s, 3H, H-14), 2.50 (dd, J 
= 14.7, 4.4 Hz, 1H, H-5), 1.79 (s, 3H, H-12), 1.70 (s, 1H, H-5), 1.12 (s, 9H, H-15 + H-16 + H-17); 13C 
NMR (125 MHz, CDCl3) δ 174.1 (C-9), 171.8 (C-2), 82.6 (C-7), 70.8 (C-6), 65.8 (C-1), 60.8 (C-4), 36.5 (C-
13), 35.7 (C-5), 30.7 (C-14), 28.3 (C-15 + C-16 + C-17), 27.4 (C-12). HRMS (ESI+) C13H22N2O4 [M + H]+ 
calculated: 271.1652, found: 271.1651. 
(3S,6S,7S,8aS)-3-(tert-butyl)-6,7-dihydroxy-2,6,8a-trimethylhexahydroimidazo[1,5-a]pyridine-1,5-
dione (291b) 
NMO (16.8 mg, 0.14 mmol, 2.0 equiv.) and osmium tetroxide (46 μL, 0.09 
mmol, 0.02 equiv.) were added to 275b (18.0 mg, 0.72 mmol, 1.0 equiv.) in dry 
MeCN (1.50 mL). The reaction stirred for 24 h at rt. The reaction was quenched 
with sat. Na2S2O3 (aq.). The reaction mixture was extracted with EtOAc (3x1). 
The combined organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure. The residue was chromatographed (SiO2, 
pet ether/ EtOAc 1:9) to yield the title compound as an off-white semi-solid (4.90 mg, 51% yield). Rf = 
0.08 (pet ether/ EtOAc 1:9). [𝛂]𝐃
𝟐𝟒 = -32° (c = 0.5 in CHCl3); IR (neat, cm-1): νmax 3670, 3392 (br) (OH), 
2971, 2920 (C-H), 1683 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.17 (s, 1H, H-7), 3.86 (d, J = 2.4 Hz, 1H, 
H-6), 3.83 (d, J = 3.1 Hz, 1H, H-19), 3.39 (s, 1H, H-14), 3.02 (s, 3H, H-20), 2.62 – 2.48 (m, 2H, H-2), 1.55 






9), 171.8 (C-3), 81.4 (C-7), 70.5 (C-5), 66.4 (C-1), 38.0 (C-11), 31.7 (C-20), 30.0 (C-12), 27.2 (C-15, C-16, C-




a]pyridine-1,5-dione (291c)                                                                        
NMO (47 mg, 0.40 mmol, 2.0 equiv.) and osmium tetroxide (126.5 μL, 0.02 
mmol, 0.02 equiv.) were added to 288b (50 mg, 0.20 mmol, 1.0 equiv.) in dry 
MeCN (1.50 mL). The reaction stirred for 24 h at rt. The reaction was 
quenched with sat. Na2S2O3 (aq.). The reaction mixture was extracted with 
EtOAc (3x). The combined organic phases were washed with brine, dried 
over MgSO4 and concentrated under reduced pressure. The residue was chromatographed (SiO2, pet ether/ 
EtOAc 1:9) to yield the title compound as a colourless solid (49 mg, 86% yield). Rf = 0.11 (EtOAc). [𝛂]𝐃
𝟐𝟒 
= -60° (c = 1 in CHCl3); IR (neat, cm-1): νmax 3679, 3395 (br) (OH), 2973, 2918 (C-H), 1684 (C=O); 1H 
NMR (500 MHz, CDCl3) δ 5.22 (s, 1H, H-3), 4.11 (br. s, 1H, H-14), 3.57 (q, J = 11.2 Hz, 2H, H-7), 2.98 
(s, 3H, H-20), 2.52 (s, 2H, H-13), 2.21 (d, J = 14.7 Hz, 1H, H-9), 1.88 (d, J = 14.7 Hz, 1H, H-9), 1.52 (s, 
3H, H-12), 1.01 (s, 9H, H-17, H-18, H-19). 13C NMR (125 MHz, CDCl3) δ 174.2 (C-5), 171.8 (C-10), 80.8 
(C-3), 73.2 (C-1), 70.3 (C-7), 61.2 (C-8), 44.1 (C-9), 42.0 (C-13), 37.8 (C-16), 31.6 (C-20), 27.4 (C-17, C-18, 
C-19), 24.7 (C-12). HRMS (ESI+) C14H24N2NaO4 [M + Na]+ calculated: 307.162828, found: 307.161545. 
 
Hydrogenated derivativities 
 (3S,8aS)-3-(tert-butyl)-2,8a-dimethylhexahydroimidazo[1,5-a]pyridine-1,5-dione (289a) 
A mixture of 274a (30 mg, 0.13 mmol, 1.0 equiv.), 10% palladium on carbon (8.52 
mg, 0.08 mmol, 0.63 equiv.), acetic acid (1 drop) and methanol (6 mL) was stirred 
at rt under H2 (1 atm) for 24 h. The reaction mixture was filtered through celite, 
washing with CH2Cl2 and then concentrated under reduced pressure. The residue 
was extracted with EtOAc (x3) and sat. NaHCO3 (aq.). The combined organic 
phases were washed with brine, dried over MgSO4 and concentrated under reduced pressure to yield the 
crude title compound as a light-yellow oil (30.0 mg, quantitative yield). [𝛂]𝐃
𝟐𝟒  = -36° (c = 0.5 in CHCl3); IR 
(neat, cm-1): νmax 2966, 2924 (C-H), 1706, 1665 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.25 (s, 1H, H-7), 
2.99 (s, 3H, H-14), 2.55 (ddd, J = 17.6, 9.8, 4.0 Hz, 1H, H-1), 2.42 (ddd, J = 17.6, 9.8, 6.2 Hz, 1H, H-1), 
2.12 – 2.07 (m, 1H, H-6), 2.06 – 1.99 (m, 1H, H-6), 1.95 – 1.86 (m, 1H, H-5), 1.52 (d, J = 0.7 Hz, 3H, H-
12), 1.36 (td, J = 12.7, 12.2, 5.5 Hz, 1H, H-5), 1.03 (s, 9H, H-15 + H-16 + H-17); 13C NMR (125 MHz, 
CDCl3) δ 174.3 (C-9), 172.1 (C-2), 80.8 (C-7), 62.2 (C-4), 37.6 (C-13), 33.4 (C-5), 31.3 (C-14), 30.0 (C-1), 
27.4 (C-15 + C-16 + C-17), 22.1 (C-12), 15.6 (C-6); HRMS (ESI+) C13H22N2O2 [M + H]+ calculated: 






(3S,7S,8aS)-3-(tert-butyl)-2,7,8a-trimethylhexahydroimidazo[1,5-a]pyridine-1,5-dione (289b)                                                  
A mixture of 274b (125 mg, 0.50 mmol, 1.0 equiv.), 10% palladium on carbon 
(33.5 mg, 0.31 mmol, 0.63 equiv.), acetic acid (1 drop) and methanol (25 mL, 
0.02 M) was stirred at rt under H2 (1 atm) for 24 h. The reaction mixture was 
filtered through celite, washing with CH2Cl2 and then concentrated under 
reduced pressure. The residue was extracted with EtOAc (x3) and sat. NaHCO3 
(aq.). The combined organic phases were washed with brine, dried over MgSO4 and concentrated under 
reduced pressure to yield the crude title compound as a beige solid (107.0 mg, 85%). Rf = 0.33 
(pet.ether/EtOAc = 4:1). [𝛂]𝐃
𝟐𝟎 = - 112° (c = 1 in CHCl3); m.p. 58-60 °C; IR (neat, cm-1): νmax 2965, 2920 
(C-H), 1703, 1668 (C=O); 1H NMR (500 MHz, CDCl3) δ 5.19 (s, 1H, H-7), 2.95 (s, 3H, H-11), 2.73 (dd, J 
= 17.8, 7.2 Hz, 1H, H-2), 2.36 – 2.23 (m, 1H, H-1), 2.09 – 2.05 (m, 1H, H-2), 1.96 (dd, J = 17.8, 7.2 Hz, 
1H, H-6), 1.49 (s, 3H, H-16), 1.09 – 1.00 (m, 4H, H-6, H-18), 1.00 (s, 9H, H-13, H-14, H-15). 13C NMR 
(125 MHz, CDCl3) δ 174.0, 172.2, 80.8, 61.8, 41.8, 39.0, 37.2, 31.0, 27.3, 23.0, 22.9, 22.4. HRMS (ESI+) 
C14H25N2O2 [M + H]+ calculated: 253.1910, found: 253.1901. 
(3S,8aS)-3-(tert-butyl)-7-(4-fluorophenyl)-2,8a-dimethylhexahydroimidazo[1,5-a]pyridine-1,5-
dione (289c) 
A mixture of 274d (145 mg, 0.44 mmol, 1.0 equiv.), 10% palladium on 
carbon (30 mg, 0.69 mmol, 0.65 equiv.), acetic acid (1 drop) and 
methanol (22 mL, 0.02 M) was stirred at rt under H2 (1 atm) for 24 h. 
The reaction mixture was filtered through celite, washing with CH2Cl2 
and then concentrated under reduced pressure. The residue was 
extracted with EtOAc (x3) and sat. NaHCO3 (aq.). The combined 
organic phases were washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to yield the crude title compound as a beige solid (107.0 mg, 85%). 
Rf = 0.33 (pet.ether/EtOAc = 4:1). [𝛂]𝐃
𝟐𝟒 = -36° (c = 1 in CHCl3); m.p. 58-60 °C; IR (neat, cm-1): νmax 
2965, 2920 (C-H), 1703, 1668 (C=O);  1H NMR (ESI+) (500 MHz, CDCl3) δ 7.23 – 7.15 (m, 1.54H, H-20, 
H-22), 7.15 – 7.11 (m, 0.46H, H-20, H-22), 7.10 – 7.06 (m, 0.46H, H-19, H-23), 7.04 – 6.95 (m, 1.54H, H-
19, H-23), 5.27 (s, 0.23H, H-7), 5.22 (s, 0.77H, H-7), 3.44 (tdd, J = 12.1, 7.3, 4.5 Hz, 0.23H, H-1), 3.14 (ddt, 
J = 12.1, 7.3, 4.5 Hz, 0.77H, H-1), 3.01 (s, 3H, H-11 major + minor), 3.00 (s, 0.23H, H-2B minor), 2.70 – 
2.58 (m, 1.54H, H-2A major + H-2B major), 2.44 (dd, J = 17.8, 7.3 Hz, 0.23H, H-2A minor), 2.36 – 2.27 (m, 
1H, H-6 B major + minor), 2.18 (dd, J = 14.5, 6.4 Hz, 1H, H-6 A major + minor), 1.63 (s, 0.69H, H-16), 
1.54 (s, 2.31H, H-16), 1.09 (s, 2.07H, H-13, H-14, H-15), 1.05 (s, 6.93H, H-13, H-14, H-15). 13C NMR (125 
MHz, CDCl3) δ 173.9, 173.7, 172.5, 171.7, 162.7, 162.6, 160.8, 160.7, 140.0, 139.9, 139.2, 139.1, 128.2, 
128.2, 128.2, 128.1, 115.9, 115.8, 115.7, 115.7, 81.0, 80.7, 62.4, 61.7, 41.8, 41.3, 39.0, 38.5, 37.7, 37.4, 35.7, 







Hydrolysed products   
(S)-4-(4-fluorophenyl)-2-methyl-6-oxo-1,2,3,6-tetrahydropyridine-2-carboxylic acid (295a) 
Following general procedure 9, Alkylated lactam 274d (39.2 mg, 0.12 
mmol) was dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (2.5 mL, 
0.05 M) in a microwave vial. The crude material purified by flash column 
chromatography to yield the title compound (20 mg, 68%) as a dark yellow 
oil. Rf = 0.25 (pet.ether/EtOAc 3:1, 1% formic acid); [𝛂]𝐃
𝟐𝟒  = +8° (c = 
0.5 in CHCl3); IR (neat, cm-1): νmax = 3231 (OH), 3126 (C-H) 2925 (C-H), 
1705 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H, H-4), 7.64 – 7.45 (m, 
2H, H-13, H-17), 7.19 – 7.03 (m, 2H, H-14, H-16), 6.23 (s, 1H, H-2), 3.14 (dd, J = 17.4, 2.4 Hz, 1H, H-6), 
3.03 (d, J = 17.4 Hz, 1H, H-6), 1.66 (s, 3H, H-10). 13C NMR (125 MHz, CDCl3) δ 177.4 (C-8), 167.3 (C-
3), 165.0 (C-15), 163.0 (C-15), 133.4 (C-2), 133.4 (C-12), 128.3 (C-13, C-17), 128.2 (C-13, C-17), 117.4 (C-
1), 116.3 (C-14, C-16), 116.1 (C-14, C-16), 57.8 (C-5), 35.0 (C-6), 25.0 (C-10). HRMS (ESI+) C13H13FNO3 
[M + H]+ calculated: 250.0801, found 250.0813. 
(S)-4-(4'-bromo-[1,1'-biphenyl]-4-yl)-2-methyl-6-oxo-1,2,3,6-tetrahydropyridine-2-carboxylic  
acid (295b) 
Following general procedure 9, Alkylated lactam 274g (71 mg, 
0.15 mmol) was dissolved in a mixture of TFA – 6.0 M HCl (1:4 
ratio) (3.0 mL, 0.05 M) in a microwave vial. The crude material 
purified by flash column chromatography to yield the title 
compound (41 mg, 70%) as a beige semi-solid. Rf = 0.12 
(pet.ether/EtOAc 3:1, 1% formic acid); [𝛂]𝐃
𝟐𝟒 = +44° (c = 1 in 
MeOH); IR (neat, cm-1): νmax = 3231 (OH), 3126 (C-H) 2925 (C-
H), 1705 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 7.63 – 7.55 (m, 1H, H-Ar), 7.49 
(d, J = 8.4 Hz, 1H, H-Ar), 7.35 (dd, J = 8.4, 2.2 Hz, 1H, H-Ar), 6.38 (br. s, 1H, H-4), 6.21 (s, 1H, H-2), 3.80 
– 3.67 (m, 3H, H-20), 3.28 (d, J = 16.7 Hz, 1H, H-6), 2.75 (d, J = 16.7 Hz, 1H, H-6), 1.59 (s, 3H, H-10). 
13C NMR (125 MHz, CDCl3) δ 174.0 (C-8), 166.4 (C-3), 147.7 (C-1), 137.3 (C-12), 134.3 (C-14), 133.4 (C-
15), 131.0 (C-16), 128.2 (C-13), 125.4 (C-17), 119.9 (C-2), 58.9 (C-5), 53.4 (C-20), 36.2 (C-6), 25.9 (C-10). 














Following general procedure 9, Alkylated lactam 274e (46 mg, 0.16 
mmol) was dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (3.2 
mL, 0.05 M) in a microwave vial. The crude material was washed by 
Et2O (20 ml) to yield the title compound (26 mg, 85%) as a yellow oil. 
Rf = 0.32 (pet.ether/EtOAc 3:1, 1% formic acid); [𝛂]𝐃
𝟐𝟒  = +28° (c = 
0.5 in CHCl3); IR (neat, cm-1): νmax = 3231 (OH), 3126 (C-H) 2925 (C-
H), 1705 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 7.63 – 7.55 (m, 1H, H-Ar), 7.49 
(d, J = 8.4 Hz, 1H, H-Ar), 7.35 (dd, J = 8.4, 2.2 Hz, 1H, H-Ar), 6.38 (br. s, 1H, H-4), 6.21 (s, 1H, H-2), 3.80 
– 3.67 (m, 3H, H-20), 3.28 (d, J = 16.7 Hz, 1H, H-6), 2.75 (d, J = 16.7 Hz, 1H, H-6), 1.59 (s, 3H, H-10). 
13C NMR (125 MHz, CDCl3) δ 174.0 (C-8), 166.4 (C-3), 147.7 (C-1), 137.3 (C-12), 134.3 (C-14), 133.4 (C-
15), 131.0 (C-16), 128.2 (C-13), 125.4 (C-17), 119.9 (C-2), 58.9 (C-5), 53.4 (C-20), 36.2 (C-6), 25.9 (C-10). 
HRMS (ESI+) C14H15ClN2O2 [M + H]+ calculated: 313.0432, found 313.0440. 
(S)-2,4-dimethyl-6-oxo-1,2,3,6-tetrahydropyridine-2-carboxylic acid (296a) 
Following general procedure 9, Alkylated lactam 274b (79 mg, 0.16 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (6.39 mL, 0.05 M) in a 
microwave vial. The reaction was heated in a microwave reactor at 170 °C (12 bar) 
for 4 h. The crude material purified by flash column chromatography to yield the 
title compound (42.5 mg, 80%) as a yellowish white oil. Rf = 0.37 
(pet.ether/EtOAc 3:1, 1% formic acid). [𝛂]𝐃
𝟐𝟒  = +28° (c = 0.5 in MeOH); IR (neat, cm-1): νmax = 3231 
(OH), 2925 (C-H), 1705 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 8.89 (s, 1H, H-
4), 5.72 (s, 1H, H-2), 2.76 (d, J = 17.8 Hz, 1H, H-6), 2.43 (d, J = 17.8 Hz, 1H, H-6), 1.97 (s, 3H, H-12), 1.55 
(s, 3H, H-10). 13C NMR (125 MHz, CDCl3) δ 177.3 (C-8), 167.5 (C-3), 152.3 (C-1), 118.3 (C-2), 57.7 (C-
5), 37.6 (C-6), 25.0 (C-10). HRMS (ESI+) C8H12NO3 [M + H]+ calculated: 170.0739, found 170.0744. 
(2S,4S)-2,4-dimethyl-6-oxopiperidine-2-carboxylic acid (296b) 
Following general procedure 9, Alkylated lactam 289b (96 mg, 0.38 mmol) was 
dissolved in a mixture of TFA – 6.0 M HCl (1:4 ratio) (7.6 mL, 0.05 M) in a 
microwave vial. The crude material was washed by Et2O (20 ml) to yield the title 
compound (57 mg, 88%) as a yellow oil. Rf = 0.40 (pet.ether/EtOAc 3:1, 1% 
formic acid); [𝛂]𝐃
𝟐𝟒  = -28° (c = 0.25 in MeOH); IR (neat, cm-1): νmax = 3231 (OH), 
2925 (C-H), 1705 (C=O acid), 1629 (C=O amide); 1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H, H-7), 5.86 
(br. s, 1H, H-4), 2.45 (ddd, J = 18.1, 5.6, 1.9 Hz, 1H, H-2), 2.21 – 2.02 (m, 2H, H-2, H-1), 1.83 (dd, J = 18.1, 
11.4 Hz, 1H, H-6), 1.54 (s, 4H, H-6, H-10), 1.04 (d, J = 6.4 Hz, 3H, H-12). 13C NMR (125 MHz, CDCl3) 
δ 177.4 (C-8), 173.6 (C-3), 58.7 (C-5), 38.7 (C-2), 38.1 (C-6), 27.1 (C-10), 23.5 (C-1), 21.5 (C-12). HRMS 
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[62] C. Giro ́ Mañas, V. L. Paddock, C. G. Bochet, A. C. Spivey, A. J. P. White, I. Mann, W. Oppolzer, 
J. Am. Chem. Soc. 2010, 132, 5176. 
[63] H. Haning, C. Giró-Mañas, V. L. Paddock, C. G. Bochet, A. J. P. White, G. Bernardinelli, I. Mann, 
W. Oppolzer, A. C. Spivey, Org. Biomol. Chem. 2011, 9, 2809. 
[64] K. Nishimura, N. Fukuyama, T. Yasuhara, M. Yamashita, T. Sumiyoshi, Y. Yamamoto, K. I. 
Yamada, K. Tomioka, Tetrahedron 2015, 71, 7222. 
[65] T. W. Bingham, L. W. Hernandez, D. G. Olson, R. L. Svec, P. J. Hergenrother, D. Sarlah, J. Am. 
Chem. Soc. 2019, 141, 657. 
[66] C. C. Liu, K. Parthasarathy, C. H. Cheng, Org. Lett. 2010, 12, 3518. 
[67] Y. Kajita, S. Matsubara, T. Kurahashi, J. Am. Chem. Soc. 2008, 130, 6058. 
[68] T. Miura, M. Yamauchi, M. Murakami, Org. Lett. 2008, 10, 3085. 
[69] D. K. Rayabarapu, T. Sambaiah, C. Cheng, Angew. Chemie Int. Ed. 2001, 40, 1286. 
[70] M. Liu, J. L. Niu, D. Yang, M. P. Song, J. Org. Chem. 2020, 85, 4067. 
[71] L. Grigorjeva, O. Daugulis, Angew. Chemie - Int. Ed. 2014, 53, 10209. 
[72] R. Mei, H. Wang, S. Warratz, S. A. MacGregor, L. Ackermann, Chem. - A Eur. J. 2016, 22, 6759. 
[73] W. Zhou, S. Ni, H. Mei, J. Han, Y. Pan, Org. Lett. 2015, 17, 2724. 
[74] S. Zhou, M. Wang, L. Wang, K. Chen, J. Wang, C. Song, J. Zhu, Org. Lett. 2016, 18, 5632. 
[75] X. C. Li, C. Du, H. Zhang, J. L. Niu, M. P. Song, Org. Lett. 2019, 21, 2863. 
[76] Y. Wang, C. Du, Y. Wang, X. Guo, L. Fang, M. P. Song, J. L. Niu, D. Wei, Adv. Synth. Catal. 2018, 
360, 2668. 
[77] X. K. Guo, L. B. Zhang, D. Wei, J. L. Niu, Chem. Sci. 2015, 6, 7059. 
[78] D. S. Deshmukh, P. A. Yadav, B. M. Bhanage, Org. Biomol. Chem. 2019, 17, 3489. 
[79] C. Tian, L. Massignan, T. H. Meyer, L. Ackermann, Angew. Chemie - Int. Ed. 2018, 57, 2383. 
[80] Y. H. Seo, J.-K. Kim, J.-G. Jun, Bioorg. Med. Chem. Lett. 2014, 24, 5727. 
[81] O. Planas, C. J. Whiteoak, V. Martin-Diaconescu, I. Gamba, J. M. Luis, T. Parella, A. Company, X. 
Ribas, J. Am. Chem. Soc. 2016, 138, 14388. 
[82] B. Ye, N. Cramer, Science (80-. ). 2012, 338, 504. 
[83] N. Guimond, C. Gouliaras, K. Fagnou, J. Am. Chem. Soc. 2010, 132, 6908. 
[84] N. J. Webb, S. P. Marsden, S. A. Raw, Org. Lett. 2014, 16, 4718. 
[85] G. Cera, T. Haven, L. Ackermann, Chem. Commun. 2017, 53, 6460. 
[86] J. Mo, T. Müller, J. C. A. Oliveira, L. Ackermann, Angew. Chemie - Int. Ed. 2018, 57, 7719. 
[87] S. Zhai, S. Qiu, X. Chen, J. Wu, H. Zhao, C. Tao, Y. Li, B. Cheng, H. Wang, H. Zhai, Chem. Commun. 
2018, 54, 98. 






[89] H. Shiota, Y. Ano, Y. Aihara, Y. Fukumoto, N. Chatani, J. Am. Chem. Soc. 2011, 133, 14952. 
[90] A. Obata, Y. Ano, N. Chatani, Chem. Sci. 2017, 8, 6650. 
[91] G.-D. Xu, Z.-Z. Huang, Org. Lett. 2017, 19, 6265. 
[92] H. Wang, F. Glorius, Angew. Chemie Int. Ed. 2012, 51, 7318. 
[93] T. K. Hyster, T. Rovis, J. Am. Chem. Soc. 2010, 132, 10565. 
[94] D. G. Yu, F. De Azambuja, F. Glorius, Angew. Chemie - Int. Ed. 2014, 53, 2754. 
[95] L. Shi, K. Yu, B. Wang, Chem. Commun. 2015, 51, 17277. 
[96] N. S. Upadhyay, V. H. Thorat, R. Sato, P. Annamalai, S. C. Chuang, C. H. Cheng, Green Chem. 2017, 
19, 3219. 
[97] L. Ackermann, A. V. Lygin, N. Hofmann, Angew. Chemie - Int. Ed. 2011, 50, 6379. 
[98] M. Deponti, S. I. Kozhushkov, D. S. Yufit, L. Ackermann, Org. Biomol. Chem. 2013, 11, 142. 
[99] S. L. Yedage, B. M. Bhanage, Green Chem. 2016, 18, 5635. 
[100] Z. Shu, W. Li, B. Wang, ChemCatChem 2015, 7, 605. 
[101] Z. Shu, Y. Guo, W. Li, B. Wang, Catal. Today 2017, 297, 292. 
[102] R. S. Phatake, P. Patel, C. V. Ramana, Org. Lett. 2016, 18, 2828. 
[103] R. Sun, X. Yang, Q. Li, K. Xu, J. Tang, X. Zheng, M. Yuan, H. Fu, R. Li, H. Chen, Org. Lett. 2019, 
21, 9425. 
[104] L. Ackermann, S. Fenner, Org. Lett. 2011, 13, 6548. 
[105] J. Yang, L. Wu, H. Xu, H. Gao, Z. Zhou, W. Yi, Org. Lett. 2019, 21, 9904. 
[106] W. Zhou, Y. X. Zhang, X. Di Nie, C. M. Si, X. Sun, B. G. Wei, J. Org. Chem. 2018, 83, 9879. 
[107] K. Kurihara, Y. Yamamoto, N. Miyaura, Adv. Synth. Catal. 2009, 351, 260. 
[108] J. Lee, H. Y. Kim, K. Oh, Org. Lett. 2020, 22, 474. 
[109] M. M. Amer, H. Abas, D. J. Leonard, J. W. Ward, J. Clayden, J. Org. Chem. 2019, 84, 7199. 
[110] D. J. Leonard, J. W. Ward, J. Clayden, Nature 2018, 562, 105. 
[111] D. Seebach, A. R. Sting, M. Hoffmann, Angew. Chemie Int. Ed. English 1996, 35, 2708. 
[112] K. Anjema, M. van Rijn, P. H. Verkerk, J. G. M. Burgerhof, M. R. Heiner-Fokkema, F. J. van 
Spronsen, Mol. Genet. Metab. 2011, 104, 231. 
[113] J. Yang, P. Cron, V. M. Good, V. Thompson, B. A. Hemmings, D. Barford, Nat. Struct. Biol. 2002, 
9, 940. 
[114] R. J. Wakeham, J. E. Taylor, S. D. Bull, J. A. Morris, J. M. J. Williams, Org. Lett. 2013, 15, 702. 
[115] M. L. Leathen, B. R. Rosen, J. P. Wolfe, J. Org. Chem. 2009, 74, 5107. 
[116] I. Olaizola, R. A. A. Abdine, H. Dhimane, P. I. Dalko, Synth. 2017, 49, 391. 
[117] M. Chrzanowska, A. Grajewska, M. D. Rozwadowska, Chem. Rev. 2016, 116, 12369. 
[118] R. E. Gawley, Q. Zhang, J. Org. Chem. 1995, 60, 5763. 






[120] R. Fitzi, D. Seebach, Tetrahedron 1988, 44, 5277. 
[121] D. Seebach, E. Dziadulewicz, L. Behrendt, S. Cantoreggi, R. Fitzi, Liebigs Ann. der Chemie 1989, 1989, 
1215. 
[122] M. Gander-Coquoz, D. Seebach, Helv. Chim. Acta 1988, 71, 224. 
[123] R. O. Duthaler, Tetrahedron 1994, 50, 1539. 
[124] A. TSUGITA, J.-J. SCHEFFLER, Proc. Japan Acad. Ser. B Phys. Biol. Sci. 1982, 58, 1. 
[125] P. Lei, Y. Ding, X. Zhang, A. Adijiang, H. Li, Y. Ling, J. An, Org. Lett. 2018, 20, 3439. 
[126] Z. Guo, A. G. Schultz, J. Org. Chem. 2001, 66, 2154. 
[127] A. G. Schultz, T. J. Guzi, E. Larsson, R. Rahm, K. Thakkar, J. M. Bidlack, J. Org. Chem. 1998, 63, 
7795. 
[128] A. G. Schultz, S. J. Kirincich, R. Rahm, Tetrahedron Lett. 1995, 36, 4551. 
[129] D. Kaiser, V. Tona, C. R. Gonçalves, S. Shaaban, A. Oppedisano, N. Maulide, Angew. Chemie Int. 
Ed. 2019, 58, 14639. 
[130] D. Kaiser, A. Bauer, M. Lemmerer, N. Maulide, Chem. Soc. Rev. 2018, 47, 7899. 
[131] P. Adler, C. J. Teskey, D. Kaiser, M. Holy, H. H. Sitte, N. Maulide, Nat. Chem. 2019, 11, 329. 
[132] J. Li, M. Berger, W. Zawodny, M. Simaan, N. Maulide, Chem 2019, 5, 1883. 
[133] H. Zhang, M. Riomet, A. Roller, N. Maulide, Org. Lett. 2020, 22, 2376. 
[134] G. Di Mauro, B. Maryasin, D. Kaiser, S. Shaaban, L. González, N. Maulide, Org. Lett. 2017, 19, 3815. 
[135] V. Tona, A. De La Torre, M. Padmanaban, S. Ruider, L. González, N. Maulide, J. Am. Chem. Soc. 
2016, 138, 8348. 
[136] D. Kaiser, N. Maulide, J. Org. Chem. 2016, 81, 4421. 
[137] A. De La Torre, D. Kaiser, N. Maulide, J. Am. Chem. Soc. 2017, 139, 6578. 
[138] C. J. Teskey, P. Adler, C. R. Gonçalves, N. Maulide, Angew. Chemie - Int. Ed. 2019, 58, 447. 
[139] J. Li, A. Bauer, G. Di Mauro, N. Maulide, Angew. Chemie - Int. Ed. 2019, 58, 9816. 
[140] S. Shaaban, V. Tona, B. Peng, N. Maulide, Angew. Chemie - Int. Ed. 2017, 56, 10938. 
[141] K. J. Xiao, Y. Wang, K. Y. Ye, P. Q. Huang, Chem. - A Eur. J. 2010, 16, 12792. 
[142] C. Lindemann, C. Schneider, Synthesis (Stuttg). 2016, 48, 828. 
[143] M. Movassaghi, M. D. Hill, J. Am. Chem. Soc. 2006, 128, 4592. 
[144] M. Geffe, T. Opatz, Org. Lett. 2014, 16, 5282. 
[145] H. Abas, M. M. Amer, O. Olaizola, J. Clayden, Org. Lett. 2019, 21, 1908. 
[146] A. F. Kornahrens, A. B. Cognetta, D. M. Brody, M. L. Matthews, B. F. Cravatt, D. L. Boger, J. Am. 
Chem. Soc. 2017, 139, 7052. 
[147] J. C. Conrad, J. Kong, B. N. Laforteza, D. W. C. MacMillan, J. Am. Chem. Soc. 2009, 131, 11640. 
[148] M. M. Amer, O. Olaizola, J. Carter, H. Abas, J. Clayden, Org. Lett. 2020, 22, 253. 






[150] R. M. Zacharius, J. F. Thompson, F. C. Steward, J. Am. Chem. Soc. 1952, 74, 2949. 
[151] M. Di Nisio, S. Middeldorp, H. R. Büller, N. Engl. J. Med. 2005, 353, 1028. 
[152] D. Lamarre, G. Croteau, E. Wardrop, L. Bourgon, D. Thibeault, C. Clouette, M. Vaillancourt, E. 
Cohen, C. Pargellis, C. Yoakim, et al., Antimicrob. Agents Chemother. 1997, 41, 965. 
[153] T. D. Copeland, E. M. Wondrak, J. Tozser, M. M. Roberts, S. Oroszlan, Biochem. Biophys. Res. 
Commun. 1990, 169, 310. 
[154] B. M. Wickwire, C. Wagner, H. P. Broquist, J. Biol. Chem. 1990, 265, 14748. 
[155] S. Dhillon, Am. J. Cardiovasc. Drugs 2009, 9, 261. 
[156] K. Satyanarayana, K. Srinivas, V. Himabindu, G. M. Reddy, Org. Process Res. Dev. 2007, 11, 842. 
[157] J. Szychowski, J.-F. O. Truchon, Y. L. Bennani, J. Med. Chem 2014, 57, 9292. 
[158] D. M. Jensen, M. Brunda, R. Elston, E. J. Gane, J. George, K. Glavini, J. M. Hammond, S. Le 
Pogam, I. Nájera, S. Passe, et al., Liver Int. 2016, 36, 505. 
[159] W. Chen, W. Lian, Y. Yuan, M. Li, Cell Death Dis. 2019, 10, 600. 
[160] X. Huang, S. Broadbent, C. Dvorak, S.-H. Zhao, Org. Process Res. Dev. 2010, 14, 612. 
[161] C. Kadouri-Puchot, S. Comesse, Amino Acids 2005, 29, 101. 
[162] F. Couty, Amino Acids 1999, 16, 297. 
[163] P. D. Bailey, P. A. Millwood, P. D. Smith, Chem. Commun. 1998, 633. 
[164] A. A. Cant, A. Sutherland, Synth. 2012, 44, 1935. 
[165] T. Kano, T. Kumano, R. Sakamoto, K. Maruoka, Org. Biomol. Chem. 2013, 11, 271. 
[166] P. J. Murray, I. D. Starkey, Tetrahedron Lett. 1996, 37, 1875. 
[167] S. Hanessian, L. Riber, J. Marin, Synlett 2009, 2009, 71. 
[168] A. Golubev, N. Sewald, K. Burger, Tetrahedron Lett. 1995, 36, 2037. 
[169] D. R. Adams, P. D. Bailey, I. D. Collier, J. D. Heffernan, S. Stokes, Chem. Commun. 1996, 349. 
[170] P. S. Shirude, V. A. Kumar, K. N. Ganesh, Tetrahedron 2004, 60, 9485. 
[171] T. J. Greshock, R. L. Funk, J. Am. Chem. Soc. 2002, 124, 754. 
[172] R. Polt, D. Seebach, J. Am. Chem. Soc. 1989, 111, 2622. 
[173] F. P. J. T. Rutjes, H. E. Schoemaker, Tetrahedron Lett. 1997, 38, 677. 
[174] D. Bhattacherjee, Shaifali, A. Kumar, A. Sharma, R. Purohit, P. Das, Org. Biomol. Chem. 2020, 18, 
745. 
[175] Y. Yasui, I. Kakinokihara, H. Takeda, Y. Takemoto, Synthesis (Stuttg). 2009, 3989. 
[176] T. J. Donohoe, M. J. Connolly, L. Walton, Org. Lett. 2009, 11, 5562. 
[177] S. G. Wierschke, J. Chandrasekhar, W. L. Jorgensen, J. Am. Chem. Soc. 1985, 107, 1496. 
[178] A. I. Meyers, M. A. Seefeld, B. A. Lefker, J. Org. Chem. 1996, 61, 5712. 
[179] R. A. Snelling, G. Amberchan, A. Resendez, C. L. Murphy, L. Porter, B. Singaram, Tetrahedron Lett. 






[180] M. Malik, G. Witkowski, M. Ceborska, S. Jarosz, Org. Lett. 2013, 15, 6214. 
[181] J. Xie, T. Güveli, S. Hebbe, L. Dechoux, Tetrahedron Lett. 2004, 45, 4903. 
[182] S. N. Patil, S. G. Tilve, Tetrahedron Lett. 2016, 57, 3371. 
[183] W. J. Mijs, C. R. H. I. de Jonge, Eds. , Organic Syntheses by Oxidation with Metal Compounds, Springer 
US, Boston, MA, 1986. 
[184] R. D. Reeves, A. M. Phelps, W. A. T. Raimbach, J. M. Schomaker, Org. Lett. 2017, 19, 3394. 
[185] T. W. Bingham, L. W. Hernandez, D. G. Olson, R. L. Svec, P. J. Hergenrother, D. Sarlah, J. Am. 
Chem. Soc. 2019, 141, 657. 
[186] M. Ghavre, J. Froese, M. Pour, T. Hudlicky, Angew. Chemie - Int. Ed. 2016, 55, 5642. 
[187] K. M. Byrd, Beilstein J. Org. Chem. 2015, 11, 530. 
[188] E. García, E. Lete, N. Sotomayor, 2006, DOI 10.1021/jo060903w. 
[189] E. Prommer, Support. Care Cancer 2007, 15, 259. 
[190] A. Yazici, S. G. Pyne, Org. Lett. 2013, 15, 5878. 
[191] A. B. Charette, P. Chua, J. Org. Chem. 1998, 63, 908. 
[192] A. B. Charette, M. Grenon, A. Lemire, M. Pourashraf, J. Martel, J. Am. Chem. Soc. 2001, 123, 11829. 
[193] K.-J. Xiao, Y. Wang, K.-Y. Ye, P.-Q. Huang, Chem. - A Eur. J. 2010, 16, 12792. 
[194] Y. Cai, X. Liu, P. Zhou, X. Feng, J. Org. Chem. 2019, 84, 1. 
[195] D. Chen, C. Timmons, S. Chao, G. Li, European J. Org. Chem. 2004, 3097. 
[196] G. Li, H.-X. Wei, S. H. Kim, Org. Lett. 2000, 2, 2249. 
[197] Y. Murata, M. Yokoyama, T. Unuma, N. U. Sata, R. Kuwahara, M. Kaneniwa, I. Oohara, Dev. Food 
Sci. 2004, 42, 289. 
[198] P. Brewster, F. Hiron, E. D. Hughes, C. K. Ingold, P. A. D. S. Rao, Nature 1950, 166, 179. 
[199] M. Larchevêque, Y. Petit, Tetrahedron Lett. 1987, 28, 1993. 
[200] Y. Murata, N. U. Sata, J. Agric. Food Chem. 2000, 48, 5557. 
[201] N. U. Sata, R. Kuwahara, Y. Murata, Tetrahedron Lett. 2002, 43, 115. 
[202] L. Palatinus, G. Chapuis, J. Appl. Crystallogr. 2007, 40, 786. 
[203] L. Palatinus, S. J. Prathapa, S. Van Smaalen, J. Appl. Crystallogr. 2012, 45, 575. 
[204] G. M. Sheldrick, Acta Crystallogr. Sect. A Found. Crystallogr. 2008, 64, 112. 
[205] G. M. Sheldrick, Acta Crystallogr. Sect. C Struct. Chem. 2015, 71, 3. 
[206] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, J. Appl. Crystallogr. 
2009, 42, 339. 
[207] T. Miyazawa, K. Imagawa, H. Minowa, T. Miyamoto, T. Yamada, Tetrahedron 2005, 61, 10254. 
[208] B. Xu, Z. Huang, C. Liu, Z. Cai, W. Pan, P. Cao, X. Hao, G. Liang, Bioorg. Med. Chem. 2009, 17, 
3118. 






[210] L. Samulis, N. C. O. Tomkinson, Tetrahedron 2011, 67, 4263. 
[211] G. A. Reichard, C. Stengone, S. Paliwal, I. Mergelsberg, S. Majmundar, C. Wang, R. Tiberi, A. T. 
McPhail, J. J. Piwinski, N.-Y. Shih, Org. Lett. 2003, 5, 4249. 
[212] M. C. Holland, J. B. Metternich, C. Daniliuc, W. B. Schweizer, R. Gilmour, Chem. - A Eur. J. 2015, 
21, 10031. 
[213] T. J. Donohoe, L. P. Fishlock, P. A. Procopiou, Org. Lett. 2008, 10, 285. 
[214] A. Cabré, G. Sciortino, G. Ujaque, X. Verdaguer, A. Lledós, A. Riera, Org. Lett. 2018, 20, 5747. 









7 Appendices  
 Appendix 1 – Eyring Analyses of Variable-Temperature NMR 
All Eyring plots were constructed using rate constants that were attained by line shape fitting of 
experimental spectra at different temperatures. Spectra were simulated using Spinworks 4 NMR processing 
software (available at ftp://davinci.chem.umanitoba.ca/pub/marat/SpinWorks/) with appropriate 
exchange vectors. For each temperature, the corresponding rate of hydrogen-bond-directionality reversal 
was estimated using the dynamic NMR simulation module DNMR3. The Eyring-Polanyi equation was 
rearranged to give an equation of the form y = mx + c such that a plot of 1/T against ln(k/T) gives a 
straight line of gradient −Δ𝐻‡/𝑅 and intercept ln (
𝑘𝐵
ℎ
) + Δ𝑆‡/𝑅. These data were used with the Gibbs 
free energy equation to extrapolate Δ𝐺‡ at room temperature. Examples of simulation of systems in mutual 
exchange and non-mutual exchange are shown below. 
 





















Temperature (K) Rate Constant (s-1) 1/T (K-1) ln(kA/T) ΔG‡ minor to major (kJ mol-1) 
273 6 0.0037 -3.6354 62.5136 
278 9 0.0036 -3.2481 62.6774 
283 12 0.0035 -2.9782 62.8412 
287 15 0.0035 -2.7691 62.9722 
291 19 0.0034 -2.5466 63.1033 
295 28 0.0034 -2.1724 63.2343 
300 49 0.0033 -1.6296 63.3981 
304 73 0.0033 -1.2442 63.5291 
308 98 0.0032 -0.9628 63.6602 
 
Temperature (K) Rate Constant (s-1) 1/T (K-1) ln(kB/T) ΔG‡ major to minor (kJ mol-1) 
273 6 0.0037 -4.0409 63.4352 
278 9 0.0036 -3.6535 63.6159 
283 12 0.0035 -3.3837 63.7965 
287 15 0.0035 -3.1746 63.9411 
291 19 0.0034 -2.9520 64.0856 
295 28 0.0034 -2.5779 64.2301 
300 49 0.0033 -2.0351 64.4108 
304 73 0.0033 -1.6497 64.5554 
















































y = -3801.6x + 7.8529
R² = 0.9934




















Temperature (K) Rate Constant (s-1) 1/T (K-1) ln(kA/T) ΔG‡ minor to major (kJ mol-1) 
298 2 0.0034 -4.9086 71.0214 
308 3 0.0032 -4.5362 72.3440 
313 4 0.0032 -4.2646 73.0053 
318 5 0.0031 -4.0573 73.6666 
323 6 0.0031 -3.8906 74.3279 
328 7 0.0030 -3.7518 74.9892 
333 8 0.0030 -3.6334 75.6504 
338 11 0.0030 -3.3298 76.3117 
343 12 0.0029 -3.2575 76.9730 
348 15 0.0029 -3.0488 77.6343 
353 18 0.0028 -2.8808 78.2956 
358 21 0.0028 -2.7407 78.9569 
363 25 0.0028 -2.5802 79.6182 
368 30 0.0027 -2.4116 80.2795 
374 47 0.0027 -1.9788 81.0731 
 
Temperature (K) Rate Constant (s-1) 1/T (K-1) ln(kB/T) ΔG‡ major to minor (kJ mol-1) 
298 2 0.0034 -5.1093 71.5187 
308 3 0.0032 -4.7368 72.8579 
313 4 0.0032 -4.4653 73.5276 
318 5 0.0031 -4.2580 74.1972 
323 6 0.0031 -4.0913 74.8669 
328 7 0.0030 -3.9525 75.5365 
333 8 0.0030 -3.8341 76.2061 
338 11 0.0030 -3.5305 76.8758 
343 12 0.0029 -3.4582 77.5454 
348 15 0.0029 -3.2495 78.2150 
353 18 0.0028 -3.0815 78.8847 
358 21 0.0028 -2.9414 79.5543 
363 25 0.0028 -2.7809 80.2240 
368 30 0.0027 -2.6122 80.8936 














 Miscellaneous NMR experiments 
 
 






















































  Appendix 2 – Crystallographic Data 
Single crystal X-ray diffraction experiments were carried out at 100(2) K on a Bruker APEX II CCD 
diffractometer using Mo-K α radiation (λ = 0.71073 Å). Intensities were integrated and absorption 
corrections were based on equivalent reflections using SADABS. The structure was solved using 
Superflip202,203 and refined against F 2 in SHELXL204,205 using Olex2.206 All of the non-hydrogen atoms 
were refined anisotropically. While all of the hydrogen atoms were located geometrically and refined using 
a riding model.  
(2S,5S)-5-Benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154a) 
 
Figure 27: ORTEP diagram of 154a at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC deposition 1899271 μ/mm-1 0.248 
Empirical formula C16H21ClN2O2 F(000) 328.0 
Formula weight 308.80 Crystal size/mm3 0.597 × 0.461 × 0.295 
Temperature/K 100(2) Radiation MoKα (λ = 0.71073) 
Crystal system monoclinic 2Θ range for data collection/° 3.37 to 54.292 
Space group P21 Index ranges -5 ≤ h ≤ 7, -13 ≤ k ≤ 13, -15 ≤ l ≤ 12 
a/Å 6.0244(2) Reflections collected 6661 
b/Å 10.8597(4) Independent reflections 3471 [Rint = 0.0223, Rsigma = 0.0346] 
c/Å 12.0848(4) Data/restraints/parameters 3471/1/194 
α/° 90 Goodness-of-fit on F2 1.065 
β/° 90.221(2) Final R indexes [I>=2σ (I)] R1 = 0.0354, wR2 = 0.0818 
γ/° 90 Final R indexes [all data] R1 = 0.0392, wR2 = 0.0835 
Volume/Å3 790.62(5) Largest diff. peak/hole / e Å-3 0.21/-0.18 
Z 2 Flack parameter -0.07(5) 









Figure 28: ORTEP diagram of 154c at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity. The COCl group is disordered and has been modelled in two positions with a 
refined occupancy ratio of 0.809:0.191. Due to the small amount of the minor component present, atom distances in 
the minor component were restrained to be the same as corresponding distances in the major component. Atoms in 
close proximity were constrained to have the same ADP 
Crystal data and structure refinement 
CCDC deposition 1871268 μ/mm-1 0.233 
Empirical formula C18H25ClN2O4 F(000) 784.0 
Formula weight 368.85 Crystal size/mm3 0.514 × 0.488 × 0.334 
Temperature/K 100 Radiation MoKα (λ = 0.71073) 
Crystal system orthorhombic 2Θ range for data collection/° 4.078 to 54.376 
Space group P212121 Index ranges -11 ≤ h ≤ 10, -15 ≤ k ≤ 15, -21 ≤ l ≤ 21 
a/Å 8.8127(2) Reflections collected 31523 
b/Å 12.4251(3) Independent reflections 4106 [Rint = 0.0344, Rsigma = 0.0198] 
c/Å 16.7855(4) Data/restraints/parameters 4106/6/236 
α/° 90 Goodness-of-fit on F2 1.069 
β/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0298, wR2 = 0.0681 
γ/° 90 Final R indexes [all data] R1 = 0.0314, wR2 = 0.0687 
Volume/Å3 1837.99(8) Largest diff. peak/hole / e Å-3 0.24/-0.28 
Z 4 Flack parameter 0.030(18) 







(2S,5S)-2-(tert-Butyl)-5-(3-fluorobenzyl)-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154d) 
 
Figure 29: ORTEP diagram of 154d at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC deposition 1899274 μ/mm-1 0.256 
Empirical formula C16H20ClFN2O2 F(000) 688.0 
Formula weight 326.79 Crystal size/mm3 0.439 × 0.351 × 0.21 
Temperature/K 100(2) Radiation MoKα (λ = 0.71073) 
Crystal system orthorhombic 2Θ range for data collection/° 4.8 to 55.918 
Space group P212121 Index ranges -7 ≤ h ≤ 7, -20 ≤ k ≤ 20, -21 ≤ l ≤ 22 
a/Å 5.99270(10) Reflections collected 14947 
b/Å 15.8308(3) Independent reflections 3864 [Rint = 0.0341, Rsigma = 0.0323] 
c/Å 16.9752(3) Data/restraints/parameters 3864/0/203 
α/° 90 Goodness-of-fit on F2 1.043 
β/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0360, wR2 = 0.0915 
γ/° 90 Final R indexes [all data] R1 = 0.0401, wR2 = 0.0938 
Volume/Å3 1610.42(5) Largest diff. peak/hole / e Å-3 0.35/-0.42 
Z 4 Flack parameter 0.02(3) 








(2S,5S)-2-(tert-Butyl)-3-methyl-5-(4-nitrobenzyl)-4-oxoimidazolidine-1-carbonyl chloride (154e) 
 
Figure 30: ORTEP diagram of 154e at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity.  
Crystal data and structure refinement 
CCDC number 1899273 ρcalcg/cm3 1.341 
Empirical formula C16H20ClN3O4 μ/mm-1 0.243 
Formula weight 353.80 F(000) 744.0 
Temperature/K 100 Crystal size/mm3 0.554 × 0.468 × 0.164 
Crystal system monoclinic Radiation MoKα (λ = 0.71073) 
Space group P21 2Θ range for data collection/° 3.022 to 54.204 
a/Å 10.0063(3) Index ranges -12 ≤ h ≤ 12, -16 ≤ k ≤ 10, -17 ≤ l ≤ 17 
b/Å 12.9939(4) Reflections collected 14861 
c/Å 14.0411(3) Independent reflections 5383 [Rint = 0.0403, Rsigma = 0.0482] 
α/° 90 Data/restraints/parameters 5383/55/472 
β/° 106.2718(17) Goodness-of-fit on F2 1.027 
γ/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0364, wR2 = 0.0811 
Volume/Å3 1752.51(9) Final R indexes [all data] R1 = 0.0449, wR2 = 0.0854 
Z 4 Largest diff. peak/hole / e Å-3 0.20/-0.22 








(2S,5S)-2-(tert-Butyl)-3-methyl-4-oxo-5-phenylimidazolidine-1-carbonyl chloride (154i) 
 
Figure 31: ORTEP diagram of 154i at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC number 1899272 μ/mm-1 0.266 
Empirical formula C15H19ClN2O2 F(000) 624.0 
Formula weight 294.77 Crystal size/mm3 0.595 × 0.312 × 0.198 
Temperature/K 100(2) Radiation MoKα (λ = 0.71073) 
Crystal system orthorhombic 2Θ range for data collection/° 3.748 to 55.904 
Space group P212121 Index ranges -8 ≤ h ≤ 4, -19 ≤ k ≤ 19, -20 ≤ l ≤ 20 
a/Å 6.1540(4) Reflections collected 13253 
b/Å 14.8883(10) Independent reflections 3492 [Rint = 0.0322, Rsigma = 0.0305] 
c/Å 15.8902(10) Data/restraints/parameters 3492/0/185 
α/° 90 Goodness-of-fit on F2 1.045 
β/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0283, wR2 = 0.0651 
γ/° 90 Final R indexes [all data] R1 = 0.0316, wR2 = 0.0669 
Volume/Å3 1455.90(16) Largest diff. peak/hole / e Å-3 0.25/-0.17 
Z 4 Flack parameter -0.06(3) 







(2S,5S)-2-(tert-Butyl)-3,5-dimethyl-4-oxoimidazolidine-1-carbonyl chloride (154o) 
 
Figure 32: ORTEP diagram of 154o at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC number 1899277 μ/mm-1 0.300 
Empirical formula C10H17ClN2O2 F(000) 496.0 
Formula weight 232.70 Crystal size/mm3 0.497 × 0.341 × 0.291 
Temperature/K 100(2) Radiation MoKα (λ = 0.71073) 
Crystal system monoclinic 2Θ range for data collection/° 3.572 to 55.864 
Space group P21 Index ranges -8 ≤ h ≤ 8, -21 ≤ k ≤ 21, -15 ≤ l ≤ 15 
a/Å 6.60260(10) Reflections collected 22546 
b/Å 16.0983(3) Independent reflections 5810 [Rint = 0.0308, Rsigma = 0.0285] 
c/Å 11.7124(2) Data/restraints/parameters 5810/1/281 
α/° 90 Goodness-of-fit on F2 1.043 
β/° 103.2790(10) Final R indexes [I>=2σ (I)] R1 = 0.0282, wR2 = 0.0647 
γ/° 90 Final R indexes [all data] R1 = 0.0310, wR2 = 0.0660 
Volume/Å3 1211.63(4) Largest diff. peak/hole / e Å-3 0.30/-0.15 
Z 4 Flack parameter -0.020(17) 








(2S,5S)-2-(tert-Butyl)-5-isopropyl-3-methyl-4-oxoimidazolidine-1-carbonyl chloride (154r) 
 
Figure 33: ORTEP diagram of 154r at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC number 1899276 μ/mm-1 0.272 
Empirical formula C12H21ClN2O2 F(000) 560.0 
Formula weight 260.76 Crystal size/mm3 0.401 × 0.347 × 0.242 
Temperature/K 100(2) Radiation MoKα (λ = 0.71073) 
Crystal system monoclinic 2Θ range for data collection/° 3.528 to 55.872 
Space group P21 Index ranges -10 ≤ h ≤ 10, -19 ≤ k ≤ 19, -15 ≤ l ≤ 15 
a/Å 8.11000(10) Reflections collected 25490 
b/Å 14.6693(2) Independent reflections 6592 [Rint = 0.0356, Rsigma = 0.0331] 
c/Å 11.5814(2) Data/restraints/parameters 6592/1/319 
α/° 90 Goodness-of-fit on F2 1.038 
β/° 94.6170(10) Final R indexes [I>=2σ (I)] R1 = 0.0302, wR2 = 0.0680 
γ/° 90 Final R indexes [all data] R1 = 0.0340, wR2 = 0.0698 
Volume/Å3 1373.35(3) Largest diff. peak/hole / e Å-3 0.26/-0.15 
Z 4 Flack parameter 0.03(2) 







Benzyl (2S,5S)-5-benzyl-2-(tert-butyl)-3-methyl-4-oxoimidazolidine-1-carboxylate (216) 
 
Figure 34: ORTEP diagram of 216 at 50% probability ellipsoids. Hydrogen atoms of the imidazolidinone ring are 
included for stereochemical clarity 
Crystal data and structure refinement 
CCDC number 1899275 ρcalcg/cm3 1.228 
Empirical formula C23H28N2O3 μ/mm-1 0.081 
Formula weight 380.47 F(000) 408.0 
Temperature/K 100(2) Crystal size/mm3 0.27 × 0.26 × 0.23 
Crystal system monoclinic Radiation MoKα (λ = 0.71073) 
Space group P21 2Θ range for data collection/° 3.61 to 55.9 
a/Å 12.1176(4) Index ranges -15 ≤ h ≤ 15, -9 ≤ k ≤ 9, -16 ≤ l ≤ 14 
b/Å 7.5277(3) Reflections collected 9430 
c/Å 12.3487(4) Independent reflections 4906 [Rint = 0.0237, Rsigma = 0.0392] 
α/° 90 Data/restraints/parameters 4906/1/257 
β/° 114.006(2) Goodness-of-fit on F2 1.058 
γ/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0410, wR2 = 0.0926 
Volume/Å3 1028.99(6) Final R indexes [all data] R1 = 0.0475, wR2 = 0.0962 




















Figure 35: Olex2 diagram of 156a at 50% probability ellipsoids.  
 
Crystal data and structure refinement 
CCDC deposition 1871270 ρcalcg/cm3 1.242  
Empirical formula C16H20N2O2  μ/mm-1 0.661  
Formula weight 272.34  F(000) 584.0  
Temperature/K 100(2)  Crystal size/mm3 0.24 × 0.23 × 0.21  
Space group P212121  Radiation CuKα (λ = 1.54178)  
a/Å 6.5837(2)  2Θ range for data collection/° 10.62 to 144.68  
b/Å 13.2718(4)  Index ranges -6 ≤ h ≤ 8, -10 ≤ k ≤ 16, -20 ≤ l ≤ 18  
c/Å 16.6689(5)  Reflections collected 6035  
α/° 90.00  Independent reflections 2625 [Rint = 0.0313, Rsigma = N/A]  
β/° 90.00  Data/restraints/parameters 2625/0/185  
γ/° 90.00  Goodness-of-fit on F2 1.075  
Volume/Å3 1456.49(8)  Final R indexes [I>=2σ (I)] R1 = 0.0312, wR2 = 0.0798  
Z 4  Final R indexes [all data] R1 = 0.0322, wR2 = 0.0804  
























Figure 36: Olex diagram of 189g at 50% probability ellipsoids. 
 
Crystal data and structure refinement 
Empirical formula C19H28N2O5  ρcalcg/cm3 1.274  
Formula weight 364.43  μ/mm-1 0.092  
Temperature/K 100(2)  F(000) 784.0  
Crystal system orthorhombic  Crystal size/mm3 0.384 × 0.223 × 0.216  
Space group P212121  Radiation MoKα (λ = 0.71073)  
a/Å 10.4417(3)  2Θ range for data collection/° 4.296 to 52.734  
b/Å 12.4759(3)  Index ranges -13 ≤ h ≤ 12, -15 ≤ k ≤ 15, -18 ≤ l ≤ 18  
c/Å 14.5870(4)  Reflections collected 15753  
α/° 90  Independent reflections 3887 [Rint = 0.0479, Rsigma = 0.0423]  
β/° 90  Data/restraints/parameters 3887/0/245  
γ/° 90  Goodness-of-fit on F2 1.088  
Volume/Å3 1900.24(9)  Final R indexes [I>=2σ (I)] R1 = 0.0482, wR2 = 0.1202  























Figure 37: Olex diagram of 188a at 50% probability ellipsoids 
 
Crystal data and structure refinement 
CCDC deposition 1871271 ρcalcg/cm3 1.244  
Empirical formula C17H22N2O2  μ/mm-1 0.653  
Formula weight 286.37  F(000) 308.0  
Temperature/K 100(2)  Crystal size/mm3 0.28 × 0.21 × 0.17  
Space group P21  Radiation CuKα (λ = 1.54178)  
a/Å 6.0280(4)  2Θ range for data collection/° 6.42 to 144.34  
b/Å 9.2114(6)  Index ranges -7 ≤ h ≤ 5, -10 ≤ k ≤ 11, -15 ≤ l ≤ 17  
c/Å 13.8180(8)  Reflections collected 4187  
α/° 90.00  Independent reflections 2456 [Rint = 0.0188, Rsigma = N/A]  
β/° 94.810(3)  Data/restraints/parameters 2456/1/195  
γ/° 90.00  Goodness-of-fit on F2 1.046  
Volume/Å3 764.56(8)  Final R indexes [I>=2σ (I)] R1 = 0.0301, wR2 = 0.0794  
Z 2  Final R indexes [all data] R1 = 0.0304, wR2 = 0.0796  






















Figure 38: Olex diagram of 188b at 
50% probability ellipsoids 
Crystal data and structure refinement 
CCDC deposition 1871272 ρcalcg/cm3 1.265  
Empirical formula C18H24N2O2  μ/mm-1 0.656  
Formula weight 300.39  F(000) 648.0  
Temperature/K 100(2)  Crystal size/mm3 0.25 × 0.15 × 0.09  
Space group P212121  Radiation CuKα (λ = 1.54178)  
a/Å 6.0779(3)  2Θ range for data collection/° 6.26 to 144.34  
b/Å 9.1801(5)  Index ranges -7 ≤ h ≤ 7, -10 ≤ k ≤ 11, -34 ≤ l ≤ 30  
c/Å 28.2779(15)  Reflections collected 9542  
α/° 90.00  Independent reflections 3024 [Rint = 0.0251, Rsigma = N/A]  
β/° 90.00  Data/restraints/parameters 3024/0/204  
γ/° 90.00  Goodness-of-fit on F2 1.077  
Volume/Å3 1577.79(14)  Final R indexes [I>=2σ (I)] R1 = 0.0278, wR2 = 0.0718  
Z 4  Final R indexes [all data] R1 = 0.0284, wR2 = 0.0724  

























Figure 39: Olex diagram of 188d at 50% probability ellipsoids 
 
Crystal data and structure refinement 
CCDC deposition 1871273 ρcalcg/cm3 1.274  
Empirical formula C19H24N2O2  μ/mm-1 0.658  
Formula weight 312.40  F(000) 672.0  
Temperature/K 100(2)  Crystal size/mm3 0.28 × 0.20 × 0.12  
Space group P212121  Radiation CuKα (λ = 1.54178)  
a/Å 6.6476(5)  2Θ range for data collection/° 10.64 to 145.24  
b/Å 8.7006(6)  Index ranges -8 ≤ h ≤ 7, -9 ≤ k ≤ 10, -33 ≤ l ≤ 34  
c/Å 28.1553(18)  Reflections collected 8037  
α/° 90.00  Independent reflections 3059 [Rint = 0.0352, Rsigma = N/A]  
β/° 90.00  Data/restraints/parameters 3059/0/212  
γ/° 90.00  Goodness-of-fit on F2 1.029  
Volume/Å3 1628.4(2)  Final R indexes [I>=2σ (I)] R1 = 0.0372, wR2 = 0.0985  
Z 4  Final R indexes [all data] R1 = 0.0391, wR2 = 0.1000  






















Figure 40: Olex diagram of 193b at 50% probability ellipsoids 
Crystal data and structure refinement 
CCDC deposition 1872068 ρcalcg/cm3 1.211  
Empirical formula C24H28N2O2  μ/mm-1 0.077  
Formula weight 376.48  F(000) 808.0  
Temperature/K 100(2)  Crystal size/mm3 0.551 × 0.302 × 0.29  
Crystal system monoclinic  Radiation MoKα (λ = 0.71073)  
Space group P21  2Θ range for data collection/° 3.492 to 52.042  
a/Å 10.8751(6)  Index ranges -13 ≤ h ≤ 13, -20 ≤ k ≤ 18, -14 ≤ l ≤ 14  
b/Å 16.2763(9)  Reflections collected 15704  
c/Å 11.6964(6)  Independent reflections 7813 [Rint = 0.0438, Rsigma = 0.0697]  
α/° 90  Data/restraints/parameters 7813/1/515  
β/° 94.299(4)  Goodness-of-fit on F2 1.087  
γ/° 90  Final R indexes [I>=2σ (I)] R1 = 0.0598, wR2 = 0.1407  
Volume/Å3 2064.51(19)  Final R indexes [all data] R1 = 0.0828, wR2 = 0.1524  



















Figure 41: Olex diagram of 189f at 50% probability ellipsoids 
 
 
Crystal data and structure refinement 
CCDC deposition 1871269 ρcalcg/cm3 1.231  
Empirical formula C21H28N2O4  μ/mm-1 0.085  
Formula weight 372.45  F(000) 1600.0  
Temperature/K 100(2)  Crystal size/mm3 0.567 × 0.434 × 0.218  
Crystal system monoclinic  Radiation MoKα (λ = 0.71073)  
Space group C2  2Θ range for data collection/° 3.562 to 56.094  
a/Å 13.7798(4)  Index ranges -18 ≤ h ≤ 18, -16 ≤ k ≤ 12, -31 ≤ l ≤ 31  
b/Å 12.7550(4)  Reflections collected 18152  
c/Å 23.7654(6)  Independent reflections 7720 [Rint = 0.0376, Rsigma = 0.0482]  
α/° 90  Data/restraints/parameters 7720/39/518  
β/° 105.798(2)  Goodness-of-fit on F2 1.031  
γ/° 90  Final R indexes [I>=2σ (I)] R1 = 0.0393, wR2 = 0.0875  
Volume/Å3 4019.3(2)  Final R indexes [all data] R1 = 0.0495, wR2 = 0.0932  













Figure 42: Olex diagram of 207f at 50% probability ellipsoids 
 
Crystal data and structure refinement 
CCDC deposition 1895400 ρcalcg/cm3 1.242  
Empirical formula C18H24N2O3  μ/mm-1 0.085  
Formula weight 316.39  F(000) 680.0  
Temperature/K 100(2)  Crystal size/mm3 0.457 × 0.408 × 0.202  
Crystal system monoclinic  Radiation MoKα (λ = 0.71073)  
Space group P21  2Θ range for data collection/° 4.432 to 55.916  
a/Å 9.4168(3)  Index ranges -12 ≤ h ≤ 12, -12 ≤ k ≤ 13, -23 ≤ l ≤ 23  
b/Å 10.2186(3)  Reflections collected 15538  
c/Å 18.0152(5)  Independent reflections 6748 [Rint = 0.0322, Rsigma = 0.0433]  
α/° 90  Data/restraints/parameters 6748/1/427  
β/° 102.643(2)  Goodness-of-fit on F2 1.044  
γ/° 90  Final R indexes [I>=2σ (I)] R1 = 0.0463, wR2 = 0.1047  
Volume/Å3 1691.51(9)  Final R indexes [all data] R1 = 0.0544, wR2 = 0.1092  























Figure 43: Olex diagram of 274a at 50% probability ellipsoids 
Crystal data and structure refinement 
CCDC deposition 1967823 ρcalcg/cm3 1.199  
Empirical formula C13H20N2O2  μ/mm-1 0.081  
Formula weight 236.31  F(000) 256.0  
Temperature/K 100(2)  Crystal size/mm3 0.319 × 0.241 × 0.235  
Crystal system monoclinic  Radiation MoKα (λ = 0.71073)  
Space group P21  2Θ range for data collection/° 4.516 to 55.824  
a/Å 6.5807(5)  Index ranges -8 ≤ h ≤ 8, -14 ≤ k ≤ 14, -12 ≤ l ≤ 11  
b/Å 11.0274(9)  Reflections collected 5991  
c/Å 9.5134(8)  Independent reflections 2950 [Rint = 0.0296, Rsigma = 0.0458]  
α/° 90  Data/restraints/parameters 2950/1/159  
β/° 108.576(4)  Goodness-of-fit on F2 1.038  
γ/° 90  Final R indexes [I>=2σ (I)] R1 = 0.0428, wR2 = 0.0934  
Volume/Å3 654.40(9)  Final R indexes [all data] R1 = 0.0496, wR2 = 0.0977  


























Figure 44: Olex diagram of 275a at 50% probability ellipsoids 
 
Crystal data and structure refinement 
CCDC deposition 1967824 ρcalcg/cm3 1.229  
Empirical formula C13H20N2O2  μ/mm-1 0.083  
Formula weight 236.31  F(000) 512.0  
Temperature/K 99.99  Crystal size/mm3 0.571 × 0.354 × 0.208  
Crystal system monoclinic  Radiation MoKα (λ = 0.71073)  
Space group P21  2Θ range for data collection/° 3.52 to 52.744  
a/Å 12.0024(5)  Index ranges -14 ≤ h ≤ 14, -9 ≤ k ≤ 9, -17 ≤ l ≤ 17  
b/Å 7.9058(3)  Reflections collected 15867  
c/Å 13.9636(5)  Independent reflections 5057 [Rint = 0.0333, Rsigma = 0.0373]  
α/° 90  Data/restraints/parameters 5057/1/317  
β/° 105.406(2)  Goodness-of-fit on F2 1.044  
γ/° 90  Final R indexes [I>=2σ (I)] R1 = 0.0361, wR2 = 0.0828  
Volume/Å3 1277.38(9)  Final R indexes [all data] R1 = 0.0425, wR2 = 0.0861  














Figure 45: Olex diagram of 289c at 50% probability ellipsoids 
 
Crystal data and structure refinement 
CCDC deposition 1967826 ρcalcg/cm3 1.220 
Empirical formula C19H25FN2O2 μ/mm-1 0.086 
Formula weight 332.41 F(000) 356.0 
Temperature/K 99.85 Crystal size/mm3 0.44 × 0.365 × 0.1 
Crystal system monoclinic Radiation MoKα (λ = 0.71073) 
Space group P21 2Θ range for data collection/° 3.024 to 53.454 
a/Å 11.2125(6) Index ranges -14 ≤ h ≤ 14, -7 ≤ k ≤ 7, -17 ≤ l ≤ 17 
b/Å 5.9911(3) Reflections collected 14793 
c/Å 13.8305(7) Independent reflections 3804 [Rint = 0.0490, Rsigma = 0.0523] 
α/° 90 Data/restraints/parameters 3804/264/292 
β/° 103.191(3) Goodness-of-fit on F2 1.012 
γ/° 90 Final R indexes [I>=2σ (I)] R1 = 0.0434, wR2 = 0.0972 
Volume/Å3 904.55(8) Final R indexes [all data] R1 = 0.0661, wR2 = 0.1067 











 Appendix 3 – NOE Analysis 






























































































































































































  Appendix 4 – Publications 
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